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Abbreviations 
 
ABPs activity based probes 
AID autoimmune disease 
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BMDC bone marrow derived dendritic cells 
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MD-2 myeloid differentiation-2 
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PMGLP Mca-GRWPPMGLPWE-Lys(Dnp)-DArg-NH2 
PRR Pattern recognition receptor 
SBP Substrate based probes 
smDC Semi-mature dendritic cells 
STAT3 Signal transducer and activator of transcription 3 
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Treg regulatory T cell 
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Summary (English) 
 
The gut is considered to be the biggest immunological organ in mammals and the composition of the 
intestinal microbiota is therefore assumed to have widespread effects on the immune system of its 
host. During past years, more and more insights were gained concerning the correlation of intestinal 
microbiota composition and onset and progress of various autoimmune diseases, i.e. Inflammatory 
Bowel Diseases (IBD). Nevertheless, insights in defined molecular mechanisms underlying these 
observations are rare. However, a deeper knowledge of these mechanisms is necessary for proper 
drug development for gut-associated and immune system-related pathologies. With this work, 
knowledge gaps concerning molecular events of the interplay between commensal gut bacteria and 
the host immune system shall be closed. In this context, we focused on how different intestinal 
commensals, symbionts and pathobionts, differentially influence the host immune system. 
Briefly summarized, B. vulgatus mpk, a Gram negative model symbiont of the intestinal microbiota, 
was able to prevent from induction of intestinal inflammation in a mouse model for experimental 
colitis. This effect was not restricted to prevention, as even already established colonic inflammation 
was  reduced by oral administration of this bacterium, resulting in complete healing of damaged 
colonic tissue. Furthermore, isolated lipopolysaccharide from B. vulgatus mpk, providing a unique 
core oligosaccharide structure, was able to mimic both observed bacteria-mediated therapeutic 
effects. Additionally and for the first time, a symbiotic commensal such as B. vulgatus mpk was 
demonstrated to prevent from cathepsin S activity upregulation in host dendritic cells by a regulation 
mechanism involving the endogenous protein cystatin C. Cathepsin S activity regulation is a decisive 
criterion for the prevention of pathological CD4+ T cell mediated immune responses. Since many 
autoimmune diseases were already demonstrated to be associated with cathepsin S activity 
dysregulation, our observation might explain why and how the microbiota composition influences 
the progress of autoimmune diseases in various mouse models. We furthermore showed that 
cathepsin S activity regulation in dendritic cells is part of DC semi-maturation. Semi-mature DCs 
provide a a tolerant and tolerogenic phenotype contributing to (re-)establishment of intestinal 
homeostasis and prevention of pathological inflammation.  
Taken together, we hereby offer novel therapeutic approaches for the treatment of inflammatory 
bowel disease in specific and autoimmune diseases in general. First, lipopolysaccharides of symbiotic 
commensals might act as therapeutic agents and insights gained from the structural analysis of 
B. vulgatus mpk LPS might help to chemically design novel inflammation-silencing drugs. Second, 
B. vulgatus mpk was shown to prevent from pathological cathepsin S activitiy increase, making this 
bacterium an attractive alternative to chemical cathepsin S inhibitors which are widely considered to 
be promising drugs for the treatment of autoimmune diseases. 
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Zusammenfassung (Deutsch) 
Der Darm wird im Allgemeinen als größtes immunologisches Organ im Säugetierorganismus 
betrachtet. Daher ist es schlüssig anzunehmen, dass die Zusammensetzung der Darmmikrobiota 
weitreichende Auswirkungen auf das Wirtsimmunsystem besitzt. In den vergangenen Jahren konnten 
immer mehr Zusammenhänge zwischen der Mikrobiotazusammensetzung und der Induktion 
beziehungsweise dem Verlauf verschiedener Autoimmunerkrankungen aufgezeigt und nachgewiesen 
werden. Obwohl diese generellen Beobachtungen gut dokumentiert sind, fehlt es weiterhin an 
detaillierten und schlüssig nachgewiesenen molekularen Grundlagen, die diese Beobachtungen 
zufriedenstellend erklären. Es ist jedoch nötig, genau diese molekularen Mechanismen zu kennen, 
um neue Therapieansätze für darmassoziierte immunologische Erkrankungen zu entwickeln. Diese 
Arbeit soll daher einen Beitrag dazu leisten, die Kenntnisse molekularer Ereignisse bei der 
Wechselwirkung kommensaler Darmbakterien mit dem Wirtsimmunsystem zu erweitern. Dabei steht 
insbesondere die unterschiedliche Wirkung von symbiotischen und pathobiontischen Kommensalen 
auf das Immunsystem des Wirts im Fokus. 
In früheren Arbeiten konnte bereits gezeigt werden, dass B. vulgatus mpk, ein gramnegativer 
kommensaler Modellsymbiont der intestinalen Mikrobiota in einem Mausmodell vor experimenteller 
Kolitis schützen kann. Diese entzündungsregulierende Eigenschaft ist nicht nur darauf beschränkt, 
einen gesunden Darm vor beginnender Inflammation zu bewahren. Vielmehr ist dieses Bakterium 
auch in der Lage, bereits stattfindende entzündliche Prozesse in einer etablierten Kolitis derart zu 
reduzieren, dass eine komplette Regeneration des betroffenen Kolongewebes stattfindet und ein 
immunologisches Gleichgewicht wiederhergestellt wird. Aufgereinigtes Lipopolysaccharid dieses 
Bakteriums, dessen molekulare Struktur bisher einzigartig unter kommensalen Darmbakterien ist, 
spielt hierbei eine entscheidende Rolle. Des Weiteren konnte zum ersten Mal gezeigt werden, dass  
ein darmkommensaler Symbiont wie B. vulgatus mpk über einen Cystatin C-vermittelten 
Regulationsmechanismus vor einer pathologischen Erhöhung der enzymatischen Aktivität von 
Cathepsin S im Wirt schützt. Die Regulation der enzymatischen Aktivität dieser Protease ist 
entscheidend, um eine pathologische Aktivierung CD4+ T-Zellen zu verhindern. Da viele 
Autoimmunerkrankungen mit einer pathologisch veränderten Cathepsin S-Aktivität einhergehen, 
könnte diese Beobachtung erklären, warum die Mikrobiotazusammensetzung die eingangs 
beschriebenen Auswirkungen auf den Verlauf von Autoimmunerkrankungen in verschiedenen 
Tiermodellen hat. Es ist weiterhin bereits bekannt, dass CD11c+ Zellen im Intestinum eine 
entscheidene Rolle dabei spielen, die Immunhomöostase im Darm aufrecht zu erhalten und damit 
wichtig sind, um vor pathologischen entzündlichen Prozessen zu schützen. Wir konnten zeigen, dass 
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B. vulgatus mpk diese CD11c+ Zellen in einen sowohl toleranten, als auch tolerogenen Zellphänotyp 
konvertiert, der direkt mit der strikten Regulation der Cathepsin S-Aktivität assoziiert ist. 
Zusammenfassend wollen wir mit den in dieser Arbeit diskutierten Ergebnissen neue therapeutische 
Ansätze, die zur Behandlung chronisch entzündlicher Darmerkrankungen im Speziellen und zur 
Verhinderung pathologischer Immunreaktionen im Allgemeinen geeignet sind, anbieten. 
Oberflächenbestandteile von gramnegativen Bakterien (wie Lipopolysaccharide) könnten als 
Therapeutika für die erwähnten Pathologien fungieren. Zusätzlich könnten Erkentnisse, die aus der 
detaillierten Strukturanalyse des B. vulgatus mpk LPS gewonnen wurden, dazu beitragen, neuartige 
entzündungshemmende Substanzen chemisch zu generieren. Außerdem konnten wir zeigen, dass B. 
vulgatus mpk in der Lage ist, die proteolytische Aktivität von Cathepsin S zu regulieren. Somit liegt 
der Schluss nahe, dass dieses Bakterium eine attraktive Alternative zu chemischen Cathepsin S 
Inhibitoren darstellt, die weithin als vielversprechende Therapeutika für die Behandlung 
verschiedenster Autoimmunerkrankungen diskutiert werden. 
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1. The intestinal microbiota  
1.1 Evolution and function of the intestinal microbiota  
During the evolution of complex eukaryotic organisms, these organisms became hosts to so-called 
commensal microbes. Commensals are hereby defined as organisms that live in a relationship in 
which the host derives food or other benefits from commensals without being negatively affected by 
their presence. Besides fungi, intestinal commensals mainly consist of bacteria [1]. This symbiotic co-
evolution of a eukayrotic host and commensals resulted in the formation of huge metaorganisms 
consisting of prokaryotic and eukaryotic cells. These metaorganisms share a common metabolome 
despite having a separate metagenome [2, 3]. The entirety of commensal microorganisms, which are 
adapted to a certain host, are termed “microbiota”. Since these microorganisms are present in 
abundant numbers in and on mammals and other complex organisms, this symbiotic form of life 
made up of a single eukaryotic and several million prokaryotic organisms is often called a 
“superorganism” [4, 5]. 
The biggest numbers and the greatest variety of commensal bacteria in a mammalian organism is 
found in the intestine with the largest number of microorganisms existing in the colon and distal 
ileum [6]. This intestinal microbiota consists of a pool of approximately 1012 microorganisms per 
gram luminal content with 99% of these microorganisms being obligate or facultative anaerobes [7]. 
The resulting interplay between host and intestinal microbiota influences and regulates various 
functions of the host organisms, such as (I) nutrition, (II) metabolism, (III) integrity maintenance of 
the intestinal epithelial barrier, (IV) inhibition of pathogen attachment and proliferation, (V) general 
homeostasis and promotion of gut microbial diversity as well as (VI) development and regulation of 
the innate and the adaptive immune system [8-12]. For example, microbiota components produce 
and secrete vitamins in excess of their own requirements therefore being important for host vitamin 
supply [13]. Besides vitamins, also other bacterially produced substances are important for the host 
organism by supporting the growth of the gut epithelium and influencing metabolic functions. 
Indeed, bacterial colonization is required for the induction of host digestive enzymes [13, 14]. 
Additionally, a normal microbiota is crucial for the development of the adaptive immune system and 
lymphatic structures [15, 16]. The gut-associated lymphoid tissue (GALT) harbours immune 
structures where antigens are taken up and presented via antigen-presenting cells (APCs). The 
requirement of the intestinal microbiota for the development of the GALT has been convincingly 
demonstrated by studies using germfree mice underlying the importance of the intestinal microbiota 
for host immune system development [17]. 
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1.2. The composition of the gut microbiota 
The intestinal microbiota of mice and humans (as the most well studied mammalian organisms) 
mainly consists of seven major bacterial phyla: Gram positive Firmicutes and Actinobacteria as well as 
Gram negative Bacteroidetes, Proteobacteria, Fusobacteria, Verrumicrobia and Cyanobacteria. 
Among these, Firmicutes and Bacteroidetes bacteria alone account for more than 90% of all bacterial 
strains in an “average” intestinal microbiota [18, 19]. However, the composition of the microbiota is 
not static. Nutrition, the presence of toxins, medication such as antibiotics and various other 
environmental factors influence a certain individual’s microbiota composition [20, 21]. Besides these 
extrinsic factors, instrinsic properties of the host, such as its genetic background, greatly affect the 
constitution of the intestinal microbiota [22-24]. Importantly, this host genetic background is decisive 
whether a specific microbiota composition is healthy or, in other words “balanced” for a certain host. 
Therefore, host genetics is relevant for the definition of a so-called “microbiota dysbiosis” or 
“imbalance”. The term “dysbiosis” often refers to describe a microbiota composition that is 
considered to be harmful, or potentially harmful, for a certain host individual by disrupting a normal 
and balanced state of the gut [25]. 
1.3. Subgroups of intestinal commensals:  the concept of “symbionts” and “pathobionts”  
Although mostly consisting of bacteria belonging to a handful of different bacterial phyla, the 
intestinal microbiota is a highly heterogeneous mixture of microorganisms. However, microbiota 
components can be classified and subgrouped into different functional classes, dependent on their 
effect on the host immune system [17]. In general, the intestinal microbiota is composed of 
commensals and, sometimes, pathogens. Commensals are generally considered to be harmless or 
even beneficial for the host, while pathogens cause infections or diseases. However, it remains 
largely unclear how exactly the host immune system manages to discriminate between pathogens 
and commensals. According to a certain definition concept, commensals can be further subdivided 
into symbionts and pathobionts. Pathobionts are hereby defined as commensal and resident bacteria 
that may cause non-beneficial effects on the host such as induction of overshooting inflammatory 
reactions in the gut. However, pathobionts exhibit these potentially pathological properties only 
when the host provides certain genetic or environmental preconditions [26], which defines the 
decisive difference between pathobionts and pathogens. Contrariwise, symbiotic commensals never 
trigger intestinal inflammatory reactions [17] and symbionts rather actively suppress pathological 
properties of pathobionts by the induction of regulatory immune functions, i.e. via interleukin-10 (IL-
10) and the induction of regulatory T cells (Tregs). These different properties of symbionts and 
pathobionts concerning induction of inflammatory reactions in the gut have been demonstrated in 
various studies focusing on the induction of colitis in mice [27-29]. 
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1.5 Bacteroides vulgatus mpk – a model symbiotic commensal 
Some commensals have been already reported to exhibit either symbiotic or pathobiotic properties. 
Examples for commensal pathobionts include (among others) Bilophila wadsworthia [30], Escherichia 
coli [28, 31], Porphyromonas gingivalis [32], Clostridium difficile [33], Enterococcus faecalis and 
members of the Prevotellaceae family [34]. Prominent examples of commensal symbionts comprise 
members of the genera Bifidobacterium [35], Lactobacillus [36] and Ruminococcus [37, 38]. 
Concerning Bacteroides, it seems to be more complicated to class this genus adequately into such a 
bipolar symbiont/pathobiont classification scheme. While some groups consider the whole 
Bacteroidetes phylum to be pathobiotic [39, 40], others classify the entire genus Bacteroides as 
symbionts [41]. Supporting the latter classification, Bacteroides fragilis [42, 43] and Bacteroides 
thetaiotaomicron [44, 45] as prominent members of this genus were convincingly reported to be 
symbionts.  
Our group has extensively reported on another intestinal commensal of the Bacteroides genus: 
B. vulgatus mpk. So far, this bacterium was demonstrated to provide strikingly symbiotic features in 
mice and we therefore assume B. vulgatus mpk to be a model symbiont for the mouse intestine. We 
could already demonstrate that this strain protects from colitis induction in Rag1-/- mice [46] and 
promotes survival in Il2-/- [28] mice, with both mouse models for experimental colitis being highly 
dependent on microbiota composition and both studies underlying the symbiotic properties of this 
commensal bacterium. Detailed analysis of the B. vulgatus mpk genome revealed a high genomic 
plasticity [47] which we consider to be a survival and adaption strategy to different intestinal 
environments, helping this strain to mediate and exhibit its immune system-silencing properties. 
 
2. Inflammatory disorders of the gut  
Due to their different immunogenic properties, intestinal symbionts and pathobionts exhibit distinct 
effects on the mucosal immune system and immune system-related pathologies. Therefore, 
microbiota-driven or –influenced pathological inflammatory reactions in the intestine may lead to 
the manifestation of Inflammatory Bowel Disease (IBD). IBD is characterised by chronic relapsing 
intestinal inflammation with Crohn’s Disease (CD) and Ulcerative Colitis (UC) being the most frequent 
and clinically relevant forms of this disease complex in humans [48, 49]. IBD is associated with either 
an inappropriate immune response to normally harmless commensal microbes, an inefficient 
clearance of immune response-stimulating microorganisms leading to a continuous activation of the 
immune system or failing to turn from an adequate proinflammatory response to inflammation-
reducing anti-inflammatory immune reactions [50, 51]. It is furthermore considered to be a 
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multifactorial disease with genetics [52], environmental factors [53] and intestinal microbiota 
composition [54] contributing to its pathology [49]. In fact, changes in the microbiota composition 
were observed in IBD patients and a decrease in general diversity but also an increase in certain 
species [55, 56] was associated with IBD development [49]. In UC patients, the proportion of 
Bacteroides species is markedly decreased [57] supporting the idea of Bacteroides strains being 
important symbionts in the intestinal microbiota [49]. Concerning the influence of host genetic 
predisposition on IBD pathology, single nucleotide polymorphisms in more than 160 human genes 
are associated with an increased incidence of IBD [52, 58]. However, these genetic risk factors are 
not specific for either UC or CD [58]. Since the human genetic pool remained relatively constant 
during past generations, the increasing incidence and prevalence of IBD in developed countries is 
therefore traced back to be most likely provoked by environmental factors [59]. Thus, changes in the 
microbiota composition are considered to be relevant for IBD incidence. In general, a more diverse 
microbiota is regarded to be beneficial for the host. In fact, changes in microbiota composition in the 
colon of IBD patients were demonstrated in various studies [54, 60-64].  
 
3. Bacterial structural compounds and their influence on the immune system 
An important factor for the interplay between commensals and the host immune system is an 
adequate recognition of bacteria and bacterial compounds in the intestine. Therefore, recognizing 
bacterial structures is a prerequisite for an efficient host innate immune system and important for 
the clearance of initial or persisting bacterial infections. The host immune system is able to detect 
and recognize conserved bacterial molecular structures which are termed microbe-associated 
molecular patterns (MAMPs) with MAMPs being originally defined as conserved molecules present in 
whole classes of microbes (nonself) with an essential function for these microbes [65]. 
3.1. Lipopolysaccharides of Gram negative bacteria 
One of the most important MAMPs of Gram negative bacteria are lipopolysaccharides (LPS). LPS is 
anchored in the outer bacterial membrane providing a barrier against surrounding environments that 
could be harmful for bacterial survival [49, 66]. Usually, LPS consists of a lipid A part, a core 
oligosaccharide (OS) and sometimes additionally of a so-called O-antigen. Figure 1 illustrates the 
general structure of LPS which is embedded in the outer leaflet of the bacterial cell wall via the 
hydrophobic acyl chains of its lipid A part [67, 68]. E. coli lipid A is considered to be the “prototype” 
lipid A and consists of a β(1→6)-linked glucosamine disaccharide backbone, mostly phosphorylated 
at position 1 and 4’, which is additionally acylated at positions 2  
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Figure 1: Schematic diagram of the general structure of lipopolysaccharides of Gram negative 
bacteria. Lipolysaccharides of Gram negative bacteria consist of three main subunits (from left to right): lipid 
A, the core region and the O-antigen. Lipid A and the core region form rough (R)-type LPS. Lipid A, the core-
region and the O-antigen together form smooth (S)-type LPS. The number and chemical structure of the acyl 
chains can vary. Suger moieties are depticted as hexagons in different colors. The number and chemical 
structure of these sugar moieties can vary. Taken from Steimle & Frick (2016) [68] and slightly changed. 
 
and 3 of each monosaccharide residue [68-71]. The immunogenicity of LPS, or the strength of the 
host immune response to bacterial LPS, is regarded to be mainly mediated by lipid A [49, 68, 72, 73]. 
However, despite LPS of all Gram negative bacteria follows this general structural make up, slight 
differences in the phosphorylation pattern as well as in the number, length and distribution of the 
acyl chains may influence the immunogenicity of lipid A and therefore of LPS as a whole (reviewed in 
[68, 74]). The LPS core OS is coupled to lipid A via at least one residue of 3-deoxy-D-manno-oct-
ulosonic acid (Kdo) and contains up to 15 sugar residues [68]. Adjacent to the core oligosaccharide, 
repeating units of usually not more than five different sugar moieties build up the so-called O-
antigen [68]. However, the O-antigen is not always part of LPS. LPS structures missing an O-antigen 
are called “rough”, the ones containing the O-antigen are named “smooth” [75]. 
Figure 2: Detailed structure of E. coli lipid A.  
E. coli lipid A contains a β(16)-linked glucosamine 
disaccharide backbone (light brown). The hydroxyl 
group (light yellow) of the distal glucosamine links 
lipid A to the Core region. The two phosphate groups 
are depicted in light green. Primary acyl chains (light 
grey) are directly linked to the sugar moieties, 
secondary acyl chains (light red) are esterified with 
the hydroxyl groups of primary acyl chains. All 
primary acyl chains of E. coli lipid are 
hydroxymyristates, one of the two secondary acyl 
chains is myristate while the other one being 
laurate. Taken from Steimle & Frick (2016) [68] 
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3.2. MAMP recognition receptors – a focus on the MD-2/TLR4 receptor complex 
The general conservatism of LPS structures allowed for the development of evenly conserved LPS 
recognition structures in mammals [76]. Extracellular recognition of LPS occurs via the myeloid 
differentiation-2/Toll-like receptor receptor 4 (MD-2/TLR4) receptor complex [76]. This receptor 
complex belongs to the group of pattern recognition receptors (PRR), which allow host cells to sense 
microbiota component-derived MAMPs [9]. Expressed on intestinal epithelial cells and dendritic cells 
[41], the MD-2/TLR4 receptor complex stands in the front line of the host microbe-sensing 
machinery. In general, LPS is a potent MD-2/TLR4 receptor complex agonist, leading to strong 
intracellular signalling in target cells and resulting in transcription of genes associated with pro-
inflammatory immune responses [49, 77]. For the cellular detection of  low LPS concentrations, a 
series of different proteins is necessary:  the LPS binding protein (LBP) [78, 79] which is supposed to 
deliver LPS monomers to soluble or membrane bound CD14 [80] followed by LPS binding of MD-2 
which forms a heterodimer with the TLR4 ectodomain [81, 82]. LPS binding of MD-2/TLR4 results in a 
conformational change of the heterodimer resulting in (MD-2/TLR4)2 heterotetramerization leading 
to activation of intracellular signalling [49, 83-85]. However, LPS is not only recognized in 
extracellular environments but also intracellularly inside target cells. Recently, caspase-11 (Casp11) 
has been identified as such an intracellular LPS recognition receptor [86-91] which is able to bind the 
lipid A part via its CARD-domain, resulting in secretion of pro-inflammatory cytokines [68, 92, 93]. 
However, intracellular Casp11-mediated LPS sensing requires previous transcription of the Casp11 
gene which can be initiated by recognition of bacterial components not only via TLR4, but also via 
TLR2 and/or TLR7 [68, 94]. 
 
4. Dendritic cells: major players in immunity 
Although not being the only TLR4 expressing cells in mammals, dendritic cells (DCs) are major 
components of the innate as well as of the adaptive immune system and represent the most 
important cell type connecting both immune responses [95, 96]. They provide important functions in 
mucosal immunity since, besides intestinal epithelial cells, DCs are among the first PRR-expressing 
cells encountering microbiota components (see above). In general, DCs comprise a heterogenous 
leukocyte population of different developmental origin and with distinct surface markers and 
biological functions [51]. DCs patrol virtually all lymphoid and non-lymphoid organs and are 
specialized antigen presenting cells (APCs) which are able to induce a variety of different immune 
responses [51, 95].  One of the most prominent functions of DCs is to induce an adaptive immunity 
against pathogens while simultaneously maintaining tolerance to self-antigens and, importantly, to 
the own commensal microbiota [51, 97]. 
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4.1 Dendritic cell tolerance, tolerogenicity and semi-maturation 
Usually, antigen encounter leads to induction of a maturation program in DCs and certain 
components of complex antigens are sufficient to induce DC maturation. As an example, binding of 
agonistic LPS to the MD-2/TLR4 receptor complex leads to complete maturation of DCs. DC 
maturation is characterized by efficient antigen sampling from the extracellular environment and 
effective subsequent antigen processing [51]. These cellular effects are accompanied by upregulation 
of major histocompatibility class-II (MHC-II) and T cell co-stimulatory molecules like CD40, CD80 and 
CD86 which are essential for proper T cell activation [51]. Secretion of pro-inflammatory cytokines 
such as IL-1β, IL-6, TNF, IL-12 and others complete this mature DC phenotype [95, 98]. 
However, dependent on the nature of the encountered antigen, DCs can be prevented to become 
fully mature but rather develop into different other phenotypes. Many groups have already 
characterized a DC phenotype called semi-mature [99-106] which is strongly distinct from a classical 
mature state [51]. However, the exact definition of DC semi-maturation is less distinct and depends 
on the agent that is used to induce this certain phenotype [51]. The most important property of 
semi-mature DCs, uniting different definitions, is the inability to induce a pro-inflammatory Th1 or 
Th17 immune response and to be non-responsive, or in other words “tolerant” towards subsequent 
maturation stimuli [51, 99, 107]. Semi-mature or “tolerant” DCs often provide additional 
“tolerogenic” properties. This means, they possess one, several or all of the following criteria: (1) 
induction of unresponsiveness of T cells, (2) active induction of regulatory T cells (Tregs), (3) active 
inhibition of pro-inflammatory T cell responses and (4) promotion of T cell apoptosis or T cell anergy 
[51, 108].  
4.2 The connection between inflammatory disorders, gut microbiota and phenotypes of 
intestinal DCs 
As mentioned above, the composition of the intestinal microbiota plays an important role in 
manifestation, onset or progress of intestinal inflammatory disorders like IBD, not only in mouse 
models for experimental colitis  but also in human patients [109]. The distinct components of the 
intestinal microbiota have different effects on the phenotype and maturation state of intestinal 
dendritic cells which are crucial for driving immune responses into either a proinflammatory or a 
rather homeostatic condition [51]. In this context, tolerogenic and semi-mature DCs have been 
reported to play decisive roles for the maintenance of intestinal homeostasis and the prevention of 
pathological intestinal inflammatory processes [28, 31, 46, 51, 110]. Most notably, symbiotic 
commensals are able to induce tolerogenic intestinal DCs via direct interaction with this important 
type of APCs [41]. This initial interaction at the mucosal interface is a crucial event for the 
subsequent onset of a series of immunological cellular reactions that finally define the overall 
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inflammatory status of the intestine. As mentioned, the microbiota-induced DC phenotype decides 
on whether intestinal T cells are polarized into an inflammation-promoting Th1 and, notably, Th17 
directions or the induction of Foxp3+ Tregs is favoured. While intestinal Foxp3+ Tregs favour mucosal 
homeostasis, Th17 T cells play a pivotal role for the manifestation of inflammatory disorders. These 
Th17 T cells are associated with the induction of autoimmune diseases in general [111], a fact that 
also highlights their role for onset and development of IBD [112]. We could already provide evidence, 
that symbiotic and pathobiotic commensals differentially modulate DC maturation phenotypes 
which, in turn, directly affect the polarization type of T cells and therefore the induction or 
prevention of intestinal inflammation. In various mouse models, pathobionts induced maturation of 
intestinal DCs leading to enhanced Th1/Th17 T cell polarization resulting in enhanced colonic 
inflammation while symbionts induced DC semi-maturation which was associated with lower 
Th1/Th17 responses and a prevention of pathological inflammation [28, 31, 110]. 
 
5. The role of cathepsin S for MHC-II surface expression and DC maturation  
Dendritic cells activate T cells and influence their polarization profile via the secretion of a certain 
cytokine pattern and the surface expression of proteins that directly interact with receptors on the T 
cell surface. Among these DC surface proteins, MHC-II is one of the most important activators for 
CD4+ T cells and the extent of MHC-II surface expression is one major criterion for the determination 
of the DC phenotype and therefore for the ability to induce or prevent inflammatory responses [46, 
51]. MHC-II expression is regulated on transcriptional and post-transcriptional levels [113] and TLR 
signalling leads to enhanced MHC-II protein synthesis [114]. However, in immature DCs, large 
amounts of already synthesized MHC-II molecules are present in endosomal and lysosomal 
compartments [115, 116]. Upon induction of DC maturation, MHC-II protein complexes are 
translocated from these intracellular vesicular compartments to the cell surface [115, 116]. One of 
the most important post-transcriptional regulation mechanisms for MHC-II surface expression is 
cleavage of the MHC-II associated invariant chain, a proteolytical step that is catalyzed and therefore 
regulated by cathepsin S (CTSS) in professional antigen-presenting cells (APCs) [117].  
5.1 CTSS as an important general regulator of immune responses 
Cathepsin S (CTSS) is a lysosomal single-chain protease that is expressed APCs like macrophages, 
dendritic cells (DC) [118] and B cells as well as in non-professional APCs like intestinal epithelial cells 
[46, 119, 120]. It belongs to the papain-like cysteine protease family that currently comprises eleven 
known members in humans [46, 121]. It is mainly involved in the stepwise degradation of the MHC-II 
associated chaperone invariant chain (Ii) [46, 122]. These proteolytic events are crucial for the 
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loading of antigen-derived peptides on MHC-II and the subsequent transport of this MHC-II-peptide 
complex to the APC surface where it promotes CD4+ T cell activation [46, 117]. CTSS activity can be 
influenced by transcriptional and post-translational regulation or by protein-protein-interaction with 
endogenous inhibitors, mainly cystatins [46, 123].  However, there are contradictory reports on 
cystatin-mediated CTSS activity regulation [46, 124-127]. Though, adequate regulation of CTSS is 
necessary to retain the steady state of CD4+ T cell dependent immune responses, which, in turn, is 
crucial for the onset of CD4+ T cell mediated autoimmune diseases (AID) [46]. 
5.2 Impact of cathepsin S on IBD and onset or progression of autoimmune diseases – a 
short overview 
In fact, dysregulation of CTSS activity, expression or secretion into the extracellular space is 
associated with the pathogenesis of various AID, i.e. arthritis [128, 129], type-I-diabetes [130], 
Sjögren’s syndrome [131, 132], multiple sclerosis [125, 133] and atherosclerosis [134, 135]. 
Furthermore, CTSS secretion contributes to pain induction during inflammatory bowel disease (IBD) 
[136]. Due to the implications of CTSS dysregulation for the pathogenesis of AID, there is an intense 
search ongoing for the development of drugs that are able to specifically inhibit CTSS proteolytic 
activity [137] in order to offer novel therapeutic approaches for the treatment of AID. 
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Aim of this work 
Insights of molecular events caused by gut microbiota leading to novel 
therapeutic strategies for the treatment of IBD and AID 
In previous studies, we could demonstrate that the composition of the intestinal microbiota is a 
decisive factor for the induction or prevention of pathological immune responses in mouse models 
for experimental colitis. We could show that a certain mouse-associated symbiotic gut commensal, 
Bacteroides vulgatus mpk, is able to prevent from pro-inflammatory immune responses by induction 
of semi-maturation in dendritic cells, thus favouring homeostatic conditions in the intestine [28, 31, 
99]. Furthermore, we could show that not only the microbiota composition but also the detailed 
structure of LPS from Gram negative gut commensals determines the outcome of inflammation in 
Rag1-/- mice [110].  
Due to these implications, we were interested, (I) in the exact molecular mechanisms that underly 
induction and preservation of DC semi-maturation, (II) if the proteolytic activity of cathepsin S as a 
major mediator of CD4+ T cell driven immune responses is regulated by commensal bacteria (and 
especially by B. vulgatus mpk), (III) if B. vulgatus mpk is not only able to prevent from intestinal 
inflammation, but might also be able to actively reduce already established intestinal inflammation 
and (IV) if the anti-inflammatory and DC semi-maturation inducing properties of B. vulgatus mpk 
requires living bacteria or whether isolated LPS as a MD-2/TLR4 receptor complex ligand might mimic 
these immunomodulatory effect. 
All these questions to be answered aim to find new therapeutical approaches not only for the 
treatment of IBD, but also for AID in general. Since cathepsin S is a crucial enzyme for the induction 
of almost all known AID, a proven microbiota-dependent (or microbiota-derived component 
dependent) regulation of this enzyme might be a major step forward into the development of novel 
drugs. 
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Dendritic cells play a crucial role in the activation of T cell-mediated immune responses. The exact DC 
phenotype is thereby decisive if T cells are activated and if yes, how these activated T cells are 
polarized. We and others could already demonstrate that this immature-versus-mature phenotype 
characterisation is not as bipolar as it seems to be since other DC phenotypes with different 
immunomodulating properties have been discovered. We could show that a certain symbiotic gut 
commensal bacterium, B. vulgatus mpk, converts DCs into a semi-mature phenotype which is distinct 
from an immature or mature phenotype [31, 99, 105]. This semi-mature phenotype was 
demonstrated to be crucial for maintenance of intestinal homeostasis, thus preventing from 
pathological inflammatory reactions [28, 31, 99, 110]. 
A characteristic feature of a semi-mature DC phenotype is, besides others, their low to intermediate 
expression of CD40, a T cell co-activating surface protein. In general, activation of T cells by dendritic 
cells includes three different ligation events resulting in activating processes in the T cell (reviewed in 
[139]). The first event is recognition of MHC-II which is loaded with antigenic peptide by binding to 
the corresponding T cell receptor (TCR) on the T cell surface. The second event is the ligation of CD80 
or CD86 on the DC surface with CD28 on the T cell surface and the third and last required signal is 
mediated by ligation of CD40 on DCs with the corresponding CD40 ligand (CD40L) on T cells. CD40 
expression on DCs is therefore important for the induction of a CD4+ T cell mediated immune 
response [140, 141]. Binding of CD40L to CD40 leads to increased expression of CD83, CD80, CD86 
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and MHC-II on dendritic cells, therefore acting as an expression booster of these surface proteins 
[142-145].  CD40 ligation may also positively influence survival of DCs [146, 147] as well as enhancing 
the secretion of pro-inflammatory cytokines [143-145, 148]. 
These findings underly that there are two principal mechanisms how CD40 expression on DCs can be 
regulated or activated. The first mechanism is antigenic encounter leading to DC maturation and 
enhanced expression of T cell activating surface proteins and cytokines. The second mechanism is 
feedback activation by ligation of CD40 and CD40L. 
We already know that once a DC was converted into a semi-mature phenotype with a characteristic 
low to intermediate expression of CD40 cannot be overcome by additional antigenic encounter. We 
were therefore interested if and how the binding of CD40L to CD40 of semi-mature DCs alters their 
phenotype and in consequence their immunomodulatory properties or, in other words, can DC semi-
maturation be overcome by T cell binding and activation? 
In order to clarify the impact of CD40 expression on the T-cell activation capacity of semi-mature DC, 
we examined the effect of CD40 ligation on immature, semi-mature and mature DCs [138]. Semi-
mature DC were induced by stimulation with B. vulgatus and are characterized by a low positive 
expression of co-stimulatory molecules like e.g. CD40, secretion of only IL-6, and nonresponsiveness 
toward subsequent TLR activation [99, 105, 138]. We could demonstrate that, upon CD40 ligation 
with an α-CD40 antibody, B. vulgatus primed semi-mature DCs secrete increased amounts of IL-
12p40 and IL-6, but not IL-12p70 in contrast to E. coli primed mature DCs which secrete high 
amounts of all three cytokines [138]. CD40-ligated semi-mature DCs express slightly more T cell co-
stimulatory molecules (such as CD80, CD86 and CD40) than their non-CD40-ligated semi-mature 
counterparts. However, this slight increase in surface expression of CD40, CD80 and CD86 upon CD40 
ligation led to an expression level that was still significantly lower than the expression level of these 
proteins in E. coli-stimulated mature DCs. These findings prompted us to check for intracellular 
signalling events upon CD40 ligation in immature, mature and semi-mature DCs. Usually, binding of 
CD40L to CD40 leads to enhanced intracellular signalling in DCs resulting in phosphorylation, and 
therefore activation, of the MAP kinase p38. We could demonstrate that in mature and immature 
DCs, CD40 ligation leads to enhanced phosphorylation of p38. However, this was not observed in 
semi-mature DCs. Mature DCs which were treated with a p38-inhibitor before CD40 ligation provided 
reduced secretion rates of IL-12p70 compared to non-inhibitor treated samples. However, this effect 
was not observed in immature or semi-mature DCs. Taken together, we conclude that inhibited p38-
phosphorylation in semi-mature DCs is, at least in part, responsible for their reduced secretion of IL-
12p70 [138]. A graphical summary of the obtained results is depicted in Figure 3. 
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With this study, we demonstrated that CD40 ligation does not overcome DC semi-maturation in 
terms of expression of activation surface markers and results in production of only IL-6 and IL-12p40, 
but not the bioactive form of IL-12, IL-12p70 [138]. The slightly reduced p38 phosphorylation levels in 
semi-mature DC as compared to mature DC might at least partially contribute to this effect [138]. In 
line with other studies [149, 150], we observed that on mature DCs no significant further increase in 
the expression levels of the already highly expressed co-stimulatory molecules CD40, CD80 and CD86 
could be triggered upon additional stimulation by CD40 ligation [138]. Upon CD40 ligation immature 
and semi-mature DC expressed intermediate levels of CD40, CD80 and CD86, but did not reach the 
expression level of mature DC [138] (Figure 3). However, the intermediate expression of co-
stimulatory molecules was not associated with production of pro-inflammatory cytokines like IL-
12p70 [138]. It is known that immature DCs, which are characterized by low expression levels of co-
stimulatory molecules and by lacking secretion of pro-inflammatory cytokines, induce tolerance by 
promoting T-cell anergy, apoptosis or differentiation into Treg cells via antigen presentation in the 
absence of co-stimulatory signals [138, 151, 152]. Additionally, CD40 deficient DCs or DCs with a 
suppressed CD40 expression were shown to have a reduced potential to activate T-cell proliferation 
and polarization into Th1 or Th2 direction [138, 153-157]. This effect might also contribute to the 
inhibited T cell activation induced by the intermediate expression of co-stimulatory molecules on 
semi-mature lamina propria (lp) DC of B. vulgatus mono-colonized Il2−/− mice [31, 138]. On the other 
hand, it was shown that a high positive expression of co-stimulatory molecules in absence of pro-
inflammatory mediators like e.g. TNF-α or IL-12p70 favours T-cell tolerance and suppression of T-cell 
activation [138]. This type of DC is mainly induced by autocrine or paracrine stimulation with 
inflammatory mediators like e. g. TNF [138, 158, 159]. The cytokine secretion pattern upon CD40 
ligation differed between immature/semi-mature DC and mature DC [138]. In immature and semi-
mature DC, CD40 ligation did not result in induction of IL-12p70 secretion, in contrast to mature DC 
where CD40 ligation led to increased IL-12p70 secretion [138]. This is in line with other studies 
showing that TLR4 stimulation and CD40 ligation synergize in inducing IL-12p70 secretion [138, 150, 
160]. The additive microbial priming signals are necessary to trigger the production of the IL-12p35 
subunit [161] which was shown to be not induced by CD40 ligation only [138, 162, 163]. Additionally, 
these accessory stimuli have the potential to augment the CD40 expression on antigen presenting 
cells (APC) [164-166] which results in a more effective CD40 ligation [138]. However, DCs primed with 
B. vulgatus as a microbial stimulus do not secrete IL-12p70 upon CD40 ligation [138] (Figure 3). This 
mechanism might also contribute to the tolerogenic effects of B. vulgatus in the maintenance of 
intestinal homeostasis [28, 31]. Upon CD40 ligation, semi-mature DC produced significantly enhanced 
levels of IL-6 but not TNF-α or IL-12p70 [138]. This is in line with our previous studies showing a 
crucial role for IL-6 in induction of DC semi-maturation and tolerance [99, 105]. This is interesting as 
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the secretion of IL-6 upon CD40 ligation by semi-mature DC might help to sustain the semi-mature 
differentiation state and influence the T-cell activation pattern [138]. We hypothesize that the 
inability of CD40 ligation in overcoming DC semi-maturation might contribute to the tolerogenic 
phenotype of semi-mature DC and at least partially account for maintenance of intestinal 
homeostasis [138]. 
 
 
Figure 3: Schematic depiction of intracellular events upon CD40 ligation of semi-mature dendritic 
cells. B. vulgatus mpk stimulation of immature dendritic cells leads to induction of a certain 
intracellular semi-maturation program resulting in characteristic immunological properties as 
published [46, 99]. Among other features, semi-mature DCs secrete only low amounts of IL-12p70 
and TNF but remarkable amounts of immune response-modulating IL-6. Additionally, B. vulgatus mpk 
stimulation only leads to low to intermediate expression of MHC-II and T cell co-stimulatory 
molecules, such as CD40. CD40 ligation usually leads to an increase in surface expression of these 
proteins. However, semi-maturation of dendritic cells prevents from these CD40-ligation induced 
events. CD40 ligation is also reported to result in intracellular p38 phosphorylation, resulting in 
enhanced secretion of IL-6 and IL-12p70. p38 phosphorylation upon CD40 ligation is reduced in semi-
mature dendritic cells. (+) stands for activation, secretion or expression increase, (-) stands for 
inhibition. 
 
 
 
23 
 
 
 
 
Paper 2: Molecular mechanisms of induction of tolerant and tolerogenic 
intestinal dendritic cells in mice 
 
Review 
 
Alex Steimle and Julia-Stefanie Frick 
 
J Immunol Research (2016) 2016:1958650 [51] 
 
 
How does the host manage to tolerate its own intestinal microbiota? A simple question leading to 
complicated answers [51]. In order to maintain balanced immune responses in the intestine, the host 
immune system must tolerate commensal bacteria in the gut while it has to simultaneously keep the 
ability to fight pathogens and clear infections [51]. If this tender equilibrium is disturbed, severe 
chronic inflammatory reactions might result [51]. Tolerogenic intestinal dendritic cells fulfil a crucial 
role in balancing immune responses and therefore creating homeostatic conditions and preventing 
from uncontrolled inflammation [51]. Although several dendritic cell subsets have already been 
characterised to play a pivotal role in this process, less is known about definite molecular 
mechanisms how intestinal dendritic cells are converted into tolerogenic ones [51]. Different 
commensal bacteria can have distinct effects on the phenotype of intestinal dendritic cells and these 
effects are mainly mediated by impacting toll-like receptor signalling in dendritic cells [51]. 
The gut-associated lymphoid tissue (GALT) is the largest immune organ of the body [51]. The GALT 
has to ensure that there is a dynamic balance between protective immunity by fighting pathogens 
and regulatory mechanisms to prevent autoimmunity [51, 167]. Since the GALT is constantly exposed 
to large amounts of luminal antigens like food metabolites, foreign pathogens and commensal 
microbes, this balance has to be well adjusted in order to create homeostatic conditions in the 
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intestine [51]. Dendritic cells are hereby the players for the maintenance of intestinal homeostasis 
[51, 108]. They are spread out in the connective tissue underlying the epithelial layer of the gut [51, 
168]. 
The capability of initiating an immune response depends on the current DC maturation state [51]. 
Usually, antigen encounter results in rapid DC maturation which is characterized by efficient 
endocytosis and antigen processing [51]. Furthermore, upregulation of MHC-II, T cell co-stimulatory 
molecules like CD40, CD80 and CD86, enhanced expression of chemokine receptors and the secretion 
of pro-inflammatory cytokines like IL-1β, IL-6, TNF and IL-12 are part of DC maturation [51]. These 
events influence and activate other cellular components of an induced immune response like 
macrophages, neutrophils and especially T cells [51, 98]. Induction of DC maturation is accompanied 
by a loss of the capacity to take up and process antigen [51, 169]. However, they literally develop 
into professional antigen presenting cells (APCs) which are characterized by powerful antigen 
presentation to naïve T cells, as well as by their ability to migrate to secondary lymphatic organs 
where they present antigens to T cells [51]. Immature DCs (iDCs) express low amounts of MHC-II and 
T cell co-stimulatory molecules [51]. They tend to promote T cell anergy and to generate Tregs, with 
both effects being crucial for intestinal homeostasis [51, 151]. iDCs furthermore express high levels of 
PRRs with which they mediate the recognition of potential antigens and therefore their endocytosis 
[51, 169]. The definition of a semi-mature DC phenotype is less distinct [51]. The most important 
property of smDCs, uniting different definitions, is the inability to induce a pro-inflammatory Th1 or 
Th17 response and to be non-responsive, or in other words “tolerant”, towards subsequent 
maturation stimuli [99, 107] with the latter being the criterium that mediates the tolerogenic 
functions of smDCs [51, 107]. DC semi-maturation leads to a certain expression of T cell activation 
and a cytokine secretion pattern that is distinct from the ones of immature and mature DCs [51]. The 
definite phenotype varies from one semi-maturation inducing strategy to another [51]. SmDCs that 
are generated by treating immature DCs with TNF display a phenotype that can be summarized as 
CD11c+MHCIIhiCD86hiCD80hiCD40loCD54+CD205hiCD25hiTNFloIL-12p40loIL-10lo [51, 100]. Induction of 
semi-maturation via low-dose LPS and subsequent dexamethasone treatment results in 
CD14+CD1aloCD80hiCD86hiMHCIIhiIL-10hiTNFlo DCs [51, 101]. We use a Gram negative gut commensal, 
Bacteroides vulgatus, to induce semi-maturation and define the smDC phenotype as 
CD11c+MHCIIintCD40loCD80loCD86loTNFloIL-12loIL-6int [51, 99]. Besides these strategies, DC semi-
maturation can be induced by treating immature DCs with ATP and LPS [170], low dose Salmonella 
LPS [105], α-1 antitrypsin [106], Bacteroides fragilis PSA [102] or Echinococcus multilocularis cell 
aggregates [51, 171].  
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While mature DCs (mDCs) promote efficient induction of inflammatory immune responses, iDCs and 
smDCs fail to do so. They rather have the property to actively prevent from inflammatory reactions 
and are therefore also termed tolerogenic DCs (tolDCs) [51].  
More generally, regulatory or tolerogenic DCs keep their ability to present antigens, but at the same 
time they downregulate the expression of T cell co-stimulatory molecules and pro-inflammatory 
cytokines, but in turn upregulate inhibitory molecules like PD-L1, CD95L or IDO as well as anti-
inflammatory cytokines such as TGF-β and IL-10 [51, 172]. Furthermore, they are resistant to a 
second maturation-inducing signal [51, 172]. Importantly, DCs also influence the differentiation of 
naïve T cells into Th1, Th2, Th17 or Treg cells, mostly due to supplying a certain cytokine environment 
[51, 173]. In a healthy individual, the presence of tolDCs is important and a loss of tolDCs can result in 
the development of AID [51, 97]. Semi-mature DCs are potent tolerant and tolerogenic DCs since 
they fulfil many to all of the above mentioned criteria, dependent on the agent with which 
seminaturation is induced [51]. As already mentioned before, the main characteristic that makes 
semi-mature DCs tolerogenic is their unresponsiveness (tolerance) towards subsequent maturating 
stimuli [51, 99, 105, 106]. 
Less is known about defined mechanisms of tolerance induction in intestinal DCs [51]. However, 
knowledge about tolerance induction mechanisms of other DC subsets or of in vitro generated DCs 
can be transferred to intestinal DCs to explain how they manage to tolerate luminal bacterial or food 
antigens and therefore prevent from uncontrolled inflammatory reactions [51]. Here, we want to 
present latest research results and discuss how and if these findings can be assigned also to intestinal 
DCs. All proposed mechanisms are summarized in figure 4 [51].  
(1) Cell-to-cell-contact and STAT3 signaling 
Epithelial cells of the intestine express the surface protein CD47 which can directly interact with 
signal regulatory protein α (SIRPα) expressed on the surface of DCs which underlie the intestinal 
epithelial cell layer [51]. This protein-protein-interaction has been shown to result in a janus kinase-2 
(JAK-2) dependent signal transducer and activator of transcription 3 (STAT3) activation downstream 
of SIRPα in DCs [51, 174]. STAT3 activation, in turn, leads to enhanced IL-10 secretion from DCs and 
therefore promotes tolerogenic properties in the intestinal environment [51, 174]. STAT3 has long 
been known as a crucial negative regulator of immunity [51]. Disruption of STAT3 leads to a loss of T 
cell tolerance in mice and efficient STAT3 signaling is associated with the immature DC phenotype, 
general IL-10 secretion and tolerance induction [51, 175]. Therefore, not only DC alone seem to be 
important for homeostasis maintenance but also the “teamwork” with neighbouring epithelial cells 
seems to contribute to tolerance mechanisms [51]. 
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Figure 4: Possible molecular mechnisms of tolerance induction in intestinal dendritic cells.  
The white numbers in black circles refer to the numbering of regulation mechanisms in the text. See text for 
details. 
 
 
 (2) IL-10 as a central cytokine for intestinal homeostasis 
Interleukin-10 is a key inhibitory cytokine in T cell activation and a mediator of intestinal homeostasis 
[51, 176]. It is secreted by T cells, B cells and most myeloid-derived cells [51, 177]. Mice lacking 
functional IL-10 or its IL-10R receptor counterpart spontaneously develop severe intestinal 
inflammation supporting the idea of IL-10 being a crucial mediator for intestinal homeostasis [51, 
178]. Also humans with defective mutations in the genes encoding for IL-10 or IL-10R develop a 
severe form of enterocolitis within the first months after birth [51, 179]. These observations made IL-
10 a promising therapeutic candidate in order to treat chronic inflammatory conditions of the 
intestine. However, results were not convincing since in mice as well as in humans, IL-10 
administration did not ameliorate the inflammatory conditions [51, 180]. IL-10 does not only affect T 
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cell responses but can also provide autocrine and paracrine effects on DCs. Since DCs express the IL-
10 receptor (IL10R), IL-10 can bind to IL10R resulting in a negative regulation of myeloid 
differentiation primary response 88 (MyD88) signaling inside DCs. MyD88 is an adaptor molecule of 
TLRs and is required for downstream TLR signalling. IL-10/IL10R interaction mediates this negative 
regulation by a downregulation of interleukin 1 receptor associated kinase 4 (IRAK4) on the protein 
level without altering IRAK4 gene transcription rates [51, 181]. It also leads to dissociation of MyD88 
from TLRs and subsequently promotes proteasomal degradation of IRAK1, IRAK4 and TRAF6, 
therefore silencing MyD88-dependend TLR signalling [51, 181]. However, this is just the case if LPS as 
a TLR4 ligand is present at the same time to induce TLR signaling. IL-10 silencing of MyD88 signaling 
seems to be crucial for the maintenance of intestinal homeostasis since Il10-/- mice fail to develop 
intestinal inflammation if these mice simultaneously lack MyD88 [51, 182]. As a consequence, the 
cytokine environment does also affect DCs in their ability to induce tolerance mechanisms. 
(3) NFκB signalling as a mediator for tolerogenicity 
A key regulator for DC maturation and inflammatory reactions in general is NFκB [51, 183, 184]. NFκB 
family members do not only have an activating potential for the induction of pro-inflammatory 
cytokines. Two NFκB proteins, p50 and p52 have been associated with transcription repression 
functions and therefore induction of tolerance [51, 185, 186]. Both proteins lack the carboxyterminal 
transactivation domain and can form inhibitory homodimer complexes that prevent from 
transcription of pro-inflammatory genes [51]. NFκB p50 has been shown to promote a tolerogenic DC 
phenotype by negatively affecting DC survival and their capacity to efficiently activate T cells [51, 
187]. Accumulation of p50 in the nucleus of tolerogenic DCs can be accompanied by enhanced 
expression of tolerance-promoting molecules like indoleamine deoxygenases (IDOs) and decreased 
expression of pro-inflammatory cytokines like IFNβ, IL-1β and IL-18 [51, 187]. These implications for 
p50 in the induction of tolDCs is supported by the finding that p50-deficient DCs are weak inducers of 
a Foxp3+ Treg differentiation [51, 188]. Formation of p50-p50 homodimers contribute to LPS 
tolerance in MΦ [189] and p50 expression in immature DCs is crucial to prevent from autoreactive T 
cells [51, 187]. 
(4) β-catenin promotes DC tolerogenicity 
β-catenin is a transcription factor and part of the wnt signalling pathway. It could be demonstrated 
that this signalling pathway with the subsequent release of β-catenin into the nucleus results in the 
induction of tolDCs [51, 190]. Gene expression profiles of intestinal LP DCs revealed that this 
signalling pathway is decisive for the DC to become either mature or tolerogenic. β-catenin 
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translocation into the DC nucleus resulted in the expression of various tolerance-associated factors 
like retinoic acid-metabolizing enzmyes, IL-10 and TGF-β [51, 190]. 
(5) Prevention of V-ATPase domain assembly induces tolerogenic DCs 
Vacuolar (H+)-ATPases (V-ATPases) are ATP-driven proton pumps. They are composed of two 
domains: a peripheral V1 domain and membrane-embedded V0 domain [51, 191]. V-ATPases are 
involved in acidification of lysosomes by shuffling protons from the cytosol into the lysosomic lumen 
[51, 192]. The pH value of lysosomes is a crucial regulator for the efficiency of antigen processing 
since lysosomal proteases being involved in antigen proteolysis require acidic environments [51, 
191]. The most important mechanism to regulate lysosomal acidification is to control the assembly of 
the two V-ATPase domains which is a required event for forming a functional proton pump [51]. It is 
known that activation of TLRs promotes domain assembly and therefore supports DC maturation [51, 
192]. Domain assembly seems to be a PI-3 kinase and mTOR mediated event since inhibitory 
substances for both molecules could block V-ATPase domain assembly and therefore prevent from 
DC maturation and promote the induction of a tolerogenic phenotype [51, 191]. Also, stimulation of 
integrins and E-cadherins by cluster disruption of DC prevents from domain assembly and supports 
induction of a tolerogenic phenotype [51, 192, 193]. 
(6) p38α expression influences expression of ALDH1A2 
MAP kinases like ERK, JNK and p38α form central pathways that are activated by innate immune 
signals like PAMPs [194, 195] and excessive activation of MAP kinases are reported to be associated 
with many autoimmune and inflammatory diseases [51, 195]. However, the MAP kinase p38α 
provides a dichotomic role. Besides being involved in promoting pro-inflammatory responses its 
activity also seems to be crucial for the induction of a tolerogenic phenotype in intestinal CD103+ DCs 
[51]. In these DCs, p38α is constitutively active and this activity is crucial for the expression of TGF-β 
and aldehyde dehydrogenase 1A2 (ALDH1A2), the latter being involved in metabolizing retinoic acid 
(RA) [51]. TGF-β and RA are involved in Treg generation and therefore promote gut homing 
properties of T cells [51, 195].  
(7) Gadd45α-mediated TLR2 signalling contributes to tolerogenic features of intestinal DCs 
An abundant bacterial gut commensal, B. fragilis, is able to protect from the induction of EAE and 
experimental colitis and increases the proportions of CD103+CD11c+ DCs [51, 196, 197]. It could be 
demonstrated that this effect is mediated by polysaccharide A (PSA), an immunomodulatory 
component present in outer membrane vesicles derived from B. fragilis bacteria [51, 102]. PSA 
promotes immunological tolerance by inducing IL-10 producing Foxp3+ Tregs and protect animals 
from experimental colitis [51, 198]. The PSA caused induction of tolDCs is dependent on TLR2 and 
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growth arrest and DNA-damage-inducible 45 α (Gadd45α), since Gadd45α-deficient DCs are unable 
to mediate PSA-induced protection of experimental colitis [51, 102]. Gadd45α itself inhibits an 
alternative way of MAPK p38-mediated signalling [199] and PSA-containing outer membrane vesicles 
lead to an upregulation of Gadd45α [51, 102]. 
In order to be suitable as an administrable therapeutic, tolerogenic DCs (tolDCs) have to be 
generated in vitro [51]. One efficient way to induce tolDCs is co-incubating them with apoptotic cells 
[51]. Phagocytosis of apoptotic cells through DCs results in production of TGF-β which in turn 
contributes to immune tolerance [51]. Apoptotic cell-treated DCs efficiently converted naïve CD4+ T 
cells into Foxp3+ Tregs. [51, 200, 201]. In general, apoptotic cell induced tolDCs are important for 
induction of immune tolerance [51, 202, 203]. They provide upregulation of Galectin-1 and CD205 
[204], two molecules that facilitate the manifestation of immune tolerance [51, 205, 206]. At the 
same time, apoptotic cell treated DCs downregulate Gr-1 and B-220 [204], two molecules triggering 
inflammatory responses [51]. These DCs furthermore downregulate the transcription factor RORγt 
which is the decisive transcription factor for Th17 differentiation [51]. Not only treatment with 
apoptotic cells leads to induction of tolDCs but also treatment with herbal coumarins [207] and the 
macrocyclic antibiotic rapamycin [208] lead to tolDC induction [51]. In vitro generated tolDCs have 
already been successfully used for the treatment of autoimmune disorders in animal models and 
peripheral tolerance could be restored by administrating tolerogenic DCs [51, 209]. Approaches to 
treat autoimmune type 1 diabetes in a mouse model using non-obese diabetic (NOD) mice with 
tolerogenic DCs were very successful [51, 204]. To do so, apoptotic islet cells were used to induce DC 
mediated tolerance against own islet cells [51, 210]. All these applications lead to the question, if 
transfer of tolerogenic dendritic cells would also be an approach to treat IBD. And if yes, which 
method to induce DC tolerance would be the method of choice [51]. A published approach for the 
treatment of Crohn’s Disease patients is in vitro generation of DCs followed by pulsing with 
dexamethasone, pro-inflammatory cytokines IL-6, IL-1β and TNFα as well as PGE2 [51, 211]. 
Concerning our findings that a certain gut commensal, B. vulgatus mpk, efficiently induces tolerant 
and tolerogenic DCs in vitro as well as in vivo [28, 31, 99], we would recommend to use host gut 
commensal bacteria for in vitro tolDC generation [51]. In order to provide more potential luminal 
antigens presented by MHC-II of tolDCs a defined mixture of commensal bacteria could be used [51]. 
This would enlarge the amount of antigenic peptides against which tolerance would be induced [51]. 
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Paper 3: A novel approach for reliable detection of cathepsin S activities in 
mouse antigen presenting cells 
 
Research Paper 
 
Alex Steimle, Hubert Kalbacher, Andreas Maurer, Brigitte Beifuss, Annika Bender, Andrea Schäfer, 
Ricarda Müller, Ingo B. Autenrieth and Julia-Stefanie Frick 
 
J Immunol Method (2016) 432: 87-94 [212] 
 
 
In enzyme-related research, detecting activities of the enzyme-of-interest is of special importance. 
Concerning cathepsins, activity detection of one specific cathepsin causes difficulties in experimental 
procedures since cathepsins in general provide a broad and overall very similar substrate specificity 
towards endogenous and exogenous substrates [212, 213]. This physiologically valuable property 
makes cathepsins poor targets for specific activity detection in experimental settings [212]. We were 
especially interested in the reliable detection of cathepsin S activities in mouse-derived antigen 
presenting cells. Several different methods have already been described in the literature (reviewed in 
[120]). However, most of these methods have only been shown to be suitable for human samples, do 
not deliver quantitative results or the experimental procedure requires technical equipment that is 
not commonly available in a standard laboratory [212]. Therefore it was necessary to establish a 
novel method for a reliable detection of mouse cathepsin S activities which fits into our experimental 
scheme. The method we established is based on a fluorogen substrate that has previously been 
described to be exclusively cleaved by human CTSS [214]. However we could demonstrate that this 
substrate is also suitable for detection of mouse-derived samples by using a novel protocol [212]. 
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This method is cheap, specific, reliable and easy to perform in a standard laboratory without the 
requirement of special technical equipment, besides the requisition of a fluorescence compatible 
photometer [212]. 
The substrate we intended to use for CTSS activity detection was Mca-GRWPPMGLPWE-Lys(Dnp)-
DArg-NH2 (PMGLP) [214]. In a first step, we checked for PMGLP cleaving specificity using various 
recombinant murine cathepsins. We could demonstrate that PMGLP was cleaved by recombinant 
murine CTSS as efficiently as by recombinant human CTSS. However, we could also detect slight 
PMGLP turnover caused by recombinant murine cathepsin L (CTSL) at pH 5.0, yet not at pH 7.5. Since 
we could not detect any loss of CTSS activity at pH 7.5 we decided to perform all prospective activity 
assays at this pH in order to prevent from potential PMGLP cleavage caused by CTSL [212]. 
In a second step, we used complex protein solutions by lysing bone-marrow derived dendritic cells 
(BMDCs) and checked for PMGLP turnover rates caused by components of these lysates. We tested 
several lysing methods and buffer systems and discovered hypotonic lysis avoiding addition of 
detergents as the most effective lysing method. Furthermore, detection of PMGLP hydrolysis was 
best using a phosphate buffer system at pH 7.5.  In order to elucidate the contribution of CTSS to 
PMGLP turnover in cell lysates, we compared lysates of BMDCs generated from wt mice to lysates 
derived from BMDCs of Ctss-/- mice. Thereby, we could demonstrate that PMGLP is cleaved by murine 
CTSS in cell lysates and no other cathepsin contributes to PMGLP turnover. However, a yet 
unidentified cellular component causes PMGLP hydrolysis. Nevertheless this “background” hydrolysis 
occuring in every mouse cell-derived lysate, is not dependent on any DC maturation inducing stimuli 
and remains relatively constant. We therefore define the difference between overall PMGLP 
hydrolysis and background PMGLP hydrolysis as specific CTSS activity in mouse cell-derived samples 
and CTSS activity was proven to be higher in mature BMDCs compared to CTSS activity in immature 
DCs [212]. In summary, we recommend the following workflow using PMGLP as a fluorogen substrate 
for the detection of cathepsin S activities from mouse derived cells (Fig. 5) [212]. Cells are harvested 
as carefully as possible followed by hypotonic lysis as described in the methods and materials section 
[212]. In order to compare cathepsin S activities in different samples, equal protein amounts should 
be used in all tested samples [212]. Each sample is then devided into two: one sample is pre-
incubated with cathepsin inhibitor E-64, whereas the other one is not [212]. PMGLP is added into 
both samples followed by measuring fluorescence intensity increase as a function of time [212]. 
PMGLP turnover 
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Figure 5: Experimental workflow for the detection of 
CTSS activities in mouse APC. Cells of interest are lysed 
hypotonically followed by blast freezing in liquid nitrogen 
as described in materials and methods section. Supernatant 
is used for CTSS activity detection. Out of each sample, two 
reaction samples containing the same amount of whole cell 
protein are created. The first sample contains the fluorogen 
substrate, the second both, the substrate and the cathepsin 
inhibitor E-64. Reaction buffer provides a pH of 7.5 to 
minimize false positive substrate conversion caused by 
other cathepsins. Substrate conversion is monitored for 60 
min at 37 °C. A linear regression at the very beginning of 
the sigmoidal conversion curve is performed for both 
reaction samples. The slope magnitude of this linear 
regression is equivalent to the substrate conversion per 
time unit. The difference in the slope magnitude of both 
reaction samples is equivalent to the CTSS activity in the 
sample the lysate was taken from. CTSS activities can 
therefore be expressed as the difference of fluorescence 
intensity per µg cell protein and time unit, i.e. ∆AU min-1µg-
1. Taken from Steimle et al. (2016) [212] 
 
 
 
rates are computed as described [212]. The 
mathematical difference between the PMGLP 
turnover rates in the E-64 pre-incubated sample and 
the non-inhibited sample is directly equivalent to the 
activity of mouse cathepsin S [212]. We want to 
underline that it is crucial for a successful CTSS activity 
detection to keep the samples on ice throughout the 
entire experiment [212]. Unfortunately, after blast 
freezing in liquid nitrogen, samples cannot be frozen 
again for longtime storage since this leads to a 
dramatic loss of enzymaticv activity.  Additionally, 
long time storage in liquid nitrogen, starting directly 
after adding deionized water for the hypotonic lysis, 
also leads to a remarkable, yet not complete, 
reduction of enzymatic activity [212]. Hence, the 
whole experimental setup should be performed in 
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one go in order to obtain the best possible results [212]. In contrast to the cleavage behavior in 
human APC [214], mouse bone marrow derived dendritic cells provide a certain background cleavage 
of this substrate that is not caused by CTSS or any other protease that can be inhibited by E-64 or the 
Roche Complete Protease Inhibitor [212]. We still do not know what the cause for this background 
hydrolysis of PMGLP is [212]. We could demonstrate that this background hydrolysis is not abolished 
through addition of any tested protease inhibitor. Furthermore, crude cell lysates and spontaneous 
substrate hydrolysis do not contribute to this effect. However, our recommended workflow (Fig. 5) 
offers a possibility to detect specific mouse CTSS activities besides background substrate hydrolysis 
[212]. After hypotonic lysis of the cells, we recommend to create two different reaction samples out 
of one sample of interest [212]. The first sample contains the substrate, the second both, the 
substrate and E-64, an inhibitor against all cysteine cathepsins to detect the background activity 
[212]. CTSS activity is therefore equivalent to the difference in PMGLP conversion between the 
reaction sample containing no inhibitor and the sample containing E-64 [212].  
Since CTSS is exclusively expressed in professional antigen presenting cells, we recommend using cell 
populations which are as homogenous as possible for CTSS activity detection [212]. Otherwise the 
cell amount of CTSS expressing cells can fall below a critical level for reliable CTSS activity detection 
[212]. 
In summary, we have shown (I) that a specific CTSS inhibitor is not necessary for the detection of 
background activity, therefore the easily commercially available E-64 can be used and (II) that the 
background activity is not different between differentially stimulated APC [212]. Therefore, this 
PMGLP assisted CTSS activity assay is also useable for high-throughput experiments within a short 
period of time and we think that this experimental assay contributes to simplify CTSS related 
research [212]. 
 
 
 
 
 
 
 
34 
 
 
 
Paper 4: The challenge of specific Cathepsin S activity detection in 
experimental settings 
 
Mini Review 
Alex Steimle and Julia-Stefanie Frick 
J Neurol Neuromed (2016) 1(3): 6-12 [120] 
 
As mentioned above, cathepsins in general provide a broad and overall similar substrate specifity 
[213]. This makes CTSS activity detection a challenge, in vitro, ex vivo and especially in vivo. But how 
can an experimentator achieve the goal to reliably detect CTSS activity in the biological system of 
choice? [120] There are several possibilities how CTSS activity can be detected, all of them with their 
characteristic advantages and limitations [120]. A suitable CTSS activity detection method should 
match the following four criteria: (i) high specifity, (ii) high sensitivity since CTSS expression is 
restricted to APCs, (iii) the experimental workflow should be able to be performed in a more or less 
standard laboratory without the requirement of highly special technical equipment and (iv) the 
method should deliver reproducible and quantifiable results [120]. We summarize some currently 
available techniques for CTSS activity detection with their characteristic pros and cons in table 1.  
Popular approaches for CTSS activity detection include activity based probes (ABPs) [120]. These are 
small reporters of proteolytic activity which bind covalently and irreversibly to the active site of the 
target enzymes [215] leading to a loss of enzymatic activity [120]. This irreversible CTSS inhibition 
should be kept in mind if in vivo monitoring shall be performed [120]. ABPs usually consist of three 
distinct functionalities (Fig. 6): (1) The so-called warhead functionality leads the probe to enzymes 
sharing a common catalytic mechanism, (2) the recognition element that enhances specificity for one 
or more specific enzymes and (3) a tag for a later detection of the tagged enzymes [120]. Such ABPs 
are available for the  
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Table 1: Summary of various CTSS activity detection techniques. The techniques are grouped into the 
major functional classes. Taken from Steimle et al. (2016) [120] 
Application 
category 
Characteristic Example target Year 
published 
Quantification 
method 
Limitation Outstanding 
advantage 
Activity 
based 
probe 
(ABPs) 
covalent 
binding to 
CTSS active 
site leading to 
enzyme 
inhibition 
GB123 [216] Human 
CTSS and 
CTSB 
2015 Fluorescent 
label 
Binds also to 
CTSB. Gel-
assisted 
enzyme 
separation or IP 
needed 
Non invasive in vivo 
imaging possible 
Probe 7 [217] Human 
CTSS 
2015 Fluorescent 
label  
Not cell 
permeable 
Specificity for CTSS 
Z-PraVG-DMG 
[218] 
Human 
CTSS, 
CTSB and 
CTSL 
2016 Rhodamine 
azide labelling 
Similar Ki values 
for CTSS, CTSB 
and CTSL 
Cell-permeability of 
the substrate 
CM-279 [219] Human 
CTSS and 
CTSL 
2013 Luciferase 
assisted light 
detection 
Also labels CTSL Reliable detection 
of combined CTSS 
and CTSL activity 
BMV157 
[220] 
Mouse 
CTSS 
2015 Fluorescent 
label 
aviailability Highly specific, in 
vivo and in vitro 
application possible 
BIL-DMK 
[221] 
Human 
CTSS 
2011 Radioactive 
label 
Radioactivity Specificity for CTSS 
Probe 10 
[222] 
Human 
CTSS, 
CTSL, 
CTSB and 
CTSK 
2014 Fluorescent 
label 
Not specific for 
CTSS 
Suitable for complex 
protein mixtures 
Biot-(PEG)2-
Ahx-
LeuValGly-
DMK [223] 
Human 
CTSS, 
CTSL, 
CTSB and 
CTSL 
2015 SDS Page 
assisted 
chemi-
luminescence 
Not specific for 
CTSS 
Easy to perform 
Substrate 
based 
probes 
(SBP) 
Substrate 
turnover; 
enzyme is not 
inhibited and 
remains 
proteolytically 
active 
PMGLP Human 
CTSS 
[214] and 
mouse 
CTSS 
[212] 
2016 Fluorescence 
increase 
Requires cell 
lysis and 
inhibition 
control 
Simple enzymatic 
assay, easy-to-
perform, time 
saving.  
 
Ac-KQKLR-
AMC 
Mouse 
CTSS 
2014 Fluorescence 
increase 
Requires cell 
lysis and 
inhibition 
control 
Simple enzymatic 
assay 
NB200 [224] Mouse 
CTSS, 
CTSK and 
CTSB 
2015 Fluorescence 
increase 
Detects also 
CTSK at pH7.5 
and CTSB at pH 
5.5 
Simple enzymatic 
assay 
Z-FR-AMC Mouse 
CTSS, 
CTSB and 
CTSL 
2002 Fluorescence 
increase 
Unspecificity, 
requires 
extensive 
experimental 
setting 
Simple enzymatic 
assay 
Indirect 
detection 
methods 
Does not 
directly 
interact with 
CTSS 
Detection of 
CTSS 
substrate 
accumulation 
by western 
blotting [135] 
Mouse 
invariant 
chain 
p10 
detection 
2015 Western blot 
band intensity 
of Iip10 
Does not detect 
CTSS activity 
directly 
Simple to perform 
Western 
blotting of 24 
kDa CTSS 
[225] 
Human 
CTSS 
2014 Western blot 
band intensity 
of 24 kDa 
CTSS 
Does not 
consider 
potential 
binding of 
endogenous 
inhibitors and 
does not refer 
to activity 
Simple to perform 
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detection of human and mouse CTSS [120]. General disadvantages of such ABPs include a lack of 
specificity for CTSS for some of these ABPs since other cathepsins with similar substrate specifity 
might deliver false positive detection [120]. This has then to be compensated by further time-
consuming experimental approaches like western blotting, immunoprecipitations etc [120]. 
Additionally, CTSS activity can often only be determined in a semi-quantitative manner like detection 
of  band intensities on a gel or a detection of overall fluorescence intensity [120]. However, the 
potential labelling of proteolytically active CTSS in live cells due to cell permeability is a big advantage 
of some ABPs [120]. Veilleux et al. developed a radioiodinated ABPs to selectively label active CTSS in 
human whole blood [120, 221]. Ben-Aderet et al. [216] and Oresic Bender et al. [220] used 
fluorogenic ABPs to monitor enzymatically active CTSS in human cells or live mice, respectively [120]. 
Other examples of recent ABPs development for CTSS activity detection include the publications of 
Barlow et al. [224], Hughes et al. [218], Mertens et al. [222] and Garenne et al. [223], [120]. 
However, some of them provide a lack of specificity for CTSS and also label other cathepsins [216, 
218, 219, 222, 223] while other ABPs selectively label human or mouse CTSS [217, 220, 221], [120]. 
Another general disadvantage of ABPs include the requirement of more specialized detection 
techniques that a non-specialized lab could tentatively not afford [120].  
 
Figure 6: Functional comparison of the two major classes of probes for direct CTSS activity 
detection 
(A) activity based probes (ABPs): The so-called warhead covalently links the probe with CTSS, leading to the 
inhibition of its enzymatic activity. The recognition elements supports the specificity for CTSS alone or some 
related cysteine cathepsins. The tag allows for later detection of the tagged enzymes. 
(B) substrate based probes (SBPs): The thiol group at the active site of CTSS nucleophilically attacks the peptide 
bond of the peptidyl substrate leading to a deliberation of the aminomethylcoumarin. The resulting change in 
the fluorogenic behaviour of free aminomethylcoumarin can then be detected in a fluorescent compatible 
photometer. Taken from Steimle et al. (2016) [120] 
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Other approaches include an indirect method to determine CTSS proteolytic (table 1) activity by not 
directly assessing the enzymatic activity but rather determining the intracellular amount of the MHC 
II-bound invariant chain fragment (Iip10), which is a substrate for CTSS [120]. Therefore, decreased 
amounts of Iip10 is stated to correlate with enhanced CTSS activity [226], [120]. Since CTSS is 
translated into an inactive pro-enzyme requiring proteolytical cleaving which results in a 24 kDa 
active enzyme, some publications refer to the band intensities of this 24 kDa band when making 
statements on CTSS activity [225], [120]. However this does not take the potential binding of 
endogenous inhibitors into account [120]. 
Another possibility for direct CTSS activity determination is to use substrate-based probes (SBP) like 
i.e. fluorochrome-coupled peptidyl substrates (Figure 6) [120]. Prominent examples are Z-VVR-AMC 
[127] , Z-FR-AMC [217, 227] or Ac-KQKLR-AMC [228, 229], [120] . All of them share the aminomethyl 
coumarin group. Coumarins are popular fluorescent labels due to their large stoke’s shifts [230] and 
their small size allowing for incorporation into small peptides [222], [120]. These peptidyl substrates 
generally provide the disadvantage to be usable only in cell lysates and not in living cells or organisms 
[120]. The major potential problem with these peptidyl substrates is the unsatisfactory specificity for 
CTSS [120]. Due to the already mentioned similar substrate specificity among cysteine cathepsins, 
other cathepsins than CTSS can deliver false positive results due to unspecific cleavage of the 
substrate [120]. 
We could recently report on an alternative method for reliable CTSS activity detection using the 
peptide-derived substrate-based probe Mca-GRWPPMGLPWE-Lys(Dnp)-DArg-NH2 (PMGLP) [212], 
[120]. PMGLP was shown to be cleaved specifically by murine CTSS at a pH of 7.5 with no other 
murine cathepsin contributing to substrate cleaving in cell lysates [212], [120]. The obtained results 
were easily quantifiable and highly reproducible as demonstrated in mouse bone marrow derived 
dendritic cells that were differentiated from the bone marrow of different individuals [120]. The 
presented method therefore delivers specific CTSS activities and only requires a phosphate buffer 
system and a fluorescence compatible heatable photometer making the application attractive for 
less specialized laboratories [120]. 
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Paper 5: Symbiotic gut commensal bacteria act as host cathepsin S activity 
regulators  
Research paper 
 
Alex Steimle, Kerstin Gronbach, Brigitte Beifuss, Andrea Schäfer, Robin Harmening, Annika Bender,  
Jan Maerz, Anna Lange, Lena Michaelis, Andreas Maurer, Sarah Menz, Kathy McCoy, Ingo B. 
Autenrieth, Hubert Kalbacher and Julia-Stefanie Frick 
 
J Autoimmun (2016) xxx:1-14 (Epub, ahead of print) [46] 
 
 
Cathepsin S (CTSS) is a lysosomal protease whose activity regulation is important for MHC-II signaling 
and subsequent activation of CD4+ T cell mediated immune responses [46]. Dysregulation of its 
enzymatic activity or enhanced secretion into extracellular environments is associated with the 
induction or progression of several autoimmune diseases [46]. Here we demonstrate that 
commensal intestinal bacteria influence secretion rates and activity of CTSS and that symbiotic 
bacteria, i.e. Bacteroides vulgatus mpk, may actively regulate this process and help to maintain 
physiological levels of CTSS activities in order to prevent from induction of inflammation [46]. 
Dysregulation of CTSS activity, expression or secretion into the extracellular space is associated with 
the pathogenesis of various autoimmune diseases (AID) making CTSS a popular drug target for the 
treatment of these diseases [46]. Eventually, we demonstrate that an alteration of the gut microbiota 
composition can contribute to host CTSS regulation and that the microbiota composition itself could 
be decisive to control host CTSS secretion and activity, hence treatment with chemical drugs might 
not be necessary [46]. As most autoimmune diseases are associated with dysbiosis of the intestinal 
microbiota [46, 231], we compared effects of symbiotic or pathobiotic commensals on host CTSS 
activities and protein levels in vivo and in vitro. B. vulgatus mpk could already be demonstrated to be 
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a symbiotic bacteria, mediating anti-inflammatory effects [28, 31, 99] which are directly associated 
with the induction of a tolerant DC phenotype termed semi-mature [28, 31, 46, 110].  
It is known that apathogenic commensal bacteria can have either symbiotic or pathobiotic properties 
concerning the activation of the immune system [46]. In previous work, we identified symbiotic B. 
vulgatus mpk which protects Il2-/- mice from induction of colitis, hence promoting the immunological 
equilibrium, whereas pathobiont E. coli mpk promotes induction of colitis, thus featuring pathobiotic 
effects [28, 31, 46]. Likewise, in IBD patients, Bacteroidetes proportions in the intestine are 
decreased while Enterobacteriaceae proportions are enhanced [46, 232, 233]. Therefore, we 
consider B. vulgatus mpk and E. coli mpk to represent adequate symbiotic and pathobiotic model 
organisms, respectively [46]. Thus, we wanted to elucidate the distinct T cell activation potential of 
these two model organisms [46]. We could demonstrate that monocolonization of T cell transplanted 
Rag1-/- mice with symbiotic B. vulgatus mpk induces tolerant semi-mature colonic lamina propria 
(cLP) DCs and does not promote T cell proliferation whereas monocolonization with of T cell 
transplanted Rag1-/- mice pathobiotic E. coli mpk induces DC maturation and clearly promotes 
proliferation of transplanted T cells [46]. Since the semi-mature phenotype of cLP DCs, especially the 
MHC-II surface expression, plays a pivotal role for the observed prevention of T cell activation in B. 
vulgatus mpk monocolonized and B. vulgatus mpk and E. coli mpk cocolonized gnotobiotic mice, we 
had a closer look on the molecular mechanisms of semi-maturation in vitro [46]. We could 
demonstrate the significance of CTSS activity control for the induction of tolerant semi-mature DCs 
since complete DC maturation could not be induced in Ctss-deficient BMDCs [46]. Thus, we 
demonstrate that B. vulgatus mpk stimulated, semi-mature DC also provide non-responsiveness in 
terms of CTSS activity which therefore seems to be part of the tolerant semi-mature DC phenotype 
[46]. Since we detected different CTSS activities in BMDCs that were stimulated with either B. 
vulgatus mpk or E. coli mpk finally resulting in different MHC-II surface expression and T cell 
activation the question of the regulation mechanism arised [46]. It is known that upon increase of 
intracellular ROS amounts, cystatin C monomers preferentially form protein homodimers leading to a 
loss of the inhibitory potential [46, 234]. We could demonstrate that B. vulgatus mpk stimulation of 
BMDCs does not induce ROS production [46]. This would, in turn, promote maintenance of cystatin C 
monomers that are able to bind to CTSS, therefore inhibiting CTSS proteolytic activity [46].  E. coli 
mpk stimulation, however, leads to significantly higher intracellular ROS amounts compared to B. 
vulgatus mpk stimulated cells. E. coli mpk induced higher ROS levels would favor homodimerisation 
of cystatin C which would subsequently lead to a loss of CTSS inhibition, resulting in CTSS activity 
increase [46]. Therefore we conclude that lower intracellular ROS amounts are, at least in part, 
responsible for CTSS activity control in semi-mature DC. Furthermore, application of B. vulgatus mpk 
protects T cell transplanted Rag1-/- mice from induction of CD4+ T cell driven transfer colitis and B. 
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vulgatus mpk dependent prevention of colitis is associated with prevention of CTSS secretion into 
serum [46]. Additionally, feeding symbiont B. vulgatus to T cell transplanted Rag1-/- mice is equally 
effective in prevention of colitis induction and intestinal inflammation as  administration of a 
chemical CTSS inhibitor, since both therapeutic approaches led to significant less inflammation in this 
mouse model for experimental colitis [46]. In summary, we demonstrate that regulation of cathepsin 
S (CTSS) activity importantly contributes to the maintenance of the intestinal immune equilibrium 
[46]. CTSS activity can be regulated by the intestinal microbiota with symbionts triggering 
physiological CTSS activity and pathobionts inducing pathological CTSS activity increase, the latter 
resulting in T cell activation and proliferation which, in turn, supports pro-inflammatory host immune 
responses [46]. The microbiota dependent regulation of CTSS activity is mediated by the induction of 
reactive oxygen species (ROS) [46]. Pathobionts, but not symbionts, induced high intracellular ROS 
levels in DCs, allowing for homodimerization of cystatin C (CysC) and resulting in an abrogation of the 
CysC- mediated inhibition of CTSS activity.This promotes intestinal inflammatory host responses, in  
Figure 7: Postulated mechanism how 
commensal symbiont Bacteroides vulgatus 
mpk prevents from inflammation induction via 
cathepsin S activity regulation. Left panel: B. 
vulgatus mpk is suspected to promote only a weak 
immunological signal resulting in low amounts of 
reactive oxygen species (ROS). These low ROS 
amounts favour cystatin C monomers which can 
therefore efficiently bind to cathepsin S (CTSS) and 
thus cause inhibition of CTSS proteolytic activity. 
This results in less efficient cleaving of the invariant 
chain (Ii) and therefore in lower amounts of surface 
MHC-II and reduced DC mobility. Additionally, CTSS 
secretion into the extracellular space is omitted. 
These events lead to the conversion of immature DC 
into tolerant semi-mature DC that fail to induce a 
CD4+ T cell mediated immune response and 
therefore protect from inflammatory reactions. 
Right panel: In contrast to symbiont commensals, 
pathobionts like E. coli mpk induce intracellular ROS 
formation promoting homodimerization of Cystatin 
C leading to a loss of its inhibitory capacity towards 
CTSS. This leads to enhanced invariant chain 
cleaving, high MHC-II expression, increased DC 
mobility and high CTSS secretion. These events 
characterize a mature DC which are finally capable 
to induce a CD4+ T cell mediated immune response. 
Taken from Steimle et al., 2016 [46] 
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our mouse model resulting in induction of colitis [46]. The symbiont induced low intracellular ROS 
levels lead to a preservation of CysC monomers, mediating inhibition of CTSS via direct protein-
protein-interactions, which therefore results in physiological CTSS activity levels and maintenance of 
intestinal homeostasis [46].  
Pathogenesis of most autoimmune diseases (AID), and of IBD in particular, is associated with an 
induction of a CD4+ T cell mediated immune responses, highlighting the importance of the MHC-II 
mediated antigen presenting pathway for the onset of AID [46]. Therefore a strict regulation of the 
CTSS activity is important to retain a balanced immune system homeostasis [46]. CTSS exerts its 
physiological functions intracellularly [46]. However, secretion can occur since CTSS is part of the 
lysosomal compartment [46]. This might cause additional pathophysiological processes in the 
extracellular space [46]. Upon secretion, cathepsins end in extracellular environments whose pH 
values strongly affect their proteolytical activity [46]. Among all cathepsins, CTSS is the only enzyme 
with significant activity within a broader pH range since it is also capable of catalysing peptide bond 
cleavage at neutral pH [46, 235]. All other cathepsins provide their maximum activity at acidic pH 
values [46, 236]. Since in extracellular environments a neutral pH is dominant, CTSS is not 
automatically inactivated like other cathepsins [46]. Extracellular or, in other words, secreted CTSS is 
involved in the pathology of a variety of autoimmune diseases [46]. For example, increased CTSS 
levels in the serum or cerebrospinal fluid can be found in multiple sclerosis patients [46, 125]. In the 
mouse model of experimental autoimmune encephalomyelitis (EAE), resembling the  multiple 
sclerosis phenotype in humans, increased CTSS levels could be detected [46, 237]. Its extracellular 
pathological function might be proteolysis of the myelin basic protein which could be observed in 
vitro [46, 238]. In Sjögren’s syndrome patients, enhanced CTSS activity could be detected in tear fluid 
[46, 131], therefore making CTSS activity in tears an appropriate biomarker for the diagnosis of this 
disease [132]. Especially the atheriosclerosis phenotype is affected by extracellular CTSS. Secreted 
CTSS cleaves proteins of the extracellular matrix (ECM) like laminin, collagen or elastin [46, 239]. 
Resulting elastin peptides are able to incite inflammation and stimulate macrophage chemotaxis [46, 
240]. Concerning inflammatory bowel disease, general ECM degradation therefore could promote 
epithelial damage or relieve bacterial contact to APC leading to accelerated T cell responses and IBD 
promotion [46]. CTSS secretion into the colonic lumen might cause damage of the epithelial barrier 
leading to intensified colitis symptoms as enhanced encounter of gut bacteria with immune cells on 
the basolateral side of the epithelium would be possible [46]. We could now demonstrate in a mouse 
model for T cell mediated colitis, using Rag1-/- mice, that feeding symbiotic B. vulgatus mpk via 
drinking water protects mice from colitis induction and we provide evidence that this is due to a 
strict regulation of CTSS activity and a prevention of secretion from DCs into extracellular 
environments [46]. There is a clear correlation between the CTSS concentration in blood serum and 
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severity of colonic damage and we could demonstrate that administration of a chemical CTSS 
inhibitor prevents from colitis induction in a CD4+ T cell mediated mouse model for experiment colitis 
using Rag1-/- mice [46]. We could confirm this observation in vitro by detecting low CTSS secretion 
rates in B. vulgatus mpk stimulated bone marrow derived dendritic cells (BMDCs) [46]. It has already 
been shown that CTSS secretion promotes pain induction during colitis via cleaving of the PAR-2 
receptor [46, 136].  However, our data support the idea that CTSS activity dysregulation and 
enhanced secretion is the decisive trigger for colitis induction [46]. 
Intracellular CTSS activity also requires precise regulation. CTSS is the main protease in DCs that is 
responsible for cleaving the MHC-II associated chaperone invariant chain (Ii) [46]. This cleaving event 
is the major regulation step for loading antigen-derived peptides onto the MHC-II binding groove and 
the subsequent transport of peptide-loaded MHC-II to the cell surface [46]. We could show that DC 
maturation induced by the pathobiotic commensal E. coli mpk results in strong intracellular CTSS 
activity increase and therefore enhanced MHC-II surface expression which is required for a powerful 
CD4+ T cell mediated immune response [46]. Symbiotic commensal B. vulgatus mpk priming of DC, 
however, prevents from E. coli mpk induced CTSS activity increase and therefore from Ii cleaving and 
enhanced MHC-II surface expression [46]. We have previously shown that B. vulgatus mpk converts 
DC into a tolerant semi-mature phenotype [31, 99]. These tolerant semi-mature DCs are non-
responsive to further stimuli, they fail to activate CD4+ T cells and they are associated with the 
prevention of colitis in various mouse models [31, 99]. We now demonstrate that CTSS activity 
regulation is one of the most important reasons for induction of DC semi-maturation and the 
circumvention of T cell activation [46]. Prevention of CTSS activity increase results in less efficient Ii 
cleaving [46]. It was shown that CTSS deficiency significantly impairs DC mobility since Ii seems to 
interact with cellular myosin II [241] and efficient Ii cleaving therefore seems to be required for 
adequate interaction of Ii with myosin II and thus for DC mobility [46]. Therefore, reduced Ii cleaving 
might contribute to impaired mobility of semi-mature DC [31]. Furthermore, CTSS catalysed Ii 
cleaving leads to NFκB activation resulting in enhanced secretion of pro-inflammatory cytokines 
[242]. In fact, smDCs express only low amounts of pro-inflammatory cytokines [99] and this might be, 
at least in part, due to reduced cleaving of MHC-II bound Ii in smDCs [46]. 
The question emerges which intracellular regulation mechanisms are involved in B. vulgatus mpk 
mediated CTSS activity regulation [46]. In principle, CTSS activity can be regulated by various 
mechanisms. Possible regulation via transcriptional control, i.e. induced by IL-10 binding and STAT3 
dimerisation [243] can be excluded in this case since we could not detect any transcriptional 
regulation of the Ctss gene [46]. Another potential regulation mechanism is control of the lysosomal 
pH, but this might not be of importance in case of CTSS due to the broad pH range in which CTSS 
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provides remarkable activity [46]. Possible post-translational regulation might occur through 
inhibition by chondroitin-4-sulfate [121] or the creation of an oxidizing environment by NADPH 
oxidase NOX2 [244, 245]. Another prominently discussed endogenous CTSS inhibitor is cystatin C 
(CysC) [46]. However, there are contradictory reports about the role of CysC for CTSS activity 
regulation [46]. Although some groups claim CysC to be the major CTSS activity regulator [124-126], 
Magister et al. published that CysF might be the more important regulator protein [127]. In order to 
elucidate the role of CysC during B. vulgatus mpk induced DC semi-maturation and the effect on CTSS 
activity, we first performed immunoprecipitations against CysC that proved convincing interaction 
between CysC and CTSS [46]. We could further demonstrate that B. vulgatus mpk fails to induce DC 
semi-maturation in Cystatin C-deficient Cst3-/- DCs indicating a central role for CysC in this process 
[46]. We conclude that B. vulgatus mpk mediates its CTSS regulating functions via Cystatin C [46]. 
There are different possibilities how a bacterial stimulus on DCs might affect the interaction between 
CysC and CTSS [46]. Transcriptional regulation of the CysC gene might be the first possibility since it 
could be shown that transcription factors like IRF-8 and PU.1 enhance CysC mRNA transcription [46, 
246]. However, we could not detect any alteration in CysC gene transcription during the DC 
maturation or semi-maturation process [46]. In line with this, we could also not detect any 
differences in the amount of CysC protein in DCs of different maturation states [46]. CysC inhibits 
target proteases like CTSS by forming tight and non-covalent complexes [46, 247]. Complex forming 
with CTSS is limited to CysC monomers [46]. However, CysC protein expression in the endoplasmatic 
reticulum (ER) does not only yield in the formation of monomers but also in dimers that do not form 
inhibitory complexes with target proteases [46, 248]. Xu et al. demonstrated that the formation of 
non-inhibitory CysC dimers is dependent on the amount of ROS inside the cell, whereupon ROS 
presence promotes dimer formation [234]. Since bacterial lipopolysaccharide (LPS) induced DC 
maturation leads to an increase in intracellular ROS concentrations [249], we hypothesized that  a 
weaker B. vulgatus mpk LPS signalling  leads to less ROS formation and therefore enhanced levels of 
monomeric CysC compared to completely mature DC [46]. In fact, B. vulgatus mpk stimulation does 
not lead to an increase of intracellular ROS amounts, in contrast to E. coli mpk stimulation which 
efficiently enhances ROS production [46]. We therefore assume that B. vulgatus mpk stimulation 
leads to less CysC dimer formation, thus resulting in increased proportions of monomeric cystatin C 
[46]. These enhanced amounts of monomeric CysC can subsequently form inhibitory complexes with 
CTSS, which we could prove via immunoprecipitation, resulting in permanently low CTSS activities 
[46]. In line with this, we could detect a CysC-regulation dependent MHC-II surface expression of DCs 
supporting the findings of Pierre et al. [250]  but opposing findings of El-Sukkari et al. [251], [46]. In 
line with this, we detected extremely efficient Ii cleavage in Cst3-/- BMDCs, with Ii cleaving being the 
precondition for MHC-II translocation to the cell surface [46]. 
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There is an intense ongoing research for adequate CTSS inhibitors for the use as potential drugs in 
order to treat autoimmune diseases [46]. Some groups developed chemical CTSS inhibitors and 
chemical CTSS inhibition could attenuate atherosclerosis in mice [135] and T cell mediated 
inflammation in the murine central nervous system [252], [46]. However, a non site-directed 
complete inhibition of CTSS might have severe side effects on the host organism [46]. Furthermore, 
the effectiveness of chemical substances is dependent on bioavailability and membrane passage 
behaviour if inhibitors are supposed to act intracellularly [46].  In contrast to a chemical inhibitor, B. 
vulgatus mpk does not lead to a complete CTSS inhibition as demonstrated in our experiments [46]. 
This is a strong advantage over a chemical inhibitor that usually leads to a complete inhibition of its 
target enzyme [46]. Therefore, B. vulgatus mpk treatment still allows for CTSS to achieve its 
physiological role and only prevents from pathophysiological activation [46]. 
We could show that B. vulgatus mpk prevents from pathological reactions of the immune system via 
regulation of host CTSS activity and therefore contributes to the maintenance of the intestinal 
homeostasis [46]. This could be underlined by the observation that the B. vulgatus mpk associated 
protection of Rag1-/- mice from colitis induction is accompanied by inducing DC semi-maturation and 
inhibition of CTSS secretion [46]. This makes B. vulgatus mpk a promising candidate for the treatment 
for IBD and other CTSS-associated AID [46]. We think that B. vulgatus mpk might be an even better 
tool than a chemical inhibitor to treat CTSS-associated AID since (i) it is easily administrable, (ii) it 
does not completely suppress physiological functions of CTSS but only suppresses pathological 
activities and (iii) it acts as a commensal symbiont [46]. It does not influence a normal immune 
response due to acute infections but strongly inhibits pathological gut microbiota associated immune 
responses [46]. Therefore severe side effects of symbiont-mediated CTSS activity regulation should 
not occur and could not be observed in the used mouse model, another advantage over a chemical 
inhibitor [46].  
Taken together, we demonstrate that symbionts of the intestinal microbiota regulate host CTSS 
activity and secretion and might therefore be an attractive approach to deal with CTSS associated 
autoimmune diseases [46]. 
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Lipopolysaccharides (LPS) of Gram negative bacteria are one of the most potent stimulators of the 
host innate immune system and LPS recognition is essential for the host organism to clear infections 
of invading bacterial pathogens [68] A lot is known about host immunological reactions to fight 
pathogens via recognition of their LPS, as well as of strategies of pathogens to modulate their LPS 
structure in order to evade the immune system [68]. However, less is published about differential 
sensing of lipopolysaccharides of commensal bacteria in the intestine and how this contributes to 
manifestation or destruction of the intestinal homeostasis [68]. LPS sensing is necessary to fight 
pathogens [68]. However, sensing of LPS of gut commensal bacteria can simultaneously be 
disadvantageous for the genetically predisposed host, since this might lead to damage of the 
intestinal homeostasis and therefore to chronic intestinal inflammation [68]. However, less 
immunogenic LPS could also serve as therapeutics to antagonize an overreacting innate immune 
system [68]. Therefore, commensal gut bacteria-derived LPS could prevent from uncontrolled 
intestinal immune response in the intestine which makes LPS an attractive therapeutical approach to 
treat IBD [68]. 
As already mentioned, LPS structure, especially its lipid A chemistry, differs among distinct bacterial 
species [68]. Indeed, the exact LPS structure, and in this context mainly the lipid A structure, 
determines LPS immunogenicity and is therefore decisive for its function [68, 72, 73]. LPS triggering 
strong pro-inflammatory reactions of host cells are named “agonistic” lipolysaccharides. In contrast, 
structurally different lipid A can also result in weak inflammatory host responses, hence being called 
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“weak agonistic” [68]. Certain lipid A can even completely block any pro-inflammatory reactions by 
binding to corresponding host receptors [68]. These latter lipopolysaccharides are therefore called 
“antagonistic” [68]. Most Gram negative bacteria possess agonistic hexaacylated LPS like E. coli LPS, 
which is one of the most potent agonists of the human innate immune system [68, 253-255]. Usually 
the number of lipid A acyl chains directly correlates with the ability to induce cytokine production 
whereat the hexaacylated forms are the most immunostimulating ones [68, 256]. Within a biological 
system, distinct lipid A structures compete for binding to host receptors [68]. Antagonistic lipid A 
might therefore compete with agonistic LPS for host receptor binding [68]. Hexaacylated lipid A 
seems to promote the strongest proinflammatory immune reactions after binding to TLR4 [68]. This 
is due to the fact that the first five acyl chains are buried in a hydrophobic cavity of the TLR4 adaptor 
molecule MD-2 while the sixth chain mediates the binding to TLR4, the precondition for TLR4-
mediated intracellular signalling [68, 77, 257]. Therefore, TLR4-mediated signalling is usually 
drastically reduced if this sixth acyl chain is missing [68]. However, due to the already mentioned 
differences in the structures of the lipid A binding cavity of the TLR4 receptor between different 
mammalian species, distinct lipid A structures can provide a different immunogenic potential among 
these species [68].  
However, not only acyl chains contribute to the immunogenic properties of lipid A, but also the 
number of phosphate groups [68]. A deletion of a phosphate group results in a loss of endotoxic 
activity [68, 253]. Most lipid A structures contain two phosphate residues, one on each sugar moiety 
[68]. However, some bacterial lipid As lack one or even both of them, therefore altering its 
immunogenic potential [68]. For example, Francisella tularensis lacks one or both phosphate groups 
and this is considered to be, at least in part, the reason for its weak agonistic property [68, 74]. 
Furthermore, the non-phosphorylation might also be seen as an immune evasion strategy for certain 
bacteria since some antimicrobial peptides (AMPs) specifically target negative charges on bacterial 
surfaces and a loss of negatively charged phosphate residues therefore renders bacteria to be 
invisible for these AMPs [68]. 
It is widely accepted that in inflammatory bowel diseases (IBD) which are chronic inflammatory 
disorders of the intestine, the mucosal immune system reacts inappropriately towards the 
endogenous intestinal commensal microbiota [68, 258]. However and until now, no particular 
microbial species was consistently linked to IBD pathogenesis, but some symbiotic bacteria species 
have been shown to prevent from pathological inflammatory host responses [26, 30, 55, 68, 259, 
260].  
For example, the mono-colonization of Il2-/- mice with E. coli is reported to induce severe colitis, 
whereas monocolonization with Bacteroides vulgatus does not and B. vulgatus even inhibits the 
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E. coli induced inflammation in co-colonized Il2-/- mice [28, 68]. Recently we showed that a low 
endotoxicity of the intestinal microbiota was associated with mucosal immune homeostasis in a 
mouse model of chronic intestinal inflammation [68, 110]. T cell transplanted Rag1 -/-  harboring a low 
endotoxic complex intestinal microbiota, characterized by high numbers of Bacteroidetes and low 
numbers of Enterobacteriaceae did not develop colitis, whereas T cell transplanted Rag1-/-  mice 
harboring a high endotoxic complex intestinal microbiota, characterized by high numbers of 
Enterobacteriaceae and low numbers of Bacteroidetes developed severe intestinal inflammation [68, 
110]. In line with this, administration of commensal but pathobiontic E. coli JM83 to Rag1-/- mice 
harboring a low endotoxic microbiota resulted in intestinal inflammation, whereas the administration 
of an E. coli JM83 mutant containing an acyltransferase from Porphyromonas gingivalis (E. coliMUT) 
protected Rag1-/- mice harboring the high endotoxic microbiota from induction of disease [68, 261]. 
We isolated and purified LPS from both E. coliWT and E. coliMUT and characterized its fatty acid 
composition [68]. Investigations by high-resolution electrospray ionization Fourier transform ion 
cyclotron mass spectrometry revealed the same hexaacetylated lipid A molecules in both strains [68]. 
In addition, E. coliMUT contained a major portion of lipid A, in which a 12 carbon atom laurate acyl 
chain is replaced by a 16 carbon atom palmitate acyl chain[68, 110]. This minor modification in E. coli 
JM83 is reported to significantly affect host cell signaling [68, 261]. To verify the altered stimulatory 
capacity of LPSMUT compared with LPSWT, we used TLR4-overexpressing human embryonic kidney cells 
(HEK293) [68, 110]. Stimulation of cells with the modified LPSMUT resulted in a significantly reduced 
IL-8 secretion 4 hours after stimulation, as compared with LPSWT indicating a reduced endotoxicity 
but not TLR4 antagonism of the altered LPSMUT [68, 110]. Feeding of Rag 1-/- mice harboring the low 
endotoxic microbiota with LPSWT resulted in severe intestinal inflammation, however challenging 
mice which were colonized with the high endotoxic microbiota protected these animal from 
induction of colitis [68, 110]. This data suggest that the ratio of high endotoxic and low endotoxic LPS 
is crucial for the regulation of the intestinal immune balance [68]. A predominance of high endotoxic 
LPS might promote a Th1/Th17 response, subsequently supporting intestinal inflammation, and a 
predominance of low endotoxic LPS might induce an altered activation of the innate immune system, 
and either induction of regulatory T cells or prevention of a Th1/Th17 response, associated with 
intestinal immune homeostasis [68, 110]. Therefore LPS might act as a key microbial symbiosis factor 
that, depending on its structure, can induce or prevent bowel inflammation by shaping the innate 
immunity via TLR4-dependent signaling mechanisms [68, 110, 262].  
Could LPS be used as a potential drug for the treatment of inflammatory bowel disease? 
The role of LPS for the host immune system provides ambivalent features [68]. While LPS is essential 
for the host organism to sense infections of bacterial pathogens at an early stage, therefore helping 
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to clear the infection, an imbalanced LPS sensing can have severe effects for the host organism with 
fatal sepsis being the most severe consequence [68]. When LPS is thought to be used as a potential 
therapeutic agent, the different modes of LPS sensing in mammalian organisms hast to be kept in 
mind (Fig. 8). Blocking TLR4 mediated downstream signaling has been implicated to be useful as a 
drug to prevent from septic shock [68, 263]. Therefore, synthetic antagonistic lipid A structures were 
invented in order to block TLR4 receptor signaling, such as Eritroran [68]. Eritroran strongly prevents 
from binding of agonistic lipid A to MD-2 and therefore terminates MD-2/TLR4-mediated signaling in 
vitro, ex vivo and in vivo [68, 264-266]. Despite these findings, Eritroran failed to improve survival in a 
phase III trial in patients with severe sepsis [68, 267]. Until now, it is not known why Eritroran gavage 
failed to prevent from fatal sepsis [68]. Possible explanations might be the delayed administration of 
this strong TLR4 agonist or a failure in trial design [68, 267, 268]. Nevertheless, antagonistic lipid A 
structures still seem to be a promising tool for the treatment of bacterially induced sepsis [68]. This 
strategy to prevent from an uncontrolled, or “imbalanced”, TLR4 signaling-mediated immune 
response might also be an attractive approach to deal with inflammatory disorders of the gut [68]. 
Inflammatory bowel disease develops from an uncontrolled immune response directed towards the 
intrinsic microbiota [68]. In this case, not pathogens are the target of the immune system, but rather 
commensal bacteria located in the intestine [68]. It might therefore be possible that antagonistic or 
weakly agonistic lipid A structures could prevent from uncontrolled TLR4-mediated immune 
responses towards the own microbiota [68]. In fact, we could already show that the lipid A structure 
of commensal bacteria is a decisive trigger for the induction of colitis in a genetically predisposed 
host [68, 110].  
Two main questions remain concerning the administration of isolated LPS (or lipid A) for the 
treatment of IBD. (I) Which lipid A structure might provide the best results and (II) is TLR4 blocking 
really “the method of choice”? 
The specific structure of lipid A can have profound and even unpredictable effects upon TLR4 
signaling [68]. Although detailed studies about the interaction of lipid A with its corresponding MD-2 
co-receptors are available [68, 77, 85], the precise immunogenicity cannot be predicted from 
knowing the structure alone [68]. However, a recent report by Paramo et al. means a major advance 
concerning this issue, since they manage to predict the binding behavior of lipid A structures to MD-2 
by measuring their potentials of mean force [68, 269]. The second question is even more 
complicated to answer. It is possible that TLR4 blocking might not restore homeostasis in every case, 
since TLR4 signaling seems to be important for the prevention of dextran sodium sulfate (DSS)-
induced colitis in mice [68, 270, 271]. Therefore, an antagonistic lipid A structure, completely 
preventing from TLR4 signaling, might not be the lipid A of choice [68]. Possibly, a rather weakly 
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agonistic lipid A structure, allowing basic TLR4-mediated signaling, but preventing from uncontrolled 
TLR4 activation might be a better tool [68]. Additionally, the recent discovery of Caspase-11 as an 
intracellular lipid A binding LPS sensor [90, 91, 272] leads to the question, if blocking the TLR4 binding 
cavity is sufficient to influence LPS-mediated induction of the host immune system [68] (Fig. 8). As 
described, a block of TLR4 is not sufficient to prevent from LPS induced Casp11-mediated 
inflammasome activation [68]. Other bacterial components, largely present in the intestine, can 
activate other TLRs than TLR4 to induce an increase in cytosolic amounts of Casp11 being a 
precondition for intracellular lipid A sensing [68]. Therefore, a potential lipid A-derived drug needs to 
have access to the cytosol of host target cells [68]. Although being highly speculative, this might be  
Figure 8:  Molecular mechanisms of 
extracellular and intracellular sensing of 
bacterial LPS. (A) Extracellular LPS sensing. 
The host lipid binding protein (LBP) samples 
LPS from theouter membrane of Gram 
negative bacteria and mediates its transport 
to host CD14. CD14 can either be soluble 
(sCD14) or anchored in the membrane of 
TLR4 expressing cells. CD14 shuttles LPS to 
the TLR4 co-receptor protein MD-2 which 
initiates a conformational change in MD-2 
and TLR4, resulting in dimerization of the 
extracellular and subsequently of the 
intracellular TIR domains. TIR domain 
dimerization finally mediates downstream 
signaling [68]. (B) Intracellular LPS sensing. 
Left side: LPS that is present in the 
extracellular space can enter the vacuoles of 
caspase-11 (Casp11) expressing cells. LPS 
escapes the vacuoles via a yet unidentified 
mechanism. Right side: Bacteria can be 
sampled by phagocytotic cells like Casp11 
expressing macrophages. The LPS of non-cell 
invading bacteria or whole cell invading 
bacteria are relieved into the cytosol. Both: 
LPS present in the cytosol actively binds to 
the CARD domain of Casp11 leading to 
Casp11 oligomerization that results in 
Casp11 activation. By a yet unknown 
mechanism, this Casp11 activation results in 
inflammasome assembly resulting in 
Caspase-1 (Casp1) mediated secretion of the 
pro-inflammatory cytokines IL-1β and IL-18. 
Casp11 oligomerization can also lead to 
pyroptosis, a special kind of cell death. 
Taken from Steimle et al., (2016) [68] 
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another explanation why Eritroran failed in the clinical study since it was not granted access to the 
cytosolic compartment [68]. This fact rises drug development to a severe challenge and strategies 
need to be developped to target therapeutic lipid A to the cytosolic compartment [68]. Since it could 
be shown that lipid A structures that act antagonistically in TLR4-signaling also prevent from Casp11 
oligomerization and activation despite efficient binding [68, 272].Therefore, it seems that the 
immunogenicity of lipid A structure concerning TLR4 activation, described by the terms agonistic and 
antagonistic, also accounts for intracellular lipid A induced intracellular inflammasome activation 
[68].  
There is an ongoing research for new lipid A structures in order to be used as therapeutic. Although 
most research on this topic focuses on the treatment of sepsis, the idea behind it can easily be 
transferred to the treatment of chronic inflammatory intestinal disorders [68]. Besides synthetic or 
chemical development of lipid A structure-related TLR4 antagonists, there is an ongoing interest also 
on LPS structures of more ”exotic” bacteria and how they might contribute to a research progress on 
this topic [68]. For example, di Lorenzo et al. identified a lipid A structure with strong antagonistic 
activity in a bacterium living in hot springs: Thermomonas hydrothermalis [273]. However, a closer 
and more detailed look on the lipid A structures of symbiotic commensal bacteria might be helpful 
for the development of a lipid A structure providing weak agonistic activity to prevent from both, 
TLR4- and Casp11-mediated, uncontrolled immune responses of the host organism towards its own 
microbiota [68]. 
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Inflammatory Bowel Diseases are digestive tract-associated pathologies that are characterised by  
chronic relapsing intestinal inflammation with Crohn’s Disease (CD) and Ulcerative Colitis (UC) being 
the most frequent and clinically relevant forms of this disease complex [48]. As already mentioned, 
IBD is considered to be a multifactorial disease with genetics [52], environmental factors [53] and 
intestinal microbiota composition [54] contributing to the pathology and disease outcome. Therapy 
of IBD patients is, to date, restricted to general suppression of the patient’s immune system [49]. 
However, scarce data or unsatisfactory treatment effects characterize the properties of available or 
currently discussed therapeutical approaches for the treatment of IBD [49]. One of the most popular 
approaches include the utilization of TNF antagonists leading to general immunosuppression [49]. 
However, only one third of patients treated with TNF antagonists respond to this therapy in a 
satisfactory way (reviewed in [274]). Other generalized immunomodulatory therapies are currently 
investigated in experimental trials, such as using anti-adhesive agents which block interactions of 
lymphocytes with epithelial cells [275], restoring TGFβ activity by blocking pathologically enhanced 
levels of TGFβ inhibitors in UC patients [276] or targeting Janus kinases to achieve a general 
reduction of pro-inflammatory cytokine secretion [277]. However, all these therapeutical approaches 
aim for a generalized reduction of pro-inflammatory responses resulting in general 
immunosuppression, often associated with many undesirable side effects [49]. 
We could already demonstrate that mouse symbiotic gut commensal Bacteroides vulgatus mpk 
exhibits anti-inflammatory properties in various mouse models for experimental colitis, such as in Il2-
/- mice [28, 31] and T cell transplanted Rag1-/- mice [46]. These anti-inflammatory properties lead to a 
prevention of the induction of intestinal inflammation when B. vulgatus mpk is administered via 
drinking water before onset of disease [49]. This considerably demonstrated that, due to the anti-
inflammatory properties of the commensal symbiont B. vulgatus mpk , this bacterium is not only able 
to prevent from inducing inflammation but also to actively silence established inflammatory 
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reactions, alleviating symptoms of colitis in Rag1-/- mice [49]. Since one of the major immunoreactive 
compounds of Gram-negative bacteria is LPS, we were interested whether the administration of pure 
B. vulgatus mpk LPS (LPSBV) exhibits the same anti-inflammatory and inflammation-silencing 
properties in the colon like the live bacterium [49]. In summary, our data indicate that both, live B. 
vulgatus mpk bacteria and isolated LPSBV are equally capable of silencing established inflammatory 
processes in the large intestine by downregulation of pro-inflammatory cytokines and by favouring 
Treg inducing environmental conditions [49]. 
Due to the immune response silencing properties of isolated LPSBV, we gave a closer look at its 
chemical structure [49]. LPSBV lipid A resulted to be a heterogeneous mixture of tetra- and 
pentaacylated species, whose fatty acids nature and distribution was similar to the previously 
reported lipid A structure of Bacteroides dorei [278], a close relative of Bacteroides vulgatus [49]. 
Moreover, the lipid A blend resulted to be phosphorylated only at the reducing glucosamine (α-GlcN) 
of the lipid A disaccharide, as also observed in B. dorei [49, 278].  From the carbohydrate and LPS 
chemical point of view, it is very important to underline the unusual presence of galactofuranose in 
the core region [49]. This finding is even more interesting if one takes into account that the presence 
of five membered rings in the LPS core oligosaccharide is very rare [49, 279]. 
We were further interested whether the typical immunogenic properties of the used bacteria on 
dendritic cells in vitro can be completely mimicked by their respective isolated LPS, thus explaining 
the observations made in in vivo experiments [49]. In view of this, we also isolated the LPS from E. 
coli mpk (LPSEC) which contains a bisphosphorylated and hexaacylated lipid A [49]. Therefore, pure 
LPS seems to be able to mimic the immunogenic properties of both commensal bacteria with LPSBV 
providing low and LPSEC providing strong immuno-stimulating properties [49]. Therefore it can be 
stated that LPSBV is not a TLR4 antagonist since it provides weakly agonistic activity as demonstrated 
by the low, but still detectable amounts of secreted cytokines and by the slight enhancement of T cell 
stimulatory surface proteins as MHC-II, CD40, CD80 and CD86 [49]. In summary, differential 
maturation of DCs by commensal bacteria is highly dependent on their LPS structure and live 
B. vulgatus mpk bacteria are not necessary to induce semi-mature DCs providing immune 
homeostasis maintaining properties, since using isolated LPSBV was sufficient to induce DC semi-
maturation [49]. The observation that both LPS structures, LPSBV and LPSEC, showed different 
immunological effects on DCs in vitro, prompted us to define their binding affinity to the MD-2/TLR4 
receptor complex and we determined binding constants KD for both LPS structures [49]. The KD of 
LPSBV could was determined to be 0.412 mg L-1 while the KD of LPSEC was determined to be 0.304 mg 
L-1, being in the same biologically relevant range as LPSBV KD [49]. 
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Since both LPS, LPSEC and LPSBV, provided similar binding affinity towards the murine MD-2/TLR4 
receptor complex, we tested the capability of each of these two distinct LPS to remove already 
bound LPS from the receptor complex [49]. We could finally demonstrate  that LPSBV was able to 
remove about 20% of already bound LPSEC, while LPSEC was able to remove about 50% of already 
bound LPSBV [49]. 
As already mentioned, LPSBV was able to induce tolerant semi-mature DCs in vitro. However, the 
experiments to demonstrate that were performed in absence of other LPS structures for the first 16h 
of the semi-maturation process [49]. Physiological conditions in the colonic lumen provide the 
presence of lots of different LPS structures at the same time [49]. Therefore, we stimulated BMDCs 
with both LPS molecules, weakly agonistic LPSBV and strong agonistic LPSEC, at the same time and at 
different concentrations for 16 h [49]. Simultaneous presence of LPSBV could not anticipate LPSEC-
induced maturation effects on DCs as it could be demonstrated in case of subsequent stimulation of 
DCs that were primed with LPSBV and challenged with LPSEC  [49]. 
Figure 9 summarizes the observations of this study into a concluding hypothesis. We have 
demonstrated that LPSBV provides weakly agonistic activities and binds to the murine MD-2/TLR4 
receptor complex with an affinity that is comparable to the binding affinity of strong agonistic LPSEC 
[49]. Since the downstream signalling, and therefore the immunogenicity, is dependent on effective 
(MD-2/TLR4)2 heterotetramerization [77], we hypothesize that the specific and unique overall LPSBV 
structure blocks the conformational change of the receptor complex which is necessary for tetramer 
formation (Fig. 9a) [49]. Concerning the therapeutical effects of LPSBV in strongly reducing 
inflammatory processes in a mouse model for experimental colitis, we conclude that the 
concentration of LPSBV located in the intestinal lumen must exceed the number of agonistic LPS from 
other commensal bacteria in order to be able to induce tolerant and semi-mature DCs [49]. 
Exceeding LPSBV concentrations are thought to enhance the probability that intestinal DCs only 
encounter weakly agonistic LPSBV since we could demonstrate that simultaneous encounter with 
another agonistic LPS prevents from DC semi-maturation and induces pro-inflammatory responses 
mediating DC maturation [49]. In this case, the ability of LPSEC to remove already bound LPSBV from 
the MD-2/TLR4 receptor more efficiently than vice versa would not be relevant [49] (Fig. 9b). As 
demonstrated, the endotoxicity of LPSBV is dependent on its concentration and very high LPSBV 
concentration might lead to complete DC maturation [49]. However and as mentioned before, this 
concentration exceeds physiological LPS levels in the intestine [49]. We could demonstrate that using 
160 µg mL-1 in the drinking water leads to the observed healing effects in Rag1-/- mice, indicating that 
this concentration is sufficient to exceed the amount of already present LPS in the colon while 
simultaneously being in a semi-maturation  
54 
 
 
 
Figure 9: Proposed mechanism how weakly agonistic B. vulgatus mpk LPS influences MD-2/TLR4 receptor 
activation and prevents from initiation of a CD4+ T cell mediated immune response via modulation of 
intestinal CD11c+ cells  
(a) Right side: agonistic LPS like E. coli mpk LPS binds to the MD-2/TLR4 receptor complex. Its LPS structure 
harbouring a bisphosphylated and hexaacylated lipid A leads to a conformational change in the receptor 
complex leading to heterotetramerization of two MD-2/TLR4-dimers resulting in efficient intracellular 
signalling, overshooting a pro-inflammatory signalling threshold. Left side: weakly agonistic B. vulgatus mpk LPS 
binds to the MD-2/TLR4-receptor complex with a similar affinity as strong agonistic E. coli mpk LPS. However, 
its structural characteristics like harbouring a monophosphorylated, mixed tetra- and pentaacylated lipid A, as 
well as a unique galactofuranose-containing core structure probably lead to a block of the heterotetramer 
formation resulting in a weak intracellular signalling that does not exceed a pro-inflammatory threshold but 
rather mediates anti-inflammatory immune responses. (b) Therapeutical administration of LPS from symbiotic 
B. vulgatus mpk ends up in large amounts in the intestine, exceeding the amount of present LPS from other 
intestinal commensal bacteria. Excess B. vulgatus mpk LPS primes naïve CD11c+ cells into a tolerant, tolerogenic 
and semi-mature phenotype that fails to activate CD4+ T cells. This prevention of a de novo activation of CD4+ T 
cells leads to a phase-out of ongoing inflammatory processes while de novo induction of an immune response is 
prevented. However, our data indicate that this only happens if B. vulgatus mpk LPS is the only TLR4 ligand 
which CD11c+ cells encounter when they are still naïve and immature. B. vulgatus mpk LPS needs a certain 
period of time to induce CD11c+ cell tolerance. Simultaneous encounter with agonistic LPS does not lead to 
CD11c+ cell tolerance and does therefore not promote abrogation of inflammatory processes. Taken from the 
manuscript [49], see appendix 
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inducing concentration range [49]. Once DC semi-maturation is induced, this phenotype cannot be 
overcome and would therefore lead to a prevention of a de novo T cell activation [49]. Therefore, 
after a phase-out of ongoing inflammatory processes, newly induced smDCs through LPSBV 
administration would prevent from a continuing T cell activation and therefore promote healing of 
damaged colonic tissue [49]. With this study, we want to offer an alternative therapeutical approach 
avoiding disadvantages of current state-of-the art IBD therapies by using intestinal commensal-
derived isolated LPS [49]. LPS-like structures acting as TLR4 antagonists have already been considered 
to be suitable therapeutical agents for the treatment of i.e. sepsis [49]. However an initial trial was 
not successful [267]. We think, that a complete TLR4 antagonist might not be the right choice for 
inflammatory disorders, neither for sepsis nor for other immune system-related pathologies like IBD 
[49]. We therefore want to promote a commensal-derived isolated LPS from mouse gut-associated B. 
vulgatus mpk as a potential immunomodulatory drug for the treatment of IBD [49]. LPSBV does not 
act antagonistically to the murine MD-2/TLR4 receptor complex but rather weakly agonistic, probably 
being the key feature of its immune system silencing functions [49]. The observed weakly agonistic 
activity of B. vulgatus LPS is traced back to its unique molecular structure which influences its 
activating potential towards the murine MD-2/TLR4 receptor complex. Structural analysis of LPSBV 
revealed a mixture of penta- and tetraacylated mono-phosphorylated lipid A, chemically related to 
the B. dorei [278] and B. fragilis [280] lipid As, a galactofuranose-containing core OS and an O-chain 
composed of rhamnose and mannose [49]. Interestingly, the core structure revealed a novel 
carbohydrate composition that has not yet been detected in any other bacterial LPS [49]. In 
particular, the presence of galactofuranose in the inner part of the LPS core as well as the presence 
of a rhamnose residue, as the first sugar linked to the Kdo, are surely an innovative hallmark for LPS 
[49]. Thus it can be speculated that such an unusual architecture has a key role in the MD-2/TLR4 
complexation with LPS and the following downstream signalling [49]. 
The immunogenicity, or the strength of this intracellular signalling, triggered by LPS is considered to 
be mostly mediated by the structure of the lipid A part [72, 73]. Hexa-acylated and bis-
phosphorylated lipid A therefore seems to be the most potent activator of the MD-2/TLR4-receptor 
complex mediated signalling [82].  
In an important study, Park et al. [77] revealed the structural basis for the explanation of these 
observations [49]. Five of the six acyl chains are buried inside the MD-2 binding cavity while the sixth 
acyl chain points out to the MD-2 surface mediating hydrophobic interactions with the TLR4 
ectodomain [49, 77]. 
This partly explains the lower endotoxicity of hypoacylated lipid A structures lacking this sixth acyl 
chain and the weakly agonistic activity of hypoacylated LPSBV. Furthermore, both 1- and 4’- 
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phosphates on the lipid A diglucosamine backbone were demonstrated to be important moieties for 
MD-2/TLR4 receptor complex activation [49, 77]. Since LPSBV possesses only one phosphate at 
position 1 of the reducing glucosamine, this may also contribute to its weakly agonistic effects as a 
missing 4’-phosphate was demonstrated to result in a 100-fold reduction in endotoxic activity [49, 
281]. Within this frame, the occurrence of a minor bis-phosphorylated lipid A species did not increase 
the LPSBV immunogenicity as previously demonstrated for the bis-phosphorylated LPS lipid A from 
the mutant strain of B. thetaiotaomicron (ΔLpxFI) [49, 282]. Additionally, recent studies revealed that 
not only the lipid A phosphorylation and acylation pattern determines LPS endotoxicity [49]. Indeed, 
it was demonstrated that charged groups, other than glucosamine backbone associated phosphates, 
can increase LPS mediated endotoxicity [49]. The positively charged aminoarabinose residue 
attached to the lipid A disaccharide backbone combined with longer chained fatty acids rendered the 
potentially low endotoxic pentaacylated lipid A of Burkholderia cenocepacia highly endotoxic [49, 
283]. Furthermore, it was previously demonstrated that even chemical modifications of the core OS 
with additionally charged substituents may have influence on TLR4-mediated signalling [49]. As an 
example, an additional negatively charged carboxyl group present in the LPS inner core was 
responsible for the high endotoxicity of a pentaacylated lipid A containing LPS of Capnocytophaga 
canimorsus [49, 284]. These extra charged groups, either in lipid A or in the core OS are likely 
creating or stabilizing electrostatic interactions between MD-2 and TLR4, resulting in efficient 
heterotetramerization followed by strong intracellular signalling [74, 77, 283, 284]. Besides Kdo-
phosphate, LPSBV does neither contain any further charged groups in the lipid A part nor in the core 
OS [49]. Therefore, we can hypothesize that LPSBV provides features and properties of a TLR4 
antagonist, which is usually able to bind to MD-2 but it failed to induce receptor multimer formation 
and prevented from induction of any intracellular signalling [49, 285-287]. LPSBV bound to the MD-
2/TLR4 receptor complex with a comparable affinity as highly agonistic LPSEC but it did not lead to 
strong intracellular pro-inflammatory signalling [49]. Nevertheless, LPSBV did not act as a pure 
antagonist since it actively induced semi-maturation and tolerance in dendritic cells, making it rather 
weakly agonistic than completely antagonistic [49]. This is highly interesting as Vatanen et al. 
demonstrated that B. dorei LPS, which provides the same lipid A structure as LPSBV, acts as a strong 
MD-2/TLR4 receptor complex antagonist [278]. This difference in immunogenicity of the respective 
LPS supports the hypothesis of the unique LPSBV core structure to contribute to its weakly agonistic 
activity [49]. However, this hypothesis remains speculative at the moment and requires further 
investigation [49].  Nevertheless, the weakly agonistic features of LPSBV seem to be responsible for 
the observed healing effects in mice suffering from intestinal inflammation [49]. Therefore, LPSBV led 
to weak intracellular signalling, providing a basic anti-inflammatory intracellular transcription 
program without exceeding a pro-inflammatory threshold [49]. Furthermore, LPSBV leads to the 
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induction of tolerogenic DCs [49]. These properties clearly distinguishes LPSBV from strong agonistic 
LPSEC, which induces endotoxin tolerance but also strong pro-inflammatory signalling, and from 
antagonistic B. dorei LPS, which does not promote pro-inflammatory reactions but does also not 
promote tolerance induction in TLR4-expressing cells [49, 278]. The property of LPSBV of being an 
effective ligand for the MD-2/TLR4 receptor complex and, at the same time, of being a weak agonist 
must of course be attributed to its chemical structure [49]. We are not aware, whether this is a 
“chemical paradigm” of the intestinal microbiota LPS since so far, only very few chemical structures 
of intestinal commensals have been established [49]. However, this is a logical follow up of the 
present work and further work is in progress [49]. 
These observations led to a speculation on the potential use of such a LPS structure as a suitable tool 
to restore homeostatic conditions not only in experimental mouse models, but also in IBD patients 
[49]. Therapy of IBD patients is, to date, restricted to a general suppression of the patient’s immune 
response often associated with undesirable side effects [49]. 
LPS (derivative)-based treatment might avoid this problem by acting only locally at the site of 
inflammation: the intestine [5]. Therefore, we would promote pure LPSBV as an alternative for the 
treatment of intestinal inflammatory disorders or IBD providing evidence that this compound 
demonstrated its beneficial effects as not being an antagonist but rather a weak agonist [5]. 
Alternatively, the structure of LPSBV could act as a starting point for a structure-activity relationship 
study in order to obtain a proper LPS derivative that could be used as a prospective therapeutic 
agent [5]. Concluding, we hope to contribute to IBD therapy-related research offering a completely 
new approach avoiding disadvantages of current state-of-the-art IBD therapies [5]. 
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Outlook 
 
The two main findings of this work, a commensal-dependent regulation of host cathepsin S activity 
and the inflammation-silencing properties of symbiotic B. vulgatus mpk lipopolysaccharide, offer 
widespread possibilities for future investigations. 
So far, we were focused on the effect of cathepsin S activity regulation locally in the intestine. 
However, we could already prove that the secretion of cathepsin S into the blood serum is 
dependent on the inflammatory status of the gut, indicating generalized effects of cathepsin S 
secretion and activity regulation by intestinal commensals. This might denote that gut microbiota 
components regulate the enzymatic activity of this protease not only locally in the gut but also on a 
more generalized level, making colonic inflammation-dependent cathepsin S secretion interesting 
concerning the etiology and therapy of autoimmune diseases other than IBD, such as multiple 
sclerosis and type-1-diabetes.  
Non-published data suggest that not only cathepsin S, but other pathology-associated cathepsins like 
cathepsin B are regulated by symbionts and pathobionts of the intestinal microbiota. This is a highly 
intriguingly observation since cathepsin B malfunction and dysregulation is reported to be associated 
with various neurodegenerative diseases such as Parkinson’s and Alzheimer’s Disease. 
Additionally, we proved that not only living symbionts but also isolated surface structures of these 
commensals, such as B. vulgatus mpk lipopolysaccharide, mediate inflammation-silencing properties. 
We hereby promote this specific surface compound as a potential therapeutic alternative for the 
treatment of intestinal inflammatory disorders. However, it remains to be elucidated if this specific 
lipopolysaccharide structure exhibits comparable inflammation-silencing properties not only in mice 
but also in humans. Furthermore, more detailed insights in the dendritic cell tolerance induction 
properties of the B. vulgatus mpk lipopolysaccharide core compound galactofuranose need to be 
gained for effective and proper drug development for the treatment of such intestinal inflammatory 
disorders . 
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Role of CD40 ligation in dendritic cell
semimaturation
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Abstract
Background: DC are among the first antigen presenting cells encountering bacteria at mucosal surfaces, and play
an important role in maintenance of regular homeostasis in the intestine. Upon stimulation DC undergo activation
and maturation and as initiators of T cell responses they have the capacity to stimulate naïve T cells. However,
stimulation of naïve murine DC with B. vulgatus or LPS at low concentration drives DC to a semimature (sm) state
with low surface expression of activation-markers and a reduced capacity to activate T-cells. Additionally,
semimature DC are nonresponsive to subsequent TLR stimulation in terms of maturation, TNF-α but not IL-6
production. Ligation of CD40 is an important mechanism in enhancing DC maturation, function and capacity to
activate T-cells. We investigated whether the DC semimaturation can be overcome by CD40 ligation.
Results: Upon CD40 ligation smDC secreted IL-12p40 but not the bioactive heterodimer IL-12p70. Additionally,
CD40 ligation of smDC resulted in an increased production of IL-6 but not in an increased expression of CD40.
Analysis of the phosphorylation pattern of MAP kinases showed that in smDC the p38 phosphorylation induced by
CD40 ligation is inhibited. In contrast, phosphorylation of ERK upon CD40 ligation was independent of the DC
maturation state.
Conclusion: Our data show that the semimature differentiation state of DC can not be overcome by CD40 ligation.
We suggest that the inability of CD40 ligation in overcoming DC semimaturation might contribute to the
tolerogenic phenotype of semimature DC and at least partially account for maintenance of intestinal immune
homeostasis.
Keywords: Dendritic cells, CD40 ligation, Maturation, Cytokine, MAP Kinase, Homoeostasis, T-cell
Background
Dendritic cells (DC) are among the first antigen presen-
ting cells encountering bacteria at mucosal surfaces and
play an important role in maintenance of regular ho-
meostasis in the intestine. Stimulation of DC with e.g.
TLR agonists leads to activation and maturation of DC
by activation of NF-κB and mitogen-activated protein
kinase (MAPK) family members [1]. This results in a
rapid production of costimulatory molecules, cytokines
and pro-inflammatory mediators that affect T-cell diffe-
rentiation, for instance.
We identified Escherichia coli mpk, a commensal E. coli
strain which induces colitis in genetically predisposed
hosts and Bacteroides vulgatus mpk which does not elicit
colitis and even prevents the colitis caused by E. coli mpk
[2,3]. Stimulation of bone marrow derived dendritic cells
(BMDC) with E. coli [4] or lipopolysaccharide (LPS) at
high concentration [5] induced TNF-α, IL-12 and IL-6 se-
cretion and expression of activation-markers, whereas
stimulation with B. vulgatus or [4] LPS at low concentra-
tions [5] only led to secretion of IL-6 and DC were driven
to a semimature state with low expression of activation-
markers. Those semimature DC were nonresponsive to
subsequent TLR stimulation in terms of maturation and
TNF-α but not IL-6 production [4,5]. Moreover, the low
positive expression of activation surface marker like e.g.
CD40 on semimature DC, was not overcome by a subse-
quent stimulus via TLR4 [4]. This might contribute to the
reduced activation of T-cells by semimature DC [4] as
binding of the CD40 ligand (CD40L) on naïve T-cells to
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CD40 is a crucial signal for generation of effective CD4+
and CD8+ T-cell responses [6,7]. CD40 ligation results in
upregulation of CD83, CD80 and CD86 as well as MHC
molecules on DC. Additionally, the expression of adhesion
molecules ICAM-1 and CD58 [8-11] is upregulated and
survival of DC is supported by CD40 ligation [12,13]. Fur-
thermore, CD40 ligation of mature DC results in secretion
of proinflammatory cytokines e.g. IL-1, IL-6 and IL-
12 [9-11] [14,15].
IL-12 plays an important role in T-cell polarization
by promoting Th-1 responses. Its bioactive heterodimer
IL-12p70 consists of a p40 and p35 subunit, which are
encoded by different genes and therefore independently
regulated. IL-12p40 can also form homodimers (IL-12p80)
which were shown to inhibit IL-12p70 mediated immune
responses [16,17].
Mitogen-activated protein kinase (MAPK) signal trans-
duction pathways play a crucial role in many aspects
of immune mediated inflammatory responses [18]. The
MAPK ERK, JNK and p38 are important regulators of
host immune responses to e.g. bacterial stimuli. Extracel-
lular stimuli induce phosphorylation of MAPK–kinase-
kinase (MKKK) which in turn phosphorylate MKK.
Specific MKK are necessary to phosphorylate and ac-
tivate MAPK, which results in activation of down-
stream kinases and transcription factors [18-20]. The
products of inflammatory genes include e.g. cytokines,
chemokines and adhesion molecules which promote re-
cruitment of immunocompetent cells to inflammatory
sites. Additionally, the MAPK p38 enhances the mRNA
stability of many proinflammatory cytokines, e.g. IL-8,
TNF-α or IL-6 [21-23].
Within the present study we analyzed the effects of
DC semimaturation on cellular responses to CD40 li-
gation and showed that the semimature differentiation
state of DC, induced by stimulation with B. vulgatus or
LPSlo can not be overcome by CD40 ligation.
Methods
Mice
C57Bl/6x129sv mice were obtained from own breeding.
All mice were kept under SPF conditions. Male and fe-
male mice were sacrificed at 6–12 weeks of age. Animal
experiments were reviewed and approved by the respon-
sible institutional review committee (Regierungspräsidium
Tübingen, December 19th 2008).
Abs and reagents
Ultra pure LPS Salmonella enterica serovar Minnesota
was purchased from Calbiochem (Schwalbach, Germany).
The following antibodies were used for flow cytometry: PE
conjugated anti-mouse CD11c, clone HL3, Biotin conju-
gated anti-mouse CD40, clone 3/23, Biotin conjugated
anti-mouse CD80, clone 16-10A1, FITC conjugated anti-
mouse I-A/I-E clone 2 G9, FITC conjugated anti-mouse
CD86, clone GL1. As isotype control hamster IgG1 λ2,
hamster IgG2a κ and rat IgG2a κ were used. For CD40
ligation we used purified NA/LE hamster anti-mouse
CD40, clone HM40-3, and purified NA/LE hamster IgM,
λ1 isotype control, clone G235-1 (all antibodies from
BD, Heidelberg, Germany). p38 MAP kinase inhibitor
(SB202190) was purchased from Calbiochem (Schwalbach,
Germany), and ERK inhibitor (PD98059) from Promega
(Mannheim, Germany).
Western blotting
For p38 and pERK Western blot analysis proteins (50 μg)
were solubilized in Laemmli sample buffer. They were
separated on SDS-PAGE gels and transferred to nitrocel-
lulose membranes. The membranes were blocked for 1 h
at room temperature in 5% dry milk in TBS/T (TBS con-
taining 2,01% Tween). After that the membranes were
incubated with mouse anti-p38 MAPK (pT180/pY182) or
with mouse anti-ERK 1/2 (pT202/pY204) (both BD Phar-
migen, Heidelberg, Germany) at 4°C over night. The anti-
body solution was diluted 1:1000 in 5% dry milk in TBS/
T. After incubation the membranes were washed three
times in TBS/T and were treated with the secondary anti-
body (polyclonal rabbit anti-mouse conjugated to horse-
radish peroxidase, DakoCytomation, Hamburg, Germany;
diluted 1:1000 in 5% dry milk in TBS/T) for 2.5 h at room
temperature. After repeating the washing step the proteins
were detected by enhanced chemiluminescence. Before
using ß-actin (mouse anti-mouse β-actin; Sigma, Munich,
Germany) as a control for protein loading, the blots were
stripped for 20 min with 10 ml stripping-solution (10 mM
NaOH and 250 mM guanidinium chloride).
Bacteria and cell lines
The bacteria used for stimulation of the murine den-
dritic cells were Escherichia coli mpk [2] and Bacteroides
vulgatus mpk [2] . The E. coli strain was grown in Luria-
Bertani (LB) medium under aerobic conditions at 37°C.
Bacteroides vulgatus was grown in Brain-Heart-Infusion
(BHI) medium and anaerobic conditions at 37°C. In some
experiments, J558L/CD40L cells were used for CD40
ligation. The cells were cultured in DMEM (Dulbecco’s
modified Eagle’s medium,Invitrogen, Darmstadt, Germany)
supplemented with 1 g/l glucose, L-glutamine, pyruvate,
50 μmol/l 2-mercaptoethanol, 10% FCS and penicillin/
streptomycin.
Mouse DC isolation
Bone marrow cells were isolated and cultured as des-
cribed previously [4] with minor modifications. Cells
were harvested at day 7 and used to evaluate the effects
of cellular challenge with E. coli mpk, B. vulgatus mpk
and LPS on subsequent CD40 ligation. Cytokine release
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and expression of surface markers were determined after
CD40 ligation as described below.
Stimulation of isolated DC
At day 7, DC were stimulated with viable bacteria at a
MOI of 1 at 37°C, 5% CO2. Gentamicin was added one
hour after stimulation and cells were incubated for 24
hour. To exclude bacterial overgrowth, CFU of viable
bacteria was determined at the end of incubation period.
Respectively, DC were stimulated with LPS (1 ng/ml and
1 μg/ml). After 24 h cell culture supernatant was har-
vested for analysis of cytokine expression and cells were
used for flow cytometry of surface marker expression.
CD40 ligation
To determine the effects of CD40 ligation on DC cyto-
kine production and expression of surface markers DC
were restimulated using an agonistic anti-CD40 mAb
(BD, Heidelberg, Germany). Therefore, DCs pretreated
with E. coli, B. vulgatus or LPS were harvested, washed
twice and cultured at 1.5x105 DC in the presence of
5 μg/ml anti-CD40 mAb in DC culture medium at 37°C,
5% CO2. As a control, DCs were incubated with 5 μg/ml
of the IgM isotype control antibody (BD, Heidelberg,
Germany). After 48 h, DC culture supernatants were
harvested and analyzed for cytokine concentrations by
ELISA. The expression of CD80 and CD86 on the DC
surface was determined by FACS analysis.
For determination of CD40 expression of DC upon
CD40 ligation the J558/LCD40L cell line was irradiated
with 180 Gy in a Gammacell 1000 EliteW (Nordion,
Ottawa, Canada) prior to co-culture with DC. 5x104
J558L/CD40L cells were cultured with 1.5x105 DC in DC
culture medium for 48 h at 37°C, 5% CO2. DC were har-
vested and analyzed for expression of CD40 by FACS.
Inhibition of MAP kinase signaling
DC were incubated with the p38 MAP kinase inhibitor
SB202190 (2 μmol/l) or the ERK inhibitor PD98059
(50 μmol/l) for 30 min prior to CD40 ligation. After
30 min the cells were washed. CD40 ligation with anti
CD40 mAb was performed for 24 h. Cell culture super-
natants were harvested and used for determination of
cytokine concentrations.
Cytokine analysis by ELISA
For analysis of IL-6, IL-12p40 and IL-12p70 concentra-
tions in cell culture supernatants commercially available
ELISA kits (BD, Heidelberg, Germany) were used accor-
ding to the manufacturer’s instructions.
Flow cytometry analysis
3x105 DC were incubated in 150 μl PBS containing 0.5-μl
of fluorochrome conjugated antibodies and applied to flow
cytometry analysis. 30,000 cells were analyzed using a
FACS Calibur (BD, Heidelberg, Germany).
Statistical analysis
Statistical analysis was performed using the two sided
unpaired Student’s t-test. P values < 0.05 were considered
significant. Error bars represent ± SEM.
Results
CD40 ligation does not overcome DC semimaturation
Stimulation of DC with B. vulgatus or LPSlo (1 ng/ml)
leads to induction of DC semimaturation [4,5] whereas
stimulation of immature DC with E. coli or LPShi (1 μg/ml)
induces DC maturation. The semimature DC phenotype is
characterized by tolerance towards a subsequent sti-
mulation via TLR2 or TLR4 in terms of TNF-α and
IL-12p70 but not IL-6 secretion and a low positive
expression of costimulatory molecules like e.g. CD40,
CD80 CD86 [4,5]. Herein we investigated whether CD40
ligation as a TLR independent DC activation signal can
overcome the semimature DC phenotype and induce acti-
vation and maturation of semimature DC.
By stimulation of immature DC with B. vulgatus or
LPSlo we induced semimature DC, and by stimulation
with E. coli or LPShi DC maturation was induced. Secre-
tion of IL-12p40 (Figure 1A), IL-12p70 (Figure 1B) and
IL-6 (Figure 1C) was determined by ELISA. CD40 liga-
tion of semimature DC led to secretion of IL-12p40 but
not to secretion of the bioactive heterodimer IL-12p70.
In contrast, CD40 ligation of mature DC resulted in sig-
nificant enhanced secretion of IL-12p70 as compared to
cells treated with the anti-CD40 mAb isotype control.
Mature DC revealed a high spontaneous production of
IL-12p40 which was only slightly enhanced by CD40
ligation (Figure 1A, B). Additionally, CD40 ligation of
semimature DC resulted in increased levels of IL-6
compared to immature DC. In mature DC which also
showed a high spontaneous secretion rate of IL-6 CD40
ligation only led to a slight further increase of IL-6 pro-
duction (Figure 1C).
Next, we investigated whether CD40 ligation can over-
come the low positive expression of DC activation ma-
rkers on semimature DC. Therefore, we analysed the
expression of CD80 (Figure 2A), CD86 (Figure 2B), and
CD40 (Figure 2C) on immature, mature and semimature
DC upon CD40 ligation in comparison to mock cells or
cells treated with the anti-CD40 mAb isotype control by
FACS.
On semimature DC the expression of CD80 was slightly
enhanced upon CD40 ligation, as compared to the control
cells (mock or isotype treated). However, in comparison to
mature DC, in semimature DC the expression of CD80
was still significantly reduced after subsequent CD40
ligation (E. coli 76.7%±1.5% vs. B. vulgatus 37.1%±0.6%;
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LPShi 79.0%±1.9% vs. LPSlo 53.4%± 3.7%) (Figure 2A).
Analysis of the expression of CD86 on immature, semima-
ture and mature DC upon CD40 ligation revealed a slight
increase of CD86 expression in immature (9.1%± 0.5%
to 27.2% ± 4.7%) and semimature DC (B. vulgatus:
20.4% ± 5.1% to 42.5% ± 8.6%; LPSlo 44.3% ± 7.9% to
58.7% ± 9.5%). However, the expression levels of CD86
on semimature DC after CD40 ligation did not reach
the expression levels of mature DC (E. coli: 54.8%± 6.7%
to 59.9%±6.5%; LPShi 56.6%±3.3% to 61.3%± 5.5%)
(Figure 2B).
The MHC class II expression on immature, semima-
ture and mature DC was slightly increased upon CD40
ligation. These changes, however, proved not to be sta-
tistically significant (data not shown).
As anti-CD40 antibodies used for ligation assays and
anti-CD40 antibodies used for FACS analysis might
compete for binding of CD40 we used the J558L/CD40L
cell line to analyze the influence of CD40 ligation on the
expression of CD40 itself on DC. In B. vulgatus treated
semimature DC we found an increase of CD40 expres-
sion upon CD40 ligation (B. vulgatus 26.8%± 7.4% to
55.0%± 0.1%). In LPSlo treated semimature DC we ob-
served a similar effect, however, the increase in CD40
expression was statistically not significant (57.8% ± 6.6%
to 63.5% ± 8.9%). Interestingly, CD40 ligation of se-
mimature DC did not lead to an increase of CD40
resulting in as high expression levels as on mature DC
(E. coli 77.1%±4.2%; LPShi 75.2%±4.0%) (Figure 2C).
In DC semimaturation CD40L induced p38
phosphorylation is inhibited
To analyze phosphorylation of the MAP kinase p38 in res-
ponse to CD40 ligation, immature, semimature and ma-
ture DC were activated by CD40 ligation and pp38 levels
were determined by Western blotting. CD40 ligation of
immature and mature DC resulted in phosphorylation of
Figure 1 Cytokine secretion of differentially primed BMDC in response to secondary CD40 ligation. Wildtype BMDC were stimulated with
B. vulgatus mpk (MOI 1) or E. coli mpk (MOI 1) and LPS at low (1 ng/ml) or high concentration (1 μg/ml), respectively, for 24 hour. Unstimulated
DC (PBS) served as a control. Subsequently, these DC were washed twice and were re-stimulated with an agonistic anti-CD40 mAb (5 μg/ml) for
48 hours (black bars). As a control, DC were further incubated in medium only (white bars) or in the presence of the isotype control (grey bars).
The concentrations of IL-12p40 (A), IL-12p70 (B) and IL-6 (C) were determined by ELISA. The bars represent the mean values of three
independent experiments, each performed as duplicate, + SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
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p38, whereas in semimature DC p38 phosphorylation
upon CD40 ligation slightly reduced (Figure 3).
To investigate the biological relevance of p38 MAP
kinase activation we treated immature, semimature and
mature DC with the p38 inhibitor SB202190 prior to
CD40 ligation. Levels of IL-12p40, IL-12p70 and IL-6
were determined in cell culture supernatants by ELISA
(Figure 4 A-C).
Inhibition of p38 had no influence on the CD40L
induced secretion of IL-12p40 by DC, independent of
the maturation state (Figure 4A). However, in mature
DC the production of IL-12p70 upon CD40 ligation was
Figure 2 Expression of CD80, CD86 and CD40 on differentially primed BMDC after secondary CD40 ligation. Wildtype BMDC were
stimulated with B. vulgatus mpk (MOI 1) or E. coli mpk (MOI 1) and LPS at low (1 ng/ml) or high concentration (1 μg/ml), respectively, for 24
hours. Unstimulated DCs (PBS) served as a control. Figure 2A and 2B: The pre-treated DC were washed twice and were re-stimulated with an
agonistic anti-CD40 mAb (5 μg/ml) for 48 hours. As a control, DCs were further incubated in medium only (mock) or in the presence of the
isotype control. The expression levels of CD80 (A) and CD86 (B) were measured by FACS analysis. Figure 2C: The pre-treated DC were washed
twice and were re-stimulated with CD40L by co-culture with J558L/CD40L transfectants or were cultured in medium only as a control
(− J558L/CD40L). After 48 hours, the expression of CD40 was determined by FACS analysis. Each histogram is representative of three independent
experiments. The data are mean values of the percentages of the positive cell populations determined in these three experiments, ± SD.
* p < 0.05, ** p < 0.01, *** p < 0.001; # p < 0.05 compared to the respective control (PBS).
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inhibited partially by SB202190. Inhibition of p38 did not
influence the IL-12p70 expression pattern in imma-
ture or semimature DC as CD40 ligation did not induce
any IL-12p70 secretion in these cells (Figure 4B). In ma-
ture DC, both spontaneous and CD40L induced IL-6
secretion levels were partially reduced by inhibition of
the p38 MAP kinase. In contrast, IL-6 production of
immature as well as semimature DC upon CD40 liga-
tion was not significantly affected by inhibition of p38
(Figure 4C).
In DC semimaturation ERK suppresses CD40L induced
IL-12p40 production
To analyze the role of the extracellular signal regulated
kinase (ERK) we used the ERK inhibitor PD98059. Upon
CD40 ligation the inhibition of ERK resulted in a signifi-
cant increase of IL-12p40 in immature and semimature
DC but only a slight increase in mature DC (Figure 5A).
In contrast, inhibition of ERK had not the ability to in-
duce IL-12p70 production in immature and semimature
DC and resulted in only slightly enhanced IL-12p70
secretion levels in mature DC (Figure 5B). The CD40L
induced IL-6 production by DC was not affected by
ERK inhibition, independent of the maturation state
(Figure 5C). In line with this, analysis of pERK levels
upon CD40 ligation of immature, semimature and mature
DC showed similar levels independent of the DC matu-
ration state (data not shown).
Taken together, our data showed that the semimature
differentiation state of DC, induced by stimulation with
B. vulgatus or LPSlo can not be overcome by CD40
ligation.
Discussion
In order to clarify the impact of CD40 expression on the
T-cell activation capacity of semimature DC, we exami-
ned the effect of CD40 ligation on immature, semima-
ture and mature DC. Semimature DC were induced by
either stimulation with B. vulgatus or LPS at low con-
centration (1 ng/ml), and are characterized by a low
positive expression of costimulatory molecules like e.g.
CD40, secretion of only IL-6, and nonresponsiveness to-
ward subsequent TLR activation [4,5].
In brief, we showed that CD40 ligation does not over-
come DC semimaturation in terms of expression of acti-
vation surface markers and results in production of only
IL-6 and IL-12p40, but not the bioactive form IL-12p70.
The slightly reduced p38 phosphorylation levels in semi-
mature DC as compared to mature DC might at least
partially contribute to this effect. The expression of
IL-12p40 turned out to be limited by pERK.
In line with other studies [24,25], we observed that on
mature DCs no significant further increase in the ex-
pression levels of the already highly expressed costi-
mulatory molecules CD40, CD80 and CD86 could be
triggered upon additional stimulation by CD40 ligation.
Upon CD40 ligation immature and semimature DC
expressed intermediate levels of CD40 CD80 and CD86,
but did not reach the expression level of mature DC.
However, the intermediate expression of costimulatory
molecules was not associated with production of pro-
inflammatory cytokines like IL-12p70.
It is known that immature DCs characterized by low
expression levels of costimulatory molecules and lacking
secretion of proinflammatory cytokines induce tolerance
Figure 3 Phosphorylation of p38 MAPK upon secondary CD40 ligation in immature, semimature and mature DC. Wildtype BMDC were
stimulated with B. vulgatus mpk or LPS 1 ng/ml (LPSlow) to generate semimature DC and E. coli mpk or LPS 1 μg/ml (LPShigh), respectively, to
generate mature DC. Immature DC were maintained by incubation in the absence of further stimuli (PBS). After 24 hours, DC were re-stimulated
with anti-CD40 mAb (1 μg/ml) for 15 minutes or treated with the isotype control (Isotype). The expression of pp38 was analyzed by Western
blotting. As loading control, β-actin expression was determined. The results shown are representative of three independent experiments.
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by promoting T-cell anergy, apoptosis or differentiation
into Treg cells via antigen presentation in the absence of
costimulatory signals [26-29]. Additionally, CD40 defi-
cient DCs or DCs with a suppressed CD40 expression
were shown to have a reduced potential to activate T-cell
proliferation and polarization in Th1 or Th2 direction
[30-34]. This effect might also contribute to the inhibited
T-cell activation induced by the intermediate expression
of costimulatory molecules on semimature lamina propria
(lp) DC of B. vulgatus monocolonized IL-2−/− mice [3].
On the other hand it was shown that a high positive
expression of costimulatory molecules in absence of
Figure 4 Role of p38 MAPK on CD40L induced cytokine secretion in DC of different maturation status. Wildtype BMDC were primed with
B. vulgatus mpk or LPS 1 ng/ml to obtain semimature DC and E. coli mpk or LPS 1 μg/ml, respectively, to obtain mature DC. Immature DC were
maintained by incubation in the absence of further stimuli (PBS). Subsequently, the DC were washed and treated with the p38 inhibitor SB202190
(2 μmol/l, black bars) or as a control with DMSO (grey bars) for 30 minutes, washed and re-stimulated with 1 μg/ml anti-CD40 mAb (+) or the
isotype control (−). After 24 hours, the concentrations of IL-12p40 (A), IL-12p70 (B) and IL-6 (C) were measured in the cell culture supernatants by
ELISA. The bars represent the mean values of three independent experiments, each performed as duplicate, ± SD. * p < 0.05, *** p < 0.001 for
SB202190 compared to DMSO.
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pro-inflammatory mediators like e.g. TNF-α or IL-12p70
favours T-cell tolerance and suppression of T-cell activa-
tion. This type of DC is mainly induced by autocrine or
paracrine stimulation with inflammatory mediators like
e. g. TNF-α [35-38].
The cytokine secretion pattern upon CD40 ligation
differed between immature/semimature DC and mature
DC. In immature and semimature DC, CD40 ligation
did not result in induction of IL-12p70 secretion, in con-
trast to mature DC where CD40 ligation led to increased
IL-12p70 secretion. This is in line with other studies
showing that TLR4 stimulation and CD40 ligation syner-
gize in inducing IL-12 p70 secretion [25,39]. The addi-
tive microbial priming signals are necessary to trigger
Figure 5 Role of ERK on CD40L induced cytokine secretion in DC of different maturation status. Wildtype BMDC were primed with
B. vulgatus mpk or LPS 1 ng/ml to obtain semimature DC and E. coli mpk or LPS 1 μg/ml, respectively, to obtain mature DC. Immature DC were
maintained by incubation in the absence of further stimuli (PBS). Subsequently, the DC were washed and treated with the ERK inhibitor PD98059
(50 μmol/l, black bars) or as a control with DMSO (grey bars) for 30 minutes, washed and re-stimulated with 1 μg/ml anti-CD40 mAb (+) or the isotype
control (−). After 24 hours, the concentrations of IL-12p40 (A), IL-12p70 (B) and IL-6 (C) were measured in the cell culture supernatants by ELISA. The
bars represent the mean values of three independent experiments, each performed as duplicate, ± SD. * p< 0.05 for PD98059 compared to DMSO.
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the production of the IL-12p35 subunit [40] which was
shown to be not induced by exclusive CD40 ligation
[41,42]. Additionally, these accessory stimuli have the
potential to augment the CD40 expression on antigen
presenting cells (APC) [43-45] which results in a more
effective CD40 ligation. However, DC primed with
Bacteroides vulgatus as a microbial stimulus do not
secrete IL-12p70 upon CD40 ligation. This might be
one mechanism accounting for the tolerogenic effects
of B. vulgatus in maintenance of intestinal homeostasis
[2,3]. As Porphyromonas gingivalis which is phylogeneti-
cally closely related to B. vulgatus signals mainly vial
TLR2 [46], this might be also the main receptor for recog-
nition of B. vulgatus. In turn, TLR2 activation is reported
to result in transcription of the p40 but not the p35 sub-
unit of IL-12p70 [1,47]. This might account for the in-
duction of IL-12p40 but not p70 upon stimulation of
B. vulgatus primed DC via CD40 ligation. The production
of IL-12p40 in the absence of the p35 unit might result in
the formation of IL-12p40 homodimers which are known
to act as potent antagonists at the IL-12p70 receptor
[48-50]. Additionally, in IL-12p40 transgenic mice Th1
responses are significantly reduced suggesting that also
in vivo p40 functions as an IL-12 antagonist [51].
Upon CD40 ligation semimature DC produced signifi-
cantly enhanced levels of IL-6 but not TNF-α (data not
shown) or IL-12p70. This is in line with our previous
studies showing a crucial role for IL-6 in induction of
DC semimaturation and tolerance [4,5,52]. This is inter-
esting as the secretion of IL-6 upon CD40 ligation by
semimature DC might help to sustain the semimature
differentiation state and influence the T-cell activation
pattern. IL-6 plays an important role in T-cell differenti-
ation through two independent molecular mechanisms.
First, IL-6 stimulation of T-cells leads to an upregulation
of nuclear factor of activated T cells (NFAT) [53], a tran-
scription factor regulating IL-4 transcription [54] resul-
ting in IL-4 expression, and thereby promotion of Th2
polarized T cell differentiation [55]. Second, IL-6 upre-
gulates the expression of silencer of cytokine signaling
(SOCS) 1 in CD4+ cells which inhibits IFN-γ signaling
and thus Th1 differentiation [56]. The presence of IL-6
may shift the Th1/Th2 balance towards Th2 [55].
CD40 ligation of DC is known to result in phosphory-
lation of MAP kinases like e.g. p38 and ERK [57,58] and
the ratio between pp38 and pERK is thought to play a
crucial role in directing the cytokine secretion pattern of
DC towards pro- or anti-inflammatory host responses
[59-61]. CD40 ligation of mature DC resulted in phos-
phorylation of p38, inhibition of pp38 using the inhibitor
SB202190 partially reduced of IL-12p70 and IL-6 but
not IL-12p40 levels. Therefore, in mature DC pp38 might
contribute to positive regulation of the p35 subunit of
IL-12p70 [62]. This is in line with others showing that
pp38 is important for production of IL-12p70 [61,63].
Additionally, pp38 is known to increase the stability of
IL-6, TNF-α and IL-8 mRNA [22,23,64] which might
result in increased secretion of these cytokines. Further-
more, via the mitogen and stress activated protein kinase
(MSK) 1 pp38 is involved in NFκB activation [65,66]. In
contrast, CD40L induced IL-12p40 secretion from mature
DC has been shown to be independent of p38 phosphory-
lation, but dependent on the NFκB inducing kinase (NIK)
[67].
As we observed an only slight reduction of p38 phos-
phorylation in semimature DC we hypothesize that inhi-
bition of p38 phosphorylation due to DC semimaturation
is only one of many factors that may affect in interaction
with others the cytokine secretion pattern of semimature
dendritic cells in response to secondary CD40 stimulation
and thus their reduced pro-inflammatory capability [3-5].
The slight differences in the MAP kinase phosphorylation
pattern in response to CD40 ligation might be based on
differences in CD40 expression of immature, semimature
or mature DC. A strong CD40 signal is known to prefe-
rentially activate p38, whereas weak CD40 signals are
thought to favour ERK phosphorylation [60].
Inhibition of pERK during CD40 ligation turned out to
have no significant effect of cytokine secretion in mature
DC. In contrast, in semimature DC phosphorylation
of ERK was at least partially responsible for limiting
IL-12p40 expression. This is in line with others showing
similar effects [68]. However, the Western blot analysis
did not reveal significant differences of pERK levels in im-
mature, semimature or mature DC. We speculate that in
semimature DC the ERK activation might probably con-
trol the IL-12p40 production and therefore contribute to
the limitation of the IL-12 p70 production. We are aware
that this is highly speculative and that further work has to
elucidate the role of ERK in DC semimaturation.
Conclusion
We hypothesize that the inability of CD40 ligation in
overcoming DC semimaturation might contribute to the
tolerogenic phenotype of semimature DC and at least par-
tially account for maintenance of intestinal homeostasis.
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How does the host manage to tolerate its own intestinal microbiota? A simple question leading to complicated answers. In order to
maintain balanced immune responses in the intestine, the host immune system must tolerate commensal bacteria in the gut while
it has to simultaneously keep the ability to ight pathogens and to clear infections. If this tender equilibrium is disturbed, severe
chronic inlammatory reactions can result. Tolerogenic intestinal dendritic cells fulil a crucial role in balancing immune responses
and therefore creating homeostatic conditions and preventing from uncontrolled inlammation. Although several dendritic cell
subsets have already been characterized to play a pivotal role in this process, less is known about deinite molecular mechanisms
of how intestinal dendritic cells are converted into tolerogenic ones. Here we review how gut commensal bacteria interact with
intestinal dendritic cells andwhy this bacteria-host cell interaction is crucial for induction of dendritic cell tolerance in the intestine.
Hereby, diferent commensal bacteria can have distinct efects on the phenotype of intestinal dendritic cells and these efects are
mainly mediated by impacting toll-like receptor signalling in dendritic cells.
1. Introduction
he mammalian intestinal immune system has to rise to
diferent challenges. On the one hand, it has to tolerate
the intestinal microbiota consisting of commensal bacteria,
fungi, and other microbes, thereby proiting from beneicial
bacterial metabolites and other advantages. On the other
hand, pathogen induced infections of the intestine have to
be cleared without spacious damage of the intestinal tissue.
Since a loss of tolerance to the own microbiota causes
chronic inlammation of the gut, eicient sensing of the
intestinal homeostasis is crucial to avoid pathophysiological
immune responses. In this context, intestinal tolerogenic
dendritic cells play a crucial role as key mediators for the
maintenance of the intestinal homeostasis. While the main
question “how does the host manage to tolerate its own
intestinal microbiota?” is pretty simple, the answer is not
trivial.
Here, we want to focus on (1) the molecular mechanisms
that might contribute to the induction of tolerogenic DCs in
the intestine and (2) the potential clinical applications arising
from these indings for the treatment of chronic inlamma-
tory disorders of the gut: inlammatory bowel diseases.
2. Intestinal Dendritic Cells: Subsets and
Biological Functions
Dendritic cells (DCs) comprise a heterogeneous leukocyte
population of diferent developmental origin and with dis-
tinct surface markers and biological functions. DCs originate
from blood monocytes or a common DC progenitor in the
bone marrow under steady-state conditions. he diferen-
tiation into DCs relies on local presence of GM-CSF [1].
DCs in general are utterly specialized antigen presenting cells
(APCs)which are able to induce a variety of diferent immune
responses. hey are the most important cell type connecting
the innate immune system with adaptive immune responses
[2]. DCs patrol almost all lymphoid and nonlymphoid organs
andmeld properties of the innate and adaptive immunity and
therefore link these two mechanistically distinct branches of
the immune system [3]. Furthermore, DCs play a pivotal
role in mediating a protective adaptive immunity against
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pathogens while maintaining immune tolerance to self-
antigens. heir crucial role for mediating self-tolerance is
conirmed by the observation that DC depletion leads to a
loss of self-tolerance and results inmyeloid inlammation and
the induction of autoimmune processes [4].
he gut-associated lymphoid tissue (GALT) is the largest
immune organ of the body. he GALT has to ensure that
there is a dynamic balance between protective immunity by
ighting pathogens and regulatory mechanisms to prevent
autoimmunity [5]. Since the GALT is constantly exposed
to large amounts of luminal antigens like food metabolites,
foreign pathogens, and commensalmicrobes, this balance has
to be well adjusted in order to create homeostatic conditions
in the intestine. Dendritic cells are hereby the key players for
maintaining intestinal homeostasis [6]. hey are spread out
in the connective tissue underlying the epithelial layer of the
gut [7].
2.1. Morphological Diferences between DCs and Macrophages
(MΦ) in the Murine Intestine. DCs belong to the group
of mononuclear phagocytes (MPs) with macrophages
(MΦ) being another cell type belonging to this group.
Discrimination between DCs on one hand and MΦ on the
other hand is still a matter of ongoing debate. However,
concerning intestinal DCs and MΦ, certain surface markers
and transcription factors have been reported to be uniquely
expressed by only one of these two groups. In the murine
intestine, surface proteins which are exclusively expressed
by DCs are CD103 [8–10], CD26, and CD272 [9]. However,
CD103 is not expressed from every DC subset (see below)
[11–13]. A DC speciic transcription factor is Zbtb46 [13].
he only MPs in the murine intestine that express the
proteins CD14, MerTK [9, 14], F4/80, and CD64 [15] are
intestinal MΦ. he widely used surface markers for DC-
macrophage discrimination, CD11c and MHC-II, are not
useful to distinguish murine intestinal DCs from MΦ,
since both proteins can be expressed in DC or macrophage
subpopulations [13, 15–19]. he expression of CD11b and
MHC-II varies among DC and MΦ subpopulations [13].
herefore, the protein expression pattern of murine intestinal
DCs under steady state conditions can be summarized as
CD11c+CD103+/−CD11b+/−MHC-II+CD26+CD272+Zbtb46+
CD14−MerTK−F4/80−CD64−, while the phenotype of intesti-
nal murine MΦ is CD11c+/−CD103−CD11b+/−MHC-II+/−
CD26−CD272−Zbtb46−CD14+MerTK+F4/80+CD64+. An-
other distinctive feature between DCs and MΦ is the
migratory and proliferation behaviour. In general, intestinal
DCs are short-lived, proliferating migratory cells while MΦ
are tissue resident, long-lived, and nonproliferating [13].
2.2. DC Subpopulations in the Intestine. Asmentioned above,
dendritic cells do not comprise a homogenous cell popu-
lation. Diferent ways to distinguish one DC from another
are published and popular. he most prominent approach
to diferentiate between distinguishable DC subsets is to
focus on diferent expression of surface proteins, especially
CD103 and CD11b [12, 13]. However, Guilliams and van de
Laar have recently proposed to distinguish DCs rather by
their biological function and cellular origin than their surface
marker expression [11, 12]. We will adapt this system, but we
will focus on DC subsets located in the intestine and add
latest indings on diferent surface marker expression among
these subsets [13]. In general, DCs derive from common
dendritic cell progenitors (CDP) which, in turn, develop
from hematopoietic precursor cells. CDPs may diferentiate
into either preplasmacytoid DCs (pre-pDCs) or precommon
DCs (pre-cDCs) precursor cells [20, 21]. Murine pDCs are
characterized by PDCA1 expression and their development
is dependent on the transcription factors BATF3 [22], ID2
[23], NFIL3 [24], E2-2 [25], and IRF8 [22]. Murine cDCs
commonly express XCR1 and SIRP� [26] and need RelB
[27], RPBJ [28], and IRF4 [29] for diferentiation. Intestinal
murine cDCs additionally express CD103 and can be further
subdivided into two ontogenetically diferent populations,
dependent on their surface expression of CD11b [30]. IRF4
is needed for the CD11b+ lineage of these CD103-expressing
or CD103-nonexpressing conventional DCs [29, 31, 32].
CD103+CD11b− build up cDC subset 1 (cDC1) whereas
CD103+CD11b+ form subgroup cDC2 (see Figure 1). One of
the most important events for the maintenance of intestinal
homeostasis is the induction of regulatory T cells (Tregs) (see
below). Besides TGF-�, Treg formation is dependent on the
presence of retinoic acid (RA) that is produced by dendritic
cells [33, 34]. But only DCs possessing retinaldehyde dehy-
drogenases (ALDHs) can convert vitamin A-derived retinol
to RA.herefore, ALDH is a crucial enzyme for a subsequent
induction of Tregs and thus promotion of intestinal tolerance
and homeostasis. It was not clear which CD103+ DC subset
is responsible for Treg induction, since both CD103+CD11b+
and CD103+CD11b− DCs can produce RA and induce Tregs
in vitro [35, 36]. Meanwhile, it could be demonstrated
that each CD103+ DC subset (CD11b+ versus CD11b−) can
be subdivided in an ALDH-expressing and a non-ALDH-
expressing subset [35]. herefore, both CD11b+CD103+ and
CD11b−CD103+ DCs are able to induce a RA-mediated Treg
formation. his was initially demonstrated in skin-draining
lymph nodes [35], but Janelsins et al. conirmed the presence
of CD103+CD11b+ALDH+/− DCs also in the murine cLP
[37]. Both CD103+ DC subsets together monitor the luminal
environment in the intestine. Not only are CD103+ DCs able
to induce Treg-mediated immune tolerance in the intestine
but they are also able to promoteh17 diferentiation of na¨ıve
T cells. h17 cells contribute to the manifestation of autoim-
mune diseases [38, 39] and CD103+CD11b+ seem to be more
eicient in h17 promotion than their CD11b− counterparts
[36, 40]. It can be assumed that ALDH−CD103+CD11b+/−
might promote thish17 immune response, but inal evidence
is missing until now.
Concerning their distribution in the intestine, CD103+
CD11b− DCs are prominent in the colonic lamina propria
(cLP), while CD103+CD11b+ DCs are mostly found in the
LP of the small intestine [29]. Additionally, CD103+CD11b+
DCs from the mesenteric lymph nodes (MLN) also express
ALDH, which is, surprisingly, abdicable for the induction of
Tregs since a loss of ALDH activity in the MLN did not afect
Treg induction [29]. his might support the hypothesis that
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Figure 1: Ontogenetic development of intestinal dendritic cells subpopulations. Adapted fromGuilliams et al. [35] and expanded by indings
from Scott et al. [13]. See text for details. Common dendritic cell progenitor (CDP), preplasmacytoid dendritic cell (pre-pDC), precommon
dendritic cell (pre-cDC), plasmacytoid dendritic cell (pDC), common dendritic cell (cDC), aldehyde dehydrogenase (ALDH), regulatory T
cell (Treg), retinoic acid (RA), and T-helper 17 cell (h17). Arrows with solid lines represent published data, and arrows with broken lines
represent speculative hypotheses with missing inal evidence.
ALDH activity is more important at other intestinal sites like
the lamina propria of the small or large intestine for later Treg
induction ater DC migration.
Recently, Scott et al. discovered an additional CD103-
negative DC population in the murine intestine [13]. here is
a CD11c+MHC-II+CD103−CD11b+ cell population, of which
about 15% provide features of DCs like Zbtb64, CD26,
and CD272 expression; they respond to Flt3L; they are
migratory cells and lack macrophage markers like F4/80 and
CD64 [13, 41]. hey could be shown to be derived from
committed pre-DCs as are CD103+ mucosal DCs [8]. hese
CD103− DCs can be further subdivided into two functionally
distinct subpopulations dependent on their CCR2 expres-
sion. CCR2+CD103+CD11b+ DCs are more eicient in h17
induction than their CCR-negative counterparts and a loss
of the CCR2+CD103−CD11b+ DCs leads to a defective h17
response and therefore fails to clear a Citrobacter infection in
vivo.
Another speciic protein that is expressed exclusively by
intestinal DCs and not by intestinalMΦ or nonintestinal DCs
is SIRP� [42, 43]. It seems to be essential for the generation of
CD103+CD11b+ since a loss of function of SIRP� results in a
decrease of this DC population in the intestine, accompanied
by markedly reduced induction of h17 immune responses
under steady-state and inlammatory conditions [42].
In general, it is important to keep in mind that CD103
expression on DCs is not a marker for universal tolero-
genicity, since (1) even CD103+ DCs can fail to induce
tolerogenicity if ALDH is not expressed and (2) a tolerogenic
environment can be established even in the absence of
CD103+ DCs [44].
2.3. Locations of Intestinal DCs. he murine intestine is a
multifarious habitat for DCs where distinct sites harbour
diferentDC subsets. A common feature of intestinalDCsdis-
tinguishing them from DCs from other nonintestinal tissues
4 Journal of Immunology Research
is the expression of CD103, with the already mentioned
exception of CCR2+/−CD103−CD11b+ DCs, especially DCs in
the small intestine (SI) and Peyer’s Patches (PP) inmesenteric
lymph nodes (MLN) and, with minor occurrence, in the
colonic lamina propria (cLP) [8, 29, 41, 43, 45]. DCs from
nonlymph node tissues remain some days at their inherent
site before migrating to neighbouring draining lymph nodes
[35, 46].
3. Antigen Sensing and Sampling by
Intestinal Dendritic Cells
Invading microorganisms are recognized by pattern recog-
nition receptors (PRRs) on the DC surface. PRRs include
toll-like receptors (TLRs), retinoic acid-inducible gene I-
like receptors (RLRs), and nucleotide-binding oligomeriza-
tion domain-like receptors (NLRs) [47, 48]. PRRs recog-
nize pathogen-associated molecular patterns (PAMPs) [49].
PAMPs comprise a heterogeneous class of diferent antigens,
that is, surface components of bacteria. One of the most
prominent PAMPs which usually induces DC maturation is
lipopolysaccharide (LPS), an integral cell surface component
of all Gram-negative bacteria.Usually, dendritic cells underlie
the intestinal epithelium and therefore the connection to
the colonic lumen is restricted. However, there are three
prominent ways how intestinal dendritic cells can sample
luminal antigens: (1) with participation of goblet cells which
deliver soluble and preferably low molecular weight antigen
to neighbouring DCs [50], (2) with the support of CX3CR1+
phagocytotic cells which can actively capture antigen fol-
lowed by transport to neighbouring DCs via tight junctions
[51], and (3) a direct sampling by DCs that extend their
dendrites towards the lumen establishing a direct connection
to the colonic lumen [52].
4. Intestinal Dendritic Cells and
the Gut Microbiota
CD103+ DCs are reported to sample mainly bacteria [52]
in contrast to CX3CR1+ MΦ which also capture soluble
proteins and fungi [51, 53]. his illustrates the relevance
of the bacterial microbiota composition for intestinal DCs.
Interaction of DCs with the gutmicrobiota can occur directly
by sampling bacterial antigen or by interaction with bacterial
metabolic products like short chain fatty acids (SCFAs).
SCFAs like butyrate can interact with the DC receptor
GPR109A which inally leads to an IL-10 mediated induction
of Tregs [54]. Since not all gut commensal bacteria produce
SCFAs, amicrobiota shit leading to dysbiosis can profoundly
afect immunological mechanisms in the intestine. Toll-like
receptor (TLR) signalling in DCs also seems to be crucial
for the maintenance of intestinal homeostasis. Diferent
bacterial components bind to distinct TLRs on the surface
of DCs resulting in the activation of intracellular signalling
cascades which leads to DC maturation or semimaturation
(see below) accompanied by secretion of pro- or anti-
inlammatory cytokines. he TLT adaptor molecule TNF-
receptor associated factor 6 (TRAF6) seems to play a pivotal
role in maintaining intestinal homeostasis since Traf6−/−
mice fail to maintain intestinal homeostasis mediated by
a reduction of Tregs and an increase of T-helper 2 (h2)
cells, inally resulting in amicrobiota composition-dependent
induction of colonic inlammation [55].
5. The Different Maturation Phenotypes of
Dendritic Cells
he capability of initiating an immune response depends on
the current DC maturation state. Usually, antigen encounter
results in rapid DC maturation which is characterized
by eicient endocytosis and antigen processing. Further-
more, upregulation of MHC-II and T cell costimulatory
molecules like CD40, CD80, and CD86 enhanced expression
of chemokine receptors and the secretion of proinlammatory
cytokines like IL-1�, IL-6, TNF�, and IL-12 are part of
DC maturation. hese events inluence and activate other
cellular components of an induced immune response like
MΦ, neutrophils, and especially T cells [56].
5.1. Mature DCs (mDCs). Induction of DC maturation is
accompanied by a loss of the capacity to take up and
process antigen [57]. However, they literally develop into
professional antigen presenting cells (APCs) indicated by
powerful antigen presentation to na¨ıve T cells [2], aswell as by
their ability to migrate to secondary lymphatic organs where
they present antigens to T cells.
5.2. Immature DCs (iDCs). Immature DCs (iDCs) express
low amounts of MHC-II and T cell costimulatory molecules.
hey tend to promote T cell anergy and to generate Tregs,
with both efects being crucial for intestinal homeostasis
[58]. iDCs furthermore express high levels of PRRs with
which they mediate the recognition of potential antigens and
therefore their endocytosis [57].
5.3. Semimature DCs (smDCs) and Tolerant DCs. he
deinition of a semimature DC phenotype is less distinct.
he most important property of smDCs uniting diferent
deinitions is the inability to induce a proinlammatory
h1 or h17 response and to be nonresponsive, or in other
words “tolerant,” towards subsequent maturation stimuli
[59, 60] with the latter being the criterion that mediates the
tolerogenic functions of smDCs [60]. DC semimaturation
leads to a certain expression of T cell activation and a cytokine
secretion pattern that is distinct from the ones of immature
and mature DCs. he deinite phenotype varies from one
semimaturation inducing strategy to another. SmDCs
that are generated by treating immature DCs with TNF�
display a phenotype that can be summarized as CD11c+
MHCIIhiCD86hiCD80hiCD40loCD54+CD205hiCD25hiTNFlo
IL-12p40loIL-10lo [61]. Induction of semimaturation via low-
dose LPS and subsequent dexamethasone treatment results
in CD14+CD1aloCD80hiCD86hiMHCIIhiIL-10hiTNFlo DCs
[62]. We use a Gram-negative gut commensal, Bacteroides
vulgatus, to induce semimaturation and deine the smDC
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Table 1: Phenotypes of semimature dendritic cells dependent on semimaturation inducing agent. LPS (lipopolysaccharide), Dex (dexameth-
asone), and PSA (polysaccharide A); high expression (hi), low expression (lo), intermediate expression (int), and not determined (n.d.).
Semimaturation inducing agent MHC-II CD40 CD80 CD86 IL-10 IL-6 TNF� IL-12 Source
B. vulgatus int lo lo lo n.d. int lo lo [59]
TNF� hi lo hi hi lo n.d. lo lo [61]
LPS + Dex hi n.d. hi hi hi n.d. lo n.d. [62]
B. fragilis PSA int n.d. n.d. n.d. hi n.d. n.d. n.d. [66]
ATP + LPS hi lo hi hi hi n.d. lo lo [120]
E. multilocularis lo n.d. n.d. lo int lo n.d. lo [121]
Low dose LPS int lo lo lo n.d. int lo lo [64]
�-1 Antitrypsin int lo n.d. int hi lo n.d. n.d. [65]
phenotype as CD11c+MHCIIintCD40loCD80loCD86lo
TNF�loIL-12loIL-6int [59]. Besides these strategies, DC sem-
imaturation can be induced by treating immature DCs
with ATP and LPS [63], low dose Salmonella LPS [64], �-1
antitrypsin [65],Bacteroides fragilisPSA [66], orEchinococcus
multilocularis cell aggregates [67]. he resulting phenotypes
concerning the most important immunomodulatory mole-
cules are summarized in Table 1.
5.4. Tolerogenic DCs. While mature DCs (mDCs) promote
eicient induction of inlammatory immune responses, iDCs
and smDCs fail to do so. hey rather have the property
to actively prevent from inlammatory reactions and are
therefore also termed tolerogenic DCs (tolDCs). he term
“tolerogenic” includes one, several, or all of the following
features DCs must provide to be considered “tolerogenic”:
(1) the induction of unresponsiveness of T cells, (2) active
induction of Tregs, (3) inhibition of proinlammatory T
cell responses, and (4) promotion of T cell apoptosis or T
cell anergy [6]. In this context, the interplay between the
intestinal epithelial cells and the host immune system is of
essential importance.
More generally, regulatory or tolerogenic DCs keep their
ability to present antigens, but at the same time they down-
regulate the expression of T cell costimulatory molecules and
proinlammatory cytokines but in turn upregulate inhibitory
molecules like PD-L1, CD95L, or IDO as well as anti-
inlammatory cytokines such as TGF-� and IL-10 [68]. Fur-
thermore, they are resistant to a second maturation inducing
signal [68]. Importantly, DCs also inluence the diferentia-
tion of na¨ıve T cells into h1, h2, h17, or Treg cells, mostly
due to supplying a certain cytokine environment [69]. In
a healthy individual, the presence of tolDCs is important
and a loss of tolDCs can result in the development of AID
[4]. Semimature DCs are potent tolerant and tolerogenic
DCs since they fulil many to all of the above-mentioned
criteria, dependent on the agent with which semimaturation
is induced. As already mentioned before, the main char-
acteristic that makes semimature DCs tolerogenic is their
unresponsiveness (tolerance) towards subsequentmaturating
stimuli [59, 64, 65].
6. The Role of Dendritic Cells in Induction of
Inflammatory Bowel Disease (IBD)
he development of inlammatory bowel diseases (IBD)
with its two major representatives Crohn’s disease (CD) and
ulcerative colitis (UC) is associated with (1) an inappropriate
immune response to normally benign stimuli like commensal
microbes, (2) an ineicient clearance of microbes leading
to a continuous stimulation of the immune system, or (3)
failing to turn from an adequate proinlammatory response
to inlammation resolving anti-inlammatory immune reac-
tions [70]. In this context, the composition of the intestinal
microbiota is decisive for the onset of colonic inlammation
in most mouse models of experimental colitis [71] and
intestinal DCs are crucial for driving immune responses in
either a proinlammatory or a rather homeostatic direction
[72]. For example, Il10−/− mice develop chronic colitis which
results from the absence of suppression ofMyD88-dependent
commensal-induced inlammation by IL-10 [73].
Under steady-state conditions, circulating Ly6Chi mono-
cytes are repopulated into tolerogenic F4/80lowCD103+
CD11c+ LP DCs, which contribute to homeostasis by sup-
porting tolerogenic functions [16]. On the other hand, under
inlammatory conditions during colitis, Ly6Chi monocytes
develop into CD103−CX3CR1intCD11b+ LP DCs, which
mediate inlammation during colitis [16].
he tolerogenic functions of intestinal DCs are mainly
mediated by the induction of regulatory T cells (Tregs).
As a characteristic feature, Tregs express the transcrip-
tion factor forkhead box P3 (Foxp3) [74]. Induction of
CD4+CD25+Foxp3+ Tregs is essential for intestinal home-
ostasis [75] and a loss of Tregs leads to a fatal multiple-
organ-associated autoimmune disease [76]. Tregs are usually
converted in the peripheral immune system with the help of
CD103+ dendritic cells [77] whereupon this Treg induction is
dependent on the presence of TGF-� and retinoic acid (RA)
[78].
However, during colitis, CD103−CXCR1intCD11b+ DCs,
although also present under steady-state conditions, mas-
sively iniltrate the colonic LP and mediate proinlammatory
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Figure 2: Possible molecular mechanisms of tolerance induction in intestinal dendritic cells. he white numbers in black circles refer to the
numbering of regulation mechanisms in the text. See text for details.
immune responses by producing IL-12, IL-23, iNOS, andTNF
[16].
7. Possible Molecular Mechanisms of
DC Tolerance Induction in the Intestine
Less is known about deined mechanisms of tolerance induc-
tion in intestinal DCs. However, knowledge about tolerance
induction mechanisms of other DC subsets or of in vitro
generated DCs can be transferred to intestinal DCs to explain
how they manage to tolerate luminal bacterial or food anti-
gens and therefore prevent from uncontrolled inlammatory
reactions. Here, we want to present latest research results and
discuss how and if these indings can be assigned also to
intestinal DCs. All proposed mechanisms are summarized in
Figure 2.
(1) Cell-to-Cell-Contact and STAT3 Signaling. Epithelial cells
of the intestine express the surface protein CD47 which can
directly interact with signal regulatory protein � (SIRP�)
expressed on the surface of DCs which underlie the intestinal
epithelial cell layer.his protein-protein-interaction has been
shown to result in a janus kinase-2 (JAK-2) dependent signal
transducer and activator of transcription 3 (STAT3) activa-
tion downstream of SIRP� in DCs [79]. STAT3 activation,
in turn, leads to enhanced IL-10 secretion from DCs and
therefore promotes tolerogenic properties in the intestinal
environment [79]. STAT3 has long been known as a crucial
negative regulator of immunity. Disruption of STAT3 leads to
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a loss of T cell tolerance inmice and eicient STAT3 signaling
is associated with the immature DC phenotype, general IL-
10 secretion, and tolerance induction [80]. herefore, not
only does DC alone seem to be important for homeostasis
maintenance but also the “teamwork” with neighbouring
epithelial cells seems to contribute to tolerance mechanisms.
(2) IL-10 as a Central Cytokine for Intestinal Homeostasis.
Interleukin-10 is a key inhibitory cytokine in T cell activation
and a mediator of intestinal homeostasis [81]. It is secreted
by T cells, B cells, and most myeloid-derived cells [82]. Mice
lacking functional IL-10 or its IL-10R receptor counterpart
spontaneously develop severe intestinal inlammation.
Supporting the idea of IL-10 being a crucial mediator
for intestinal homeostasis [83]. Also humans with defec-
tive mutations in the genes encoding for IL-10 or IL-
10R develop a severe form of enterocolitis within the irst
months ater birth [84]. hese observations made IL-10 a
promising therapeutic candidate in order to treat chronic
inlammatory conditions of the intestine. However, results
were not convincing since, in mice as well as in humans,
IL-10 administration did not ameliorate the inlammatory
conditions [85]. IL-10 not only afects T cell responses but
can also provide autocrine and paracrine efects on DCs.
Since DCs express the IL-10 receptor (IL10R), IL-10 can
bind to IL10R resulting in a negative regulation of myeloid
diferentiation primary response 88 (MyD88) signaling inside
DCs. MyD88 is an adaptor molecule of TLRs and is required
for downstream TLR signalling. IL-10/IL10R interaction
mediates this negative regulation by a downregulation of
interleukin 1 receptor associated kinase 4 (IRAK4) on the
protein level without altering IRAK4 gene transcription rates
[86]. It also leads to dissociation of MyD88 from TLRs and
subsequently promotes proteasomal degradation of IRAK1,
IRAK4, and TRAF6, therefore silencing MyD88-dependent
TLR signalling [86]. However, this is just the case if LPS as
a TLR4 ligand is present at the same time to induce TLR
signaling. IL-10 silencing of MyD88 signaling seems to be
crucial for the maintenance of intestinal homeostasis since
IL-10−/− mice fail to develop intestinal inlammation if these
mice simultaneously lack MyD88 [73]. As a consequence, the
cytokine environment does also afect DCs in their ability to
induce tolerance mechanisms.
(3) NF�B Signalling as a Mediator for Tolerogenicity. A key
regulator for DC maturation and inlammatory reactions
in general is NF�B [87, 88]. NF�B family members do
not only have an activating potential for the induction of
proinlammatory cytokines. Two NF�B proteins, p50 and
p52, have been associated with transcription repression func-
tions and therefore induction of tolerance [89, 90]. Both
proteins lack the carboxyterminal transactivation domain
and can form inhibitory homodimer complexes that prevent
from transcription of proinlammatory genes. NF�B p50
has been shown to promote a tolerogenic DC phenotype
by negatively afecting DC survival and their capacity to
eiciently activate T cells [91]. Accumulation of p50 in
the nucleus of tolerogenic DCs can be accompanied by
enhanced expression of tolerance-promoting molecules like
indoleamine dioxygenases (IDOs) and decreased expression
of proinlammatory cytokines like IFN�, IL-1�, and IL-18
[91]. hese implications for p50 in the induction of tolDCs
are supported by the inding that p50-deicient DCs are weak
inducers of a Foxp3+ Treg diferentiation [92]. Formation of
p50-p50 homodimers contributes to LPS tolerance in MΦ
[93] and p50 expression in immatureDCs is crucial to prevent
from autoreactive T cells [91].
(4) �-Catenin Promotes DC Tolerogenicity. �-catenin is a
transcription factor and part of the wnt signalling pathway.
It could be demonstrated that this signalling pathway with
the subsequent release of �-catenin into the nucleus results
in the induction of tolDCs [94]. Gene expression proiles
of intestinal LP DCs revealed that this signalling pathway is
decisive for the DC to become either mature or tolerogenic.
�-catenin translocation into the DC nucleus resulted in
the expression of various tolerance-associated factors like
retinoic acid-metabolizing enzymes, IL-10 and TGF-� [94].
(5) Prevention of V-ATPase Domain Assembly Induces Tolero-
genic DCs. Vacuolar (H+)-ATPases (V-ATPases) are ATP-
driven proton pumps. hey are composed of two domains: a
peripheral V1 domain and membrane-embedded V0 domain
[95]. V-ATPases are involved in acidiication of lysosomes by
shuling protons from the cytosol into the lysosomic lumen
[96]. he pH value of lysosomes is a crucial regulator for
the eiciency of antigen processing since lysosomal proteases
being involved in antigen proteolysis require acidic envi-
ronments [95]. he most important mechanism to regulate
lysosomal acidiication is to control the assembly of the two
V-ATPase domains which is a required event for forming
a functional proton pump. It is known that activation of
TLRs promotes domain assembly and therefore supports
DC maturation [96]. Domain assembly seems to be a PI-3
kinase andmTORmediated event since inhibitory substances
for both molecules could block V-ATPase domain assembly
and therefore prevent from DC maturation and promote the
induction of a tolerogenic phenotype [95]. Also, stimulation
of integrins and E-cadherins by cluster disruption of DC
prevents from domain assembly and supports induction of
a tolerogenic phenotype [96, 97].
(6) p38� Expression Inluences Expression of ALDH1A2. MAP
kinases like ERK, JNK, and p38� form central pathways
that are activated by innate immune signals like PAMPs
[98, 99] and excessive activation ofMAP kinases are reported
to be associated with many autoimmune and inlammatory
diseases [99]. However, the MAP kinase p38� provides a
dichotomic role. Besides being involved in promoting proin-
lammatory responses, its activity seems also to be crucial
for the induction of a tolerogenic phenotype in intestinal
CD103+ DCs. In these DCs, p38� is constitutively active
and this activity is crucial for the expression of TGF-� and
aldehyde dehydrogenase 1A2 (ALDH1A2), the latter being
involved in metabolizing retinoic acid (RA). TGF-� and RA
are involved in Treg generation and therefore promote gut
homing properties of T cells [99].
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(7) Gadd45�-Mediated TLR2 Signalling Contributes to Tolero-
genic Features of Intestinal DCs. An abundant bacterial gut
commensal, B. fragilis, is able to protect from the induction of
EAE and experimental colitis and increases the proportions
of CD103+CD11c+ DCs [100, 101]. It could be demonstrated
that this efect is mediated by polysaccharide A (PSA), an
immunomodulatory component present in outer membrane
vesicles derived from B. fragilis bacteria [66]. PSA pro-
motes immunological tolerance by inducing IL-10 producing
Foxp3+ Tregs and protects animals from experimental colitis
[102]. he PSA caused induction of tolDCs is dependent
on TLR2 and growth arrest and DNA-damage-inducible
45 � (Gadd45�), since Gadd45�-deicient DCs are unable
to mediate PSA-induced protection of experimental colitis
[66]. Gadd45� itself inhibits an alternative way of MAPK
p38-mediated signalling [103] and PSA-containing outer
membrane vesicles lead to upregulation of Gadd45� [66].
Taken together, all of the mentioned molecular mech-
anisms of tolerance induction in DCs are potentially able
to take place in the intestine, either through participation
of neighbouring intestinal epithelial cells or through direct
interaction ofDCswith luminal content. Concerning luminal
content, bacteria and their PAMPs could promote all of
the potential mechanisms via interaction with host pattern
PRRs, especially TLRs. We identiied apathogenic Gram-
negative commensal strains, namely, Bacteroides vulgatus
mpk andEscherichia colimpk,mediating completely contrary
efects on DC maturation and, in consequence, the progress
of experimental colitis in mice [104, 105]. As mentioned
above, B. vulgatus interaction with immature DCs converted
them into a tolerant and tolerogenic semimature phenotype
characterized by low to intermediate expression of MHC-
II, CD40, CD80, and CD86, almost absent secretion rates of
TNF� and IL-12p70, and remarkable IL-6 secretion [59]. As
a characteristic of tolerant DC, this phenotype could not be
overcome with a subsequent maturating bacterial stimulus
or by CD40 ligation [106]. E. coli mpk stimulation, however,
resulted in eicient DCmaturation. As a consequence, E. coli
mpk colonization in experimental mouse colitis using Il2−/−
mice resulted in colonic inlammation, a feature that could
be prevented by simultaneous B. vulgatus mpk colonization
[104, 105]. We could prove that both bacteria diferentially
alter the phenotype of dendritic cells not only in vitro but also
in vivo in the colonic LP via adjusted bacterial colonization
of the gut [105]. In this context, feeding B. vulgatus always
induced tolerant and tolerogenic DC in the colonic LP. In
another study using distinct E. coli bacteria that just difer in
the structure of their cell surface LPS, we could prove that
the LPS structure alone decides if LP DCs are converted into
a mature phenotype and therefore promote inlammation or
if they are converted into tolerogenic semimature DCs and
thus maintain intestinal homeostasis [107]. As LPS primarily
signals via TLR4, tolerance induction mechanisms where
NF�B p50, Gadd45�, MyD88-signaling, �-catenin, and/or
V-ATPase domain assembly are involved could be possible.
Since LPS is a cell wall component of all Gram-negative
bacteria, the resulting abundance in the intestinal lumen
could largely contribute to tolerance induction in intestinal
DCs. As we have demonstrated, diferent commensal bacteria
can have opposite efects on DC maturation. his makes
the composition of the microbiota decisive on whether DCs
mediate tolerogenic or inlammatory LPS-triggered immune
responses.
8. Perspectives for Clinical Approaches for
the Treatment of IBD Using Tolerant and
Tolerogenic Dendritic Cells
In order to be suitable as an administrable therapeutic,
tolerogenic DCs (tolDCs) have to be generated in vitro. One
eicient way to induce tolDCs is coincubating them with
apoptotic cells. Phagocytosis of apoptotic cells through DCs
results in production of TGF-� which in turn contributes
to immune tolerance. Apoptotic cell-treated DCs eiciently
converted na¨ıve CD4+ T cells into Foxp3+ Tregs [108, 109].
In general, apoptotic cell induced tolDCs are important for
induction of immune tolerance [110, 111].hey provide upreg-
ulation of Galectin-1 and CD205 [112], two molecules that
facilitate the manifestation of immune tolerance [113, 114].
At the same time, apoptotic cell treated DCs downregulate
Gr-1 and B-220 [112], two molecules triggering inlammatory
responses. hese DCs furthermore downregulate the tran-
scription factor ROR�t which is the decisive transcription
factor for h17 diferentiation. Not only does treatment
with apoptotic cells lead to induction of tolDCs but also
treatment with herbal coumarins [115] and the macrocyclic
antibiotic rapamycin [116] leads to tolDC induction. In vitro
generated tolDCs have already been successfully used for
the treatment of autoimmune disorders in animal models
and peripheral tolerance could be restored by administrating
tolerogenic DCs [117]. Approaches to treat autoimmune type
1 diabetes in a mouse model using nonobese diabetic (NOD)
mice with tolerogenic DCs were very successful [112]. To do
so, apoptotic islet cells were used to induce DC mediated
tolerance against own islet cells [118]. All these applications
lead to the question if transfer of tolerogenic dendritic cells
would also be an approach to treat IBD and, if yes, which
method to induce DC tolerance would be the method of
choice. A published approach for the treatment of Crohn’s
disease patients is in vitro generation of DCs followed by
pulsing with dexamethasone, proinlammatory cytokines IL-
6, IL-1�, and TNF�, and PGE2 [119]. Concerning our indings
that a certain gut commensal, B. vulgatus mpk, eiciently
induces tolerant and tolerogenic DCs in vitro as well as in
vivo [59, 104, 105], we would recommend using host gut
commensal bacteria for in vitro tolDC generation. In order to
provide more potential luminal antigens presented by MHC-
II of tolDCs, a deined mixture of commensal bacteria could
be used.his would enlarge the amount of antigenic peptides
against which tolerance would be induced.
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Cathepsin S (CTSS) is a eukaryotic protease mostly expressed in professional antigen presenting cells (APCs). Since
CTSS activity regulation plays a role in the pathogenesis of various autoimmune diseases likemultiple sclerosis, ath-
erosclerosis, Sjögren's syndrome and psoriasis as well as in cancer progression, there is an ongoing interest in the
reliable detection of cathepsin S activity. Various applications have been invented for speciﬁc detection of this en-
zyme. However, most of them have only been shown to be suitable for human samples, do not deliver quantitative
results or the experimental procedure requires technical equipment that is not commonly available in a standard
laboratory. We have tested a ﬂuorogen substrate, Mca-GRWPPMGLPWE-Lys(Dnp)-DArg-NH2, that has been de-
scribed to speciﬁcally detect CTSS activities in human APCs for its potential use for mouse samples. We have mod-
iﬁed the protocol and thereby offer a cheap, easy, reproducible and quick activity assay to detect CTSS activities in
mouse APCs. Since most of basic research on CTSS is performed in mice, this method closes a gap and offers a pos-
sibility for reliable and quantitative CTSS activity detection that can be performed in almost every laboratory.
© 2016 Published by Elsevier B.V.
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1. Introduction
Cathepsin S (CTSS) belongs to a group of eleven currently known
human cysteine cathepsins (Turk et al., 2012). CTSS is a lysosomal and
endosomal cysteine protease expressed in professional antigen present-
ing cells (APCs) such as macrophages, B cells and dendritic cells
(Driessen et al., 1999). Though, also non-professional antigen present-
ing cells such as intestinal epithelial cells have been shown to express
CTSS (Beers et al., 2005). Its main physiological role is the control of
the maturation of MHC class II molecules by generating the class II-
associated invariant chain peptide (CLIP) fragment through invariant
chain (Ii) proteolysis. This proteolysis is a required step for the loading
of antigenic peptide onto the MHC class II heterodimer and the subse-
quent transport to the cell surface where it is involved in T cell activa-
tion (Conus and Simon, 2010). This makes CTSS the main regulator for
MHC class II surface expression in professional and non-professional
APCs (Driessen et al., 1999). Therefore, CTSS is assigned to play a crucial
role for the activation of MHC class II mediated immune responses.
Hence, regulation of this protease seems to be of high importance for
avoiding uncontrolled CD4+ T cell activation. Indeed, enhanced CTSS
protein expression, mRNA expression, protein secretion and activity
dysregulation have an implication for the induction or progress of a
variety of autoimmune diseases. CTSS dysregulation-associated autoim-
mune diseases are, i.e. atherosclerosis (Figueiredo et al., 2015), multiple
sclerosis (Haves-Zburof et al., 2011; Fissolo et al., 2008), psoriasis
(Schonefuss et al., 2010) and the Sjögren's syndrome (Hamm-Alvarez
et al., 2014). Additionally, enhanced CTSS secretion into the intestinal
lumen is reported to promote pain induction during inﬂammatory
bowel disease (Cattaruzza et al., 2011). Furthermore, CTSS dysregula-
tion is also involved in cancer progression (Sobotic et al., 2015). This
involvement of CTSS in the pathogenesis of various diseases makes
this protease an intensely studied drug target (Figueiredo et al., 2015;
Kohl et al., 2015; Vazquez et al., 2015; Jadhav et al., 2014). In order to
evaluate the precise role of CTSS function in this context, not only
protein concentrations of CTSS should be detected but rather its catalyt-
ic activity as protein amount and enzymatic activity do not necessarily
need to correlate. Cathepsins in general provide a broad and overall
similar substrate speciﬁcity which makes it difﬁcult to distinguish
them in experimental settings (Choe et al., 2006).
Different methods have been used to detect speciﬁc CTSS activities
in vitro or in vivo, all of them providing different advantages and
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disadvantages. Most of them focus on the detection of human CTSS.
Here we present a method for in vitro detection of also mouse CTSS
activities based on a ﬂuorogen substrate that has previously been
described to be exclusively cleaved by human CTSS (Lutzner and
Kalbacher, 2008). This method is cheap, speciﬁc, reliable and easy to
perform in a standard laboratory without the requirement of special
technical equipment, besides the requisition of a ﬂuorescence compati-
ble photometer. We think this method could contribute to a progress in
CTSS-related research.
2. Results
2.1. PMGLP is well recognized by recombinant mouse CTSS (rmCTSS)
The CTSS proteolysis activity detecting substrate Mca-
GRWPPMGLPWE-Lys(Dnp)-DArg-NH2 (PMGLP) was primarily de-
signed for the detection of human CTSS activities (Lutzner and
Kalbacher, 2008). Our aim was to determine whether PMGLP is also
suitable for the detection of mouse CTSS. In a ﬁrst step, we therefore
tested several recombinant mouse cathepsins for their cleavage behav-
ior towards PMGLP and compared them to recombinant human (rh)
CTSS (Fig. 1). To assess the general enzymatic activity of the commer-
cially purchased recombinant mouse (rm) cathepsins, we ﬁrst looked
for possible protein digestion in a Coomassie-stained 12% SDS gel
(Fig. 1A, right panel). Since we could not detect any possible
proteolysis-caused loss of function of rhCTSS, rmCTSS, rm cathepsin B
(rmCTSB) and rm cathepsin D (rmCTSD), we next checked for their
ability to cleave the substrate Z-FR-AMC. This substrate (Z-FR-AMC) is
published as being recognized and cleaved by CTSS (Lutzner and
Kalbacher, 2008), CTSB (Barrett, 1980) and CTSL (Malagon et al.,
2010) and was used as a positive control to evaluate the proteolytic
function and protein integrity of these cathepsins. However, rmCTSD
integrity could not be checked by using Z-FR-AMC since this enzyme
is not capable of cleavage this substrate. Both, PMGLP and Z-FR-AMC
display ﬂuorescent properties upon enzymatically catalyzed hydrolytic
cleavage. The increase in detected ﬂuorescence intensity change over
time is therefore equivalent to the amount of proteolytically processed
substrate. This enzymatically catalyzed substrate conversion into a
ﬂuorescent substance was monitored by measuring the ﬂuorescence
intensity change over time, therefore delivering substrate conversion
curves (Fig. 1A, left panels). Fluorescence intensities are measured in
dimensionless “arbitrary units” (AU). Absolute enzymatic activities
were then calculated by performing a linear regression at the beginning
of the substrate turnover curve (Fig. 1B). The slope magnitude of this
linear regression delivers a value for the activity of the tested enzyme
that can be expressed as the difference of ﬂuorescence intensity in
Fig. 1. Recombinant mouse CTSS efﬁciently cleaves PMGLP. Various recombinant mouse (rm) and human (rh) cathepsins (CTS) were tested for their cleavage behavior towards human
cathepsin S (rhCTSS) substrate PMGLP. Z-FR-AMC was used as an activity control since it is efﬁciently cleaved by cathepsin B (CTSB), cathepsin S (CTSS) and cathepsin L (CTSL) but not
cathepsin D (CTSD). Equimolar amounts of recombinant cathepsins were preincubated in either a phosphate buffer at pH 7.5 or a sodium citrate buffer at pH 5.0. After addition of the
ﬂuorogen substrates PMGLP or Z-FR-AMC, ﬂuorescence increase due to substrate conversion was monitored for 60 min at 37 °C. (A) Monitoring of substrate conversion. Fluorescence
increase was recorded for 60 min. Fluorescence intensities were adjusted to the conversion curve with the highest ﬂuorescence increase. Illustrated conversion curves are averaged
curves of three independent experiments. On the right, one representative Coomassie staining of each tested recombinant cathepsin that was separated on a 12% SDS gel.
(B) Illustration of the way how enzymatic activities are calculated. Gray dots represent data points of the substrate conversion that results in an increase of ﬂuorescence intensity. The
solid line indicates the linear regression at the beginning of the enzymatic reaction. The broken line represents the slope magnitude of the linear regression. For details on how the
linearization was performed, see the Materials and methods section. (C) Substrate conversion rates in ΔAU min−1 (pmol enzyme)−1 were computed from the substrate conversion
curves in (A) as described in (B) (see text for further information) (n = 3), error bars represent standard deviation (SD).
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arbitrary units (AU) per time unit and per amount of applied enzyme, or
brieﬂy, as∆AUmin−1 pmol (enzyme)−1 (Fig. 1B). All tested cathepsins,
besides rmCTSD, provided remarkable Z-FR-AMC hydrolysis. Since,
aside from CTSS (Turk et al., 2012), cathepsins generally exhibit stron-
ger proteolysis activity at acidic pH values, we detected enhanced Z-
FR-AMC cleavage at pH 5.0 compared to pH 7.5. The lysosomal location
of cathepsins requires them to be active at acidic conditions, therefore
adapting to the acidic environment in lysosomes providing pH values
usually lower than pH 5 (Mindell, 2012). Hence, most cathepsins pro-
vide their pH optimum at acidic conditions. For example, CTSB requires
a pH around 5.0 (Linebaugh et al., 1999), CTSD a pH around 4
(Cunningham and Tang, 1976) and CTSL, which is autocatalytically acti-
vated at pH 4 and provides maximum activity at pH 5.0 (Dolinar et al.,
1995). Nevertheless, all tested cathepsins were catalytically active and
therefore usable for testing PMGLP (Fig. 1A, left panel). We used
1.0 nmol PMGLP for the detection of 100 pmol recombinant enzyme.
rmCTSB and rmCTSD did not provide any cleavage of PMGLP at both
tested pH values. rmCTSL provided little PMGLP conversion at pH 5.0
but none at pH 7.5 (Fig. 1A and B). As expected, rhCTSS provided
efﬁcient PMGLP hydrolysis at both pH values, pH 5.0 and pH 7.5,
respectively. rmCTSS also provided excellent cleavage of PMGLP at
both of these pH values. The conversion rate per pmol enzyme at
pH 5.0 was even higher than the conversion rate of the human
recombinant CTSS. At a neutral pH of 7.5, both recombinant cathepsin
S proteins, mouse and human, provided comparable PMGLP turnover
(Fig. 1A and B).
2.2. PMGLP is efﬁciently cleaved by lysates of mouse bone marrow-derived
dendritic cells
Recombinant mouse CTSL provided low, but measurable PMGLP con-
version at pH 5. However, no rmCTSL-catalyzed PMGLP turnover could be
detected at pH7.5. Therefore,weperformed further testing for PMGLPus-
ability using a phosphate buffer system at pH 7.5, in order to exclude po-
tential false positive results that might by generated by CTSL activity.
rmCTSS has been shown to provide excellent cleavage behavior also at
neutral pH values (Fig. 1A and B). PMGLP was designed to be used for
the detection of enzymatic activities in human antigen presenting cells
(Lutzner and Kalbacher, 2008). In order to verify the hypothesis that
PMGLP is also suitable for the use in mouse-derived cells or cell lines,
we ﬁrst generated bone marrow derived dendritic cells (BMDCs) from
the bone marrow of wt (Ctss+/+) and CTSS-deﬁcient (Ctss−/−) mice. In
order to lyse the cells efﬁciently without affecting cathepsin activity sev-
eral lysing procedures have been tested. In general, hypotonic lysis was
less harmful to cathepsins compared to lysing procedures using
detergents (data not shown). Therefore, we performed all following ex-
periments using hypotonic cell lysis as described in Materials and
methods. The protein amount of the obtained cell lysate was determined
in every case in order to equalizewhole cell protein amount in each assay
sample. In general, we used 25 μg whole cell protein in a 100 μL sample
containing 10 μM PMGLP. DTT was added in relatively high concentra-
tions (2.8 mM in the reaction assay) to ensure that the catalytic cysteine
residue at the active site remains in a reduced state and therefore pre-
vents from uncontrolled oxidation of the sulfhydryl group that might fal-
sify obtained results. Besides DTT, the buffer contained EDTA to inhibit
metalloproteases, pepstatin A for the inhibition of aspartyl proteases
and Pefabloc for serine and threonine protease inhibition. Lysates from
Ctss+/+ (wt) BMDCs provided efﬁcient PMGLP conversion (Fig. 2A). Addi-
tion of the CTSS-speciﬁc inhibitor LHVSwas expected to completely antic-
ipate substrate hydrolysis. However, aA remarkable substrate conversion
was detected. This could also not be prevented by adding E-64, a highly
selective cysteine protease inhibitor that inhibits all cathepsins. Next,
we used cell lysates of CTSS-deﬁcient (Ctss−/−) BMDCs and checked for
PMGLP hydrolysis (Fig. 2A). Again, we could observe certain background
PMGLP cleavage in untreated as well as in LHVS- and E-64-treated sam-
ples. Surprisingly, we could show that E-64- and LHVS-treated Ctss+/+
samples provided the same background PMGLP hydrolysis as did CTSS-
deﬁcient samples. We therefore concluded that this background PMGLP
hydrolysis occurred independently of the presence of CTSS. Since inhibi-
tion of CTSS using either LHVS or E-64 in Ctss+/+ samples reduced the de-
tected conversion to the same level as in non-inhibited CTSS-deﬁcient
samples, we concluded that the difference is equal to the actual activity
of mouse CTSS. From the obtained results shown in Fig. 2A, we hypothe-
sized that background PMGLP hydrolysis might be caused by any other
protease containing a cysteine residue at its active site that might not be
inhibited by E-64. We therefore incubated cell lysates with Roche Com-
plete Protease Inhibitor that is reported to efﬁciently inhibit all types of
endogenous eukaryotic proteases (Fig. 2B). However, even the use of
this inhibitor did not affect background cleavage and delivered the same
PMGLP hydrolysis rates as did E-64- or LHVS-treated samples from wt
BMDCs as well as samples from Ctss−/− BMDCs. We also checked for
ﬂuorogen behavior of BMDC lysates to evaluate any intrinsic cell
component ﬂuorescence and its putative contribution to the detected
background turnover. Fig. 2C shows that we could not detect any ﬂuores-
cence increase in non-PMGLP treated BMDC lysates. PMGLP itself is also
not cleaved under measuring buffer conditions without adding cell
lysates. We therefore conclude that a yet unidentiﬁed cell lysate compo-
nent contributes to background PMGLP turnover.
2.3. Background turnover remains constant under different stimulation
conditions
In order to prove that PMGLP is suitable for reliable detection of CTSS
activities in mouse cell lysates despite the observed background hydro-
lysis, we differentially stimulated mouse BMDCs and tested for PMGLP
cleavage with and without cathepsin inhibitor E-64.
Stimulation of BMDCs with TLR ligands like gram-negative bacteria
results in a maturation process altering the phenotype of the dendritic
cell. We have already shown that a commensal pathobiotic gut bacteria,
Escherichia coli mpk, induces complete DC maturation in vitro as well
in vivo (Muller et al., 2008; Frick et al., 2006). One of themost important
maturation-associated proteins is MHC II, whose surface expression is
drastically enhanced during DC maturation (Frick et al., 2006). Since
CTSS is known to play a critical role in this process (Driessen et al.,
1999), we stimulated BMDCs with maturation-inducing gram-
negative E. colimpk for 2 h or 18 h, respectively. Since the maturation
process should be in a different stage after 18 h of bacterial stimulation
compared to 2 h stimulation, we expected to detect different MHC II
surface expression and therefore different CTSS activity.
We generated mouse BMDCs from three different individuals and
ﬁrst checked the maturation state of the respective cells after E. coli
mpk stimulation. For this purpose, we deﬁned the maturation state of
CD11c+ BMDCs by their proportion of MHC II high positive (hi+) cells,
as published previously (Frick et al., 2006). Fig. 3A demonstrates that
stimulation of immature CD11c+ BMDCs for 2 h with E. coli mpk led
to slight enhancement of the proportion of MHC II hi+ CD11c+
BDMCs. However, the proportion of MHC II hi+ cells among all
CD11c+ BMDCs rose up to about 61% after 18 h of E. colimpk stimula-
tion compared to only about only 31% MHC II hi+ CD11c+ BMDCs in
the unstimulated mock control (Fig. 3A).
Additionally, we checked for PMGLP hydrolysis efﬁciency in BMDCs
that were stimulatedwith E. colimpk for either 2 h or 18 h, respectively.
Fig. 3B shows that PMGLP hydrolysis 2 h after E. coli mpk stimulation
was signiﬁcantly higher compared to PMGLP conversion in BMDCs
that were stimulated for 18 h. We used E-64 to check for background
PMGLP conversion (Fig. 3C). Although not being a selective CTSS
inhibitor, we consider E-64 to be suitable for ﬁnal speciﬁc CTSS activity
computation, since we demonstrated that the use of E-64 and the
speciﬁc CTSS inhibitor LHVS resulted in the detection of the same
background activity (Fig. 2A). E-64 has the advantage of being cheap
and easily commercially available without being disadvantageous for
reliable background activity detection. Although we could observe
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slight differences in PMGLP hydrolysis under E-64 treatment between
BMDCs generated from different individuals (Fig. 3C), there was no
signiﬁcant difference between BMDCs that were stimulated for 2 h
and 18 h with E. coli mpk (Fig. 3D). Final CTSS activity has been
determined by subtracting the slope magnitude of a linear regression
at the beginning of the enzymatically catalyzed PMGLP hydrolysis in
inhibitor-treated samples from the slope magnitude of non-inhibitor-
treated samples of BMDCs generated from the same individual. This re-
sulted in a signiﬁcantly enhanced CTSS activity for 2 h E. colimpk treated
BMDCs compared to 18 h stimulated BMDCs (Fig. 3D). This correlates
well with the detected surface expression of MHC II (Fig. 3A), since
2 h after TLR-inducedmaturation of BMDCs, CTSS activity is upregulated
to start the maturation of the MHC II complex through invariant chain
processing, ﬁnally resulting in enhanced MHC II surface expression
18 h after E. colimpk stimulation. At this point, CTSS activity seems to
be downregulated since no further MHC II transport to the cell surface
is required for BMDC maturation.
2.4. Recommended experimental workﬂow for the detection of CTSS activi-
ties in mouse antigen presenting cells
In summary, we recommend the following workﬂow using PMGLP
as a ﬂuorogen substrate for the detection of cathepsin S activities from
mouse derived cells (Fig. 4). Cells are harvested as carefully as possible
followed by hypotonic lysis as described in the Materials and methods
section. In order to compare cathepsin S activities in different samples,
equal protein amounts should be used in all tested samples. Each
sample is then divided into two: one sample is pre-incubated with
cathepsin inhibitor E-64, whereas the other one is not. PMGLP is
added into both samples followed by measuring ﬂuorescence intensity
increase as a function of time. PMGLP turnover rates are computed as
described in Fig. 1B and the Materials and methods section. The
mathematical difference between the PMGLP turnover rates in the E-
64 pre-incubated sample and the non-inhibited sample is directly
equivalent to the activity of mouse cathepsin S. We want to underline
that it is crucial for a successful CTSS activity detection to keep the
samples on ice throughout the entire experiment. Unfortunately, after
blast freezing in liquid nitrogen, samples cannot be frozen again for
longtime storage since this leads to a dramatic loss of enzymatic activity
(data not shown). Additionally, long time storage in liquid nitrogen,
starting directly after adding deionized water for the hypotonic lysis,
also leads to a remarkable, yet not complete, reduction of enzymatic
activity (data not shown). Hence, the whole experimental setup should
be performed in one go in order to obtain the best possible results.
3. Discussion
Altered cathepsin S (CTSS) activities have been published to play
crucial roles in the pathology of several ailments, especially autoim-
munediseases (Figueiredo et al., 2015;Haves-Zburof et al., 2011; Fissolo
et al., 2008; Schonefuss et al., 2010; Hamm-Alvarez et al., 2014;
Cattaruzza et al., 2011). In light of these ﬁndings, the interest in reliable
methods of detecting the activity of CTSS in human andmouse samples
has grown, especially in the context of investigations into intrinsic CTSS
regulation mechanisms. Several new applications for CTSS activity de-
tection have been published within the last few years. Most of them,
Fig. 2. Ctss+/+BMDCs fail to speciﬁcally cleave PMGLP. Bone marrow derived dendritic cells (BMDCs) from wildtype (Ctss+/+) and cathepsin S-deﬁcient (Ctss−/−) mice were generated
and lysed as described. 25 μg whole BMDC lysate protein was tested for PMGLP cleavage behavior at pH 7.5. Substrate cleavage was monitored by observing ﬂuorescence increase at
405 nm. (A) Ctss+/+ and Ctss−/− BMDC lysates were pre-incubated with all-cathepsin-inhibitor E-64, speciﬁc CTSS inhibitor LHVS or without any inhibitor before PMGLP addition.
PMGLP cleavage was monitored for 60 min at 37 °C. Conversion curves are shown on the left. Speciﬁc substrate conversion rates in ΔAU per minute and μg whole BMDC lysate protein
(ΔAU min−1 μg−1) were computed as described in the Materials and methods section and are shown on the right. (B) Pre-incubation of Ctss+/+ BMDC lysate with LHVS was
compared to Roche Complete Protease Inhibitor (RC). Conversion curves are shown on the left, speciﬁc conversion rates on the right. (C) Top: conversion curve of PMGLP at 405 nm in
pH 7.5 and pH 5.0 measuring buffer without addition of BMDC lysates, bottom: conversion curve of BMDC lysates without addition of PMGLP at 405 nm in pH 7.5 and pH 5.0
measuring buffer. (A–C) Illustrated conversion curves are averaged curves of three independent experiments. Statistical analyses were performed using Student's t-test. *p b 0.05,
**p b 0.01, n = 3, error bars represent standard deviation (SD).
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however, provide distinct disadvantages for high-throughput usage.
Four criteria should be fulﬁlled to deliver an adequate substrate or
detection method: First, since most basic research is performed using
mouse models or mouse cell lines, an application must not only be
suitable for human samples but also for mouse-derived samples.
Second, high speciﬁcity has to be guaranteed. Cathepsins in general pro-
vide a broad range of potential endogenous or exogenous substrates
(Choe et al., 2006). This physiologically valuable property makes them
poor targets for speciﬁc detection. Other cathepsins than CTSS, especial-
ly abundant and highly expressed cathepsins like cathepsin B (CTSB),
need to be prevented from interfering with the detection method, as
they might otherwise falsify obtained results. Third, the application
should be able to be performed in a standard laboratory without
requiring specialized and expensive equipment. Fourth, the results
should be quantitative and reproducible. For the in vitro detection of
mouse CTSS activities, several oligopeptide substrates have been used.
A commercially available aminomethylcoumarine coupled pentapep-
tide Ac-KQKLR-AMC is described as detecting speciﬁcmouse CTSS activ-
ities (Balce et al., 2014). However, this substrate has also been shown to
be efﬁciently cleaved by CTSB (O'Brien et al., 2008). The dipeptide sub-
strate Z-FR-AMC has been widely used to detect the activities of CTSB,
CTSS and CTSL in one experimental setting. Since the substrate is
cleaved by all three cathepsins, the main discrimination between CTSS
on the one side and CTSL and CTSB on the other side was performed
by measuring at different pH values. In contrast to CTSB and CTSL,
CTSS shows efﬁcient protease activity even at neutral pH values. The ac-
tivity optimum of cathepsins B and L at acidic pH values is due to their
location in acidiﬁed lysosomes where they have to fulﬁll their biological
role in degrading proteins (Turk et al., 2012), but CTSS retains activity at
pH 7.0 to 7.5 (Kirschke et al., 1989). However, as demonstrated here,
slight Z-FR-AMC hydrolysis caused by CTSB can even occur at neutral
pH and therefore makes reliable CTSS activity detection using this
method unlikely. Activity probes of different chemical structures are
widely used for activity detection of one or more cathepsins in one sin-
gle assay. DCG-04 and DCG-0N are probably the most prominent ones
(Hoogendoorn et al., 2011). Garenne et al. have recently published a
diazomethylketone probe for the detection of extra- and intracellular
human CTSS activities (Garenne et al., 2015). However, it has not been
demonstrated to be suitable for the detection of mouse CTSS. Like all
activity based probes, DCG-04 and the diazomethylketone probe only
deliver semi-quantitative results based on normalized band intensities
on an electrophoresis-assisted gel. For the generation of quantitative
results, the use of a ﬂuorogen substrate provides advantages over
activity probes. A certain ﬂuorogen substrate, Mca-GRWPPMGLPWE-
Lys(Dnp)-DArg-NH2 (PMGLP), has been shown to be cleaved speciﬁcal-
ly by CTSS in human antigen presenting cells (Lutzner and Kalbacher,
2008). We showed that the use of this substrate is also suitable for the
quantitative detection of CTSS in mouse antigen presenting cells. The
experimental procedure is easy, fast, cheap, and delivers reliable and
highly reproducible results. Besides the substrate itself, all other compo-
nents and chemicals are easily available and the detection of substrate
conversion merely requires the availability of a heatable ﬂuorescence
compatible photometer and no further expensive or special technical
equipment.We strongly recommend performing the entire experiment,
Fig. 3. Background PMGLP conversion remains constant in samples with different CTSS activity. Bone marrow derived dendritic cells from wildtype (Ctss+/+) mice were generated as
described. At day 7 after bone marrow isolation, differentiated BMDCs were stimulated with E. colimpk for 2 h or 18 h respectively. (A) E. colimpk stimulated and non-stimulated
(mock) control BMDCs were stained with antibodies against CD11c and MHC II for ﬂow cytometrical analysis. Only CD11c+ cells were analyzed for MHC II surface expression (lower
panel). Each contour blot is representative for 3 independent experiments. Mean proportions (±SEM) of MHC IIhi+ cells among all CD11c+ cells are indicated inside the contour blots.
(B, C, D) After stimulation, BMDCs were lysed and 25 μg whole BMDC lysate protein was tested for PMGLP cleavage behavior at pH 7.5. Substrate cleavage was monitored by observing
ﬂuorescence increase at 405 nm. (B) Conversion curves of PMGLP without addition of inhibitor. Each curve represents one of three independent experiments. (C) Conversion curves of
the same samples as in (A), but with the addition of 10 μM E-64. (D) Speciﬁc substrate conversion rates in ΔAU per minute and μg whole BMDC lysate protein (ΔAU min−1 μg−1)
were computed as described in Fig. 1B. Lower panel: result of the mathematical subtraction of the obtained conversion rates in (B)(Aw/o inhibitor) and (C) (A + E-64). Each dot represents
data fromBMDCs generated froma different individual. Statistical analyseswere performedusing Student's t-test. *p b 0.05, **p b 0.01, n=3. Error bars represent standard deviation (SD).
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beginning with cell lysis and ending with ﬂuorometer-based detection
of substrate conversion, in one go. Unfortunately, this means that
samples cannot be stored at temperatures of −80 °C or below since
this results in remarkable loss of CTSS activity in cell lysates therefore
making reliable detection impossible.
In contrast to the cleavage behavior in human APC (Lutzner and
Kalbacher, 2008), mouse bone marrow-derived dendritic cells provide
a certain background cleavage of this substrate that is not caused by
CTSS or any other protease that can be inhibited by E-64 or the Roche
Complete Protease Inhibitor. We still do not know what the cause for
this background hydrolysis of PMGLP is. However, our recommended
workﬂow (Fig. 4) offers a possibility to detect speciﬁc mouse CTSS
activities besides background substrate hydrolysis. After hypotonic
lysis of the cells, we recommend to create two different reaction
samples out of one sample of interest. The ﬁrst sample contains the
substrate, the second both, the substrate and E-64, an inhibitor against
all cysteine cathepsins to detect the background activity. CTSS activity
is therefore equivalent to the difference in PMGLP conversion between
the reaction sample containing no inhibitor and the sample containing
E-64.
Since CTSS is exclusively expressed in professional antigen
presenting cells, we recommend using cell populations which are as
homogenous as possible for CTSS activity detection. Otherwise the cell
amount of CTSS expressing cells can fall below a critical level for reliable
CTSS activity detection.
In summary, we have shown (I) that a speciﬁc CTSS inhibitor is not
necessary for the detection of background activity, therefore the easily
commercially available E-64 can be used and (II) that the background
activity is not different between differentially stimulated APC.
Therefore, this PMGLP-assisted CTSS activity assay is also useable for
high-throughput experiments within a short period of time and we
think that this experimental assay contributes to simplify CTSS related
research.
4. Materials and methods
4.1. Mice
Cathepsin S-deﬁcient (Ctss−/−) and wildtype (Ctss+/+) mice have
been generated by mating Ctss+/− mice. Ctss+/−mice were kindly
provided by the lab of Thomas Reinheckel, University of Freiburg,
Germany. All animal experiments were reviewed and approved by the
responsible Institutional Review Board.
4.2. Bacteria
E. coli mpk was used for stimulation of mouse bone marrow
dendritic cells (BMDCs). This E. coli mpk strain was grown in Luria-
Bertani (LB) medium under aerobic conditions at 37 °C. At the day of
BMDC stimulation, 200 μL of a 5 mL overnight culture was subcultured
and added to 20 mL of fresh LB medium. Bacteria were then cultivated
for another 1.5 h until reaching an OD600 of about 2–3. This guaranteed
using bacteria in the exponential growth phase. Quantiﬁcation of
bacteria was performed by measuring OD at 600 nm. An OD600 of 1.0
is equal to a concentration of 5 × 108 bacteria per mL. This OD-to-
Fig. 4. Experimental workﬂow for the detection of CTSS activities in mouse APC. Cells of
interest are lysed hypotonically followed by blast freezing in liquid nitrogen as
described in Materials and methods section. Supernatant is used for CTSS activity
detection. Out of each sample, two reaction samples containing the same amount of
whole cell protein are created. The ﬁrst sample contains the ﬂuorogen substrate, the
second both, the substrate and the cathepsin inhibitor E-64. Reaction buffer provides a
pH of 7.5 to minimize false positive substrate conversion caused by other cathepsins.
Substrate conversion is monitored for 60 min at 37 °C. A linear regression at the very
beginning of the sigmoidal conversion curve is performed for both reaction samples. The
slope magnitude of this linear regression is equivalent to the substrate conversion per
time unit. The difference in the slope magnitude of both reaction samples is equivalent
to the CTSS activity in the sample the lysate was taken from. CTSS activities can
therefore be expressed as the difference of ﬂuorescence intensity per μg cell protein and
time unit, i.e. ∆AU min−1 μg−1.
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concentration correlation was conﬁrmed by plating E. coli mpk on LB
agar plates.
4.3. Recombinant cathepsins
The recombinant mouse (rm) cathepsins cathepsin S (rmCTSS) and
cathepsin B (rmCTSB) were purchased from Sino Biological.
Recombinant mouse cathepsin D (rmCTSD) and recombinant mouse
cathepsin L (rmCTSL) were purchased from R&D. Recombinant human
CTSS (rhCTSS) was kindly provided by the lab of Hubert Kalbacher,
University of Tübingen.
4.4. Fluorogen cathepsin activity substrates
The substrate for speciﬁc detection of human CTSS activities, Mca-
GRWPPMGLPWE-Lys(Dnp)-DArg-NH2 (PMGLP), was provided by the
lab of Hubert Kalbacher, University of Tübingen,Germany. The substrate
Z-FR-AMC was purchased from Peptide Institute, Rep. of Korea.
4.5. Generation of bone marrow-derived dendritic cells
Bonemarrowcellswere isolated fromwt (Ctss+/+) and Ctss−/−mice
and differentiated to bone marrow derived dendritic cells (BMDCs) as
described previously (Lutz et al., 1999).
4.6. Stimulation of bone marrow-derived dendritic cells
At day 7 after bone marrow isolation, resulting CD11c+ bone
marrow derived dendritic cells were stimulated for 2 h or 18 h with
E. colimpk. BMDCs were harvested, counted and 2 × 106 BMDCs were
incubated with E. coli mpk using MOI 1 for 2 h and 18 h respectively
at 37 °C and 5% CO2. MOI stands for “multiplicity of infection” and refers
to the number of bacteria used per cell for stimulation. The usedMOI of
1.0 is known to efﬁciently induce maturation of BMDCs (Frick et al.,
2006). As cell purity controls, a part of each sample was analyzed by
ﬂow cytometry to determine CD11c surface expression. All samples
contained at least 80% CD11c+ cells and were therefore named BMDCs.
4.7. SDS gel electrophoresis and Coomassie staining of recombinant
cathepsins
500 ng of each recombinant cathepsin were loaded on a 12%
polyacrylamide gel. Proteins were then separated via SDS-PAGE. After-
wards, gels were transferred into a staining solution consisting of 10%
(v/v) glacial acetic acid, 40% (v/v) MeOH, 0.1% (w/v) Coomassie R250
dye. Gels were incubated in this staining solution at room temperature
overnight followed by destaining in 10% (v/v) glacial acetic acid and 20%
(v/v) MeOH for approximately 2 h.
4.8. Hypotonic lysis of bone marrow derived dendritic cells
BMDCs were harvested and centrifuged for 5 min at 400 ×g. Cells
were then lysed hypotonically using 100 μL de-ionized sterile water
per onemillion cells. After incubation for 30min on ice, cell suspensions
were shock frozen at −170 °C and thawed carefully immediately
afterwards, followed by centrifugation for 10 min at 1000 ×g and 4 °C.
Supernatants were taken for CTSS activity determination.
4.9. Determination of protein concentrations in BMDC lysates
Protein concentrations of BMDC lysates were determined using a
commercially available BCA kit (ThermoScientiﬁc).
4.10. Detection of CTSS activities using PMGLP or Z-FR-AMC as ﬂuorogen
substrates
25 μL de-ionized water containing 25 μg whole cell protein of lysed
BMDCs or 25 μL deionized water containing 0.5 pmol recombinant
cathepsin were added to 70 μL pH 7.5 reaction buffer (0.1 M phosphate
buffer pH 7.5, 4mMDTT, 4mMEDTA, 1mMPefabloc (Sigma) and 1 μM
pepstatin A) or pH 5.0 reaction buffer (0.1 M sodium citrate buffer
pH 5.0, 4 mM DTT, 4 mM EDTA, 1 mM Pefabloc (Sigma, Germany) and
1 μM pepstatin A), respectively. After 10 min pre-incubation at RT,
PMGLP was added at a ﬁnal concentration of 10 μM or Z-FR-AMC at a
ﬁnal concentration of 10 μg mL−1. Hydrolysis of PMGLP was tracked
by observing the ﬂuorescence increase of the ﬂuorophore at 405 nm
when excited at 340 nm using a Tecan Inﬁnite 200 Fluororeader. Z-FR-
AMC hydrolysis was observed at 441 nm when excited at 342 nm. For
the determination of substrate conversion rates and therefore
enzymatic activities, a linearization of the substrate conversion curve
was performed. For this purpose, ﬂuorescence increase as a function of
time was detected for 60 min at 37 °C. At the very beginning of the
enzymatically catalyzed substrate conversion leading to an increase in
ﬂuorescence intensity, the ﬂuorescence intensity increases linearly
before reaching a plateau. Fifteen to twenty pairs of variates of the linear
ﬂuorescence progression at the very beginning of the substrate
conversion were taken for mathematical linearization. This was
performed using GraphPad Prism 5.0. This program was used to (Turk
et al., 2012) determine the R2 value in order to assess the quality of ﬁt
of the linear curve and (Driessen et al., 1999) to determine the slope
of the linear regression. Only linear curves providing R2 values greater
than 0.99 were further analyzed. The obtained slopes from the linear
curves directly correspond to the ﬂuorescence increase per time unit
usually expressed as ∆AU min−1. AU stands for “arbitrary units” in
order to refer to the dimensionless measurements of ﬂuorescence
intensities. If protein amounts or concentrations are known, this
information can be included into the unit, leading to ∆AU min−1 μg−1
or ∆AU min−1 nmol−1.
4.11. Inhibition of proteases
In order to inhibit all cathepsins or CTSS alone in the reaction sample
(2.10), E-64 and LHVS were added 10 min before substrate addition to
the reaction buffer at ﬁnal concentrations of 500 nM or 10 nM, respec-
tively. Roche Complete Protease Inhibitor (RC) was added according to
the manufacturer's instructions.
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ABSTRACT
In recent years, a growing interest in pathophysiological processes that are 
associated with the endosomal and lysosomal protease cathepsin S (CTSS) 
results in an increasing number of various published methods for CTSS 
aĐiǀitǇ deteĐioŶ. CTSS has ďeeŶ ƌepoƌted to ďe iŶǀolǀed iŶ the pathologǇ of 
autoiŵŵuŶe diseases like ŵuliple sĐleƌosis as ǁell as iŶ tuŵoƌ gƌoǁth aŶd 
Alzheiŵeƌ’s disease. These iŵpliĐaioŶs ŵake this eŶzǇŵe a iƌst Đlass dƌug 
taƌget. IŶ oƌdeƌ to fullǇ uŶdeƌstaŶd the iŶǀolǀeŵeŶt of CTSS iŶ the foƌŵaioŶ of 
pathologiĐal pƌoĐesses, geŶe aŶd pƌoteiŶ eǆpƌessioŶ aŶalǇsis is Ŷot suiĐieŶt. 
Ratheƌ, oŶe should foĐus oŶ the ƌegulaioŶ of its eŶzǇŵaiĐ aĐiǀitǇ. DifeƌeŶt 
appƌoaĐhes foƌ CTSS aĐiǀitǇ deteĐioŶ aƌe aǀailaďle aŶd desĐƌiďed. Hoǁeǀeƌ, 
some of these approaches are not suitable for a standard laboratory without 
speĐial eƋuipŵeŶt oƌ teĐhŶiĐal eǆpeƌise oƌ pƌoǀide otheƌ liŵitaioŶs. We haǀe 
ƌeĐeŶtlǇ puďlished aŶ easǇ-to-peƌfoƌŵ pƌotoĐol foƌ ƌeliaďle, ƋuaŶiiaďle aŶd 
ƌepƌoduĐiďle CTSS aĐiǀitǇ deteĐioŶ. IŶ this ƌeǀieǁ ǁe ǁaŶt to disĐuss ouƌ 
appliĐaioŶ aŶd Đoŵpaƌe it ǁith otheƌ puďlished ŵethods aŶd pƌotoĐols. This 
might help researchers who are interested in CTSS research to decide which 
appliĐaioŶ its ďest to theiƌ teĐhŶiĐal oƌ peƌsoŶal faĐiliies. 
The challenge of specific Cathepsin S activity detection in 
experimental settings 
Alex Steimle and Julia-Stefanie Frick*
Institute of Medical Microbiology and Hygiene, University of Tuebingen, Tübingen, Germany
Text
Cathepsin S (CTSS) is a protease located in lysosomes or 
endosomes of professional antigen presenting cells (APC), such 
as macrophages, dendritic cells and B cells1. Dysregulated CTSS 
expression and/or activity has been reported to be involved in the 
pathogenesis of various diseases. CTSS is the major regulator of major 
histocompatibility complex (MHC) II surface expression. Therefore, 
especially autoimmune diseases which are caused by (or which are 
associated with) pathologically enhanced CD4+ T cell activation 
are part of this disease portfolio. In this context, the Sjögren’s 
syndrome2, atherosclerosis3, psoriasis4 and an animal model of 
rheumatic arthritis5 play dominant roles. But not only autoimmune 
diseases are associated with CTSS dysregulation. Enhanced CTSS 
activity could also be detected in the bronchoalveolar lavage of cystic fibrosis patients6. Neurologists might focus on the role of CTSS 
in the development of multiple sclerosis (MS) and experimental 
autoimmune encephalomyelitis (EAE), the corresponding mouse 
model of MS7. Indeed, it could already been shown that CTSS is 
capable of myelin basic protein proteolysis8 which might contribute 
to the observed phenotypes in MS patients. In fact, enhanced 
CTSS levels could be found in peripheral blood mononuclear cells, serum and the cerebrospinal fluid of MS patients9-12. In line with 
these observations, chemical inhibition of CTSS led to a reduction 
of phenotypical severity in the EAE mouse model5,13. Besides MS 
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patients, enhanced CTSS activity at the primary site in breast 
cancer patients correlated with an increased frequency 
of the appearance of brain metastases14. The implication 
of CTSS concerning cancer was linked with with tumor-
associated APCs, namely macrophages15. Alzheimer’s 
disease (AD) was already reported to be associated with a 
malfunctioning Cathepsin B (CTSB) activity regulation16,17. 
But also human Cathepsin S seems to be involved in the 
manifestation of the disease phenotype since also CTSS provides Ⱦ-secretase activity18 which leads to the AD phenotype causing agent AȾ peptide through amyloid 
precursor protein proteolysis19. One important feature of 
CTSS, distinguishing it from other cysteine cathepsins, is the 
retention of its proteolytic activity at neutral pH. Being part 
of the endosomal and lysosomal compartment, CTSS can 
be secreted into the extracellular space providing neutral 
pH where it can cause additional pathologies. Extracellular 
CTSS activity has already been shown to be involved in 
activating protease-activated receptors (PAR) like PAR
2
 as 
well as G-protein coupled receptors like Mrgprs leading to 
the promotion of itch and pain sensation in both cases20-23.
All the above mentioned implications for CTSS activity 
dysregulation which are linked with manifestation of various 
pathologies makes this enzyme an attractive and intensely 
studied drug target. Some studies just refer to enhanced 
Ctss gene expression rates or increased protein amounts 
inside or outside of target cells. However, mRNA expression 
levels of a protease-encoding gene or expression of the 
corresponding protein does not necessarily correlate with 
the overall detected activity of the respective enzyme. This 
is due to several possible posttranscriptional regulation 
mechanisms that can occur inside or outside a eukaryotic 
cell. Proteases can be (i) translated as inactive zymogens 
requiring proteolytic activation, (ii) activated by co-
factors, (iii) separated from their substrates by localization 
in distinct intra- or extracellular compartments or (iv) 
inhibited by binding of endogenous inhibitors to the active 
site of the protease24. All these examples illustrate that focusing on mRNA or protein expression is not sufficient 
to reliably investigate the role of proteases in biological or pathophysiological processes. Therefore, specific detection 
of the activity of a certain protease has to be guaranteed 
in order to exclude false positive detection of one or more other proteases with a similar substrate specifity. This is a 
grave problem concerning the protease group “cathepsins”, 
which consists of currently eleven known members25, since 
cathepsins in general provide a broad and overall similar substrate specifity26. This makes CTSS activity detection a 
challenge, in vitro, ex vivo and especially in vivo.
But how can an experimentator achieve the goal to 
reliably detect CTSS activity in the biological system of 
choice? There are several possibilities how CTSS activity 
can be detected, all of them with their characteristic 
advantages and limitations. A suitable CTSS activity 
detection method should match the following four criteria: ȋiȌ high specifity, ȋiiȌ high sensitivity since CTSS expression is restricted to APC, ȋiiiȌ the experimental workflow 
should be able to be performed in a more or less standard 
laboratory without the requirement of highly special 
technical equipment and (iv) the method should deliver reproducible and quantifiable results. We summarize some 
available techniques for CTSS activity detection with their 
characteristic pros and cons in table 1. 
Popular approaches include activity based probes 
(ABPs). These are small reporters of proteolytic activity 
which bind covalently and irreversibly to the active site 
of the target enzymes27 leading to a loss of enzymatic 
activity. This irreversible CTSS inhibition should be kept 
in mind if in vivo monitoring shall be performed. ABPs 
usually consist of three distinct functionalities (Fig. 1A): 
(1) The so-called warhead functionality leads the probe to 
enzymes sharing a common catalytic mechanism, (2) the recognition element that enhances specificity for one or more specific enzymes and ȋ͵Ȍ a tag for a later detection 
of the tagged enzymes. Such ABPs exist for the detection 
of human and mouse CTSS. General disadvantages of such ABPs include a lack of specificity for CTSS for some of these 
ABPs. This has then to be compensated by further time-
consuming experimental approaches like western blotting, 
immunoprecipitations etc. Additionally, CTSS activity can 
often only be determined in a semi-quantitative manner 
like measuring band intensities on a gel or a detection of overall fluorescence intensity. (owever, the potential 
labelling of proteolytically active CTSS in live cells due to 
cell permeability is a big advantage of some ABPs. Veilleux 
et al. developed radioiodinated ABPs to selectively label 
active CTSS in human whole blood28. Ben-Aderet et al.29 
and Oresic Bender et al.30 used fluorogenic ABPs to monitor 
enzymatically active CTSS in human cells or live mice, 
respectively. Other examples of recent ABPs development 
for CTSS activity detection include the publications of 
Barlow et al.31, Hughes et al.32, Mertens et al.33 and Garenne 
et al34. (owever, some of them provide a lack of specificity 
for CTSS and also label other cathepsins29,32-35 while other 
ABPs selectively label human or mouse CTSS28,30,36. Another 
general disadvantage of ABPs include the requirement 
of more specialized detection techniques that a non-
specialized lab could tentatively not afford. 
Recently, commercially available CTSS activity detection 
kits have been developed and are sold. Experiences made 
by our group revealed, however, that these kits are far less specific than they are advertised to be and we strongly 
recommend to use alternative techniques for reliable CTSS 
activity detection. If this is not possible, a strict validation of the claimed specificity for CTSS should be performed, i.e. 
using recombinant enzymes or knock-out cells for various 
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cysteine cathepsins.
Other approaches include an indirect method to 
determine CTSS proteolytic (table 1) activity by not directly 
assessing the enzymatic activity but rather determining the 
intracellular amount of the MHC II-bound invariant chain 
fragment (Iip10), which is a substrate for CTSS. Therefore, 
decreased amounts of Iip10 is stated to correlate with 
enhanced CTSS activity5. Since CTSS is translated into an 
inactive pro-enzyme requiring proteolytical cleaving which 
results in a 24 kDa active enzyme, some publications refer 
to the band intensities of this 24 kDa band when making 
statements on CTSS activity37. However this does not 
AppliĐaioŶ 
ĐategoƌǇ ChaƌaĐteƌisiĐ Example taƌget
Yeaƌ 
puďlished
QuaŶiiĐaioŶ 
ŵethod LiŵitaioŶ
OutstaŶdiŶg 
adǀaŶtage
AĐiǀitǇ ďased 
probe (ABPs)
covalent 
binding to 
CTSS aĐiǀe 
site leading 
to enzyme 
iŶhiďiioŶ
GB12329
HuŵaŶ CTSS 
and CTSB
2015 Fluorescent label
BiŶds also to CTSB. 
Gel-assisted enzyme 
sepaƌaioŶ oƌ IP 
needed
Non invasive 
in vivo imaging 
possible
Probe 736 HuŵaŶ CTSS 2015 Fluorescent label Not cell permeable SpeĐiiĐitǇ foƌ 
CTSS
)-PƌaVG-DMG32
HuŵaŶ CTSS, 
CTSB and 
CTSL
2016
Rhodamine azide 
labelling
Similar K
i
 values for 
CTSS, CTSB and CTSL
Cell-
permeability of 
the substrate
CM-Ϯϳ935 HuŵaŶ CTSS 
and CTSL
2013
Luciferase assisted 
light deteĐioŶ Also labels CTSL
Reliable 
deteĐioŶ of 
combined CTSS 
aŶd CTSL aĐiǀitǇ
BMVϭϱϳ30 Mouse CTSS 2015 Fluorescent label availability
HighlǇ speĐiiĐ, 
in vivo and in 
ǀitƌo appliĐaioŶ 
possible
BIL-DMK28 HuŵaŶ CTSS 2011 RadioaĐiǀe laďel RadioaĐiǀitǇ SpeĐiiĐitǇ foƌ 
CTSS
Probe 1033
HuŵaŶ CTSS, 
CTSL, CTSB 
aŶd CTSK
2014 Fluorescent label Not speĐiiĐ foƌ CTSS
Suitable for 
complex protein 
mixtures
Biot-(PEG)
2
-Ahx-
LeuValGlǇ-DMK34
HuŵaŶ CTSS, 
CTSL, CTSB 
and CTSL
2015
SDS Page 
assisted chemi-
luminescence
Not speĐiiĐ foƌ CTSS Easy to perform
Substrate 
based probes 
(SBP)
Substrate 
turnover; 
enzyme is 
not inhibited 
and remains 
pƌoteolǇiĐallǇ 
aĐiǀe
PMGLP
HuŵaŶ 
CTSS43 aŶd 
ŵouse CTSS42
2016
FluoƌesĐeŶĐe 
iŶĐƌease
ReƋuiƌes Đell lǇsis 
aŶd iŶhiďiioŶ 
ĐoŶtƌol
Siŵple 
eŶzǇŵaiĐ 
assaǇ, easǇ-to-
peƌfoƌŵ, iŵe 
saǀiŶg. 
AĐ-KQKLR-AMC Mouse CTSS 2014 Fluorescence 
increase
Requires cell lysis 
aŶd iŶhiďiioŶ 
control
Simple 
eŶzǇŵaiĐ assaǇ
NB20031
Mouse CTSS, 
CTSK aŶd 
CTSB
2015
Fluorescence 
increase
DeteĐts also CTSK at 
pHϳ.ϱ aŶd CTSB at 
pH ϱ.ϱ
Simple 
eŶzǇŵaiĐ assaǇ
)-FR-AMC
Mouse CTSS, 
CTSB and 
CTSL
2002
Fluorescence 
increase
UŶspeĐiiĐitǇ, 
requires extensive 
eǆpeƌiŵeŶtal seiŶg
Simple 
eŶzǇŵaiĐ assaǇ
Indirect 
deteĐioŶ 
methods
Does Ŷot 
directly 
interact with 
CTSS
DeteĐioŶ of 
CTSS substrate 
aĐĐuŵulaioŶ ďǇ 
ǁesteƌŶ ďloiŶg3
Mouse 
invariant 
chain p10 
deteĐioŶ
2015
WesteƌŶ ďlot ďaŶd 
intensity of Iip10
Does Ŷot deteĐt 
CTSS aĐiǀitǇ diƌeĐtlǇ
Simple to 
perform
WesteƌŶ ďloiŶg 
of Ϯϰ kDa CTSS37 HuŵaŶ CTSS 2014
WesteƌŶ ďlot ďaŶd 
iŶteŶsitǇ of Ϯϰ kDa 
CTSS
Does Ŷot ĐoŶsideƌ 
poteŶial ďiŶdiŶg 
of endogenous 
inhibitors and does 
Ŷot ƌefeƌ to aĐiǀitǇ
Simple to 
perform
Taďle ϭ: SuŵŵaƌǇ of ǀaƌious CTSS aĐiǀitǇ deteĐioŶ teĐhŶiƋues. The teĐhŶiƋues aƌe gƌouped iŶto the ŵajoƌ fuŶĐioŶal Đlasses. 
Steimle A and Frick JS, J Neurol Neuromed (2016) 1(3): 6-12 Journal of Neurology & Neuromedicine
Page 9 of 12
take the potential binding of endogenous inhibitors into 
account.
Another possibility for direct CTSS activity 
determination is to use substrate-based probes (SBP) like i.e. fluorochrome-coupled peptidyl substrates. The 
principle mechanism includes a detection in the increase 
of a peptidyl-coupled and later proteolytically liberated fluorochrome ȋFigure ͳBȌ. SBPs provide the advantage 
of not inhibiting the target enzyme. Prominent examples 
are Z-VVR-AMC38 , Z-FR-AMC36,39 or Ac-KQKLR-AMC20,40. 
All of them share the aminomethyl coumarin group as a fluorogen tag. Coumarins are popular fluorescent labels 
due to their large stoke’s shifts41 and their small size 
allowing for incorporation into small peptides33 . These 
peptidyl substrates generally provide the disadvantage 
to be usable only in cell lysates and not in living cells 
or organisms. The major potential problem with most peptidyl substrates is the unsatisfactory specificity for 
CTSS. Due to the already mentioned similar substrate specificity among cysteine cathepsins, other cathepsins 
than CTSS can deliver false positive results due to unspecific cleavage of the substrate. (owever, we have 
recently reported on a CTSS activity detection method 
using a coumarin-coupled peptidyl substrate (PMGLP) 
that allows for highly specific CTSS activity detection 
in mouse samples42. This method is a simple standard 
enzymatic assay detecting a time-dependent increase in fluorescence intensity caused by cleaving of the peptidyl 
sequence. It is easy-to-perform, time-saving and can be 
used for high-throughput applications. Additionally, a 
standard curve using free aminomethyl coumarin can be created allowing for the detection of specific enzymatic 
activities within a tested sample which is a big advantage 
over ABPs. The oligopeptidyl substrate we use was initially published as being suitable for highly specific detection 
of CTSS activity in human antigen presenting cells43. 
However, we could demonstrate that is also suitable for mouse samples. The substrate, Mca-GRWPPMGLPWE-
Lys(Dnp)-DArg-NH
2
 (PMGLP) was shown to be cleaved specifically by murine CTSS at a p( of ͹.ͷ with no other 
murine cathepsin contributing to substrate cleaving in cell 
lysates42. The obtained results were easily quantifiable 
and highly reproducible as demonstrated in mouse bone 
marrow derived dendritic cells that were differentiated 
from the bone marrow of different individuals. The presented method therefore delivers specific CTSS 
activities and only requires a phosphate buffer system and a fluorescence compatible heatable photometer making 
the application attractive for less specialized laboratories. 
Figuƌe ϭ: FuŶĐioŶal ĐoŵpaƌisoŶ of the tǁo ŵajoƌ Đlasses of pƌoďes foƌ diƌeĐt CTSS aĐiǀitǇ deteĐioŶ
;aͿ aĐiǀitǇ ďased pƌoďes ;ABPsͿ: The so-Đalled ǁaƌhead ĐoǀaleŶtlǇ liŶks the pƌoďe ǁith CTSS, leadiŶg to the iŶhiďiioŶ of its eŶzǇŵaiĐ 
aĐiǀitǇ. The ƌeĐogŶiioŶ eleŵeŶt suppoƌts the speĐiiĐitǇ foƌ CTSS aloŶe oƌ soŵe ƌelated ĐǇsteiŶe ĐathepsiŶs. The tag alloǁs foƌ lateƌ 
deteĐioŶ of the tagged eŶzǇŵes.
;ďͿ suďstƌate ďased pƌoďes ;SBPsͿ: The thiol gƌoup at the aĐiǀe site of CTSS ŶuĐleophiliĐallǇ ataĐks the pepide ďoŶd of the pepidǇl suďstƌate 
leadiŶg to a deliďeƌaioŶ of the aŵiŶoŵethǇlĐouŵaƌiŶ. The ƌesuliŶg ĐhaŶge iŶ the luoƌogeŶiĐ ďehaǀiouƌ of fƌee aŵiŶoŵethǇlĐouŵaƌiŶ 
ĐaŶ theŶ ďe deteĐted iŶ a luoƌesĐeŶt Đoŵpaiďle photoŵeteƌ.
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We recommend the following simple workflow ȋFigure ʹȌ: 
the target cells are lysed hypotonically with the support of 
freezing in liquid nitrogen. This guarantees a minimal loss 
of CTSS activity due to cell lysis. Protein concentrations of 
the lysates are determined afterwards and each sample is separated into two samples. The first one contains the 
substrate, PMGLP, and the second one PMGLP and E-64, 
a cysteine cathepsin inhibitor that is easily commercially 
available and cheap. The latter sample is used as a negative 
control. Substrate conversion is detected for at least 20 min at ͵͹°C by detection of fluorescence increase at ͶͲͷ nm 
after excitation at 340 nm. Conversion rates are computed 
Figuƌe Ϯ: EǆpeƌiŵeŶtal ǁoƌkloǁ foƌ the deteĐioŶ of CTSS 
aĐiǀiies iŶ ŵouse APC42 ;adapted fƌoŵ Steiŵle et al., ϮϬϭ6Ϳ
Cells of interest are lysed hypotonically followed by blast freezing 
iŶ liƋuid ŶitƌogeŶ as desĐƌiďed iŶ ŵateƌials aŶd ŵethods seĐioŶ. 
SupeƌŶataŶt is used foƌ CTSS aĐiǀitǇ deteĐioŶ. Out of eaĐh saŵple, 
tǁo ƌeaĐioŶ saŵples ĐoŶtaiŶiŶg the saŵe aŵouŶt of ǁhole Đell 
pƌoteiŶ aƌe Đƌeated. The iƌst saŵple ĐoŶtaiŶs the luoƌogeŶ 
substrate, the second both, the substrate and the cathepsin 
iŶhiďitoƌ E-ϲϰ. ReaĐioŶ ďufeƌ pƌoǀides a pH of ϳ.ϱ to ŵiŶiŵize 
false posiiǀe suďstƌate ĐoŶǀeƌsioŶ Đaused ďǇ otheƌ ĐathepsiŶs. 
Suďstƌate ĐoŶǀeƌsioŶ is ŵoŶitoƌed foƌ ϲϬ ŵiŶ at ϯϳ °C. A liŶeaƌ 
regression at the very beginning of the sigmoidal conversion curve 
is peƌfoƌŵed foƌ ďoth ƌeaĐioŶ saŵples. The slope ŵagŶitude of 
this linear regression is equivalent to the substrate conversion per 
iŵe uŶit. The difeƌeŶĐe iŶ the slope ŵagŶitude of ďoth ƌeaĐioŶ 
saŵples is eƋuiǀaleŶt to the CTSS aĐiǀitǇ iŶ the saŵple the lǇsate 
ǁas takeŶ fƌoŵ. CTSS aĐiǀiies ĐaŶ theƌefoƌe ďe eǆpƌessed as the 
difeƌeŶĐe of luoƌesĐeŶĐe iŶteŶsitǇ peƌ µg Đell pƌoteiŶ aŶd iŵe 
uŶit, i.e. ∆AU ŵiŶ-ϭ µg-ϭ.
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by determination of the slopes of the linear fluorescence 
increase and the slope of the inhibitor treated negative 
control is substracted from the slope of the non-inhibitor treated sample. This workflow is fast and the obtained results are highly specific for murine CTSS as demonstrated 
in our published protocol42. We therefore hope to contribute 
to a progress in CTSS related research.
AcknowledgementsWork was supported by the DFG ȋDFG FR ʹ Ͳͺ͹/͸-ͳ, DFG 
FR 2087/8-1, CRC685, SPP1656), the Bundesministerium 
für Bildung and Forschung (BMBF) and the German Centre 
for Infection Research (DZIF)
References
1. Beers C, Burich A, Kleijmeer MJ, Griffith JM, Wong P, Rudensky AY. 
Cathepsin S controls MHC class II-mediated antigen presentation by 
epithelial cells in vivo. J Immunol. 2005;174(3):1205-12.
2. Hamm-alvarez SF, Janga SR, Edman MC, et al. Tear cathepsin S as a 
candidate biomarker for Sjögren’s syndrome. Arthritis Rheumatol. 
2014;66(7):1872-81.
3. Figueiredo JL, Aikawa M, Zheng C, et al. Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with 
chronic renal disease. Am J Pathol. 2015;185(4):1156-66.
4. Schönefuss A, Wendt W, Schattling B, et al. Upregulation of cathepsin S 
in psoriatic keratinocytes. Exp Dermatol. 2010;19(8):e80-8.
5. Baugh M, Black D, Westwood P, et al. Therapeutic dosing of an orally 
active, selective cathepsin S inhibitor suppresses disease in models of 
autoimmunity. J Autoimmun. 2011;36(3-4):201-9.
6. Weldon S, Mcnally P, Mcauley DF, et al. miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S 
production. Am J Respir Crit Care Med. 2014;190(2):165-74.
7. Baxter AG. The origin and application of experimental autoimmune 
encephalomyelitis. Nat Rev Immunol. 2007;7(11):904-12. 
8. Beck H, Schwarz G, Schröter CJ, et al. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human 
myelin basic protein in vitro. Eur J Immunol. 2001;31(12):3726-36.
9. Nagai A, Murakawa Y, Terashima M, et al. Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology. 
2000;55(12):1828-32.
10. Staun-ram E, Miller A. Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: modulation by interferon-Ⱦ and role played in cell 
migration. J Neuroimmunol. 2011;232(1-2):200-6.
11. Bever CT, Garver DW. )ncreased cathepsin B activity in multiple 
sclerosis brain. J Neurol Sci. 1995;131(1):71-3.
12. Haves-zburof D, Paperna T, Gour-lavie A, Mandel I, Glass-marmor 
L, Miller A. Cathepsins and their endogenous inhibitors cystatins: 
expression and modulation in multiple sclerosis. J Cell Mol Med. 
2011;15(11):2421-9.
13. Fissolo N, Kraus M, Reich M, et al. Dual inhibition of proteasomal 
and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J )mmunol. ʹͲͲͺ;͵ͺȋͻȌ:ʹͶͲͳ-ͳͳ.
14. Sevenich L, Bowman RL, Mason SD, et al. Analysis of tumour- and 
stroma-supplied proteolytic networks reveals a brain-metastasis-
promoting role for cathepsin S. Nat Cell Biol. 2014;16(9):876-88.
15. Verdoes M, Edgington LE, Scheeren FA, et al. A nonpeptidic cathepsin 
S activity-based probe for noninvasive optical imaging of tumor-
associated macrophages. Chem Biol. 2012;19(5):619-28.
16. Hook V, Toneff T, Bogyo M, et al. Inhibition of cathepsin B reduces 
beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-
secretase of Alzheimer’s disease. Biol Chem. 2005;386(9):931-40.
17. (ook V, Schechter ), Demuth (U, (ook G. Alternative pathways for 
production of beta-amyloid peptides of Alzheimer’s disease. Biol 
Chem. 2008;389(8):993-1006.
18. Schechter I, Ziv E. Cathepsins S, B and L with aminopeptidases display Ⱦ-secretase activity associated with the pathogenesis of Alzheimer’s 
disease. Biol Chem. 2011;392(6):555-69.
19. Poeck B, Strauss R, Kretzschmar D. Analysis of amyloid precursor 
protein function in Drosophila melanogaster. Exp Brain Res. 
2012;217(3-4):413-21.
20. Zhao P, Lieu T, Barlow N, et al. Cathepsin S causes inflammatory 
pain via biased agonism of PAR2 and TRPV4. J Biol Chem. 
2014;289(39):27215-34.
21. Cattaruzza F, Lyo V, Jones E, et al. Cathepsin S is activated during colitis 
and causes visceral hyperalgesia by a PAR2-dependent mechanism in 
mice. Gastroenterology. 2011;141(5):1864-74.e1-3.
22. Reddy VB, Sun S, Azimi E, Elmariah SB, Dong X, Lerner EA. Redefining 
the concept of protease-activated receptors: cathepsin S evokes itch 
via activation of Mrgprs. Nat Commun. 2015;6:7864.
23. Reddy VB, Shimada SG, Sikand P, Lamotte RH, Lerner EA. Cathepsin 
S elicits itch and signals via protease-activated receptors. J Invest 
Dermatol. 2010;130(5):1468-70.
24. Turk B. Targeting proteases: successes, failures and future prospects. 
Nat Rev Drug Discov. 2006;5(9):785-99.
25. Turk V, Stoka V, Vasiljeva O, et al. Cysteine cathepsins: from structure, 
function and regulation to new frontiers. Biochim Biophys Acta. 
2012;1824(1):68-88.
26. Choe Y, Leonetti F, Greenbaum DC, et al. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem. ʹͲͲ͸;ʹͺͳȋͳͺȌ:ͳʹͺʹͶ-͵ʹ.
27. Serim S, (aedke U, Verhelst S(. Activity-based probes for the study 
of proteases: recent advances and developments. ChemMedChem. 
2012;7(7):1146-59.
28. Veilleux A, Black WC, Gauthier JY, et al. Probing cathepsin S activity 
in whole blood by the activity-based probe BIL-DMK: cellular 
distribution in human leukocyte populations and evidence of diurnal 
modulation. Anal Biochem. 2011;411(1):43-9. 
29. Ben-aderet L, Merquiol E, Fahham D, et al. Detecting cathepsin activity 
in human osteoarthritis via activity-based probes. Arthritis Res Ther. 
2015;17:69.
30. Oresic bender K, Ofori L, Van der linden WA, et al. Design of a highly 
selective quenched activity-based probe and its application in dual 
color imaging studies of cathepsin S activity localization. J Am Chem 
Soc. 2015;137(14):4771-7.
31. Barlow N, Nasser Y, Zhao P, et al. Demonstration of elevated levels 
of active cathepsin S in dextran sulfate sodium colitis using a new 
activatable probe. Neurogastroenterol Motil. 2015;27(11):1675-80.
32. Hughes CS, Shaw G, Burden RE, Scott CJ, Gilmore BF. The application of a 
novel, cell permeable activity-based probe for the detection of cysteine 
cathepsins. Biochem Biophys Res Commun. 2016;472(3):444-50.
33. Mertens MD, Schmitz J, Horn M, et al. A coumarin-labeled vinyl sulfone 
as tripeptidomimetic activity-based probe for cysteine cathepsins. 
Chembiochem. 2014;15(7):955-9.
34. Garenne T, Saidi A, Gilmore BF, et al. Active site labeling of cysteine 
cathepsins by a straightforward diazomethylketone probe derived 
from the N-terminus of human cystatin C. Biochem Biophys Res 
Commun. 2015;460(2):250-4.
Steimle A and Frick JS, J Neurol Neuromed (2016) 1(3): 6-12 Journal of Neurology & Neuromedicine
Page 12 of 12
35. Caglič D, Repnik U, Jedeszko C, et al. The proinflammatory cytokines interleukin-ͳȽ and tumor necrosis factor Ƚ promote the expression 
and secretion of proteolytically active cathepsin S from human 
chondrocytes. Biol Chem. 2013;394(2):307-16.
36. Kohl F, Schmitz J, Furtmann N, et al. Design, characterization and cellular uptake studies of fluorescence-labeled prototypic cathepsin 
inhibitors. Org Biomol Chem. 2015;13(41):10310-23.
37. Castellano J, Badimon L, Llorente-cortés V. Amyloid-Ⱦ increases 
metallo- and cysteine protease activities in human macrophages. J 
Vasc Res. 2014;51(1):58-67.
38. Magister S, Obermajer N, Mirković B, et al. Regulation of cathepsins S 
and L by cystatin F during maturation of dendritic cells. Eur J Cell Biol. 
2012;91(5):391-401.
39. Schwarz G, Boehncke W(, Braun M, et al. Cathepsin S activity is 
detectable in human keratinocytes and is selectively upregulated 
upon stimulation with interferon-gamma. J Invest Dermatol. 
2002;119(1):44-9.
40. Balce DR, Allan ER, Mckenna N, Yates RM. γ-)nterferon-inducible 
lysosomal thiol reductase (GILT) maintains phagosomal 
proteolysis in alternatively activated macrophages. J Biol Chem. 
2014;289(46):31891-904.
41. Katritzky AR, Cusido J, Narindoshvili T. Monosaccharide-based water-soluble fluorescent tags. Bioconjug Chem. ʹͲͲͺ;ͳͻȋ͹Ȍ:ͳͶ͹ͳ-ͷ.
42. Steimle A, Kalbacher H, Maurer A, et al. A novel approach for reliable 
detection of cathepsin S activities in mouse antigen presenting cells. J 
Immunol Methods. 2016;432:87-94.
43. Lützner N, Kalbacher H. Quantifying cathepsin S activity in antigen presenting cells using a novel specific substrate. J Biol Chem. 
2008;283(52):36185-94.
Symbiotic gut commensal bacteria act as host cathepsin S activity
regulators
Alex Steimle a, 1, Kerstin Gronbach a, 1, Brigitte Beifuss a, Andrea Sch€afer a,
Robin Harmening a, Annika Bender a, Jan Kevin Maerz a, Anna Lange a, Lena Michaelis a,
Andreas Maurer c, Sarah Menz a, Kathy McCoy d, Ingo B. Autenrieth a, Hubert Kalbacher b,
Julia-Stefanie Frick a, *
a Institute of Medical Microbiology and Hygiene, University of Tübingen, Tübingen, Germany
b Interfacultary Institute of Biochemistry, Universitiy of Tübingen, Tübingen, Germany
c Institute of Radiology, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen,
Germany
d Department of Clinical Reasearch, Gastroenterology, University of Bern, Bern, Switzerland
a r t i c l e i n f o
Article history:
Received 7 January 2016
Received in revised form
14 July 2016
Accepted 21 July 2016
Available online xxx
Keywords:
Inﬂammatory bowel disease
Cathepsin S
Microbiota
Immunotherapy
Protease regulation
Autoimmune disease
a b s t r a c t
Cathepsin S (CTSS) is a lysosomal protease whose activity regulation is important for MHC-II signaling
and subsequent activation of CD4þ T cell mediated immune responses. Dysregulation of its enzymatic
activity or enhanced secretion into extracellular environments is associated with the induction or pro-
gression of several autoimmune diseases. Here we demonstrate that commensal intestinal bacteria in-
ﬂuence secretion rates and intracellular activity of host CTSS and that symbiotic bacteria, i.e. Bacteroides
vulgatus mpk, may actively regulate this process and help to maintain physiological levels of CTSS ac-
tivities in order to prevent from induction of pathological inﬂammation. The symbiont-controlled
regulation of CTSS activity is mediated by anticipating reactive oxygen species induction in dendritic
cells which, in turn, maintains cystatin C (CysC) monomer binding to CTSS. CysC monomers are potent
endogenous CTSS inhibitors. This Bacteroides vulgatus caused and CysC dependent CTSS activity regu-
lation is involved in the generation of tolerant intestinal dendritic cells contributing to prevention of T-
cell mediated induction of colonic inﬂammation. Taken together, we demonstrate that symbionts of the
intestinal microbiota regulate host CTSS activity and secretion and might therefore be an attractive
approach to deal with CTSS associated autoimmune diseases.
© 2016 Published by Elsevier Ltd.
1. Introduction
Cathepsin S (CTSS) is a lysosomal single-chain protease that is
expressed in professional antigen-presenting cells (APC) like mac-
rophages, dendritic cells (DC) [1] and B cells as well as in non-
professional APC like intestinal epithelial cells [2]. It belongs to
the papain-like cysteine protease family that comprises eleven
members in humans [3]. It is mainly involved in the stepwise
degradation of the MHC-II associated chaperone invariant chain (Ii)
[4]. These proteolytic events are crucial for the loading of antigen-
derived peptides on MHC-II and the subsequent transport of this
MHC-II-peptide complex to the APC surface where it promotes
CD4þ T cell activation [5]. CTSS activity can be inﬂuenced by tran-
scriptional and post-translational regulation or by protein-protein-
interaction with endogenous inhibitors, mainly cystatins [6].
However, there are contradictory reports on cystatin-mediated
CTSS activity regulation [7e10]. Though, adequate regulation of
CTSS is necessary to retain the steady state of CD4þ Tcell dependent
immune responses. In fact, dysregulation of CTSS activity, expres-
sion or secretion into the extracellular space is associated with the
pathogenesis of various autoimmune diseases (AID), i.e. arthritis
[11,12], type-I-diabetes [13], Sj€ogren's syndrome [14,15], multiple
sclerosis [8,16] and atherosclerosis [17,18]. Furthermore, CTSS
secretion contributes to pain induction during inﬂammatory bowel
disease (IBD) [19], another example of AID.
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Due to the implications of CTSS dysregulation for the patho-
genesis of AID, there is an intense search ongoing for the devel-
opment of drugs that are able to speciﬁcally inhibit CTSS proteolytic
activity [20]. Eventually, we demonstrate that an alteration of the
gut microbiota composition can contribute to host CTSS regulation
and that the microbiota composition itself could be decisive to
control host CTSS secretion and activity, hence chemical treatment
might not be necessary. As most autoimmune diseases are associ-
ated with dysbiosis of the intestinal microbiota [21], we compared
effects of symbiotic or pathobiotic commensals on host CTSS ac-
tivities and protein levels in vivo and in vitro. Bacteroides vulgatus
mpk could already be demonstrated to be a symbiotic bacteria,
mediating anti-inﬂammatory effects [22e24] which are directly
associated with the induction of a tolerant DC phenotype termed
semi-mature [23e25].
Here we demonstrate that in an experimental mouse model for
CD4þ T cell mediated colitis, B. vulgatus mpk promotes mainte-
nance of the immune equilibrium via regulation of CTSS activity
and secretion. We further provide evidence, that this regulation is
mediated by altering cystatin C binding behaviour to CTSS through
controlling intracellular levels of reactive oxygen species. This in-
testinal microbiota triggered CTSS regulation might deliver new
possibilities for the treatment of other CTSS dysregulation-
associated AID in general.
2. Materials and methods
2.1. T cell mediated induction of chronic colitis in Rag1/ mice
Germfree (GF) or conventionally colonized (CV) C57BL/6J-
Rag1tm1Mom (Rag1/) mice were transplanted with 5  105 splenic
CD4þCD62LþCD45RBhi wt T cells at 8e10 weeks of age. The con-
ventional microbiota (CV) was free of Norovirus, Rotavirus and
Helicobacter hepaticus. Rag1/ mice were kept under SPF condi-
tions and analyzed after 4e8 weeks after T cell transplantation as
indicated in the results section.
2.2. Administration of cathepsin S inhibitor into Rag1/ mice
Cathepsin S Inhibitor LY3000328 was purchased from ApexBio.
The lyophilized powder was reconstituted in 83% (v/v) NaCl (0.9%),
12% (v/v) DMSO and 5% (v/v) Tween-20 to obtain a concentration of
0.5 mg mL1200 mL suspension was administered daily by intra-
peritoneal injection in order to obtain an amount of 100 mg
Cathepsin S inhibitor per dose. The inhibitor was started to be
administered three days before T cell transplantation and was
continued to be administered for 21 days after T cell
transplantation.
2.3. Determination of cathepsin S activities in BMDC lysates
Cathepsin S activity assays of differentially stimulated bone
marrow derived dendritic cells were performed as described pre-
viously [26,27]. using the ﬂuorogenic substrate Mca-
GRWPPMGLPWEK (Dnp)-D-Arg-NH2 (abbreviated as PMGLP).
Determined activities in stimulated samples were normalized to
the activities detected in unstimulated control samples generated
from the same individual.
2.4. Cultivation of bone marrow derived dendritic cells (BMDCs)
Bone marrow cells were isolated and cultivated as described
previously [28]. At day 7 after isolation, resulting CD11c positive
bone marrow derived dendritic cells (BMDCs) were used for in vitro
experiments.
2.5. Stimulation of bone marrow derived dendritic cells
2  106 BMDCs were stimulated with either PBS or B. vulgatus
mpk or E. coli mpk at a MOI of 1. Cells were stimulated for a
maximum of 24 h. If a second challenge was used, cells were
stimulated with bacteria followed by exchanging used for fresh
medium and by challenging the cells with a second stimulus for a
maximum of 16 h. PBS was used as mock stimulation control.
2.6. Cytokine analysis by ELISA
For analysis of cathepsin S concentrations in cell culture su-
pernatants or blood serum of mice, the CTSS ELISA Kit purchased
from Cusabio Biotech was used according to the manufacturer's
instructions.
2.7. Flow cytometrical analysis
Multi-color FCM analyses were performed on a FACS Calibur or
FACS LSRII (BD Biosciences). All ﬂuorochrome-coupled antibodies
were purchased from BD Biosciences. Data were analyzed using the
FlowJo software (Tree Star Inc., USA).
2.8. Western blotting
For western blot analysis of MHC class II bound invariant chain
and, cystatin C, cathepsin S and the MHC-II bound CLIP fragment,
cells were lysed using 10 mL lysis buffer (50 mM Tris/HCl pH 7.6,
150 mM NaCl, 0.5% (v/v) NP40, 1 Roche Complete Protease In-
hibitor, 0.4 mM DTT) per 106 cells. Non lysed cell components
were removed by centrifugation at 12‘000g. Concentration of
solubilized proteins in the resulting supernatant was measured
using a commercial BCA Kit (ThermoScientiﬁc). A total of 50 mg
was transferred on polyacrylamide gels containing 8%e12% poly-
acrylamide depending on the protein to be detected. Since MHC-
II-invariant chain heterotrimers are stable in SDS solutions but
sensitive towards heating, samples were usually not heated before
electrophoretic separation. Proteins were separated via SDS-PAGE
gels and transferred to nitrocellulose membranes. Membranes
were blocked subsequently for 1 h at room temperature in a BSA
containing blocking buffer (LiCor) followed by incubation with
primary Abs diluted 1:1000 in blocking buffer over night at 4 C.
After incubation the membranes were washed three times in PBS/
T (PBS pH 7.4 þ 0.1% Tween-20) and were subsequently incubated
with ﬂuorochrome coupled secondary antibodies (LiCor) according
to the manufacturer's instruction for 2 h at room temperature.
After repeating the washing step with PBS/T the membranes were
washed twice with PBS to remove detergent from the membranes.
Proteins were detected using the LiCor visualization system.
Before using b-actin (mouse anti-mouse b-actin; Sigma) as a
control for protein loading, the blots were stripped for 20 min
with 10 mL stripping solution (10 mM NaOH, 250 mM guanidi-
nium chloride).
2.9. Puriﬁcation of RNA and quantitative real-time PCR
Puriﬁcation of RNA from BMDCs lysates was performed using
Qiagen's RNeasy Mini Kit according to the manufacturer's in-
structions. Additional DNA digestion was conducted by using 4 U
rDNase I and 40 U rRNasin for a RNA solution of 0.1 mg mL1. After
30 min of incubation at RT, DNase was inactivated using Ambion
DNase inactivation reagent which was later removed by centrifu-
gation for 1 min at 10‘000g. SybrGreen based quantitative RT-PCR
was performed on a Roche LightCycler480 using QiagenSybr-
Green RT-PCR Kit. Primer annealing occured at 60 C. 10e100 ng
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DNA-digested RNA was used for qRT-PCR. Relative mRNA expres-
sion in BMDCs stimulated with bacteria to unstimulated BMDCs
was determined with using b-actin as housekeeping gene using the
DDCp-method that included the speciﬁc ampliﬁcation efﬁciency of
every used primer pair and each PCR run.
2.10. Co-immunoprecipitation and mass spectrometrical analysis
For immunoprecipitation assays we used between 2 and 3 107
BMDCs and stimulated themwith either PBS, B. vulgatusmpkMOI1
or E. coli mpk MOI1. Cells were harvested after 16 h of stimulation,
counted and lysed using 200 mL lysis buffer (50 mM Tris/HCl pH 7.4,
150 mM NaCl, 1 mM EDTA, 1% Nonident P-40, Roche Complete
Protease Inhibitor and Phosphatase Inhibitor) for 1 107 cells. Non-
lysed structures were then separated by centrifugation for 10 min
at 1000g. Protein concentration was measured in each lysate and
the same protein amount was used for IPs in all samples that were
directly compared to each other. 10 mg anti-mouse cystatin C anti-
body (R&D) was coupled to Protein-G coupled Sepharose magnetic
beads (Dynabeads, Invitrogen) that were diluted in 600 mL
PBSþ 0.1% Tween-20 and incubated for 10 min at RT. After washing
steps, cell lysate was added and incubated for another 10 min at RT.
After additional washing steps using PBS þ0.1% Tween-20, bound
proteins were removed from the beads using 0.1 M glycine pH 2.5
and afterwards neutralized using 1 M Tris/HCl pH 8.0. MS analysis
was performed at the Proteome Center, Tübingen, Germany. CoIP
samples were loaded on an SDS gel using a non-reducing loading
buffer. After electrophoretic separation, SDS gels were silver
stained using SilverStain Plus Kit from BioRad. Each lane of a silver
stained SDS gel was cut into 7 pieces and subsequently tryptically
digested. Following analysis was performed using a LTQ-Oribitrap
XL mass spectrometer.
2.11. Isolation of lamina propria (LP) dendritic cells (DC) and T cells
and adoptive transfer of T cells
Isolation of LP cells was performed as published previously [29].
For adoptive transfer, splenic CD4þ T cells from C57BL/6 mice were
puriﬁed using a MACS-based negative selection kit (Miltenyi) ac-
cording to the manufacturer's instructions. The isolated cells were
stained for CD3ε, CD4 and CD62 for reanalysis, purity was generally
>90% with >80% being CD4þCD62LþCD45RBhi. 5  105 CD4þ T cells
were injected into the peritoneum (i.p.) of Rag1/ mice as
described previously [30].
2.12. Detection of intracellular ROS formation
Intracellular formation of ROS was measured using a kit pur-
chased by Enzo LifeScience and was performed according to man-
ufacturer's instruction. ROS formation was detected by ﬂow
cytometry, in which ﬂuorescence intensity in the FITC channel is
directly proportional to the amount of intracellular ROS. Median
ﬂuorescence intensities (MFI) of bacterially stimulated cells were
normalized to MFIs of unstimulated control cells derived from the
same individual.
2.13. Histology
Colonic tissues were ﬁxed in neutral buffered 4% formalin.
Formalin-ﬁxed tissues were embedded in parafﬁn and cut into
2 mm sections. They were stained with hematoxylin (Merck) and
eosin (Merck) for histological scoring. Scoring was conducted in a
blinded fashion on a validated scale of 0e3, weith 0 representing no
inﬂammation and 3 representing severe inﬂammation character-
ized by inﬁltration with inﬂammatory cells, crypt hyperplasia, loss
of goblet cells and distortion of architecture [31].
2.14. Statistics
Statistical analyses were performed using the unpaired stu-
dent's t-test to compare two groups with each other. For comparing
in vitro results, samples were considered to be biologically inde-
pendent if the samples were generated from BMDCs from different
mice. Differences were considered to be statistically signiﬁcant if
p < 0.05. Error bars, if shown, represent ± standard deviation (SD).
2.15. Bacteria
The bacteria used for stimulation of the murine dendritic cells
were Escherichia coli mpk and Bacteroides vulgatus mpk. The E. coli
mpk strain was grown in Luria-Bertani (LB) medium under aerobic
conditions at 37 C. Bacteroides vulgatuswas grown in Brain-Heart-
Infusion (BHI) medium and anaerobic conditions at 37 C.
2.16. Mice
C57BL/6J mice were purchased from Charles River Laboratories.
Cathepsin S-deﬁcient (Ctss/) mice were provided by the lab of
Thomas Reinheckel, University of Freiburg, Germany. Cystatin C-
deﬁcient (Cst3/) mice were handed over by the lab of Mathias
Jucker, Hertie Institute Tübingen, Germany and had initially been
created in the lab of Anders Grubb, University of Lund, Sweden.
Ctss/ mice were obtained by mating Ctssþ/ animal parents.
Resulting Ctssþ/þ pups were used as wt controls. Cst3/mice were
paired with wt 129S2/SvPasCrl mice purchased from Charles River
Laboratories. Resulting Cst3þ/ pups were mated and resulting
Cst3/ mice from the F2 generation were used for the experi-
ments. Cst3þ/þ littermates served as wt controls. All animals were
kept and bred under SPF conditions. For isolation of bone marrow,
only female mice aged 6e12 weeks were used. Animal experi-
ments were reviewed and approved by the responsible institu-
tional review committee and the local authorities in Germany and
Switzerland.
3. Results
Monocolonization with B. vulgatus mpk induces DC tolerance
and does not promote proliferation of transplanted T cells in Rag1/
 mice.
It is known that apathogenic commensal bacteria can have
either symbiotic or pathobiotic properties concerning the activa-
tion of the immune system. In previous work, we identiﬁed sym-
biotic B. vulgatusmpk which protects Il2/mice from induction of
colitis, hence promoting the immunological equilibrium, whereas
pathobiont E. colimpk promotes induction of colitis, thus featuring
pathobiotic effects [23,24]. Likewise, in IBD patients, Bacteroidetes
proportions in the intestine are decreased while Enterobactericeae
proportions are enhanced [32,33]. Therefore, we consider
B. vulgatus mpk and E. coli mpk to represent adequate symbiotic
and pathobiotic model organisms. Thus, wewanted to elucidate the
distinct T cell activation potential of these two model organisms. In
order to investigate the microbiota dependent maturation of in-
testinal dendritic cells and the resulting activation and proliferation
of naïve wt CD4þCD62LþCD45RBhi T cells, we used germfree (GF)
Rag1/ mice, lacking functional T cells and B cells, for mono-
colonization with either symbiotic B. vulgatus mpk or pathobiotic
E. coli mpk and for cocolonization with both bacteria. Cocoloniza-
tion resulted in efﬁcient colonization with both B. vulgatus and
E. coli in an almost 1:1 ratio (data not shown).
4 weeks after start of colonization 5  105 naïve wt
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CD4þCD62L þ CD45RBhi T cells were transplanted by i. p. injection.
Eight weeks after T cell transfer, the phenotype and maturation
state of lamina propria (LP) CD11cþ cells and the proliferation of
transplanted wt T cells were determined by ﬂow cytometry
(Fig. 1a). In earlier studies we could demonstrate that B. vulgatus
mpk converts immature dendritic cells into a tolerant semi-mature
phenotype in vitro as well as in vivo which prevents from T cell
activation and induction of inﬂammation [22e24]. Here, we show
that monocolonization of Rag1/ mice with B. vulgatus mpk was
associated with differentiation of LP CD11cþ cells into a semi-
mature phenotype as indicated by a low to intermediate expres-
sion of MHC-II and a low positive expression of CD40 (Fig.1c and d).
The presence of semi-mature cLP CD11cþ cells in B. vulgatus mpk
monocolonized Rag1/ mice was associated with a reduced ab-
solute cell count of CD3þCD4þ T cells in the cLP as compared to
E. colimpk monocolonized mice (Fig. 1b). The monocolonization of
Rag1/micewith E. colimpk resulted in an increased expression of
MHC-II and CD40 on CD11cþ cells in the cLP (Fig. 1c and d) and was
associated with a higher amount of T cells in the cLP (Fig. 1b).
Cocolonization resulted in higher amounts of CD3þCD4þ T cells
as well as in higher MHC-II and CD40 surface expression on colonic
CD11cþ cells compared to B. vulgatus monocolonized mice. How-
ever, all three parameters were signiﬁcantly reduced compared to
E. colimonocolonized mice, indicating an active immune regulating
mechanism that prevents from E. coli mpk induced proliferation of
CD3þCD4þ T cells.
In summary, it can be concluded that monocolonization with
symbiotic B. vulgatus mpk induces tolerant semi-mature cLP DCs
and does not promote T cell proliferation whereas monocoloniza-
tionwith pathobiotic E. colimpk induces DCmaturation and clearly
promotes proliferation of transplanted T cells.
3.1. Cathepsin S regulation is crucial for tolerance of DCs in terms of
MHC-II surface expression
Since the semi-mature phenotype of LP DCs, especially the
MHC-II surface expression, plays a pivotal role for the observed
prevention of T cell activation in B. vulgatus mpk monocolonized
and B. vulgatus mpk and E. coli mpk cocolonized gnotobiotic mice,
we had a closer look on the molecular mechanisms of semi-
maturation in vitro. We generated bone marrow derived DCs
which were stimulated with either B. vulgatus mpk or E. coli mpk
with a MOI of 1. As published previously, the stimulation of BMDCs
with B. vulgatusmpk resulted in a lower proportion of MHC-II high
positive (MHC-II hiþ) CD11cþ cells compared to stimulation with
E. coli mpk. B. vulgatus mpk stimulation generally leads to a lower
expression of CD40, CD80 and CD86 as well as lower expression of
pro-inﬂammatory cytokines [22]. We generally consider PBS
(mock) treated BMDCs to be immature (iDCs), E. coli mpk treated
ones to be fully mature (mDCs) and B. vulgatus mpk stimulated
BMDCs to be semi-mature (smDCs) withmDCs and smDCs reaching
the maximum expression level after 16 h of stimulation (Fig. 2b). A
characteristic feature of smDCs is the non-responsiveness towards
further bacterial stimuli in terms of surface MHC-II expression [22]
(Fig. 2c and d). This means, B. vulgatus mpk primed semi-mature
BMDCs that were subsequently challenged with maturation-
inducing E. coli mpk do not further upregulate MHC-II surface
expression (Fig. 2d). The lysosomal protease cathepsin S (CTSS) is
known to be crucial for the regulation of MHC-II transport from
intracellular vesicles to the cell surface. In order ﬁgure out the role
of CTSS on DC semi-maturation, especially on the non-
responsiveness in terms of MHC-II surface expression, we used
Ctss/ BMDCs, primed them with either PBS, B. vulgatus mpk or
Fig. 1. Bacteroides vulgatus monocolonization of GF Rag1/mice protects from T cell activation. Germfree (GF) Rag1/mice were colonized with either B. vulgatus mpk (GF þ BV),
E. colimpk (GF þ EC) or a combination of B. vulgatusmpk and E. colimpk (GF þ BV þ EC). After 2 weeks of colonization, wt CD4þCD62LþCD45RBhi T cells were transplanted. 8 weeks
after T cell transplantation, mice were analyzed. (a) Overview over experimental setting (b þ c þ d) ﬂow cytometry based analysis of T cells and CD11cþ cells in the colonic lamina
propria (cLP). Left panels demonstrate the used gating strategies. (b) proportion of CD40þ cells of cLP CD11cþ cells. (c) absolute cell count of repopulated CD3þCD4þ T cells in the cLP.
(d) proportion of MHC II high positive (MHC IIhiþ) cells among all MHC IIþCD11cþ cLP cells. Statistical analysis was performed using student's t-test. Error bars represent SD. The
number of replicates per group is indicated in the ﬁgure.
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E. colimpk for 24 h and challenged them afterwards with either PBS
or E. coli mpk for 16 h (see experimental design in Fig. 2c). Final
MHC-II surface expression was analyzed by ﬂow cytometry and
compared to MHC-II surface expression of equally treated wt
BMDCs (Fig. 2d). Ctss/ BMDCs generally provided decreased
MHC-II surface expression compared to equally treated wt BMDCs.
Though, E. coli mpk primed Ctss/ BMDCs provide slightly
enhanced surface MHC-II expression despite the loss of CTSS
(Fig. 2d), indicating other possible MHC-II surface expression
regulation mechanisms in these Ctss/ BMDCs. However and
importantly, the MHC-II surface expression level of these E. coli
mpk primed and E. coli mpk challenged Ctss/ BMDCs rather re-
sembles the MHC-II expression level of B. vulgatusmpk primed and
E. coli mpk challenged wt semi-mature BMDCs (p ¼ 0.703). This
clearly demonstrates the signiﬁcance of CTSS activity control for the
induction of tolerant semi-mature DCs. The CTSS deﬁciency did not
inﬂuence other immunomodulatory mechanisms of dendritic cells
since expression of pro-inﬂammatory cytokines and T cell cos-
timulatory factors were not affected (see Supplementary Fig. S1).
3.2. Semi-mature DC show non-responsiveness concerning CTSS
activity upon E. coli mpk challenge
The cleavage of the MHC-II bound Invariant chain (Ii) is one
required event for the subsequent transport of the MHC-II protein
complex to the cell surface, where MHC-II is essential for T cell
activation. The invariant chain is expressed as two different splicing
variants (Ii p31 and Ii p41) and is associated with the MHC-II het-
erodimer. The Ii cleavage includes several subsequent protease-
catalyzed hydrolysis events. The last proteolytic cleavage gener-
ates CLIP out of the MHC-II bound invariant chain p10 fragment
(MHC-II-Ii p10) and CLIP can then be replaced by exogenous
protein-derived peptide fragments. This last hydrolysis event is a
major regulation step for MHC-II transport to the surface of the cell.
Sincewe detected differentMHC-II surface expression in B. vulgatus
mpk and E. colimpk treated BMDCs, we also compared the amount
of the intracellular MHC-II-Ii p10 heterotrimer as well as the Ii p31
and Ii p41 expression between B. vulgatus mpk and E. coli mpk
stimulated bone marrow derived dendritic cells (BMDCs).
B. vulgatusmpk stimulated smDCs displayed greater band intensity
of MHC-II-Ii p10 than E. coli mpk-stimulated mDCs (Fig. 3a) sug-
gesting less efﬁcient MHC-II-Ii p10 cleaving in B. vulgatus mpk
stimulated DC compared to E. colimpk stimulated DC. This is in line
with the observation that the amount of MHC-II-CLIP is also
decreasing in E. colimpk simulated BMDCs (Fig. 3b). The amount of
non-cleaved Ii p31 was constant among all DC phenotypes (Fig. 3a)
indicating that no differential protein expression of Ii occurs. We
could also not detect any differences in mRNA expression of the
Cd74 gene, which encodes for the invariant chain (Ii) (Fig. 3c).
Additionally, only the band ratio between the MHC-II-Ii p10
Fig. 2. Induction of dendritic cell semi-maturation is cathepsin S dependent. (a) Gating strategy for the determination of MHC class II high positive (MHC-II hiþ) bone marrow
derived dendritic cells (BMDCs). CD11c-negative cells were outgated and the proportion of MHC-II hiþ DCs within the population of CD11cþ cells was determined as shown. (b) MHC
class II hiþ population of CD11cþ BMDCs that were stimulated with PBS, B. vulgatusmpk or E. colimpk for 1 he24 h (n ¼ 3 for each group). (c) Experimental setting for investigation
of dendritic cell tolerance after induction of semi-maturation. BMDCs are primed for 24 h with either PBS (mock) to preserve an immature phenotype, B. vulgatus mpk to induce
semi-maturation or E. coli mpk to induce BMDC maturation. After medium change, these cells were challenged for 16 h with either PBS (mock) as controls or E. coli mpk to
investigate possible tolerance mechanisms. (d) MHC class II hiþ population of wt and CTSS-deﬁcient (Ctss/) CD11cþ BMDCs that were primed with PBS (mock), B. vulgatus mpk or
E. coli mpk for 24 h and challenged with either PBS (mock) or E. coli mpk for 16 h. Number of replicates are indicated in the ﬁgure. All statistical analyses were performed using
student's t-test. Error bars represent SD.
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fragment compared to constantly expressed uncleaved monomeric
Ii p31 is different (Fig. 3a). Therefore we suggested that the
observed differences in MHC-II-Ii p10 amount is exclusively due to
altered cathepsin S (CTSS) activity since CTSS is the only protease in
dendritic cells that can generate the CLIP fragment out of Ii p10 [1].
Therefore we wanted to check if CTSS activity is also differentially
regulated in B. vulgatus mpk stimulated smDCs compared to E. coli
mpk stimulatedmDCswhich would explain the reduced cleaving of
the invariant chain as well as the decreased expression of surface
MHC-II (Fig. 2b and d). Furthermore, wewanted to elucidate if CTSS
activity regulation contributes to non-responsiveness of B. vulgatus
primed smDCs in terms of surface MHC-II expression. We could
demonstrate that stimulation of BMDCs with E. coli mpk leads to a
2.2-fold increase of CTSS activity 2 h after bacterial encounter
compared to stimulation with PBS (Fig. 3d). This increase in pro-
tease activity is followed by a decrease to about 50% of the activity
of PBS treated BMDCs 16 h after stimulation (Fig. 3d). However,
B. vulgatus mpk stimulated BMDCs do not provide a protease ac-
tivity upregulation 2 h after stimulation. But, after 16 h of
stimulation, the activity also decreases to about 50% activity of the
PBS stimulated control sample (Fig. 3d). The loss of proteolytic
activity after 16 h of E. colimpk stimulation can e at least in part e
be explained by the detected secretion of CTSS protein into the cell
culture supernatant (Fig. 3f) after 16 h of stimulation. However, this
could not be conﬁrmed in B. vulgatus mpk treated samples and
B. vulgatus mpk stimulation does not lead to increased CTSS
secretion from BMDCs (Fig. 3f). Since the non-responsiveness to-
wards subsequent bacterial stimuli is one of the key features of
smDCs it was necessary to check for CTSS activities in B. vulgatus
mpk primed and E. coli mpk challenged BMDCs. Therefore, we
primed BMDCs with PBS, B. vulgatusmpk and E. colimpk for 24 h to
induce iDCs, smDCs and mDCs, respectively. These BMDCs were
subsequently challenged with either PBS or E. coli mpk for 2 h
followed by cell lysis and CTSS activity detection. Fig. 3e shows that
PBS-primed (iDCs) and E. coli mpk challenged BMDCs provide a
CTSS activity increase of about 100% compared to PBS (mock)
primed and PBS (mock) challenged control BMDCs. E. coli mpk
primed and E. coli mpk challenged mDCs provided very low CTSS
Fig. 3. B. vulgatusmpk prevents from CTSS activity increase in BMDCs. (a) wt BMDCs were stimulated for 20 h with either PBS (mock), B. vulgatusmpk or E. colimpk. The amount of
the MHC-II bound invariant chain p10 fragment (Ii p10 þ MHC-II) was determined by western blotting (n ¼ 8). One representative blot is shown in the left panel. The uncleaved
invariant chain splicing variants Ii p31 and Ii p41 are also depicted. For validation of the assigned bands see Supplementary Fig. S3. Right panel: Quantiﬁcation of the Western Blot
Band using LiCor ImageStudio. The band intensities of p10 were normalized to p31 and p41, p31 and p41 band intensities were normalized to b-actin. The ratios were then
normalized to the mock stimulated band ratios of BMDCs derived from the same individual (b) Western Blot of CLIP-loaded MHC-II of BMDCs that were stimulated for 20 h with
either PBS (mock), B. vulgatus mpk or E. coli mpk. (c) mRNA expression of the Cd74 gene encoding for the invariant chain in BMDCs that were stimulated with B. vulgatus mpk or
E. coli mpk for 4 h and 16 h were determined and normalized on the expression of the PBS-stimulated mock control in BMDCs generated from the same individual (n ¼ 3), (d)
BMDCs were stimulated with either B. vulgatus mpk, E. coli mpk or PBS (mock) for 2 h and 16 h. CTSS activities were determined using PMGLP as a ﬂuorogenic CTSS speciﬁc
substrate as described. CTSS activities were normalized to the activity of the PBS-stimulated mock control in BMDCs generated from the same individual (n ¼ 4). (e) CTSS activity
determination of BMDCs that were primed (1st stimulus) with PBS (mock), B. vulgatusmpk or E. colimpk for 16 h and challenged (2nd stimulus) with either PBS or E. colimpk for 2
h (n ¼ 4). (f) CTSS secretion into the cell supernatant of BMDCs that were stimulated for 16 h with B. vulgatus mpk, E. coli mpk or PBS (mock) was determined by ELISA (n ¼ 5). The
boxes represent the 25th to the 75th percentile, the whiskers indicate the lowest and highest single value. The line within the boxes represents the statistical median. All statistical
analyses were performed using student's t-test. Error bars represent SD.
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activity rates (Fig. 3e), which might also be due to the high secre-
tion rates of CTSS in E. coli mpk primed cells (Fig. 3f). B. vulgatus
mpk primed smDCs which were subsequently challenged with
E. coli mpk did not show any increase in CTSS activity compared to
untreated PBS (mock) primed and PBS (mock) challenged control
cells (Fig. 3e). Thus, we demonstrate that B. vulgatus mpk stimu-
lated, semi-mature DC also provide non-responsiveness in terms of
CTSS activity which therefore seems to be part of the tolerant semi-
mature DC phenotype.
3.3. B. vulgatus mpkmediates CTSS activity regulation via cystatin C
Since we detected different CTSS activities in BMDCs that were
stimulated with either B. vulgatus mpk or E. coli mpk ﬁnally
resulting in different MHC-II surface expression and T cell activa-
tion, the question of the underlying regulation mechanism arised.
First, we checked for a transcriptional regulation of the Ctss gene,
encoding for CTSS protein. Ctss mRNA expression in both, E. coli
mpk and B. vulgatus mpk treated samples were not signiﬁcantly
different from those of PBS treated controls after 1 h, 2 h, 4 h and
16 h of bacterial stimulation (Fig. 4a). Therefore we assume that
transcriptional regulation does not contribute to the observed
changes in CTSS activity. Another possible regulation mechanism
would be endogenous inhibition by a regulatory protein. Cystatins
have been widely discussed to be such endogenous cathepsin in-
hibitors. For CTSS, cystatin C (CysC) [7e9] was proposed to be the
Fig. 4. B. vulgatus mpk mediates CTSS activity regulation via intracellular ROS amounts and binding behaviour of cystatin C. (a) Ctss mRNA expression of wt (Cst3þ/þ) BMDCs that
were stimulated with B. vulgatus mpk or E. coli mpk for 1 h, 2 h, 4 h and 16 h were determined and normalized on the expression of the PBS-stimulated mock control in BMDCs
generated from the same individual (n ¼ 4). (b) CoIPs using a-cystatin C antibodies were performed with cell lysates of immature wt (Cst3þ/þ) BMDCs. Potential interaction partners
were identiﬁed using MS. CTSS was detected with a reliably low PEP score, with PEP indicating the probability of a false positive detection result. Western Blots against CTSS and
Cystatin C (CysC) in a-CysC CoIPs were performed to verify these results (n ¼ 3). (c) wt (Cst3þ/þ) BMDCs were stimulated for 20 h with either PBS (mock), B. vulgatus mpk or E. coli
mpk. CysC protein amount was detected by western blotting (n ¼ 4). (d) Cst3mRNA expression (encoding for CysC) of wt (Cst3þ/þ) BMDCs that were stimulated with B. vulgatusmpk
or E. coli mpk for 4 h and 16 h were determined and normalized on the expression of the mock control in BMDCs generated from the same individual (n ¼ 4), (e) wt (Cst3þ/þ) and
Cystatin C-deﬁcient Cst3/ BMDCs were stimulated for 20 h with either PBS (mock), B. vulgatus mpk or E. coli mpk. The amount of the MHC-II bound invariant chain p10 fragment
(Ii p10) was determined by western blotting (n ¼ 3). One representative blot is shown. (f) Flow cytrometrical determination of the MHC class II hiþ population among Cst3þ/þ (wt)
and Cystatin C-deﬁcient (Cst3/) CD11cþ BMDCs that were stimulated with PBS, B. vulgatus mpk or E. colimpk for 16 h (¼3), (G) wt (Cst3þ/þ) BMDCs were stimulated for either 1 h,
1.5 h or 2 h with PBS (mock), B. vulgatus mpk or E. coli mpk. ROS formation was detected by using ﬂow cytometry as described. Relative Median Fluorescence intensities (MFI) were
determined and normalized to the MFI of the unstimulated mock control derived from cells of the same mouse (n ¼ 4). All statistical analyses were performed using student's t-test.
Error bars represent SD.
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major regulatory protein. First, we wanted to know if cystatin C
actually binds to CTSS. Thus, we performed immunoprecipitation
assays in immature BMDCs using an antibody against cystatin C and
checked for interaction partners by using mass spectrometric ap-
proaches. As a negative control, IPs from cystatin C-deﬁcient
BMDCs were used (data not shown) to exclude false positive po-
tential interaction partners. We could identify CTSS as cystatin C
interaction partner in immature DC with a reliable PEP score of
1.3  103 (Fig. 4b). Interestingly, the total amount of CysC protein
and the mRNA expression of the Cst3 gene, encoding for CysC, was
not altered between iDCs, smDCs andmDCs (Fig. 4c and d). In order
to prove CysC dependent CTSS regulation, we used BMDCs from
Cst3/ mice, lacking cystatin C, for in vitro experiments. Like in
Ctss/ DCs, the cystatin C deﬁciency did not inﬂuence other
immunomodulatory mechanisms of dendritic cells since expres-
sion of pro-inﬂammatory cytokines and T cell costimulatory factors
were not affected (see Supplementary Fig. S2). B. vulgatus mpk
stimulation in Cst3/ BMDCs led to fully mature DC in terms of
MHC-II expression and therefore failed to induce semi-maturation
as indicated by a proportion of MHC-II hiþ DC that is comparable to
E. colimpk stimulatedwtDCs (Fig. 4f). Even if CysCmight not be the
only regulator or repressor of MHC-II expression, CysC seems to be
essential for the induction of B. vulgatus mpk caused DC semi-
maturation (Fig. 4f). These results are in line with the obtained
high cleaving rates of the MHC-II bound invariant chain (MHC-II-Ii
p10) in Cst3/ BMDCs. In contrast towt BMDCs, neither B. vulgatus
mpk, nor E. colimpk stimulated Cst3/ BMDCs showed any clearly
visible band for the MHC-II-Ii p10 heterotrimer, indicating efﬁcient
cleaving probably due to generally enhanced CTSS activity (Fig. 4e).
Sincewe could prove a cystatin C-dependent regulation of invariant
chain cleaving and MHC-II surface expression, which both seemed
to be independent from Cst3 gene expression or intracellular cys-
tatin C protein amounts, we suggested that the protein-protein-
interaction between cystatin C and its target protease CTSS might
be affected by bacterial stimulation. In order to prove this hy-
pothesis we checked for intracellular levels of reactive oxygen
species (ROS) in B. vulgatusmpk and E. colimpk stimulated DCs. It is
known that upon increase of intracellular ROS amounts, cystatin C
monomers preferentially form protein homodimers leading to a
loss of the inhibitory potential [34]. Since only CysC monomers can
bind to CTSS, ROS-dependent CysC dimer formation would lead to
dissociation of cystatin C monomers from CTSS, therefore pro-
moting CTSS activity increase. We could demonstrate that
B. vulgatus mpk stimulation of BMDCs does not induce ROS pro-
duction (Fig. 4g). This would, in turn, promote maintenance of
cystatin C monomers that are able to bind to CTSS, therefore
inhibiting CTSS proteolytic activity. E. coli mpk stimulation, how-
ever, leads to signiﬁcantly higher intracellular ROS amounts
compared to B. vulgatus mpk stimulated cells (Fig. 4g). E. coli mpk
induced higher ROS levels would favour homodimerization of
cystatin C which would subsequently lead to a loss of CTSS inhi-
bition, resulting in CTSS activity increase. Therefore we conclude
that lower intracellular ROS amounts are, at least in part, respon-
sible for CTSS activity control in semi-mature DC.
3.4. Administration of B. vulgatus mpk protects mice from induction
of CD4þ T cell driven transfer colitis
In vitro and in vivo experiments (Figs. 2e4) revealed that DCs
primed with B. vulgatus mpk differentiate to tolerant semi-mature
DCs which prevent from T cell activation (Fig. 1). Rag1/ mice
harbouring a conventional (CV) microbiota with high levels of
pathobiotic Enterobactericeae develop chronic colitis upon transfer
of naïve CD4þ wt T cells. In this experiment, we tried to protect
these mice from colitis induction and promotion by applying
B. vulgatusmpk via drinking water and thus shifting the microbiota
composition in favour of Bacteroides sp. We started B. vulgatusmpk
application 3 days before T cell transplantation and continued
bacterial application until the end of the experiment (Fig. 5a). 6
weeks after T cell transplantation, B. vulgatus mpk colonization
anticipated induction of colonic mucosal inﬂammation and Rag1/
mice harbouring CV microbiota stayed without any colitis symp-
toms as indicated by the histological colitis score (Fig. 5e). This was
associated with the detection of semi-mature dendritic cells in the
colonic LP as indicated by low MHC-II (Fig. 5b) and CD40 surface
expression (Fig. 5c), as well as by a lower relative proportion of
CD3þCD4þ T cells in the cLP (Fig. 5d).
3.5. B. vulgatus mpk dependent prevention of colitis is associated
with prevention of CTSS secretion into blood serum
Enhanced CTSS serum levels have been reported to be associ-
ated with several T cell mediated autoimmune diseases. We
therefore compared the CTSS serum levels in T cell transplanted CV
Rag1/ mice suffering from chronic colitis with B. vulgatus mpk
treated CV Rag1/ mice, which stayed healthy. As negative con-
trols, we used germfree (GF) T cell transplanted Rag1/ mice.
Germfree Rag1/ mice, as well as B. vulgatus mpk treated CV
Rag1/ mice provided signiﬁcantly lower CTSS secretion into the
serum compared to non-B. vulgatus mpk treated CV Rag1/ mice
(Fig. 5f). A clear correlation between the histological colitis score,
representing the severity of disease, of each individual mouse and
its respective CTSS serum level was detectable (Fig. 5f).
3.6. Feeding symbiont B. vulgatus mpk is equally effective in
prevention of colitis induction as administration of a chemical CTSS
inhibitor
The data presented above support the hypothesis that CTSS
activity regulation is an important feature for the prevention of
pathological inﬂammatory reactions and that B. vulgatus mpk
might act as a CTSS regulatory agent. In order to prove that a hy-
pothesized CTSS activity regulation in vivo is the cause for the
B. vulgatusmpkmediated prevention of colitis induction in Rag1/
mice (Fig. 5), we compared the anti-colitogenic properties of
B. vulgatus mpk with the properties of a chemical CTSS inhibitor.
Therefore, we again used Rag1/ mice harbouring a highly col-
itogenic CV microbiota and treated them with either B. vulgatus
mpk in the drinking water, a chemical CTSS inhibitor or a vehicle,
representing the solvent mixture in which the inhibitor was dis-
solved. The CTSS inhibitor and the vehicle were administered
intraperitoneally daily, starting three days before T cell trans-
plantation. B. vulgatus mpk administration via drinking water was
also started three days before T cell transplantation and continued
throughout the experiment. Since we were focused on the induc-
tion of an inﬂammatory reaction, mice were analyzed already 21
days after T cell transplantation. We could detect a lower colonic
inﬂammation in the B. vulgatus mpk and CTSS inhibitor treated
animals compared to vehicle treated controls as indicated by a
lower histological colitis score (Fig. 6b and c). This observation was
in line with the detected increased weight loss of the vehicle
treated animals compared to both other groups (Fig. 6d). The
reduced inﬂammation of the colon of B. vulgatus mpk and CTSS
inhibitor treated animals in this CD4þ T cell mediated experimental
mouse model for colitis was associated with a lower number of
CD3þCD4þ T cells in the colon (Fig. 6f) as well as with a lower
number of MHC-IIhiþ CD11cþ cells in the colon (Fig. 6e) as
compared to the inﬂamed vehicle treated control animals. These
ﬁndings demonstrate that a chemical CTSS inhibitor and B. vulgatus
mpk have similar effects on prevention of colitis induction and that
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the B. vulgatus caused prohibition of a CD4þ T cell mediated im-
mune response in this animal model is mediated by CTSS activity
regulation (Fig. 5f). Furthermore, the data support the hypothesis
that the enhanced CTSS secretion that can be detected in mice with
colonic inﬂammation may not only be a simple consequence of
inﬂammatory processes but might rather be a feature of disease-
inducing mechanisms. However, we are aware that this is highly
speculative at themoment and further data acquisition is necessary
to deﬁne the role of secreted CTSS in colitis pathology. So far, we
cannot state any information on the activity of the secreted CTSS
since themethodwe used for intracellular CTSS activity detection is
not suitable for the detection of extracellular soluble CTSS in bio-
logical ﬂuids. Summing up, B. vulgatus mediated regulation of
intracellular CTSS activity, and MHC-II signaling in consequence, is
one crucial component in the prevention of colitis induction but it
might not be the only one due to the potential pathological effects
of secreted extracellular CTSS.
In summary, we demonstrate that the symbiotic commensal
B. vulgatus mpk induces a tolerant semi-mature DC phenotype via
ROS and cystatin C-dependent regulation of the lysosomal protease
CTSS. This, in turn, prevents from MHC-II associated pathophysio-
logical activation of CD4þ T cells. Fig. 7 summarizes the postulated
mechanism how B. vulgatus mpk regulates CTSS activities and
therefore prevents from colitis induction. B. vulgatus mpk, located
in the intestinal lumen, interacts with DC underlying the intestinal
epithelium and induces DC semi-maturation. This is accompanied
by low intracellular levels of ROS, which, in turn, favour the
maintenance of cystatin C monomers that can subsequently bind to
CTSS, inhibiting its proteolytical activity. This leads to less efﬁcient
cleaving of the MHC-II bound invariant chain, resulting in low
MHC-II surface expression preventing from CD4þ T cell activation.
As a characteristic of semi-maturation, this DC phenotype is
Fig. 5. B. vulgatus mpk protects from CD4þ T cell mediated colitis in Rag1/ mice. (a) experimental setting. Rag1/ mice harbouring conventional microbiota (CV) were either fed
B. vulgatus mpk (CV þ BV þ T) or not (CV þ T) and transplanted with CD4þCD62LþCD45RBhi wt T cells. (b þ c) Flow cytometrical determination of the MHC-II hiþ (b) and CD40 (c)
population among CD11cþ DC isolated from the colonic lamina propria (cLP). (b) sample size: CV þ T: n ¼ 6, CV þ BV þ T: n ¼ 7; (c) sample size: CV þ T: n ¼ 4, CV þ BV þ T: n ¼ 10
(d) Flow cytometrical determination of CD3þCD4þ T cells from cLP. Samples sizes: CV þ T: n ¼ 4, CV þ BV þ T: n ¼ 10 (b þ c þ d) The boxes represent the 25th to the 75th percentile,
the whiskers indicate the lowest and highest single value. The line within the boxes represent the statistical median. (e) representative H&E stained colonic sections and histological
colitis score. Each dot represents one individual. As controls, non-inﬂamed germfree (GF) mice were used (f) Correlation between CTSS serum level and histological colitis score.
Each dot represents one individual. All statistical analyses were performed using student's t-test. Error bars, if shown, represent SD.
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Fig. 6. Chemical CTSS inhibition protects from induction of a CD4þ T cell mediated colitis in Rag1/ mice. (a) experimental setting. Rag1/ mice harbouring conventional
microbiota (CV) were either fed B. vulgatus mpk or administered daily a chemical CTSS inhibitor or a vehicle, respectively. Three days after start of CTSS inhibitor and vehicle
treatment, mice were transplanted with CD4þCD62LþCD45RBhi wt T cells. (n ¼ 5 per group) Analysis of the animals was performed 21 days after T cell transplantation. (b)
Representative H&E stained colonic sections. The arrow and the box highlight the inﬂux of lymphocytes into the colonic epithelium indicating inﬂammatory processes. (c) His-
tological colitis score, (d) Weight curve. Weight was determined every 2e3 days and normalized to the weight at the day of T cell transplantation. Error bars represent SD. (e) Flow
cytometrical determination of the cell number of CD3negCD48bnegCD11cþMHC-IIþMHC-IIhiþ cells in the colonic lamina propria (cLP) Right panel: gating strategy; (f) Flow cyto-
metrical determination of the percentage (left panel) and the total cell number (right panel) of CD3þCD4þ T cells from the cLP. (c þ e þ f) box and whiskers: the boxes represent the
25th to the 75th percentile, the whiskers indicate the lowest and highest single value. The line within the boxes represents the statistical median. All statistical analyses were
performed using student's t-test.
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ultimate and cannot be overcome by a subsequent maturating
stimulus.
4. Discussion
Here we demonstrate that regulation of cathepsin S (CTSS) ac-
tivity importantly contributes to the maintenance of the intestinal
immune equilibrium. CTSS activity can be regulated by the intes-
tinal microbiota with symbionts triggering physiological CTSS ac-
tivity and pathobionts inducing pathological CTSS activity increase,
the latter resulting in T cell activation and proliferation which, in
turn, supports pro-inﬂammatory host immune responses. The
microbiota dependent regulation of CTSS activity is mediated by
the induction of reactive oxygen species (ROS). Pathobionts, but not
symbionts, induced high intracellular ROS levels in DCs, allowing
for homodimerization of cystatin C (CysC) and resulting in an
abrogation of the CysC-mediated inhibition of CTSS activity. This
promotes intestinal inﬂammatory host responses, in our mouse
model resulting in induction of colitis. The symbiont induced low
intracellular ROS levels lead to a preservation of CysC monomers,
mediating inhibition of CTSS via direct protein-protein-
interactions, which therefore results in physiological CTSS activity
levels and maintenance of intestinal homeostasis.
CTSS is a physiologically required lysosomal cysteine protease
that is mainly expressed in professional antigen presenting cells
like macrophages, dendritic cells (DC) and B cells [1,35]. It is mainly
involved in regulation of the MHC-II associated antigen presenting
pathway. This underlines its crucial role in the activation of MHC-II
dependent immune responses. Pathogenesis of most autoimmune
diseases (AID), and of IBD in particular, is associated with an in-
duction of a CD4þ T cell mediated immune response, highlighting
the importance of the MHC-II mediated antigen presenting
pathway for the onset of AID. Therefore a strict regulation of the
CTSS activity is important to retain a balanced immune system.
CTSS exerts its physiological functions intracellularly. However,
secretion can occur since CTSS is part of the lysosomal compart-
ment. This might cause additional pathophysiological processes in
the extracellular space. Upon secretion, cathepsins end in extra-
cellular environments whose pH values strongly affect their pro-
teolytical activity. Among all cathepsins, CTSS is the only enzyme
with signiﬁcant activity within a broader pH range since it is also
capable of catalysing peptide bond cleavage at neutral pH [36]. All
other cathepsins provide their maximum activity at acidic pH
values [37]. Since in extracellular environments a neutral pH is
dominant, CTSS is not automatically inactivated like other cathep-
sins. Extracellular or, in other words, secreted CTSS is involved in
the pathology of a variety of autoimmune diseases. For example,
increased CTSS levels in the serum or cerebrospinal ﬂuid can be
found in multiple sclerosis patients [8]. In the mouse model of
experimental autoimmune encephalomyelitis (EAE), resembling
themultiple sclerosis phenotype in humans, increased extracellular
CTSS levels could be detected [38]. Its extracellular pathological
function might be proteolysis of the myelin basic protein which
could be observed in vitro [39]. In Sj€ogren's syndrome patients,
enhanced CTSS activity could be detected in tear ﬂuid [14], there-
fore making CTSS activity in tears an appropriate biomarker for the
diagnosis of this disease [15]. Especially the atheriosclerosis
phenotype is affected by extracellular CTSS. Secreted CTSS cleaves
proteins of the extracellular matrix (ECM) like laminin, collagen or
elastin [40]. Resulting elastin peptides are able to incite inﬂam-
mation and stimulate macrophage chemotaxis [41]. Concerning
inﬂammatory bowel disease, general ECM degradation therefore
could promote epithelial damage or relieve bacterial contact to APC
leading to accelerated T cell responses and IBD promotion. CTSS
secretion into the colonic lumen might cause damage of the
epithelial barrier leading to intensiﬁed colitis symptoms as
enhanced encounter of gut bacteria with immune cells on the
basolateral side of the epitheliumwould be possible. We could now
show in a mouse model for T cell mediated colitis using Rag1/
mice, that feeding symbiotic B. vulgatus mpk via drinking water
protects mice from colitis induction and we provide evidence that
this is due to a strict regulation of intracellular CTSS activity and
possibly also due to a prevention of secretion from DCs into
extracellular environments. There is a clear correlation between the
CTSS concentration in blood serum and severity of colonic damage
and we could demonstrate that administration of a chemical CTSS
inhibitor prevents from colitis induction in a CD4þ T cell mediated
Fig. 7. Postulated mechanism how commensal symbiont Bacteroides vulgatus mpk
prevents from inﬂammation induction via cathepsin S activity regulation. Left panel:
B. vulgatusmpk is suspected to promote only a weak immunological signal in dendritic
cells resulting in low amounts of reactive oxygen species (ROS). These low ROS
amounts favour cystatin C monomers which can therefore efﬁciently bind to cathepsin
S (CTSS) and thus cause inhibition of CTSS proteolytic activity. This results in less
efﬁcient cleaving of the invariant chain (Ii) and therefore in lower amounts of surface
MHC-II and reduced DC mobility. Additionally, CTSS secretion into the extracellular
space is omitted. These events lead to the conversion of immature DC into tolerant
semi-mature DC that fail to induce a CD4þ T cell mediated immune response and
therefore protect from inﬂammatory reactions. Right panel: In contrast to symbiont
commensals, pathobionts like E. coli mpk induce intracellular ROS formation pro-
moting homodimerization of Cystatin C leading to a loss of its inhibitory capacity to-
wards CTSS. This leads to enhanced invariant chain cleaving, high MHC-II expression,
increased DC mobility and high CTSS secretion. These events characterize a mature DC
which are ﬁnally capable to induce a CD4þ T cell mediated immune response.
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mouse model for experiment colitis using Rag1/ mice. We could
conﬁrm this observation in vitro by detecting low CTSS secretion
rates in B. vulgatusmpk stimulated bone marrow derived dendritic
cells (BMDCs). It has already been shown that CTSS secretion pro-
motes pain induction during colitis via cleaving of the PAR-2 re-
ceptor [19]. However, our data support the idea that CTSS activity
dysregulation and enhanced secretion is the decisive trigger for
colitis induction.
Intracellular CTSS activity also requires precise regulation. CTSS
is the main protease in DCs that is responsible for cleaving the
MHC-II associated chaperone invariant chain (Ii). This cleaving
event is the major regulation step for loading antigen-derived
peptides onto the MHC-II binding groove and the subsequent
transport of peptide-loaded MHC-II to the cell surface. We could
show that DC maturation induced by the pathobiotic commensal
E. colimpk results in strong intracellular CTSS activity increase and
therefore enhanced MHC-II surface expression which is required
for a powerful CD4þ T cell mediated immune response. Symbiotic
commensal B. vulgatusmpk priming of DC, however, prevents from
E. coli mpk induced CTSS activity increase and therefore from Ii
cleaving and enhanced MHC-II surface expression. We have pre-
viously shown that B. vulgatus mpk converts DC into a tolerant
semi-mature phenotype [22,24]. These tolerant semi-mature DCs
are non-responsive to further stimuli, they fail to activate CD4þ T
cells and they are associated with the prevention of colitis in
various mouse models [22,24]. We now demonstrate that CTSS
activity regulation is one of the most important reasons for in-
duction of DC semi-maturation and the circumvention of T cell
activation. Prevention of CTSS activity increase results in less efﬁ-
cient Ii cleaving. It was shown that CTSS deﬁciency signiﬁcantly
impairs DC mobility since Ii seems to interact with cellular myosin
II [42] and efﬁcient Ii cleaving therefore seems to be required for
adequate interaction of Ii with myosin II and thus for DC mobility.
Therefore, reduced Ii cleaving might contribute to impaired
mobility of semi-mature DC [24]. Furthermore, CTSS catalyzed Ii
cleaving leads to NFkB activation resulting in enhanced secretion of
pro-inﬂammatory cytokines [43]. In fact, smDCs express only low
amounts of pro-inﬂammatory cytokines [22] and this might be, at
least in part, due to reduced cleaving of MHC-II bound Ii in smDCs.
The question emerges which intracellular regulation mecha-
nisms are involved in B. vulgatus mpk mediated CTSS activity
regulation. In principle, CTSS activity can be regulated by various
mechanisms. Possible regulation via transcriptional control, i.e.
induced by IL-10 binding and STAT3 dimerisation [44] can be
excluded in this case since we could not detect any transcriptional
regulation of the Ctss gene. Another potential regulation mecha-
nism is control of the lysosomal pH, but this might not be of
importance in case of CTSS due to the broad pH range inwhich CTSS
provides remarkable activity. Possible post-translational regulation
might occur through inhibition by chondroitin-4-sulfate [3] or the
creation of an oxidizing environment by NADPH oxidase NOX2
[45,46]. A prominently discussed endogenous CTSS inhibitor is
cystatin C (CysC). However, there are contradictory reports about
the role of CysC for CTSS activity regulation. Although some groups
claim CysC to be the major CTSS activity regulator [7e9], Magister
et al. published that CysF might be the more important regulator
protein [10]. In order to elucidate the role of CysC during B. vulgatus
mpk induced DC semi-maturation and the effect on CTSS activity,
we ﬁrst performed immunoprecipitations against CysC that proved
convincing interaction between CysC and CTSS. We could further
demonstrate that B. vulgatus mpk fails to induce DC semi-
maturation in Cystatin C-deﬁcient Cst3/ DCs indicating a cen-
tral role for CysC in the semi-maturation process. We conclude that
B. vulgatus mpk mediates its CTSS regulating functions via Cystatin
C. There are different possibilities how a bacterial stimulus on DCs
might affect the interaction between CysC and CTSS. Transcrip-
tional regulation of the CysC gene might be the ﬁrst possibility
since it could be shown that transcription factors like IRF-8 and
PU.1 enhance CysCmRNA transcription [47]. However, we could not
detect any alteration in CysC gene transcription during the DC
maturation or semi-maturation process. In line with this, we could
also not detect any differences in the amount of CysC protein in DCs
of different maturation states. CysC inhibits target proteases like
CTSS by forming tight and non-covalent complexes [48]. Complex
forming with CTSS is limited to CysC monomers. However, CysC
protein expression in the endoplasmatic reticulum (ER) does not
only yield in the formation of monomers but also in dimers that do
not form inhibitory complexes with target proteases [49]. Xu et al.
demonstrated that the formation of non-inhibitory CysC dimers is
dependent on the amount of ROS inside the cell, whereupon ROS
presence promotes dimer formation [34]. Since bacterial lipopoly-
saccharide (LPS) induced DC maturation leads to an increase in
intracellular ROS concentrations [50], we hypothesized that a
weaker B. vulgatus mpk LPS signalling (data not shown) leads to
less ROS formation and therefore enhanced levels of monomeric
CysC compared to completely mature DC. In fact, B. vulgatus mpk
stimulation does not lead to an increase of intracellular ROS
amounts, in contrast to E. coli mpk stimulation which efﬁciently
enhances ROS production. We therefore assume that B. vulgatus
mpk stimulation leads to less CysC dimer formation, thus resulting
in increased proportions of monomeric cystatin C. These enhanced
amounts of monomeric CysC can subsequently form inhibitory
complexes with CTSS, which we could prove via immunoprecipi-
tation, resulting in permanently low CTSS activities. In line with
this, we could detect a CysC-regulation dependent MHC-II surface
expression of DCs supporting the ﬁndings of Pierre et al. [35] but
opposing ﬁndings of El-Sukkari et al. [51]. In line with this, we
detected extremely efﬁcient Ii cleavage in Cst3/ BMDCs, with Ii
cleaving being the precondition for MHC-II translocation to the cell
surface.
There is an intense ongoing research for adequate CTSS in-
hibitors for the use as potential drugs in order to treat autoimmune
diseases. Some groups developed chemical CTSS inhibitors and
chemical CTSS inhibition could attenuate atherosclerosis in mice
[18] and T cell mediated inﬂammation in the murine central ner-
vous system [52]. However, a non site-directed complete inhibition
of CTSS might have severe side effects on the host organism.
Furthermore, the effectiveness of chemical substances is dependent
on bioavailability and membrane passage behaviour if inhibitors
are supposed to act intracellularly. In contrast to a chemical in-
hibitor, B. vulgatus mpk does not lead to a completely inhibited
CTSS as demonstrated in our experiments. This is a strong advan-
tage over a chemical inhibitor that usually leads to a complete in-
hibition of its target enzyme. Therefore, B. vulgatus mpk treatment
still allows for CTSS to achieve its physiological role and only pre-
vents from pathophysiological activation.
We could show that B. vulgatusmpk prevents from pathological
reactions of the immune system via regulation of intracellular host
CTSS activity and therefore contributes to the maintenance of the
intestinal homeostasis. This could be underlined by the observation
that the B. vulgatusmpk associated protection of Rag1/mice from
colitis induction is accompanied by inducing DC semi-maturation
and inhibition of CTSS secretion. This makes B. vulgatus mpk a
promising candidate for the treatment for IBD and other CTSS-
associated AID. We think that B. vulgatus mpk might be an even
better tool than a chemical inhibitor to treat CTSS-associated AID
since (i) it is easily administrable, (ii) it does not completely sup-
press physiological functions of CTSS but only suppresses patho-
logical activities and (iii) it acts as a commensal symbiont. It does
not inﬂuence a normal immune response due to acute infections
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but strongly inhibits pathological gut microbiota associated im-
mune responses. Therefore severe side effects of symbiont-
mediated CTSS activity regulation should not occur and could not
be observed in the used mouse model, another advantage over a
chemical inhibitor.
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a  b  s t  r a  c t
Lipopolysaccharides  (LPS)  of Gram  negative bacteria  are one  of the  most  potent  stimulators  of the  host
innate immune  system and LPS  recognition  is  essential for  the  host organism  to clear  infections  of  invad-
ing  bacterial pathogens.  Here  we review  on the  latest research  on how  LPS is  sensed by  host  cells  and
how  distinct LPS  structures  differentially  modulate the  strength  of the  host  immune  response.  Much  is
known  about host immunological reactions  towards pathogens via  recognition  of their LPS, as  well  as
strategies of pathogens  to modulate  their  LPS structure in order  to  evade the immune  system.  However,
less is  known  about differential  sensing  of lipopolysaccharides  of  commensal bacteria  in the  intestine
and  how this contributes  to manifestation  or destruction  of  the  intestinal homeostasis.  LPS  sensing is
necessary  to  fight pathogens.  However,  sensing of LPS  of gut commensal bacteria can  simultaneously  be
disadvantageous  for  the  genetically predisposed  host,  since this  might  lead to damage  of  the  intestinal
homeostasis and  therefore  to  chronic intestinal  inflammation.  However,  less  immunogenic  LPS could
also  serve  as  therapeutics to antagonize  an  overreacting  innate  immune  system.  Therefore,  commensal
gut  bacteria-derived  LPS could  prevent from uncontrolled  intestinal  immune  response  in  the  intestine
which  makes LPS an attractive  therapeutical approach to  treat e.g.  IBD.
© 2016 The Authors.  Published by  Elsevier GmbH. This  is an open access article under  the  CC
BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Lipopolysaccharides fulfil two major functions. First, the LPS
anchored in the outer bacterial membrane provides a  protective
function for Gram negative bacteria and therefore acts as a defence
mechanism against harsh environmental conditions. It  provides a
barrier against surrounding stress factors which therefore makes
LPS indispensable for bacterial viability in various distinct ecosys-
tems (Silipo et al., 2012). By substituting the lipid A sugar moieties
with phosphate groups, the bacterium achieves to  create a  nega-
tively charged outer membrane which can therefore interact with
divalent cations present in the surrounding milieu. This plays
an important role  for the rigidity and the tightness of the outer
membrane and hence mediates bacterial resistance to external
stress factors (Alexander and Rietschel, 2001).  Second, LPS is one
of the most conserved structures within all Gram negative bac-
terial species. This makes LPS an important pathogen associated
molecular pattern (PAMP) to be recognized by  the mammalian
innate immune system which can subsequently initiate the clear-
ance of a bacterial infection. This important immunological reaction
∗ Corresponding author. Tel.: +49 70712982351.
E-mail address: julia-stefanie.frick@med.uni-tuebingen.de (J.-S. Frick).
contributes to the manifestation of relatively conserved molecular
structures in  mammals for the recognition of this PAMP (Akira and
Takeda, 2004). A timely recognition and sensing of LPS of invading
Gram negative bacteria strongly accounts for host immune sys-
tem activation (Netea et al., 2002). However, the initiated immune
response has to  be balanced. Uncontrolled bacterial overgrowth
within the mammalian body usually leads to the release of  large
amounts of non-membrane bound LPS which can,  in turn, result in
exaggerated systemic host immune responses. In severe cases, this
leads to septic shock with fatal consequences for the host (Bone,
1991; Bone et al., 1997).
2. Structure of lipopolysaccharides
LPS consists of three genetically, biologically and chemically
distinct domains (Alexander and Rietschel, 2001)  (Fig. 1): (I) the
more or  less acylated and phosphorylated lipid A  being anchored
in  the bacterial outer membrane, (II)  the core oligosaccharide
linked by 3-deoxy-d-manno-oct-ulosonic acid (Kdo) with lipid A
and (III) the so-called O-antigen or O-specific polysaccharide, with
the latter two pointing to the aqueous environment. Lipopolysac-
charides that  comprise all three regions are called smooth (S)-form
LPS, while LPS lacking the O-antigen are named rough (R)-form
LPS or lipooligosaccharide (LOS) (Fig.  1). The lipid  A  structure in
http://dx.doi.org/10.1016/j.ijmm.2016.03.001
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Fig. 1. Schematic diagram of the  general structure of lipopolysaccharides of  Gram neg-
ative bacteria. Lipolysaccharides of Gram negative bacteria consist of three main
subunits (from bottom to top): lipid A, the core region and the O-antigen. Lipid A
and the core-region form rough (R)-type LPS. Lipid A, the core-region and the O-
antigen together form smooth (S)-type LPS. The number and chemical structure
of  the acyl chains can vary. Sugar moieties are depticted as hexagons in different
colours. The number and chemical structure of these sugar moieties can  vary.
Fig. 2. Detailed Structure of  E.  coli lipid A.  E. coli lipid A contains a  (1 → 6)-linked glu-
cosamine disaccharide backbone (light brown). The hydroxyl group (light yellow)
of the distal glucosamine links lipid A to the Core region. The  two phosphate groups
are  depicted in light green. Primary acyl chains (light grey) are directly linked to  the
sugar moieties, secondary acyl chains (light red) are esterified with the hydroxyl
groups of primary acyl chains. All primary acyl chains of E. coli lipid are hydrox-
ymyristates, one of the two secondary acyl chains is  myristate while the other one
being  laurate.
general is  highly conserved, which is  important for host receptor
recognition.
3. Lipid A
Basically, lipid A is  made up of a  ˇ(1 → 6)-linked glucosamine
disaccharide backbone which is  mostly phosphorylated at position
1 and 4′ of the saccharides and acylated at positions 2 and 3  of each
monosaccharide portion (Galanos and Freudenberg, 1993; Homma
et al., 1985; Kotani et al., 1985).
Usually, lipid A is hexaacetylated, meaning that six acyl chains of
variable length are esterified with the disaccharide backbone. Pri-
mary acyl chains are directly esterified with the sugar moiety while
so-called secondary acyl chains form ester bonds with hydroxyl
groups of primary acyl chains. “Symmetrically” acetylated lipid
A means that each glucosamine moiety carries the same number
of acyl chains. Escherichia coli LPS is  an example for containing an
“asymmetrically” acetylated lipid A, since 4 of its 6 acyl chains are
carried by the first glucosamine. Lipid A is  embedded in the outer
leaflet of the bacterial outer membrane through electrostatic and
mainly hydrophobic interactions. Here, the diglucosamine part of
the lipid A  is orientated towards the exterior environment while the
lipid A acyl chains point to  the hydrophilic interior of the membrane
(Raetz and Whitfield, 2002). Fig. 2 illustrates the detailed structure
of E. coli lipid A which is  considered to be the prototype form of all
lipid A structures. Its two  glucosamine residues are each substi-
tuted by a  phosphate residue at positions 1 and 4′,  respectively. The
hydroxyl groups at positions 2 and 3 of each monosaccharide are
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esterified with hydroxymyristate, a  saturated acyl chain with 14
carbon atoms, as primary acyl chain. Two additional secondary acyl
chains, laurate (C12)  and myristate (C14),  are coupled to  hydrox-
ymyristates at positions 2′ and 3′ (Raetz and Whitfield, 2002)
(Fig. 2).
However, Lipid A structures widely vary among the differ-
ent bacterial species. Sometimes there are even more than one
different lipid A structure within a single species (Raetz and
Whitfield, 2002). The sugar moieties of the saccharide backbone
are mostly 2-amino-2-deoxy-d-glucopyranoses (d-GlcpN) like in
E. coli lipid A, but can also be, i.e.  2,3-diamino-2,3-dideoxy-d-
glucopyranose (d-GlcpN3N) containing an additional amino group
(Molinaro et  al., 2015; Roppel and Mayer, 1975). Other poten-
tial differences refer to  the number, position and length of the
esterified acyl chains, the presence of charged groups on the polar
heads as well as the number of phosphate groups coupled to the
disaccharide backbone (Raetz et al., 2007). The lipid  A  part of
LPS is coupled to the core region through linkage via the non-
reducing distal amino sugar of lipid A (Molinaro et al., 2015)
(Fig. 2).
In E. coli lipid A, C12 and C14 acyl chains are  the only ones being
esterified with the disaccharide backbone (Fig. 2).  However, other
bacteria can provide differentially acylated lipid A which is sup-
posed to be mediated by other enzymes than the ones in  E. coli
which are specific for substituting C14 and C12. However, it could
be demonstrated that in Bacteroides fragilis and Bordetella pertussis,
the enzymes catalysing the acylation of the sugar moieties seem
to be multifunctional, therefore being able to recognize more than
one specific acyl chain as a substrate (Bainbridge et al., 2008; Sweet
et al., 2002).
The number of acyl chains esterified with the disaccharide back-
bone varies among the lipid A of different bacterial species. As
mentioned above, the prototype hexaacylated lipid A contains six
acyl chains. However, certain bacterial species can provide “under-
acylated” lipid A structures, like tetraacylated Helicobacter pylori
lipid A (Mattsby-Baltzer et al., 1992; Moran et al., 1997) (Fig. 4),
or even “overacylated” structures like heptaacylated Acinetobacter
spp. lipid A (Leone et al., 2006, 2007).
The phosphorylation pattern of the disaccharide backbone is
also not conserved among different bacterial species. As  phos-
phate groups are  negatively charged, a  more or  less phosphorylated
lipid A allows bacteria to change the net charge of their surface.
This surface net charge may  vary considerably dependent on envi-
ronmental factors like temperature, pH value or, important for
immune evasion, the presence of antibiotics and antimicrobial pep-
tides (AMPs). The phosphate groups can mediate interactions with
neighbouring phosphorylated lipid A  structures via divalent cations
being present in  the surrounding environment. These interactions
considerably increase the stability of the bacterial outer mem-
brane and reduce the permeability of the cell wall (Molinaro et al.,
2015).
4. Core and O-antigen
The core moiety of LPS starts with at least one residue of 3-
deoxy-d-manno-oct-ulosonic acid (Kdo) which is directly linked to
one of the sugar moieties of lipid A (Figs. 1 and 2).  The core contains
up to 15 sugar residues and provides antigenic properties in  the case
of a missing O-antigen (rough-type LPS) (Caroff and Karibian, 2003).
The O-antigen, sometimes also named O-specific polysaccharide or
simply “glycan” consists of repeating units of usually not more than
five sugar units. The O-antigen can only be found in smooth type LPS
where it determines its antigenic properties (Raetz and Whitfield,
2002).
5.  Molecular weight and micelle formation of isolated LPS
Usually, LPS is anchored in the bacterial outer membrane. How-
ever, for immunological sensing by the host immune system it
has to be released from the bacterial membrane. The exact con-
formation of isolated, non-bacterially attached, LPS is not easy
to determine. However, this is  an important issue for in vitro
experiments using isolated LPS in aqueous solutions. Due to  its
amphiphilic structure, with the acyl chains of the lipid A form-
ing the hydrophobic part and the sugar residues of lipid A, the
core and the O-antigen building up the hydrophilic part, isolated
LPS rarely forms monomers in  any solvent. Therefore, molecular
weight determination of either smooth or rough LPS is  not  trivial.
Dependent on the presence of divalent cations, detergents or the pH
value of the solvent, these large amphiphilic molecules form either
monomers, micelles or  even vesicles. The critical LPS concentration
in aqueous solutions for micelle formation is stated to be 11 g/mL
(Aurell and Wistrom, 1998). Additionally, micelle formation capac-
ity is dependent on the structure of LPS, especially if it consists of
the S-  or R- form. These micelles usually provide low solubility in
any solvent (Molinaro et al., 2015). However, the typical molecular
weight of monomeric S-form LPS of E. coli is reported to be between
11.8 and 18 kDa.
6. Biosynthesis of lipopolysaccharides of Gram negative
bacteria
The biosynthesis of hexaacetylated E. coli LPS has been described
in  detail in  2002 by Raetz and Whitfield (Raetz and Whitfield, 2002).
Briefly, the formation of Kdo2-substituted lipid A includes nine
enzymatic steps catalyzed by the enzymes LpxA, LpxB, LpxC, LpxD,
LpxH, LpxK, LpxL, LpxM and WaaA. This Kdo2 substituted lipid A
is synthesized in  the bacterial cytosol and acyl chain substitution
involves the aid of bacterial acyl carrier proteins. Lipid A-Kdo2 is
completely synthesized in the cytosol either by soluble cytosolic
proteins or enzymes that are associated with the cytosolic part of
the inner bacterial membrane (Carty et al., 1999; Clementz et al.,
1996, 1997; Garrett et al., 1997; Vorachek-Warren et al., 2002).
The LPS core region is  also synthesized in the cytosol. Lipid A-Kdo2
and the core region together form the rough-type (R-) LPS which
is transported across the inner membrane into the periplasmatic
space. Once located there, R-type LPS can either be  directly inserted
into the outer leaflet of the outer bacterial membrane or  it can be
converted into the S-(smooth) type LPS in  the periplasmatic space
before being shuttled to  the outer membrane. The flipping of  the
lipid A coupled LPS core is  carried out by MsbA, an ATP-binding cas-
sette (ABC) transporter protein (Karow and Georgopoulos, 1993;
Zhou et al., 1998).
Although this describes only the events during biosynthesis
of LPS in E. coli,  the general mechanisms seem to be conserved
among most Gram negative bacteria. Bioinformatics-based stud-
ies revealed that many Gram negative bacteria share enzymes like
the ones that are used in E. coli for LPS biosynthesis. But since
lipid A structures differ between distinct bacteria, alterations in the
structure are supposed to  be due to  genetic and/or environmental
differences or influences (Molinaro et al., 2015; Raetz et al., 2007).
7. Extracellular sensing of LPS through recognition by the
MD-2/TLR4 receptor complex
Long time, Toll-like receptor 4 (TLR4) was  supposed to be the
sole LPS sensor in mammalian organisms. TLR4 is a transmembrane
protein composed of 22 leucine-rich repeats (LRRs), one transmem-
brane domain and a  cytosolic Toll/IL-1 receptor (TIR) domain, the
latter being a  common feature in all TLRs. LPS is anchored in  the
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bacterial outer membrane. However, for being recognized by the
host immune system, LPS has to be removed from the membrane
or membranous structures. This can either happen indirectly by
bacterial cell death leading to a  release of LPS or  directly by the sol-
uble host protein lipid A-binding protein (LBP), a lipid transferase
that is able to remove LPS molecules from the bacterial membrane
(Miyake, 2006). LBP is  present in  the serum to  sense bacterial pres-
ence in the blood. Additionally, LBP is  secreted into the intestinal
lumen where it is involved in sensing not only invading pathogens,
but also commensal-derived LPS (Hansen et al., 2009) (Vreugdenhil
et al., 2000). In general, commensal intestinal bacteria can be sub-
divided into two distinct groups, dependent on their potential to
induce disease under certain circumstances: (1) symbiotic bacteria
that never induce disease and (2) pathobiontic bacteria which are
potentially able to induce pathological immune reactions. Sensing
of LPS molecules from these two different bacterial subgroups is
important for a balanced intestinal immune system. This fact makes
LBP essential for the maintenance of the intestinal homeostasis. LBP
transports monomeric lipid A molecules to CD14. CD14 can either
be a membrane-anchored protein of TLR4-expressing cells or  can
be secreted into the environment as a  soluble protein. The pres-
ence of CD14 is important for LPS sensing, since it increases the
susceptibility of TLR4-expressing cells to  LPS by factor 102 to  103
(Wright et al., 1990). CD14-associated monomeric LPS is  then shut-
tled to MD-2 (Fig. 3A). Like CD14, MD-2 can be a  soluble protein
secreted into the cell exterior or it can be  permanently attached
to a TLR4 monomer via hydrogen bonds (Kim et al., 2007; Visintin
et al., 2003). Binding of LPS to MD-2 leads to  formation of a het-
erooligomeric protein complex consisting of two  MD-2 and two
TLR4 molecules (Fig. 3A). This protein complex formation is  ini-
tially induced through interaction at the extracellular domains.
These extracellular protein-protein-interactions, in turn, result in
dimerization of TIR-domain containing intracellular cytosolic parts
of the TLR4 receptors leading to  Myeloid differentiation primary
response gene 88 (MyD88)- or TIR-domain-containing adapter-
inducing interferon- (TRIF)-dependent downstream signalling
(Molinaro et al., 2015) (Fig. 3A). Binding of LPS to MD-2 leads to
conformational changes within MD-2 therefore promoting MD-2
binding to the ectodomain of TLR4 (Ohto et al., 2007, 2012). In 2009,
Park et al. (2009) revealed interesting detailed informations on the
binding conditions within a  crystallized hexaacylated LPS-MD-2-
TLR4 complex with both, murine and human TLR4 ectodomains. In
general, five of the six acyl chains of hexaacylated LPS are buried
inside a binding grove in the interior of MD-2. The sixth acyl chain
is located on the surface of MD-2 and partially exposed to the
surrounding solvent. In combination with hydrophobic residues
of MD-2, this 6th acyl chain promotes intermolecular interactions
with TLR4 (Jin and Lee, 2008; Ohto et al., 2012). Taken together, the
initial binding of LPS to MD-2 creates a  new binding interface for
MD-2 and therefore promotes MD-2 binding to TLR4 (Park et al.,
2009). The resulting conformational changes within this complex
lead to dimerization of the C-termini of the TLR4 ectodomaines.
This event is supposed to mediate the dimerization also of the
cytosolic TIR domains of the TLR4 which initializes intracellular
downstream signalling (Jin and Lee, 2008; Kim et al., 2007; Ohto
et al., 2012) (Fig. 3A). Taken together, MD-2 binding of lipid A is
essential for TLR4-mediated LPS recognition. However, LBP and
CD14 are supposed to  be important for LPS sensing at low LPS
concentration whereas they seem to be dispensable at high concen-
trations (Wurfel et al., 1995; Wurfel and Wright, 1997). Activation
of the TLR4-receptor complex results in  an activation of more than
103 genes (Bjorkbacka et al., 2004) and promotes, i.e. the secre-
tion of pro-inflammatory cytokines like TNF, IL-6, IL-1 as well
as in enhanced production of the superoxide anion O2
−, hydroxyl
radicals, NO and antimicrobial peptides (AMPs) (Ohto et al., 2007;
Poltorak et al., 2000)  (Fig. 3A).
8. Intracellular sensing of LPS through recognition by
cytosolic caspase-11
Caspases are intracellular cysteine proteases. The so-called
“inflammatory caspases” comprise a  certain subset of these
enzymes which are critical for clearance of microbial infections
and initiation of the host immune system to fight pathogens
(Lamkanfi et al., 2002; Martinon and Tschopp, 2004). Among oth-
ers, murine caspases 1, 4, 5 and 11 as well as human caspases
4 and 5 are considered to be such inflammatory caspases. They
all have in common that they are synthesized as proteolytically
inactive zymogens, needing proteolytic cleavage to induce enzy-
matic activity. Furthermore, they share an N-terminal domain
responsible for protein-protein interactions called caspase activa-
tion and recruitment domain (CARD). All  genes of inflammatory
caspases are encoded in  an inflammatory gene cluster. Once
activated, inflammatory caspases lead to the maturation of  the
pro-inflammatory cytokines IL-1 and IL-18 and induce a  special
kind of cell death, pyroptosis. Both mechanisms are mediated by
activation of cytosolic inflammasomes. Inflammasome activation
can be carried out through two different mechanisms: the canon-
ical and non-canonical way. The classical, or “canonical” way to
activate inflammasomes in a  caspase-dependent manner, involves
proteins like Nod-like receptor protein 3 (NLRP3) or NLR family
CARD domain-containing protein 4 (NLRC4) engaging the intracel-
lular adaptor protein NLR family CARD domain-containing protein
4 (ASC) resulting in  an activation of caspase-1 (Casp1) which leads
to a  Casp1-catalyzed cleavage of IL-1 and IL-18 followed by secre-
tion of the mature cytokines (Mariathasan et al., 2006; Martinon
et al., 2006; Schroder and Tschopp, 2010). The non-canonical way
includes Casp1 activation with the requirement of Casp11 (Wang
et al., 1996). Interestingly, Casp11 can directly sense the presence
of cytosolic lipid A independently from TLR4 recognition but also
leading to inflammasome activation and consequently to  IL-1 and
IL-18 secretion as well as pyroptosis (Fig. 3B).
The non-canonical inflammasome activation requires two inde-
pendent activation steps: First, a  priming signal that leads to
an increase in intracellular expression of inflammasome compo-
nents like Casp1, NLRP3, ASC and Casp11. This initial event can
be lipid A binding to TLR4 (Raetz and Whitfield, 2002)  which effi-
ciently enhances Casp11 gene transcription (Hagar et al., 2013;
Kayagaki et al., 2013; Wang et al., 1996). However, the prim-
ing event is not restricted to TLR4 recognition of lipid A. In fact,
activation of TLR2 and/or TLR7 by other bacterial components is
sufficient to act as such a priming signal (Takeuchi and Akira,
2010). Second, after the priming event, intracellularly located LPS
can directly bind to  Casp11 leading to  its activation which sub-
sequently results in inflammasome activation. It could already be
shown that this Casp11-mediated non-canonical inflammasome
activation, independent of TLR4 activation, plays an important role
during bacterial challenge of the host with pathogens like Shigella
flexneri (Rathinam et al., 2012), Salmonella typhimurium (Broz et al.,
2012a), Legionella pneumophila (Case et al., 2013) or Burkholderia
thailandiensis (Aachoui et al., 2013) but is  also important for sensing
the LPS of gut  commensals like E. coli (Kayagaki et al., 2013). Fur-
thermore, it seems that Casp11-mediated sensing of Gram negative
bacteria is not  just an alternative to the TLR4-mediated way but
rather seems to be critical for an adequate response of the immune
system to  these bacteria (Aachoui et al., 2013; Broz et al., 2012b;
Kayagaki et al., 2011; Rathinam et al., 2012).
But  how can lipid A of non-invading bacteria like E. coli be sensed
intracellularly by cytosolic inflammasome components? As known
so far, Casp11 non-canonical inflammasome activation mostly
occurs in  macrophages in mice, although a  recent publications
reports on Casp11 expression in  mouse epithelial cells (Knodler
et al., 2014). Macrophages are  phagocytes which can include
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Fig. 3. Molecular mechanisms of  extracellular and intracellular sensing of  bacterial LPS.  (A) Extracellular LPS sensing. The host lipid binding protein (LBP) samples LPS from the
outer  membrane of Gram negative bacteria and mediates its transport to  host CD14. CD14 can either be soluble (sCD14) or anchored in the membrane of TLR4 expressing
cells.  CD14 shuttles LPS to  the TLR4 coreceptor protein MD-2 which initiates a  conformational change in MD-2 and TLR4, resulting in dimerization of the extracellular and
subsequently of the intracellular TIR domains. TIR domain dimerization mediates downstream signaling leading to enhanced expression of more than 1000 different genes.
(B)  Intracellular LPS sensing. Left side: LPS that is present in the extracellular space can enter (for example by, but not  exclusively due to, receptor-mediated endocytosis)
the  vacuoles of caspase-11 (Casp11) expressing cells. LPS escapes the vacuoles via a  yet unidentified mechanism. Right side: Gram negative bacteria can be sampled by
phagocytotic cells like Casp11 expressing macrophages. The LPS of non-cell invading bacteria or whole cell invading bacteria are relieved into the  cytosol. Both: LPS present
in  the cytosol actively binds to the  CARD domain of Casp11 leading to  Casp11 oligomerization that results in Casp11 activation. By a yet unknown mechanism, this Casp11
activation results in inflammasome assembly resulting in Caspase-1 (Casp1) mediated secretion of the pro-inflammatory cytokines IL-1 and IL-18. Casp11 oligomerization
can also lead to pyroptosis, a  special kind of cell death.
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extracellular bacteria into vacuolar phagolysosomes. Some bacte-
ria, which are specialized in  intracellular replication, like Burkholde-
ria spp. can actively escape the phagosomes into the cytosol of
host macrophages where they can trigger LPS-dependent Casp11
activation (Aachoui et al., 2013). Salmonella typhimurium is able to
rupture the membrane of the bacteria-containing vacuole with the
use of Guanine-binding protein 2 (GBP2). However, the presence
of GBP2 is obviously dispensable for Casp11-mediated sensing of
S. typhimurium LPS (Kayagaki et al., 2013), although other studies
report GBPs to be critical for the release of vacuole content (Meunier
et al., 2014; Pilla et al., 2014). How LPS of other Gram negative bacte-
ria which are not specialized in host cell invasion like E. coli or Cit-
robacter rodentium (Kayagaki et al., 2013; Meunier et al., 2014) can
be translocated from the vacuole to the cytosol of host macrophages
in order to be sensed by  Casp11 is unknown so far (Fig.  3B). Most
in vitro studies therefore used methods like electroporation or
transfection to make cytosolic Casp11 capable of LPS sensing.
It is already clear that, lipid A  is the decisive part for intracellular
Casp11-mediated LPS sensing (Hagar et al., 2013; Kayagaki et al.,
2013), just like it is  the case for TLR4-mediated recognition of
LPS. It could also be shown that the categories “antagonistic” and
“agonistic” in terms of LPS endotoxicity can also be  referred to
lipid A-induced Casp11 activation, since lipid A structures that
are weakly agonistic or  antagonistic for TLR4 activation also fail
to induce Casp11 activation (Hagar et al., 2013; Kayagaki et al.,
2013). This is not due to  a  lower affinity for lipid A to Casp11
since it could be demonstrated that these less agonistic lipid A
structures efficiently bind to Casp11 (Shi et al., 2014). However, it
is not known if the same structural criteria for being agonistic or
antagonistic, which are valid in  case  of MD-2/TLR4-mediated lipid
A sensing, also counts for Casp11. When lipid A is  located in  the
cytosol, it is able to directly bind to Casp11 with the help of the
Casp11- intrinsic CARD domain subsequently leading to Casp11
oligomerization (Shi et al., 2014). The exact mechanisms behind
these findings are not understood so far. However, it is  clear that
this lipid A- induced Casp11 oligomerization leads to proteolytical
activation of Casp11 within the oligomer (Shi et al., 2014; Shin
et al., 2007). Lipid A binding to Casp11 is  highly specific, since no
other LPS component could be shown to interact with Casp11 and,
inversely, no other caspase interacts with lipid A (Shi et al., 2014).
Caspase-11 (Casp11) was initially discovered by  Wang et al (Wang
et al., 1996) and two corresponding orthologues of murine Casp11
could be discovered in humans: caspase-4 (Casp4) and caspase-5
(Casp5) (Stowe et al., 2015).
9.  Other host proteins being involved in LPS sensing
Apolipoprotein CI (ApoCI) is  a small apolipoprotein which is
present in the serum. It has been shown to provide an LPS-binding
motif with which it is  able to bind to bacterial LPS, finally enhancing
an LPS induced inflammatory host response (Berbee et al., 2006). It
seems to act in a comparable way like LBP and promotes CD14/MD-
2/TLR4-mediated LPS signalling (Berbee et al., 2010). By its strong
affinity to bacterial LPS it enhances the residence time of LPS in  the
circulation (Berbee et al., 2006). This makes ApoCI an important fea-
ture to protect from fatal sepsis, since the prolonged residence time
enhanced the access for LPS-sensing blood cells in order to fight
invading pathogens, as demonstrated in  a Klebsiella pneumoniae
sepsis model (Berbee et al., 2006). Acyloxyacyl hydrolase (AOAH) is
an enzyme, expressed in host antigen presenting cells, that renders
agonistic lipid A into non-TLR4 signaling structures by  removing
acyl chains from the lipid  A disaccharide backbone (Munford and
Hall, 1986). AOAH is a critical enzyme when it comes to  inactiva-
tion of agonistic LPS of pathogens and endotoxin tolerance. Such a
tolerance towards pathogen-derived lipid A  diminishes the
immune response of the host to fight these invading microbes
(Lu et al., 2008). The restoration of a  powerful immune response
is dependent on the inactivation of the pathogen’s lipid A, mak-
ing AOAH crucial in  this context (Lu et al., 2008). The impact of
AOAH on inactivation of commensal lipid A is  less clear. It could
be shown that AOAH is preferentially expressed in a  Th17-immune
response mediating dendritic cell subpopulation and that AOAH
deficiency favours induction of Treg cells over induction of  Th17 cells
(Janelsins et al., 2014). However, the correlation between AOAH
activity, microbiota composition (and therefore lipid A structures)
and the outcome of inflammatory bowel disease still needs to be
elucidated.
10. Immunogenicity of lipopolysaccharide
As already mentioned, LPS structure, especially its lipid A chem-
istry, differs among distinct bacterial species. Indeed, the exact
LPS structure, and in this context mainly the lipid A structure,
determines LPS immunogenicity and is  therefore decisive for its
function (Brandenburg et al., 1993; Seydel et al., 2000).  LPS which
triggers a strong pro-inflammatory reactions of host cells are
named “agonistic” lipolysaccharides. In contrast, structurally dif-
ferent lipid A can also result in  weak inflammatory host responses,
hence being called “weak agonistic” or  it can even completely
block any pro-inflammatory reactions by binding to  correspond-
ing  host receptors. The latter lipopolysaccharides are therefore
called “antagonistic”. Most Gram negative bacteria express ago-
nistic hexaacylated LPS like  E. coli LPS, which is  one of  the most
potent agonists of the human innate immune system (Beutler and
Rietschel, 2003; Raetz and Whitfield, 2002; Zahringer et al., 1994)
(Fig. 4A). Usually the number of lipid A acyl chains directly cor-
relates with the ability to  induce cytokine production whereas
the hexaacylated forms usually are  the most immunostimulat-
ing ones (Munford and Varley, 2006). Within a  biological system,
distinct lipid A  structures compete for binding to host receptors.
Antagonistic lipid  A might therefore compete with agonistic LPS
for host receptor binding. Hexaacylated lipid A seems to  promote
the strongest proinflammatory immune reactions after binding to
TLR4. This is  due to  the fact that the first five acyl chains are buried in
a hydrophobic cavity of the TLR4 adaptor molecule MD-2 while the
sixth chain mediates the binding to TLR4, the precondition for TLR4-
mediated intracellular signalling (Maeshima and Fernandez, 2013;
Park et al., 2009). Therefore, TLR4-mediated signalling usually is
drastically reduced if this sixth acyl chain is missing. However, due
to the already mentioned differences in the structures of the lipid
A binding cavity of the TLR4 receptor between different mammal
species, distinct lipid A structures can provide a  different immuno-
genic potential between these species. Fig. 4 summarizes different
lipid A structures and their corresponding agonistic or antagonistic
properties.
Not only acyl chains contribute to the immunogenic properties
of lipid A, but  also the number of phosphate groups. A  deletion
of a phosphate group can result in  a loss of the endotoxic activ-
ity (Rietschel et al., 1994). Most lipid A structures contain two
phosphate residues, one on each sugar moiety. However, some bac-
terial lipid As lack one or even both of them, therefore altering
its immunogenic potential. For example, Francisella tularensis lacks
one or both phosphate groups and this is considered to be, at least
in part, the reason for its weak agonistic property (Molinaro et al.,
2015)  (Fig. 4E). Furthermore, the non-phosphorylation might also
be seen as an immune evasion strategy for certain bacteria since
some antimicrobial peptides (AMPs) specifically target negative
charges on bacterial surfaces and a loss of negatively charged phos-
phate residues therefore renders bacteria to  be invisible for these
AMPs.
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Fig. 4. Different lipid A structures of various bacteria and their  immunogenic potential. (A) prototype E. coli lipid A.  (B–C, E, G–K) lipid A structures of other bacteria. (D) structure
of  antagonistic lipid IVa. (F) structure of the chemically synthesized TLR4 antagonist Eritroran. Immunogenic phosphate groups are highlighted in light red. The  bold red
numbers below each acyl chain refers to the number of carbon atoms of the respective chain. Structural differences of the acyl chains compared to  prototype agonistic E. coli
lipid  A are highlighted in  light blue. Structural differences of the  disaccharide backbone compared to prototype agonistic E.  coli lipid A are highlighted in light yellow. The
classification of each lipid A structure as agonistic or antagonistic refers to  its immunogenic behaviour due to  TLR4 binding. See text for details.
11.  Immune-evasion
Induction of antibacterial defence by  triggering inflammatory
host responses is a crucial function of the innate immune system in
response to invading bacteria. This reaction prevents the spreading
of bacteria and suppresses the bacterial growth. In many infections
with pathogens, the innate immune responses slow the progress
of infection and allow for the adaptive immune responses to
develop (Montminy et al., 2006). Suppressing or evading the host
immune responses is a  successful strategy of pathogenic bacteria,
known as immune-evasion (Montminy et al., 2006). Immune
evasion strategies based on lipid A  modification help to  promote
the survival of Gram negative bacteria by evading host immune
responses that are directed against bacterial invasion, chronic
persistence or susceptibility to cationic antimicrobial peptides
(CAMP) (Needham and Trent, 2013).
As mentioned above, the acylation pattern of lipid A  varies
between species and is heterogeneous even within a single
species (Dixon and Darveau, 2005; Raetz and Whitfield, 2002;
Zähringer and Rietschel, 1999). Environmental conditions are
known to influence the lipid A  structure by modulating for
example the number, composition and location of acyl chains
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thereby affecting the biological activity of lipid A. The production
of weak stimulatory lipid A is  thought to be involved in  the
virulence of several Gram negative pathogens (Dixon and Darveau,
2005).
An impressive and well-characterized example of lipid A mod-
ification as immune evasion mechanism represents Yersinia pestis
(Montminy et al., 2006). Y. pestis grown at 21–28 ◦C  (flea tempera-
ture) expresses hexaacylated lipid A structures (Fig.  4H), but these
lipid A structures are mainly tetraacylated at 37 ◦C (host tempera-
ture) (Kawahara et al., 2002; Knirel et al., 2005; Rebeil et al., 2004)
(Fig. 4J). Although hexaacylated lipid A is normally a  strong activa-
tor of human TLR4, tetraacylated lipid A has a  significantly lower
activity (Golenbock et al., 1991; Kawahara et al., 2002; Lien et al.,
2000; Loppnow et al., 1989; Rebeil et al., 2004) and is thought to
act as a TLR4 antagonist (Needham and Trent, 2013). To suppress
local inflammatory immune responses, Y. pestis uses several par-
allel mechanisms that individually are  necessary for virulence like
e.g. a type 3 secretion system (T3SS), releasing immunosuppress-
ive proteins (Nakajima et al., 1995). However, evading activation of
TLR4 was shown to be  an essential part of the Y. pestis immune eva-
sion. The ability of a  Y. pestis mutant strain expressing lipid A with
an increased capacity to activate TLR4 at 37 ◦C was dominant over
the anti-host bacterial defences provided by the T3SS and other Y.
pestis activities (Montminy et al., 2006). Hence, despite retention of
multiple immune evasive proteins used by  Y. pestis to  suppress host
responses, a strain producing hexaacylated lipid A and thus being
quickly detectable by  means of TLR4-MD-2 failed to cause disease
(Montminy et al., 2006).
Similar to Y. pestis, F. tularensis (Fig. 4E)  shows a dynamic regu-
lation of lipid A acyl chain length according to  temperature (Okan
and Kasper, 2013; Needham and Trent, 2013). F. tularensis has
two homologues of the essential lipid A biosytheses acyl trans-
ferase LpxD, LpxD1/LpxD2, (Valentin-Hansen et al., 2007). LpxD1
has its optimum activity at 37 ◦C and consistent with this the lpxD1
mutant is unable to express the modified lipid A with longer acyl
groups and is severely attenuated in  mice (Okan and Kasper, 2013;
Li et al., 2012) and is  also more susceptible to antibiotics and CAMP
by reason of an increased membrane permeability (Li et al., 2012;
Needham and Trent, 2013).
Another example of evading the recognition of the host’s
immune system by modifying the lipid  A  component of LPS is
H. pylori.  Despite a robust host immune response, H. pylori per-
sists within the gastric niche and promotes a chronic infection
for the duration of the host’s life (Gaddy et al., 2015). H. pylori
uses two lipid A based immune evasion strategies, evasion of
detection by TLR4 and resistance to  CAMP. The lipid A of H. pylori has
a unique structure and lower biological activity as compared to lipid
A  from other bacteria, e.g. E. coli (Chmiela et al., 2014; Moran and
Aspinall, 1998; Muotiala et al., 1992). Interestingly H. pylori syn-
thesizes a hexaacylated lipid A but exhibits a tetraacylated lipid A
lacking phosphate groups at its surface (Needham and Trent, 2013)
(Fig. 4C). The structural differences are generated by the action of
several enzymes including deacylation by  LpxR and dephosphory-
lation by LpxE and LpxF (Gaddy et al., 2015; Needham and Trent,
2013). Hence H. pylori provides a  tetraacetylated antagonistic lipid
A structure (Fig. 4C) that not only prevents TLR4-mediated activa-
tion of the innate immune system (Moran et al., 1997; Ogawa et al.,
2003; Raetz et al., 2007), but also from Casp11-mediated inflamma-
some activation (Kayagaki et al., 2013) (Fig. 3B). Other examples for
underacetylated antagonistic lipid A are Rhodobacter sphaeroides
(Fig. 4G) and Rhodobacter capsulatus lipid A structures (Rose et al.,
1995).
Many Gram-negative bacteria utilize lipid A modifications to
survive the antimicrobial peptide response imposed by the ver-
tebrate host. Altering the bacterial surface charge by  e.g. adding
positively charged moieties reduces the binding affinity of cationic
antimicrobial peptides with the bacterial outer membrane. An
important antimicrobial factor is  calprotectin. It  is a  critical compo-
nent of the host nutrient withholding process, termed nutritional
immunity (Gaddy et al., 2015; Gebhardt et al., 2006; Urban et al.,
2009). One mechanism of nutritional immunity is  the host induced
restricted access for bacteria to essential metals (Hood and Skaar,
2012). Calprotectin binds Zn2+ and Mn2+ with high affinity which
starves bacteria of these essential metals, creating a  Zn2+ and Mn2+
limited environment. Additionally, calprotectin exhibits antimicro-
bial activity against numerous Gram-positive and Gram-negative
bacteria (Corbin et al., 2008; Damo et al., 2013; Hood et al.,
2012; Liu et al., 2012; Lusitani et al., 2003; Sohnle et al., 2000;
Steinbakk et al., 1990). Moreover calprotectin has been demon-
strated to  inhibit H. pylori growth and has the capacity to  modify
the activity of the cag type IV secretion system. However H. pylori
is able to persist in  the gastric niche despite this robust immune
response. One mechanism allowing for persistence is  the modifi-
cation of the H. pylori lipid A in  response to calprotectin. Thereby
the lipid A modification pathway is influenced by the host nutri-
tional immune response as the calprotectin dependent restricted
access to  essential metals like Zn2+ and Mn2+ perturbs the function
of H.  pylori enzymes involved in  the lipid A  modification path-
way, resulting in increased bacterial fitness and increased biofilm
formation.
Salmonella enterica subsp. enterica serovar Typhimurium is  an
intracellular pathogen which causes gastroenteritis in humans. In
S.  typhimurium the modification of lipid A is controlled by the
PhoPQ system which is  activated by low Mg2+ concentrations or
CAMPs (Guo et al., 1997; Guo  et al., 1998; Raetz et al., 2007), e.g.
by  growing cells under Mg2+ limitation or  during growth within
macrophage phagosomal vacuoles (Martin-Orozco et al., 2006). The
activation of the PhoPQ and the PmrAB systems results in  an addi-
tion of phosphoethanolamine and aminoarabinose and to a  PagP
and PagL dependent acyl chain remodelling (Richards et al., 2012).
In addition LpxO hydrolates S. typhimurium lipid A as part of  a coor-
dinated stress response (Moreira et al., 2013; Needham and Trent,
2013).
Porphyromonas gingivalis which is  considered to be an impor-
tant agent in  human periodontal disease exhibits a  very large
degree of flexibility in  the structure of its lipid A (Curtis et al.,
2011). It harbours di-and monophosphorylated and penta- and
tetraacylated moieties (Kumada et al., 1995) and in addition
a  spectrum of nonphosphorylated lipid A species (Rangarajan
et al., 2008). Dependent on the temperature P. gingivalis shifts
the lipid A from an inert nonphosphorylated and antagonizing,
monophosphorylated, tetra-acylated structure at 37 ◦C to a
monophosphorylated, penta-acylated higher-potency TLR4 ago-
nistic structure at 41 ◦C  (Curtis et al., 2011). In addition, the lipid
A structure of the tetra-acylated nonphosphorylated P. gingivalis
grown at 37 ◦C contributes to the resistance to CAMPs (Coats et al.,
2009).
12.  Other antagonistic lipid A structures
Usually, pathogenic bacteria naturally provide antagonistic
lipid A structures as a  strategy of immune evasion, since a non-
response towards their LPS renders them less visible for the host
immune system. One of the most known antagonistic lipid A
structures for the human TLR4 receptor complex is the so-called
lipid Iva (Fig. 4D). Its backbone structure strongly resembles the
structure of agonistic E. coli LPS. In fact, it constitutes a  precur-
sor form of mature E. coli lipid A. However, due to a lack of
both secondary acyl chains (Fig. 4D) that are  present in E. coli
lipid A (Fig.  4A), it provides strong antagonistic properties with
simultaneous high affinity binding to MD-2 and therefore TLR4
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(Beutler and Rietschel, 2003; Raetz and Whitfield, 2002; Zahringer
et al., 1994). Although being a  strong antagonist for the human
TLR4 receptor complex, lipid IVa is a  weak agonist for the murine
TLR4 receptor complex. This is based in minor structural differ-
ences between human and murine MD-2. Whereas lipid IVa  binding
to  human MD-2 results in  an upward shift of the phosphory-
lated disaccharide backbone mediating antagonistic properties, the
binding of lipid IVa to the murine MD-2 leads to a similar con-
formation compared to agonistic hexaacylated lipid A (Ohto et al.,
2012).
13. Endotoxicity of LPS as a  determinant of intestinal
inflammation or homoeostasis
It  is well accepted that in inflammatory bowel diseases (IBD),
chronic inflammatory disorders of the intestine, the mucosal
immune system reacts inappropriately towards the intestinal
commensal microbiota (Vijay-Kumar and Gewirtz, 2009).  How-
ever no particular microbial species has been consistently linked
to IBD pathogenesis, but some symbiotic bacteria species have
been shown to  prevent inflammatory host responses (Chassaing
and Darfeuille-Michaud, 2011; Chow and Mazmanian, 2010;
Devkota et al., 2012; Jeon et al., 2012; Round and Mazmanian,
2009).
The mono-colonization of Il2−/− mice with E. coli is reported
to induce severe colitis, whereas monocolonization with Bac-
teroides vulgatus does not and B. vulgatus even inhibits the E. coli
induced inflammation in  co-colonized Il2−/− mice (Waidmann
et al., 2003). Recently we showed that a  low endotoxicity of
the intestinal microbiota was associated with mucosal immune
homeostasis in a mouse model of chronic intestinal inflammation
(Gronbach et al., 2014). T cell transplanted Rag1−/− harboring a
low endotoxic complex intestinal microbiota, characterized by high
numbers of Bacteroidetes and low numbers of Enterobacteriaceae
did not develop colitis, whereas T  cell transplanted Rag1−/− mice
harboring a high endotoxic complex intestinal microbiota, charac-
terized by high numbers of Enterobacteriaceae and low numbers of
Bacteroidetes developed severe intestinal inflammation (Gronbach
et al., 2014). In  line with this, feeding of Rag1−/− mice, harboring
the low endotoxic microbiota with commensal but pathobion-
tic E. coli JM83 resulted in  intestinal inflammation, whereas the
administration of an E. coli JM83 mutant containing an acyl-
transferase from P. gingivalis (E. coliMUT) protected Rag1
−/− mice
harboring the high endotoxic microbiota from induction of dis-
ease (Bainbridge et al., 2006). We isolated and purified LPS from
both E. coliWT and E. coliMUT and characterized its fatty acid com-
position. Investigations by  high-resolution electrospray ionization
Fourier transform ion cyclotron mass spectrometry revealed the
same hexaacetylated lipid A molecules in both strains. In addi-
tion, E. coliMUT contained a major portion of lipid A, in which
a 12 carbon atom laurate acyl chain is  replaced by a  16 carbon
atom palmitate acyl chain (Gronbach et al., 2014)  (Fig. 4A and
B). This minor modification in  E. coli JM83 is reported to sig-
nificantly affect host cell signaling (Bainbridge et al., 2006). To
verify the altered stimulatory capacity of LPSMUT compared with
LPSWT, we used TLR4-overexpressing human embryonic kidney
cells (HEK293). Stimulation of cells with the modified LPSMUT
resulted in a  significantly reduced IL-8 secretion 4 h after stimu-
lation, as compared with LPSWT indicating a reduced endotoxicity
but not TLR4 antagonism of the altered LPSMUT. Feeding of Rag1
−/−
mice harboring the low endotoxic microbiota with LPSWT resulted
in severe intestinal inflammation, however challenging mice which
were colonized with the high endotoxic microbiota protected
these animal from induction of colitis (Gronbach et al., 2014). This
data suggest that the ratio of high endotoxic and low endotoxic
LPS is  crucial for the regulation of the intestinal immune bal-
ance. A  predominance of high endotoxic LPS might promote a
TH1/TH17 response, subsequently supporting intestinal inflamma-
tion, and a predominance of low endotoxic LPS might induce an
altered activation of the innate immune system, and either induc-
tion of regulatory T  cells or prevention of a  TH1/TH17 response,
associated with intestinal immune homeostasis (Gronbach et al.,
2014). Therefore LPS might act as a  key microbial symbiosis fac-
tor that, depending on its structure, can induce or  prevent bowel
inflammation by shaping the innate immunity via TLR4-dependent
signaling mechanisms (Gronbach et al., 2014; Yamamoto and Akira,
2009).
14. LPS as a potential drug for the treatment of
inflammatory bowel disease?
The role of LPS for the host immune system provides ambiva-
lent features. While LPS is essential for the host organism to  sense
infections of bacterial pathogens at an early stage, therefore help-
ing to clear the infection, an imbalanced LPS sensing can have
severe effects for the host organism with fatal sepsis being the
most severe consequence. Blocking TLR4 mediated downstream
signaling has been implicated to be useful as a drug to prevent
from septic shock (O’Neill et al., 2009). Therefore, synthetic antag-
onistic lipid A structures were invented in  order to block TLR4
receptor signaling, such as Eritroran (Fig. 4F). Eritroran strongly
prevents from binding of agonistic lipid A  to MD-2 and there-
fore terminates MD-2/TLR4-mediated signaling in vitro, ex vivo
and in  vivo (Mullarkey et al., 2003; Rossignol and Lynn, 2002;
Rossignol et al., 2004). Despite these findings, Eritroran failed to
improve survival in a phase III trial in patients with severe sep-
sis  (Opal et al., 2013). Until now, it is  not known why  Eritroran
gavage failed to  prevent from fatal sepsis. Possible explanations
might be the delayed administration of this strong TLR4 agonist
or a failure in trial design (Opal et al., 2013; Tse, 2013). Neverthe-
less, antagonistic lipid  A structures still seem to be a promising
tool for the treatment of bacterially induced sepsis. This strategy
to  prevent from an uncontrolled, or “imbalanced”, TLR4 signaling-
mediated immune response might also be an attractive approach to
deal with inflammatory disorders of the gut. Inflammatory bowel
disease develops from an uncontrolled immune response directed
towards the intrinsic microbiota. In this case, not  pathogens are
the target of the immune system, but rather commensal bacte-
ria located in the intestine. It  might therefore be possible that
antagonistic or weakly agonistic lipid A structures could prevent
from uncontrolled TLR4-mediated immune responses towards the
own microbiota. In fact, we could already show that the lipid A
structure of commensal bacteria is a  decisive trigger for the induc-
tion of colitis in  a genetically predisposed host (Gronbach et al.,
2014).
Two  main questions remain concerning the administration of
isolated LPS (or lipid A) for the treatment of IBD. (I) Which lipid A
structure might provide the best results and (II) is TLR4 blocking
really “the  method of choice”?
The specific structure of lipid A can have profound and even
unpredictable effects upon TLR4 signaling. Although detailed stud-
ies about the interaction of lipid A with its corresponding MD-2
co-receptors are available (Ohto et al., 2012; Park et al., 2009),
the precise immunogenicity cannot be predicted from knowing the
structure alone. However, a recent report by Paramo et al. (2015)
means a  major advance concerning this issue, since they manage
to  predict the binding behaviour of lipid A structures to  MD-2 by
measuring their potentials of mean force. The second question is
even more complicated to answer. It  is possible that TLR4 blocking
might not  restore homeostasis in  every case, since TLR4 signaling
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seems to be important for the prevention of dextran sodium sul-
fate (DSS)- induced colitis in  mice (Rakoff-Nahoum et al., 2006;
Wittmann et al., 2015). Therefore, an antagonistic lipid A struc-
ture, completely preventing from TLR4 signaling, might not  be the
lipid A of choice. Possibly, a  rather weakly agonistic lipid A struc-
ture, allowing basic TLR4-mediated signaling, but preventing from
uncontrolled TLR4 activation might be a  better tool. Additionally,
the recent discovery of caspase-11 as an intracellular lipid A bind-
ing LPS sensor (Kayagaki et al., 2011, 2013; Shi et al., 2014) leads
to the question, if blocking the TLR4 binding cavity is  sufficient to
influence LPS-mediated induction of the host immune system. As
described above, a  block of TLR4 is not sufficient to prevent from LPS
induced Casp11-mediated inflammasome activation. Other bac-
terial components, largely present in  the intestine, can activate
other TLRs than TLR4 to induce an increase in cytosolic amounts
of Casp11 being a  precondition for intracellular lipid A sensing.
Therefore, a potential lipid A-derived drug needs to have access
to the cytosol of host target cells. Although being highly specu-
lative, this might be another explanation why Eritroran failed in
the clinical study since it was not  granted access to  the cytosolic
compartment. This fact rises drug development to  a severe chal-
lenge and strategies need to  be  developed to target therapeutic
lipid A to the cytosolic compartment. Since it could be shown
that lipid A structures that act antagonistically in TLR4-signaling
also prevent from Casp11 oligomerization and activation despite
efficient binding (Shi et al., 2014). Therefore, it seems that  the
immunogenicity of lipid A structure concerning TLR4 activation,
described by the terms agonistic and antagonistic, also accounts
for intracellular lipid A induced intracellular inflammasome acti-
vation.
There is an ongoing research for new lipid A structures in  order
to be used as therapeutic. Although most research on this topic
focuses on the treatment of sepsis, the idea behind it can easily
be transferred to the treatment of chronic inflammatory intesti-
nal disorders. Besides synthetic or chemical development of lipid
A structure-related TLR4 antagonists, there is  an ongoing interest
also on LPS structures of more “exotic” bacteria and how they might
contribute to a research progress on this topic. For example, Di
Lorenzo et al. (2014) identified a  lipid A structure with strong antag-
onistic activity in a bacterium living in hot springs: Thermomonas
hydrothermalis (Fig. 4K). However, a  closer and more detailed look
on the lipid A structures of symbiotic commensal bacteria might
be helpful for the development of a  lipid A structure providing
weak agonistic activity to  prevent from both, TLR4- and Casp11-
mediated, uncontrolled immune responses of the host organism
towards its own microbiota.
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Abstract  38 
Bacteroides vulgatus mpk is a symbiotic gut commensal from the mouse intestine. It is known that 39 
administration of this bacterium protects from colonic inflammation in various mouse models for 40 
experimental colitis. Here, we demonstrate that B. vulgatus mpk even restores gut homeostasis in an already 41 
inflamed intestine. This effect is mainly mediated by the unique structure of its lipopolysaccharide (LPS). 42 
Although the binding affinity to the host MD-2/TLR4 receptor complex is similar to a strong agonistic LPS, 43 
it exhibits only weakly agonistic activity. Such activity converts intestinal dendritic cells into a tolerant and 44 
tolerogenic phenotype that mediates the intestinal homeostasis-restoring properties of B. vulgatus mpk LPS. 45 
Thus, we promote symbiotic B. vulgatus mpk LPS, as a potential alternative therapeutic approach for the 46 
treatment of Inflammatory Bowel Diseases. Furthermore, insights gained from the structural analysis of B. 47 
vulgatus mpk LPS might help to chemically design novel potent inflammation-silencing drugs. 48 
 49 
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 60 
 61 
Introduction  62 
 63 
Inflammatory Bowel Diseases (IBD) are characterized by chronic relapsing intestinal inflammation with 64 
Crohn’s Disease (CD) and Ulcerative Colitis (UC) being the most frequent and clinically relevant forms of 65 
this disease complex1. IBD is considered to be a multifactorial disease with genetics2, environmental factors3 66 
and intestinal microbiota composition4 contributing to the pathology. Therapy of IBD in humans is currently 67 
focused on symptomatic treatment, often by means of immunosuppression5. Additionally, fecal 68 
transplantation or bacteriotherapy is recently discussed as a potential therapy6, though sometimes offering 69 
more questions than answers. 70 
It is widely accepted that the composition of the intestinal microbiota can strongly influence the progress and 71 
outcome of IBD. However, we recently reported that not only the presence, abundance or proportion of 72 
certain live microbial species contribute to such microbiota-mediated effects. Indeed, the structure, and 73 
consequently the endotoxicity, of lipopolysaccharides from Gram-negative bacteria determines the outcome 74 
of inflammation in a mouse model for experimental colitis7. Lipopolysaccharides (LPS), in their smooth 75 
form, consist of three distinct domains: (1) an O-specific polysaccharide, (2) a core oligosaccharide (core 76 
OS) and (3) the lipid A which anchors LPS to the outer leaflet of the bacterial cell wall8. With its highly 77 
conserved overall structure and composition, LPS represents an important microbe-associated molecular 78 
pattern (MAMP) playing an essential role for the recognition of bacterial invasion by the host innate immune 79 
system9, 10 through recognition by the host myeloid-differentiation-2/Toll-like receptor 4 (MD-2/TLR4) 80 
receptor complex. Importantly, the fine structure of LPS, primarily the detailed composition of lipid A, 81 
drastically influences its biological activity, ranging from strong activation of the innate immune system, in 82 
case of agonistic LPS, to a complete block of immune responses, in case of antagonists9, 11. This different 83 
behaviour is reflected in diverse binding modes of such lipid A structures to the MD-2/TLR4 receptor 84 
complex12.  85 
A prominent intestinal commensal Gram-negative and, therefore, LPS-producing bacterial phylum in 86 
humans is Bacteroidetes13, 14. We have previously characterized a member of this phylum, namely 87 
Bacteroides vulgatus mpk, as a symbiotic commensal of the mouse intestine providing high genome 88 
plasticity15 and exhibiting strong immune-modulating properties leading to a prevention of colitis induction 89 
in several mouse models for experimental colitis16, 17, 18. Here, we demonstrate that this commensal symbiont, 90 
B. vulgatus mpk, drastically reduced an already established intestinal inflammation in mice leading to a 91 
complete healing of damaged intestinal tissue. Intriguingly, this effect was mirrored by only using its 92 
purified LPS. Detailed determination of the B. vulgatus mpk LPS structure revealed a hypoacylated and 93 
mono-phosphorylated lipid A species and a unique core OS structure which does not result in an 94 
antagonistic, but rather in a weakly agonistic activity. These weakly agonistic properties are responsible for 95 
its active inflammation silencing characteristics. Hence, this specific LPS structure might be a novel and 96 
effective therapeutic agent for the treatment of IBD. Furthermore, revealing its detailed molecular structure 97 
might therefore contribute to IBD therapy-related drug design. 98 
 99 
Results  100 
B. vulgatus mpk actively silences established inflammatory reactions in a mouse model for 101 
experimental colitis as confirmed by non-invasive in vivo PET imaging 102 
We have demonstrated that mouse gut-associated symbiotic commensal B. vulgatus mpk exhibits anti-103 
inflammatory properties in various mouse models for experimental colitis16, 17, 18. These anti-inflammatory 104 
properties were exhibited when B. vulgatus mpk was administered before onset of disease resulting in 105 
prevention of intestinal inflammation. This prompted us to verify whether this symbiont was also capable of 106 
reducing inflammatory reactions in an already inflamed environment thus making such a symbiotic 107 
commensal a therapeutic tool for treatment of colitis in mice. Therefore, we used Rag1-/- mice harbouring a 108 
highly colitogenic microbiota containing high proportions of Enterobactericeae7 and transplanted them with 109 
5 x 105 naïve wt CD4+CD62L+CD45Rbhi T-cells. Four weeks after T-cell transplantation, mice were 110 
administered 5 x 108 live B. vulgatus mpk per mL of drinking water until the end of the experiment, 8 weeks 111 
after T-cell transplantation. As controls, non-transplanted and transplanted but not live B. vulgatus mpk-112 
treated Rag1-/- mice were used (Fig. 1a). In order to monitor the actual degree of colonic inflammation, all 113 
mice were injected with [18F]FDG and non-invasive in vivo PET imaging was performed. [18F]FDG is 114 
suitable for the detection of ongoing inflammatory processes in living animals, since sites of inflammation 115 
are depicted as regions with higher [18F]FDG uptake in PET scans compared to non-inflamed surrounding 116 
environments19. However, some organs as heart and bladder generally provide a basic tracer uptake signal 117 
independent from their inflammatory status. We monitored the colonic [18F]FDG uptake over time from all 118 
mice used for this experiment. Therefore each mouse was injected with [18F]FDG and PET-imaging was 119 
performed at the day of T-cell transplantation (week 0) as well as 4, 6 and 8 weeks after T-cell 120 
transplantation (Fig. 1b). The obtained data were corrected for decay, due to the half life time of [18F], and 121 
normalized to the injected activity per animal. As demonstrated in the upper panel of Fig. 1b, non-122 
transplanted Rag1-/- mice provided low [18F]FDG uptake during the whole observation period, indicating no 123 
ongoing inflammatory processes in the colon. However, Rag1-/- mice transplanted with T-cells provided  124 
 125 
Figure 1: Administration of live B. vulgatus mpk reduces intestinal inflammation in Rag1-/- mice with established colonic 126 
inflammation as confirmed by non-invasive in vivo PET imaging.  127 
a. Experimental setup: Rag1-/- mice harboring a highly colitogenic microbiota were transplanted with CD4+ T-cells to induce 128 
intestinal inflammation as described. 4 weeks after T-cell transplantation, mice were started to be administered live B. vulgatus mpk 129 
in the drinking water at a concentration of 5 x 108 mL-1. B. vulgatus mpk treatment was continued for 4 more weeks. 8 weeks after T-130 
cell transplantation mice were sacrificed and analyzed. As controls, one group was transplanted without following B. vulgatus 131 
administration and one group was not T-cell transplanted.  132 
b. High resolution non-invasive small animal in vivo PET imaging. 8.3 ± 1.3 MBq  [18F]FDG was injected into the tail vein of each 133 
mouse. Static PET scans were performed at the day of T-cell transplantation and repeated 4, 6 and 8 weeks after T-cell 134 
transplantation. Data was corrected for decay and normalized to the injected activity. PET images of one representative individual per 135 
group are depicted. Organs providing high intensity signals (heart, bladder and inflamed colon) are labelled in the upper left panel. 136 
 137 
severe colonic inflammation as illustrated by a high colonic [18F]FDG uptake at weeks 4 and 6 (Fig 1b, 138 
middle panel). Since the inflammation in these animals exceeded an ethically maintainable level, we had to 139 
sacrifice the animals at week 6. As another group, T-cell transplanted Rag1-/- mice, displaying severe signs of 140 
intestinal inflammation at week 4 (Fig. 1b, lower panel) were administered B. vulgatus mpk via drinking 141 
water.In these mice, we observed a considerable reduction of colonic [18F]FDG uptake already after two 142 
weeks. Another PET scan at week 8 revealed comparably low [18F]FDG uptake indicating that the 143 
inflammatory processes, visible at week 4, were cleared by B. vulgatus mpk administration.  144 
This considerably demonstrated that the anti-inflammatory properties of the commensal symbiont B. 145 
vulgatus mpk did not only prevent from induction of inflammation. It also actively silenced already 146 
established colonic inflammation, alleviating symptoms of colitis in Rag1-/- mice. 147 
 148 
B. vulgatus mpk LPS mimics the anti-inflammatory activity exerted by live B. vulgatus mpk  149 
Since one of the major immunoreactive compounds of Gram-negative bacteria is LPS, we investigated 150 
whether the administration of pure B. vulgatus mpk LPS (LPSBV) exhibits the same anti-inflammatory and 151 
inflammation-silencing properties as the live bacterium. Therefore, we isolated LPSBV and used it for in vivo 152 
administration. Again, we used Rag1-/- mice harbouring a highly colitogenic microbiota and induced colonic 153 
inflammation through transplantation of 5 x 105 naïve wt CD4+CD62L+CD45RBhi T-cells. At week 4, 154 
transplanted mice showed clear signs of colonic inflammation such as bloody feces and diarrhea, which is in 155 
line with the PET imaging that was performed to monitor intestinal inflammation (Fig. 1b). At this point, we 156 
administered live B. vulgatus mpk, as described above, and LPSBV at a concentration of 160 µg mL-1 in the 157 
drinking water from week 4 until the end of the experiment (8 weeks after T-cell transplantation) (Fig. 2a). 158 
Figure 2b illustrates representative H&E stained colonic sections from each group. Non-treated T-cell 159 
transplanted animals showed severe signs of colonic inflammation (Fig. 2b, left panel). However, the LPSBV- 160 
and live bacteria-treated animals provided significantly lower intestinal inflammation (Fig. 2b, middle and 161 
right panel) compared to non-treated mice (Fig. 2c). CD3+CD4+ T-cells isolated from the colonic lamina 162 
propria (cLP) of live B. vulgatus mpk-treated Rag1-/- mice expressed significantly lower amounts of IL-17 163 
(Fig. 2e), thus providing a clearly reduced Th17 response20. Furthermore, qRT-PCRs from colonic scrapings 164 
revealed that live B. vulgatus mpk-treated animals expressed significantly higher amounts of aldehyde 165 
dehydrogenase (ALDH) mRNA, which triggers the induction of immune response silencing Foxp3+ 166 
regulatory T-cells (Tregs) by metabolizing vitamin A-derived retinol into retinoic acid (RA). RA has been 167 
shown to be a crucial mediator for the induction of Tregs and ALDH+ intestinal dendritic cells are considered 168 
to be important mediators for immune homeostasis21, 22, 23. LPSBV-treated T-cell transplanted Rag1-/- mice  169 
 170 
Figure 2: Isolated LPSBV provides the same capability to reduce intestinal inflammation in Rag1-/- mice with established 171 
colonic inflammation as live B. vulgatus mpk. 172 
a. Experimental setup: Rag1-/- mice harbouring a highly colitogenic microbiota were transplanted with CD4+ T-cells to induce 173 
intestinal inflammation as described. 4 weeks after T-cell transplantation, mice were either non-treated, treated with live B. vulgatus 174 
mpk by administration of 5 x 108 bacteria mL-1 in the drinking water or treated with isolated LPSBV in the drinking water at a 175 
concentration of 160 µg mL-1. Mice were sacrificed and analysed 8 weeks after T-cell transplantation. 176 
b. Representative H&E stained colonic sections at week 8.  177 
c. Histological colitis score at week 8, ranging from 0 to a maximum of 3.  178 
d. gating strategy to determine the CD3+CD4+ T-cell population in the colonic lamina propria (cLP) at week 8.  179 
e. Proportion of IL-17+ cells among the population of cLP CD3+CD4+ T-cells, determined by flow cytometry.  180 
f. Relative Aldh mRNA expression in colonic scrapings at week 8, determined by qRT-PCR. Data were normalized to Aldh2 mRNA 181 
expression in colonic scrapings of non-inflamed non-T-cell-transplanted Rag1-/- mice. 182 
also provided significantly lower proportions of IL-17 expressing CD3+CD4+ cLP T-cells as well as higher 183 
Aldh mRNA expression in colonic scrapings. These data indicated that both, live B. vulgatus mpk bacteria 184 
and isolated LPSBV are equally able to silence established inflammatory processes in the large intestine by 185 
downregulation of Th17 immune response promoting cytokines and by favoring Treg inducing 186 
environmental conditions. 187 
B. vulgatus mpk LPS contains tetra- and pentaacylated lipid A and provides a unique composition of 188 
its core structure  189 
Due to the immune response silencing properties of isolated LPSBV, we characterized its structure in detail. 190 
After extraction and purification of LPSBV, a mild acid hydrolysis allowed to isolate lipid A which was 191 
investigated by chemical analyses and MALDI mass spectrometry revealing a heterogeneous mixture of 192 
tetra- and pentaacylated species (Fig. 3a,b). Nature and distribution of the fatty acids were similar to the 193 
previously reported lipid A structure from B. dorei24, a close relative of B. vulgatus. 194 
Likewise, the lipid A blend resulted to be phosphorylated only at the reducing glucosamine (α-GlcN), as also 195 
observed in B. dorei24; the occurrence of a minor bis-phosphorylated lipid A species was also detected. 196 
Furthermore, NMR-based studies, in parallel to ESI MS analyses, on both the core OS and the O-chain 197 
polysaccharide (Fig. 3c,d) disclosed a novel structure of the LPS core region. Briefly, the core region was 198 
built up of a hexasaccharide bearing a phosphorylated Kdo unit, in turn, substituted at position O-5 by a 199 
rhamnose residue. This latter was found to be a branched monosaccharide bearing a β-galactofuranose unit 200 
(Galf) at its position O-3 and, at position O-4, a β-galactopyranose unit. This latter was, in turn, disubstituted 201 
by α-fucose and β-glucose. The O-chain polysaccharide was built up of repeating units of α-rhamnose and β-202 
mannose which is in full agreement with the O-chain of B. vulgatus IMCJ1204 previously characterized by 203 
Hashimoto et al.25 (Fig. 3d). Full characterization details are presented in the Supplementary Notes. 204 
Interestingly, only the Kdo sugar unit carried at O-4 a negatively charged group, namely a phosphate group. 205 
From the carbohydrate and LPS chemistry point of view, it is very important to underline the unusual 206 
presence of Galf in the core region. Indeed, to the best of our knowledge, it has only been found in an 207 
environmental Shewanella strain26 as well as in the thermophilic bacterium Thermomonas hydrothermalis27. 208 
This finding is even more interesting taking into account that the presence of five membered rings in the LPS 209 
core OS is very rare28 and that Galf is a major constituent of fungal and mycobacterial cell walls in which a  210 
 211 
Figure 3: MS and NMR based structural analysis of LPSBV.  212 
a. Reflectron MALDI TOF mass spectrum (MS), acquired in negative polarity, of purified B. vulgatus mpk lipid A. Spectrum shows 213 
two intense groups of ions around m/z 1420.5 and m/z 1660.8. Each group is characterized by the presence of mass differences of 14 214 
kDa indicative of lipid A species differing in their acyl chain length. Assignment of the lipid A species is depicted as tetraacylated 215 
lipid A and pentaacylated lipid A.  216 
b. Structure of a representative lipid A species relative to ion peak at m/z 1688.8.  217 
c. Zoom of the overlapped 1H, 13C HSQC (black/red) and 1H, 13C HMBC (blue) spectra of the fully deacylated LPS from B. vulgatus 218 
mpk. The most relevant long-range correlations that allowed the complete structural characterization of the LPS saccharide moiety 219 
are reported.  220 
d. Structure of the core OS and the O-chain (biological repeating unit) moieties from LPSBV derived from the combination of 221 
chemical, NMR and MALDI MS and MS/MS analyses. 222 
 223 
linear chain of alternating β-(1→5)- and β-(1→6)-linked Galf residues is attached to a disaccharide 224 
containing rhamnose and N-acetlyglucosamine. 225 
B. vulgatus mpk LPS exhibits weakly agonistic immunogenicity and is sufficient to render dendritic 226 
cells tolerant and semi-mature  227 
It is known that apathogenic commensal bacteria can have either symbiotic or pathobiotic properties 228 
concerning the activation of the immune system. As mentioned previously, we identified B. vulgatus mpk as 229 
such a symbiotic commensal and E. coli mpk as a representative apathogenic pathobiotic commensal. We 230 
confirmed that pure LPS was able to mimic the immunogenic properties of both commensal bacteria with 231 
LPSBV providing low and LPSEC exhibiting strong immuno-stimulating properties (Supplementary Fig. 1).  232 
Hence, LPSBV is not a MD-2/TLR4 receptor complex antagonist since it provided weakly agonistic activity 233 
as demonstrated by low, but still detectable amounts of secreted cytokines and by slight enhancement of T-234 
cell stimulatory surface proteins as MHC-II, CD40, CD80 and CD86 (Supplementary Figure 1). We have 235 
previously reported on the crucial role of semi-mature dendritic cells (smDCs) for the maintenance of 236 
intestinal homeostasis and the prevention of intestinal inflammation7, 17, 18, 29. A peculiar feature of B. 237 
vulgatus mpk induced smDCs is the non-responsiveness towards further bacterial stimuli in terms of surface 238 
expression of MHC-II, CD40, CD80 and CD86 as well as secretion of cytokines such as TNF and IL-12p40 239 
but not IL-629. Supplementary Fig. 1 indicates that LPSBV stimulated BMDCs might be semi-mature since 240 
they strongly resembled the phenotype caused by B. vulgatus mpk stimulation. However, in order to 241 
determine whether LPSBV stimulation effectively renders BMDCs semi-mature they need to be challenged 242 
with a maturating stimulus, such as E. coli mpk, checking for immunoreactivity in case of immature DCs or 243 
tolerance in case of smDCs. As controls, we primed BMDCs for 24 h with PBS to keep them immature, with 244 
B. vulgatus mpk to render them semi-mature and with E. coli mpk to induce complete BMDC maturation 245 
(Fig. 4a). Additionally, we primed BMDCs with LPSBV and LPSEC to verify their respective maturation 246 
phenotype. 24 h after priming, medium was changed for fresh medium and the cells were challenged with 247 
either PBS or E. coli mpk for further 16 h (Fig. 4a,b). As demonstrated in Fig. 4a and 4b, LPSBV-primed and 248 
 249 
 250 
Figure 4: LPSBV converts bone marrow derived dendritic cells into a tolerant semi-mature state.  251 
a. Experimental setting: Bone marrow derived dendritic cells (BMDCs) from wt mice were generated as described and primed with 252 
either PBS (mock control), B. vulgatus mpk (MOI 1), E. coli mpk (MOI 1), LPSBV (50 ng per 106 BMDCs) or E. coli mpk LPS 253 
(LPSEC) (50 ng per 106 BMDCs) for 24 h. Medium was changed and primed BMDCs were challenged with either PBS (mock 254 
control) or E. coli mpk for another 16 h.  255 
b. Secretion of TNF, IL-12p40 and IL-6 into cell supernatant after medium change followed by PBS- or E. coli mpk-challenge, 256 
determined by ELISA.  257 
c. Flow cytometric analyses of BMDC surface expression of the CD4+ T-cell activating surface proteins MHC-II, CD40, CD80 and 258 
CD86 among the population of CD11c+ cells. The proportion MHC-IIhi+, CD40+, CD80+ and CD86+ cells among the population of 259 
differentially primed and E. coli mpk challenged CD11c+ BMDCs was determined by flow cytometry and normalized to the 260 
proportion of MHC-IIhi+, CD40+, CD80+ and CD86+ CD11c+ BMDCs of equally primed, but PBS challenged controls. Statistical 261 
analyses were performed using student’s t-test. Error bars represent SD. 262 
 263 
E. coli mpk-challenged BMDCs provided significantly lower secretion of IL-12p40 and TNF, as well as 264 
MHC-II and CD86 surface expression compared to PBS-primed and E. coli mpk-challenged BMDCs. All 265 
above features are typical for tolerant smDCs. Additionally, priming with either LPSBV or B. vulgatus mpk 266 
had the same effect on DCs, since in both cases DCs became semi-mature.  As previously published, priming 267 
with E. coli mpk leads to full DC maturation (mDCs)18, 29, an effect that can be mimicked by priming with 268 
LPSEC alone.  269 
In summary, differential maturation of DCs by commensal bacteria was highly dependent on their LPS 270 
structure. Moreover, live B. vulgatus mpk bacteria were not necessary to induce smDCs providing immune 271 
homeostasis maintaining properties, as the usage of the isolated LPSBV was sufficient to induce DC semi-272 
maturation.  273 
 274 
LPSBV and LPSEC provide similar binding affinity to the MD-2/TLR4 receptor complex  275 
The observation that both, LPSBV and LPSEC, showed different immunological effects on DCs in vitro, 276 
prompted us to define and compare their binding affinity to the MD-2/TLR4 receptor complex. We 277 
established an experimental setting to determine quasi dissociation constants (KD) of both LPS structures 278 
using biotinylated LPSBV (bioLPSBV). We are aware of the fact that we cannot determine real KD-values since 279 
we do not know the exact molarity of the used LPS solutions. The assembly of amphiphilic LPS monomers 280 
into micelles, vesicles or even more complicated structures is highly dependent on the buffer and ionic 281 
strength and is therefore hardly predictable. This exacerbated the determination of the molarity of LPS 282 
monomers which effectively have access to the receptor, rendering them “active ligands” thus contributing to 283 
KD values. However, assuming that (1) bioLPSBV and LPSEC provide a comparable monomeric molecular 284 
weight, (2) bioLPSBV and LPSEC behave in a similar chemical manner under the experimental conditions and 285 
(3) all experiments were carried out incubating both LPS at the same time, we can speculate that a qualitative 286 
comparison using KD-values in the unit [g L-1] instead of [mol L-1] is qualifiable for a comparison of their 287 
binding affinity. In order to determine KD values for both LPS, we used human embryonic kidney (HEK) 288 
cells which were stably transfected with a plasmid encoding for murine CD14, MD-2 and TLR4 (HEK-289 
mTLR4). These latter were expressed by HEK-mTLR4 cells in excess and in equal amount, representing a 290 
fundamental prerequisite for KD determination. Since bioLPSBV did not show any difference in the 291 
immunological behaviour compared to LPSBV (data not shown), we concluded that biotinylation did not 292 
affect the interaction with the receptor complex. We incubated HEK-mTLR4 cells with various 293 
concentrations of bioLPSBV and we then visualized bound bioLPSBV by adding PE-coupled streptavidin 294 
followed by flow cytometric analysis of the resulting PE fluorescence. As shown in Fig. 5a, non-biotinylated 295 
LPS and cells without addition of any LPS did not contribute to the PE fluorescence signal. The resulting 296 
PE-fluorescence in bioLPSBV-treated samples was dependent on bioLPSBV concentration and showed a 297 
classical perpendicular hyperbola binding curve of a ligand to its respective receptor (Fig. 5a, right panel). In 298 
order to determine KD of bioLPSBV and LPSEC, we simultaneously incubated HEK-mTLR4 cells with 299 
different concentrations of both LPS for 1 h and detected resulting PE fluorescence, which is directly 300 
proportional to the amount of bound bioLPSBV (Fig. 5b). In order to define the KD value of bioLPSBV, various 301 
concentrations of this LPS alone without addition of LPSEC were used. The KD equalled the concentration of 302 
bioLPSBV corresponding to the half maximal MFI PE intensity, which could be determined as 0.412 mg L-1. 303 
In other words, adding 0.412 mg L-1 to the used 1 x 105 HEK-mTLR4 cells led to occupation of half of the 304 
available MD-2/TLR4 binding sites (Fig. 5c). In order to determine KD of LPSEC, several concentrations of 305 
LPSEC were co-incubated with different concentrations of bioLPSBV, resulting in 4 different binding curves 306 
representing the 4 employed LPSEC concentrations (Fig. 5d). The resulting binding curves follow the 307 
equation 308 
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 309 
with n being the number of different binding sites (which was assumed to be 1 in our case). The binding 310 
curves shown in Fig. 5d were then plotted into a double reciprocal form resulting in 4 different straight lines 311 
whose slopes were determined using GraphPad Prism (Fig. 5e). The slopes obtained from Fig. 5e were 312 
afterwards plotted against the respective LPSEC concentration resulting in a straight line whose intersection 313 
with the x-axis represented the negative value of the LPSEC binding constant which was determined to be 314 
0.304 mg L-1, being in the same biologically relevant range as bioLPSBV KD.  315 
These data allowed us to conclude that LPSBV and LPSEC provide similar binding affinity to the MD-2/TLR4 316 
receptor complex. 317 
 318 
 319 
Figure 5: LPSBV and LPSEC provide similar binding affinity to the MD-2/TLR4 receptor complex.  320 
a. HEK cells expressing murine CD14, MD-2 and TLR4 (HEK-mTLR4) were co-incubated with LPSBV, biotinylated LPSBV 321 
(bioLPSBV) or PBS (w/o LPSBV) at several concentrations. PE-coupled streptavidin (Strep-PE) was added to each sample. Cells were 322 
washed and analysed for PE fluorescence using flow cytometry. Left panel: gating strategy to determine intact HEK-mTLR4 cells. 323 
Middle panel: representative histograms of PE fluorescence of HEK-mTLR4 cells that were treated as described above. Right 324 
panel: Detected mean PE fluorescence intensity (PE (MFI)) as a function of used bioLPSBV concentration.  325 
b. Experimental setting for the determination of LPS binding affinity: HEK-mTLR4 cells were incubated simultaneously with 326 
various concentrations of non-biotinylated LPSEC or bioLPSBV for 1 h. Cells were washed and incubated with Strep-PE. PE 327 
fluorescence was detected afterwards.  328 
c. HEK-mTLR4 cells were incubated with bioLPSBV only according to the experimental setting described in (b). By using different 329 
concentrations of bioLPSBV and the resulting detected PE fluorescence, a non-linear regression for a perpendicular hyperbola was 330 
created. The bioLPSBV concentration corresponding to the half-maximal PE intensity equals to KD of bioLPSBV.  331 
d. according to (b) HEK-mTLR4 cells were simultaneously incubated with bioLPSBV and LPSEC. For each differentially coloured 332 
perpendicular hyperbola binding curve the concentration of bioLPSBV varied while the concentration of LPSEC was constant. 333 
According to (b), resulting PE fluorescence was detected as demonstrated in (a). The detected PE signal is directly proportional to 334 
bound bioLPSBV. Each data point represents a distinct combination of LPSEC and bioLPSBV concentrations (n=3).  335 
e. Data obtained from (d) were mathematically transformed into a double reciprocal form and plotted into a graph. The binding 336 
curves from (d) are therefore transformed into straight lines.  337 
f. Slopes which were obtained from the double reciprocal plotting in (e) which were derived from the binding curves in (d) were 338 
plotted against the corresponding concentration of LPSEC which was kept constant in the experiment. A linearization led to a straight 339 
line whose intersection with the x-axis represents the negative value of the dissociation constant (-KD) for the binding of LPSEC to the 340 
murine MD-2/TLR4 receptor complex. 341 
 342 
 343 
LPSBV exerts therapeutic effects only in excess concentrations compared to other commensal-derived 344 
LPS  345 
We have demonstrated that LPSBV provides weakly agonistic activities and binds to the murine MD-2/TLR4 346 
receptor complex with an affinity that is comparable to the binding affinity of strong agonistic LPSEC. Since 347 
the downstream signalling, and therefore the immunogenicity, is dependent on effective (MD-2/TLR4)2 348 
heterotetramerization, we hypothesized that the specific and unique overall LPSBV structure blocks the 349 
conformational change of the receptor complex which is necessary for tetramer formation (Fig. 6a). 350 
Concerning the therapeutical effects of LPSBV in strong reduction of intestinal inflammation, we conclude 351 
that the concentration of LPSBV located in the intestinal lumen must exceed the number of agonistic LPS 352 
from other commensal bacteria in order to induce tolerant smDCs. Exceeding LPSBV concentrations are 353 
thought to enhance the probability that intestinal DCs only encounter weakly agonistic LPSBV since we 354 
demonstrated that simultaneous encounter with a strong agonistic LPS prevented from DC semi-maturation 355 
and induces pro-inflammatory responses mediating DC maturation (Supplementary Fig. 3). In this case, the 356 
ability of LPSEC to remove already bound LPSBV from the MD-2/TLR4 receptor complex more efficiently 357 
than vice versa (Supplementary Fig. 2) would not be relevant. As demonstrated in Supplementary Fig. 3, the 358 
endotoxicity of LPSBV depends on its concentration and very high LPSBV concentration might lead to 359 
complete DC maturation. However, this concentration exceeds physiological LPS levels in the intestine. We 360 
demonstrated that using 160 µg mL-1 in the drinking water led to the observed healing effects in Rag1-/- mice, 361 
indicating that such a concentration is sufficient to exceed the amount of already present LPS in the colon 362 
while simultaneously being in a semi-maturation inducing concentration range. Once DC semi-maturation is 363 
induced, this phenotype cannot be overcome18, 29, 30, 31 and would therefore lead to a prevention of a de novo 364 
T-cell activation. Therefore, after a phase-out of ongoing inflammatory processes, newly induced smDCs 365 
through LPSBV administration would prevent from a continuous T-cell activation (Fig. 6b) and, therefore, 366 
promote healing of damaged colonic tissue. 367 
 368 
 369 
Figure 6: Proposed mechanism how weakly agonistic LPSBV influences MD-2/TLR4 receptor complex activation and 370 
prevents from initiation of a CD4+ T-cell mediated immune response via modulation of intestinal CD11c+ cells  371 
a. Right side: agonistic LPS like LPSEC binds to the MD-2/TLR4 receptor complex. Its LPS structure harbouring a bis-phosphylated 372 
and hexaacylated lipid A leads to a conformational change in the receptor complex leading to heterotetramerization of two MD-373 
2/TLR4-dimers resulting in efficient intracellular signalling, overshooting a pro-inflammatory signalling threshold. Left side: weakly 374 
agonistic LPSBV binds to the MD-2/TLR4-receptor complex with a similar affinity as strong agonistic LPSEC. However, its structural 375 
characteristics like harbouring a mono-phosphorylated, mixed tetra- and pentaacylated lipid A, as well as a unique galactofuranose-376 
containing core OS structure probably lead to a block of the heterotetramer formation resulting in a weak intracellular signalling that 377 
does not exceed a pro-inflammatory threshold but rather mediates anti-inflammatory immune responses.  378 
b. Therapeutical administration of LPS from symbiotic B. vulgatus mpk ends up in large amounts in the intestine, exceeding the 379 
amount of present LPS from other intestinal commensal bacteria. Excess LPSBV primes naïve CD11c+ cells into a tolerant, 380 
tolerogenic and semi-mature phenotype that fails to activate CD4+ T-cells. This prevention of a de novo activation of CD4+ T-cells 381 
leads to a phase-out of ongoing inflammatory processes while de novo induction of an immune response is prevented. However, our 382 
data indicate that this only happens if LPSBV is the only TLR4 ligand which CD11c+ cells encounter when they are still naïve and 383 
immature. LPSBV needs a certain period of time to induce CD11c+ cell tolerance. Simultaneous encounter with agonistic LPS does 384 
not lead to CD11c+ cell tolerance and does therefore not promote abrogation of inflammatory processes.  385 
 386 
 387 
 388 
 389 
 390 
Discussion  391 
In this study, we report that the administration of the gut commensal bacterium, B. vulgatus mpk, drastically 392 
reduces established and ongoing pathological inflammatory processes in the intestine of a mouse model for 393 
experimental colitis using Rag1-/- mice. These immune response silencing properties were mediated by the 394 
bacterial LPS as the healing effects could be obtained using pure LPSBV only. We therefore propose that 395 
LPSBV might be a novel therapeutic agent for the treatment of chronic gut inflammatory disorders or could 396 
alternatively (bio)-inspire an ad hoc chemical synthesis for novel correlated compounds.  397 
B. vulgatus mpk belongs to the Gram-negative bacterial phylum Bacteroidetes representing one of the two 398 
most prominent phyla in the mammalian gut13, 14. However, the proportion of Bacteroidetes in the intestinal 399 
microbiota is dependent on the inflammatory status of the gut. In ulcerative colitis patients, the proportion of 400 
Bacteroides spp is markedly decreased32 supporting the idea of Bacteroides strains being important 401 
beneficial players in the intestinal microbiota. Additionally, we have already shown that administration of a 402 
certain mouse gut-associated intestinal commensal Bacteroides strain, B. vulgatus mpk, prevents from 403 
disease induction in different mouse models for experimental colitis16, 17, 18, mainly by induction of tolerant 404 
semi-mature dendritic cells (smDCs) in the intestine. These smDCs are responsible for the prevention of pro-405 
inflammatory immune responses16, 17, 18, 29. Here we demonstrated that B. vulgatus mpk is not only able to 406 
prevent from the induction of pathological inflammatory responses but it is also capable of strongly reducing 407 
established and ongoing inflammation resulting in amelioration of colitis. These colitis healing effects were 408 
not restricted to administration of live B. vulgatus mpk since, intriguingly, administration of isolated LPSBV 409 
was able to completely mimic the observed homeostasis restoring effects in Rag1-/- mice.  410 
Structural analysis of LPSBV revealed a mixture of penta- and tetraacylated mono-phosphorylated lipid A, 411 
chemically related to the B. dorei24 and B. fragilis33 lipid As , a galactofuranose-containing core OS and an 412 
O-chain composed of rhamnose and mannose. Interestingly, the core structure revealed a novel carbohydrate 413 
composition that has not yet been detected in any other bacterial LPS. In particular, the presence of 414 
galactofuranose in the inner part of the LPS core as well as the presence of a rhamnose residue, as the first 415 
sugar linked to the Kdo, are surely an innovative hallmark for LPS. Thus it can be speculated that such an 416 
unusual architecture has a key role in the MD-2/TLR4 complexation with LPS and the following 417 
downstream signalling.  In general, LPS is a potent MD-2/TLR4 agonist leading to strong intracellular 418 
signalling in target T-cells resulting in transcription of genes associated with pro-inflammatory immune 419 
responses12. The immunogenicity, or the strength of this intracellular signalling, triggered by LPS is widely 420 
considered to be mostly mediated by lipid A34, 35. Hexaacylated and bis-phosphorylated E. coli lipid A is 421 
considered to be the most potent activator of the MD-2/TLR4-receptor complex mediated signalling since it 422 
was demonstrated that five of the six acyl chains are buried inside the MD-2 binding cavity while the sixth 423 
acyl chain points out to the MD-2 surface mediating hydrophobic interactions with the TLR4 ectodomain 424 
which is necessary for TLR4 activation.12,42 This partly explains the lower endotoxicity of hypoacylated lipid 425 
A structures lacking this sixth acyl chain and the weakly agonistic activity of hypoacylated LPSBV. 426 
Furthermore, both 1- and 4’- phosphates on the lipid A diglucosamine backbone were demonstrated to be 427 
important moieties for MD-2/TLR4 receptor complex activation12. Since LPSBV possesses only one 428 
phosphate at position 1 of the reducing glucosamine, this may also contribute to its weakly agonistic effects 429 
as a missing 4’-phosphate was demonstrated to result in a 100-fold reduction in endotoxic activity36. Within 430 
this frame, the occurrence of a minor bis-phosphorylated lipid A species did not increase the LPSBV 431 
immunogenicity as previously demonstrated for the bis-phosphorylated LPS lipid A from the mutant strain 432 
of B. thetaiotaomicron (ΔLpxFI)37. Additionally, recent studies revealed that not only the lipid A 433 
phosphorylation and acylation pattern determines LPS endotoxicity. Indeed, it was demonstrated that 434 
charged groups, other than glucosamine backbone associated phosphates, can increase LPS mediated 435 
endotoxicity. As examples, the positively charged aminoarabinose attached to the lipid A disaccharide 436 
backbone of the hypoacylated LPS from Burkholderia cenocepacia as well as the negatively charged 437 
carboxyl group present in the LPS core of a pentaacylated lipid A containing LPS of Capnocytophaga 438 
canimorsus were responsible for the high endotoxicity of both LPS38, 39. Besides Kdo-phosphate, LPSBV does 439 
neither contain any further charged groups in the lipid A part nor in the core OS. Therefore, we can 440 
hypothesize that LPSBV provides features and properties of a TLR4 antagonist, which is usually able to bind 441 
to MD-2 but it failed to induce receptor multimer formation and prevented from induction of any 442 
intracellular signalling40, 41, 42. LPSBV bound to the MD-2/TLR4 receptor complex with a comparable affinity 443 
as highly agonistic LPSEC but it did not lead to strong intracellular pro-inflammatory signalling. 444 
Nevertheless, LPSBV did not act as a pure antagonist since it actively induced semi-maturation and tolerance 445 
in dendritic cells, making it rather weakly agonistic than completely antagonistic. This is highly interesting 446 
as Vatanen et al. demonstrated that B. dorei LPS, which provides the same lipid A structure as LPSBV, acts as 447 
a strong MD-2/TLR4 receptor complex antagonist24. This difference in immunogenicity of the respective 448 
LPS supports the speculation of the unique LPSBV core structure to contribute to its weakly agonistic activity. 449 
Nevertheless, the weakly agonistic features of LPSBV seem to be responsible for the observed healing effects 450 
in mice suffering from intestinal inflammation. Therefore, LPSBV led to weak intracellular signalling, 451 
providing a basic anti-inflammatory intracellular transcription program without exceeding a pro-452 
inflammatory threshold. Furthermore, LPSBV leads to the induction of tolerogenic DCs. These properties 453 
clearly distinguish LPSBV from strong agonistic LPSEC, which induces endotoxin tolerance but also strong 454 
pro-inflammatory signalling, and from antagonistic B. dorei LPS, which does not promote pro-inflammatory 455 
reactions but does also not promote tolerance induction in TLR4-expressing cells24. The property of LPSBV 456 
of being an effective ligand for the MD-2/TLR4 receptor complex and, at the same time, of being a weak 457 
agonist must of course be attributed to its chemical structure. We are not aware, whether this is a “chemical 458 
paradigm” of the intestinal microbiota LPS since so far, only very few chemical structures of intestinal 459 
commensals have been established. However, this is a logical follow up of the present work and further work 460 
is in progress. 461 
These observations led to a speculation on the potential use of such a LPS structure as a suitable tool to 462 
restore homeostatic conditions not only in experimental mouse models, but also in IBD patients. Therapy of 463 
IBD patients is, to date, restricted to a general suppression of the patient’s immune response often associated 464 
with undesirable side effects. LPS (derivative)-based treatment might avoid this problem by acting only 465 
locally at the site of inflammation: the intestine.  466 
Therefore, we would promote pure LPSBV as an alternative for the treatment of intestinal inflammatory 467 
disorders or IBD providing evidence that this compound demonstrated its beneficial effects as not being an 468 
antagonist but rather a weak agonist. Alternatively, the structure of LPSBV could act as a starting point for a 469 
structure-activity relationship study in order to obtain a proper LPS derivative that could be used as a 470 
prospective therapeutic agent. Concluding, we hope to contribute to IBD therapy-related research offering a 471 
completely new approach avoiding disadvantages of current state-of-the-art IBD therapies. 472 
Methods  473 
T-cell mediated induction of chronic colitis in Rag1-/- mice  474 
Germfree (GF) or conventionally colonized (CV) C57BL/6J-Rag1tm1Mom (Rag1-/-) mice were transplanted 475 
with 5 x 105 splenic CD4+CD62L+CD45RBhiC wt T-cells at 8 to 10 weeks of age. The conventional 476 
microbiota was free of Norovirus, Rotavirus and Helicobacter hepaticus. Rag1-/- mice were kept under SPF 477 
conditions and analyzed 8 weeks after T-cell transplantation as indicated in the results section. 478 
 479 
In vivo positron emission tomography (PET)  480 
High resolution PET imaging was performed using two identical small animal Inveon microPET scanner 481 
(Siemens Medical Solutions, Knoxville, USA) with a spatial resolution of 1.4 mm in reconstructed images 482 
(Field of view (FOV): transaxial 10 cm; axial: 12.7 cm)43. List mode data were processed by applying 483 
iterative Ordered Subset Expectation Maximization (OSEM) 2D algorithm for reconstruction. Mice were 484 
anesthetized using 1.5% isoflurane (Abbott GmbH, Wiesbaden, Germany) vaporized in O2 (1.5 L/minute), an 485 
intravenously (i.v.) injection of 8.3 ± 1.3 MBq [18F]fluorodesoxyglucose (FDG) was applied into the tail 486 
vein. After tracer injection, animals were placed on a heating pad to maintain body temperature and the 487 
animals were kept anesthetized for 60 min during tracer uptake time in an anaesthesia box. Shortly before the 488 
end of the uptake time, mice were placed in the FOV of the PET scanner on a warmed scanner bed (37 °C). 489 
Static (10 min) PET scans were performed on week 0, 4, 6 and 8 after T-cell application. Data were 490 
corrected for decay, normalized to the injected activity and analyzed using Pmod Software (PMOD 491 
Technologies Ltd., Zurich, Switzerland) by drawing regions of interest over the whole intestine. 492 
 493 
Isolation of B. vulgatus mpk LPS (LPSBV) and E. coli mpk LPS (LPSEC)  494 
The Lyophilized bacterial pellet was washed several times with distilled water, ethanol and acetone followed 495 
by several ultracentrifugation steps (45,000 rpm at 4 °C), in order to remove contaminants. 496 
Cells were extracted by hot phenol/water extraction44. Water and phenol phases were both dialyzed and 497 
lyophilized. After inspection by SDS-PAGE, an enzymatic treatment to remove proteins and nucleic acids 498 
was executed, followed by a dialysis step. The SDS-PAGE executed on both purified water and phenol 499 
phases highlighted the presence of LPS only in the water phase. To further purify the LPS material from a 500 
neutral polysaccharide capsular fraction, an ultracentrifugation step was executed as well.  501 
See supplementary material for more information on experimental and analytic procedures. 502 
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Supplementary Methods 6 
Mice  7 
C57BL/6J mice were purchased from Charles River Laboratories, C57BL/6J-Rag1tm1Mom (Rag1-/-) mice from 8 
own breeding. All animals were kept and bred under SPF conditions. For isolation of bone marrow, only 9 
female mice aged 6-12 weeks were used. Animal experiments were reviewed and approved by the 10 
responsible institutional review committee and the local authorities. 11 
 12 
Radiopharmaceuticals  13 
[18F]fluoride was produced by using 18O (p,n) 18F nuclear reaction on the PETtrace cyclotron (General 14 
Electric Medical Systems, GEMS, Uppsala, Sweden). [18F]FDG synthesis was performed as described 15 
elsewhere1. After the synthesis, specific activity was calculated and revealed > 50 GBq/mmol with a 16 
radiochemical purity of > 99%. 17 
 18 
Bacteria  19 
The bacteria used for stimulation of the murine dendritic cells were Escherichia coli mpk and Bacteroides 20 
vulgatus mpk2. The E. coli mpk strain was grown in Luria-Bertani (LB) medium under aerobic conditions at 21 
37 °C. B. vulgatus mpk was grown in Brain-Heart-Infusion (BHI) medium and anaerobic conditions at 37 22 
°C. 23 
 24 
Extraction, purification and chemical analyses of lipopolysaccharide from B. vulgatus mpk (LPSBV) 25 
Bacterial dried cells (5 g) were extracted through the hot phenol/water procedure3. The row LPS (300 mg) 26 
was checked by SDS-PAGE after gel silver staining4 revealing a smooth-type LPS only in the water phase. 27 
In order to remove cell contaminants, an intensive enzymatic treatment by RNase (Roth, Germany), DNase 28 
(Roth, Germany) and Proteinase K (Roth, Germany) at 37 °C and 56 °C was executed, followed by 29 
exhaustive dialysis. In order to further purify the LPS material, an ultracentrifugation step (4 °C, 30,000 rpm, 30 
24 h) and a gel-filtration chromatography were also performed. LPS monosaccharide content was established 31 
by analysis of the acetylated O-methyl glycoside derivatives obtained by treatment with HCl/MeOH (1.25 32 
M, 85 °C, 24 h) followed by an acetylation step with acetic anhydride in pyridine (85 °C, 30 min). The 33 
absolute configuration of each sugar unit was defined through the evaluation of the O-octylglycoside 34 
derivatives as previously described5. The sugar linkage pattern was determined by the Ciucanu method6, 7: 35 
briefly, an aliquot of sample was suspended in DMSO to which NaOH in powder was added and then 36 
methylated with CH3I, hydrolyzed with trifluoroacetic acid (4 M, 100 °C, 4 h), carbonyl reduced with NaBD4 37 
and acetylated with pyridine and acetic anhydride. The total fatty acid content was established on intact LPS 38 
by treating with HCl (4 M, 100 °C, 4 h) followed by NaOH (5 M, 100 °C, 30 min). The pH was adjusted to 39 
reach slight acidity. After extraction in chloroform, fatty acids were then methylated with diazomethane8. All 40 
chemical analyses were performed by means of gas-liquid chromatography (GLC-MS) Agilent Technologies 41 
6850A equipped with a mass selective detector 5973N and a Zebron ZB-5 capillary column (Phenomenex, 42 
30 m x 0.25 mm i.d., flow rate 1 mL min-1, He used as carrier gas) and using the following temperature 43 
program: 140 °C/240 °C at 3 °C min-1. 44 
 45 
Isolation of the LPSBV saccharide domain  46 
An aliquot of pure LPS was treated with anhydrous hydrazine (2 mL), stirred at 37 °C for 90 min, cooled, 47 
poured into ice-cold acetone (20 mL) and allowed to precipitate. The precipitate was centrifuged (4000 x g, 48 
30 min), washed with ice-cold acetone, dried, dissolved in water and lyophilized9. The O-deacylated product 49 
was then N-deacylated with 4 M KOH. The removal of salts was executed by gel-filtration chromatography 50 
on a Sephadex G-10 column (Pharmacia, 50 x 1.5 cm)10. The fully deacylated product was further purified 51 
on a Toyopearl TSK HW-50 (Tosoh Bioscience). 52 
 53 
NMR spectroscopy 54 
1D and 2D 1H NMR spectra were recorded on a Bruker 600 DRX equipped with a cryo probe. The solvent 55 
employed was D2O and the temperature was 298 K and pD was 7. Spectra calibration was performed with 56 
internal acetone (δH 2.225 ppm, δC 31.45 ppm). 31P NMR experiments were carried out with a Bruker DRX-57 
400 spectrometer, aqueous 85% phosphoric acid was used as external reference (δ = 0.00 ppm). The double-58 
quantum filtered phase sensitive correlation spectroscopy (DQF-COSY) experiment was carried out by using 59 
data sets of 4096 x 256 points. Total correlation spectroscopy (TOCSY) experiments were executed with 60 
spinlock times of 100 ms, using data sets (t1 × t2) of 4096 x 256 points. Rotating frame Overhauser 61 
enhancement spectroscopy (ROESY) and Nuclear Overhauser enhancement spectroscopy (NOESY) 62 
experiments were recorded by using data sets (t1 × t2) of 4096 x 256 points and by using mixing times 63 
between 100 and 400 ms, In all homonuclear experiments the data matrix was zero-filled in both dimensions 64 
to give a matrix of 4 K x 2 K points and was resolution enhanced in both dimensions by a cosine-bell 65 
function before Fourier Transformation. The determination of coupling constants was obtained by 2D phase 66 
sensitive DQF-COSY.11,12 Heteronuclear single quantum coherence (1H, 13C HSQC) and heteronuclear 67 
multiple bound correlation (1H, 13C HMBC) experiments were recorded in 1H-detection mode by single-68 
quantum coherence with protein decoupling in the 13C domain using data sets of 2048 × 256 points. 1H, 13C 69 
HSQC was executed using sensitivity improvement and in the phase-sensitive mode using Echo/Antiecho 70 
gradient selection, with multiplicity editing during selection step.13 The 1H, 13C HMBC experiment was 71 
optimized on long-range coupling constants with low-pass J filter to suppress one-bound connectivity, using 72 
gradient pulses for selection. A delay of 60 ms was employed for the evolution of long-range correlations. It 73 
was used a long-range coupling constant value of 6 Hz. The data matrix in both heteronuclear experiments 74 
was extended to 2048 × 1024 points using forward linear prediction14.  75 
 76 
ESI MS and MS/MS analysis 77 
MS spectra of the carbohydrate part of LPSBV were acquired on an amazon SL ion trap (IT) mass 78 
spectrometer with electrospray ionization (ESI) (Bruker Daltonics, USA). The sample (75 µg) was dissolved 79 
in 50 µL of acetonitrile/water/formic acid solution (100:100:1, v/v/v) and analyzed in negative ion mode. Ion 80 
corresponding to core OS (m/z 667.3) was analyzed by MS/MS. Source parameters were as follows: sample 81 
flow, 3 µL min-1; ion source temperature, 200 °C; nitrogen flow, 5 L min-1 at a pressure of 8 psi. Spectra 82 
were scanned in the 200-2000 m/z range. He was used as the collision gas in the IT. The system was 83 
calibrated using ESI-L Tuning Mix (Agilent Technologies, USA)15. 84 
 85 
Isolation of the lipid A fraction from LPSBV 86 
Isolation of lipid A was achieved by mild acid hydrolysis by using acetate buffer (1 mL, pH = 4.4) promoted 87 
by SDS (1 mg mL-1) on ca. 20 mg of isolated LPS at 100 °C. The solution was extracted 3 times with 88 
CHCl3/MeOH/H20 (100:30:30, v/v/v) and centrifuged (4 °C, 7,000 x g, 15 min). The organic phase 89 
containing the lipid A was further purified by several washes with distilled water and then freeze-dried. 90 
 91 
MALDI MS analysis on isolated A from LPSBV 92 
Lipid A isolated after mild acid hydrolysis of LPSBV was analyzed with MALDI-TOF ultrafleXtreme 93 
sptecrometer (Bruker Daltonics, USA). 100 µg of lipid A was dissolved in 100 µL of mQ water after 10 min 94 
incubation at 40 °C in the ultrasonic bath. 10 mg of 9H-pyrido(3,4)-indole was mixed with 1 mL of 95 
CHCl3/MeOH (1:1, v/v) and 0.5 µL of the matrix was spotted onto the matrix. The sample was analyzed in 96 
reflectron, negative ion mode, scan range: 700-3500 m/z. Instrument was calibrated within 1000-3150 Da 97 
mass range, using peptide mixture (Peptide Calibration Standard, Bruker Daltonics, USA). 98 
 99 
Biotinylation of LPSBV 100 
10 mg of LPSBV were biotinylated with EZ-Link Micro Sulfo-NHS-LC-Biotinylation Kit (Thermo Scientific) 101 
according to the manufacturer’s protocol using phosphate buffered saline (PBS) as a solvent. In order to 102 
remove PBS, an exhaustive dialysis against distilled water was performed. The biotinylated LPSBV 103 
(bioLPSBV) was then collected and lyophilized. For in vitro experiments lyophilized bioLPSBV was dissolved 104 
in distilled water in concentrations not higher than 1 mg mL-1. 105 
 106 
Cultivation of bone marrow derived dendritic cells (BMDCs)  107 
Bone marrow cells were isolated from wt C57BL/6 mice (purchased from Charles River) and cultivated as 108 
described previously16. At day 7 after isolation, resulting CD11c positive dendritic cells (BMDCs) were used 109 
for further experiments. 110 
 111 
Stimulation of bone marrow derived dendritic cells  112 
2 x 106 BMDCs were stimulated with either PBS, B. vulgatus mpk or E. coli mpk at a MOI of 1 or respective 113 
isolated LPS at concentrations as indicated in the results section. Cells were stimulated for a maximum of 24 114 
h. If a second challenge was used, cells were stimulated with bacteria followed by exchanging used for fresh 115 
medium followed by challenging the cells with a second stimulus for a maximum of 16 h. PBS was used as 116 
mock stimulation control. 117 
 118 
Stimulation of human embryonic kidney (HEK) cells  119 
2 x 105 HEK cells, either expressing murine CD14, MD-2 and TLR4 (HEK-mTLR4) or not, were seeded in 1 120 
mL medium were subsequently stimulated with 1 to 1000 ng mL-1 isolated LPS or bacteria (MOI 1) for time 121 
points indicated in the results section.  122 
 123 
Detection of bound biotinylated LPSBV  124 
After end of incubation time with biotinylated LPSBV, HEK-mTLR4 cells were scraped off, washed once in 125 
PBS + 1%FCS and incubated with PE-coupled streptavidin (Strep-PE) for 30 min, followed by another 126 
washing step. Cell-attached strep-PE was detected by flow cytometry. All experiments to be compared were 127 
carried out in one experimental setting to guarantee for comparability of the detected MFI (median 128 
fluorescence intensity) values of the PE fluorescence. 129 
 130 
Cytokine analysis by ELISA  131 
For analysis of secreted cytokines (IL-6, IL-1β, IL-12p40, TNF), ELISA-based detection kits were purchased 132 
from BD Biosciences, Germany, and used according to the manufacturer’s instructions. 133 
 134 
Flow cytometrical analysis  135 
Multi-color FCM analyses were performed on a FACS Calibur or FACS LSRII (BD Biosciences, Germany). 136 
All fluorochrome-coupled antibodies were purchased from BD Biosciences, Germaany. Data were analyzed 137 
using FlowJo software (Tree Star Inc., USA). 138 
 139 
Purification of RNA and Quantitative Real-Time PCR  140 
Purification of RNA from mouse colonic scrapings was performed using Qiagen’s RNeasy Mini Kit 141 
according to the manufacturer’s instructions. Additional DNA digestion was conducted by using 4 U rDNase 142 
I and 40 U rRNasin for a RNA solution of 0.1 µg µL-1. After 30 min of incubation at RT, DNase was 143 
inactivated using Ambion DNase inactivation reagent which was later removed by centrifugation for 1 min at 144 
10‘000 x g. SybrGreen based quantitative RT-PCR was performed on a Roche LightCycler480 using  145 
QiagenSybrGreen RT-PCR Kit. Primer annealing occurred at 60 °C. 10 to 100 ng DNA-digested RNA was 146 
used for qRT-PCR. Relative mRNA expression in BMDCs stimulated with bacteria to unstimulated BMDCs 147 
was determined with β-actin as housekeeping gene using the ∆∆Cp-method that included the specific 148 
amplification efficiency of every used primer pair and each PCR run.  149 
Primer sequences  150 
Primers used for qRT-PCR were: Aldh1a2, Forward Primer: 5’- AAGACACGAGCCCATTGGAG-3’; 151 
Reverse Primer: 5’- GGAAAGCCAGCCTCCTTGAT-3’; β-actin, Forward Primer: 5’- 152 
CCCTGTGCTGCTCACCGA-3’, Reverse Primer: 5’- ACAGTGTGGGTGACCCCGTC-3’ 153 
 154 
Isolation of lamina propria (LP) dendritic cells (DC) and T cells and adoptive transfer of T cells  155 
Isolation of mouse LP cells was performed as published previously17. For adoptive transfer, splenic CD4+ T 156 
cells from C57BL/6 mice were purified using a MACS-based negative selection kit (Miltenyi) according to 157 
the manufacturer’s instructions. The isolated cells were stained for CD3ε, CD4 and CD62 for reanalysis, 158 
purity was generally >90% with >80% being CD4+CD62L+CD45RBhi. 5 x 105 CD4+ T cells were injected 159 
into the peritoneum (i.p.) of Rag1-/- mice as described previously 18. 160 
 161 
Histology  162 
Colonic tissues were fixed in neutral buffered 4% formalin. Formalin-fixed tissues were embedded in 163 
paraffin and cut into 2 µm sections. They were stained with hematoxylin (Merck) and eosin (Merck) for 164 
histological scoring. Scoring was conducted in a blinded fashion on a validated scale of 0 – 3, with 0 165 
representing no inflammation and 3 representing severe inflammation characterized by infiltration with 166 
inflammatory cells, crypt hyperplasia, loss of goblet cells and distortion of architecture 19. 167 
 168 
Statistics  169 
Statistical analyses were performed using the unpaired student’s t test to compare two groups with each 170 
other. For comparing in vitro results, samples were considered to be biologically independent if the samples 171 
were generated from BMDCs from different mice. Differences were considered to be statistically significant 172 
if p < 0.05. Error bars, if shown, represent ± standard deviation (SD). 173 
Supplementary figures: 174 
 175 
 176 
Supplementary Figure 1: Isolated LPS of B. vulgatus mpk and live B. vulgatus mpk provide similar weakly agonistic 177 
immunogenic properties on bone marrow derived dendritic cells. 178 
Bone marrow derived dendritic cells (BMDCs) from wt mice were generated as described and stimulated with either PBS (mock 179 
control), B. vulgatus mpk (MOI 1), E. coli mpk (MOI 1), B. vulgatus mpk LPS (LPSBV) (50 ng per 106 BMDCs) or E. coli mpk LPS 180 
(LPSEC) (50 ng per 106 BMDCs) for 16 h. (a) flow cytometric analyses of BMDC surface expression of MHC-II, CD40, CD80 and 181 
CD86 among the population of CD11c+ cells. (b) secretion of TNF, IL-12p40 and IL-6 into cell supernatant, determined by ELISA, 182 
 183 
 184 
Supplementary Figure 2: Weakly agonistic LPSBV provides only low capacity to remove agonistic LPSEC from the murine 185 
MD-2/TLR4 receptor complex.  186 
a. Left panel: experimental setting. 1 x 105 HEK cells expressing murine CD14, MD-2 and TLR4 (HEK-mTLR4) were incubated 187 
with a certain constant concentration of LPSEC ranging from 0 to 5 mg L-1 for 1 h. For each certain LPSEC concentration varying 188 
concentrations of biotinylated B. vulgatus mpk LPS (bioLPSBV) were added ranging from 0 to 6 mg mL-1 and incubated again for 1 h. 189 
PE-coupled streptavidin (Strep-PE) was added for 30 min and the resulting PE fluorescence associated with HEK-mTLR4 cells was 190 
detected by flow cytometry. Central panel: gating strategy to determine PE fluorescence of intact HEK-mTLR4 cells. Right panel: 191 
Binding curves of 4 distinct concentrations of LPSEC plotted against varying concentrations of subsequently added bioLPSBV.  192 
b. Left panel: experimental setting. 1 x 105 HEK-mTLR4 cells were incubated with a certain concentration of bioLPSBV ranging 193 
from 0 to 6 mg L-1 for 1 h. For each certain bioLPSBV concentration varying concentrations of LPSEC was added ranging from 0 to 5 194 
mg L-1 and incubated again for 1 h. Strep-PE was added for 30 min and fluorescence was detected by flow cytometry. Central panel: 195 
gating strategy to determine PE fluorescence of intact HEK-mTLR4 cells. Right panel: Binding curves of 4 distinct concentrations 196 
of LPSEC plotted against varying concentrations of previously added bioLPSBV. 197 
. 198 
 199 
 200 
 201 
 202 
 203 
 204 
 205 
 206 
Supplementary Figure 3: Simultaneous stimulation of bone marrow derived dendritic cells with weakly agonistic semi-207 
maturation inducing LPSBV and agonistic LPSEC does not anticipate dendritic cell maturation. 208 
a. Experimental setting: bone marrow derived dendritic cells (BMDCs) were generated as described. BMDCs were simultaneously 209 
stimulated with different concentrations of LPSBV and LPSEC for 16 h. 210 
b. Secretion of IL-1β, TNF and IL-6 into cell supernatant from BMDCs that were stimulated as shown in (a). Used concentrations of 211 
LPSBV are depicted on the x-axes, the connected coloured lines represent a distinct concentration of LPSEC each. Every data point 212 
therefore represents a certain combination of LPSEC and LPSBV concentrations (n=3).  213 
c. MHC-II surface expression. BMDCs were stimulated according to (a). Left panel: Gating strategy to determine the proportion of 214 
MHC II high positive (MHC-IIhi+) cells among the population of CD11c+ BMDCs. Right panel: Proportion of MHC-IIhi+ CD11c+ 215 
cells dependent on the used concentrations of LPSBV (depicted on the x-axes) and LPSEC (depicted as differentially coloured 216 
connected lines) (n=3).  217 
d. TLR4 expression of BMDCs which were stimulated as demonstrated in (a). Left panel: gating strategy to determine the mean 218 
fluorescence intensity (MFI) of TLR4 expression on CD11c+ BMDCs. Right panel: MFI of TLR4 expression of CD11c+ cells 219 
dependent on the used concentrations of LPSBV (depicted on the x-axes) and LPSEC (depicted as differentially coloured connected 220 
lines) (n=3). 221 
 222 
 223 
 224 
 225 
Supplementary Figure 4: 1H NMR of fully deacylated LPSBV. 226 
1H NMR spectrum of the saccharide domain of the LPS from B. vulgatus mpk obtained after full deacylation of the pure LPS. A 227 
zoom of the anomeric region is reported in the inset. Anomeric signals in the inset are as attributed in Supplementary Table 1.228 
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 230 
Supplementary Figure 5: 1H and 1H, 13C HSQC NMR spectrum of fully deacylated LPSBV. 231 
1H and 1H, 13C HSQC spectra of the deacylated LPS from B. vulgatus mpk. Key heteronuclear signals from the sugar backbone are 232 
indicated. Numbering of sugar residues is as reported in Fig. 3 and Supplementary Table 1.  233 
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 235 
Supplementary Figure 6: Long-range correlations analysis of fully deacylated LPSBV. 236 
Zoom of the overlapped 1H, 1H, 13C HMBC (blue) and 1H, 13C HSQC (black and red) NMR spectra; the key inter-residual 237 
long-range correlations involving sugar moieties (A-L) are indicated; letters are as in Supplementary Table 1. Anomeric one-238 
bond heteronuclear correlations were also reported in the spectrum.  239 
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 260 
Supplementary Figure 7: ESI-MS spectrum of fully deacylated LPSBV. 261 
Zoom of mass spectrum with ions corresponding to core OS and core OS substituted with one, two and three O-chain 262 
repeating units (m/z 444.6 and 667.3 (OS), 547.3 and 821.3 (M1), 650.0 and 975.4 (M2), as well as 1129.4 (M3) 263 
respectively). Spectrum was acquired in negative ion mode. # indicates [M-3H+Na]2- ion. Ion indicated by asterisk was not 264 
interpreted. 265 
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 285 
Supplementary Figure 8: ESI-MS2 spectrum of core OS from LPSBV. 286 
Core OS was selected for MS2 fragmentation. The glycosidic bond cleavage resulted in daughter ion B3, corresponding to 287 
oligosaccharide fragment containing Kdo, two hexoses, two deoxy-hexoses and phosphate, as well as complementary Y2 ion 288 
attributed to mono-phosphorylated dihexosamine. Other ions indicate fragmentation inside the sugar ring (A3 and X2) with 289 
loss of formyl (m/z 645.3, 636.3 and X2). The inset structure represents general structure of core OS. The precursor ion (m/z 290 
667.3) is indicated by diamond. Ion indicated by asterisk was not interpreted. 291 
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Supplementary Table 1. 307 
1H, 13C (italic) and 31P (bold) chemical shift values of the saccharide region of the LPSBV. 308 
Chemical shifts (δ) 
Unit 1 2 3 4 5 6 7 8 
A 5.50 3.22 3.81 3.27 4.07 4.12/3.80   
6-α-GlcpN 90.4 
2.99 
54.3 69.9 70.1 73.0 68.0   
B 4.90 2.86 3.52 3.43 3.55 3.69/3.47   
6-β-GlcpN 99.6 55.6 72.3 69.8 74.5 61.3   
C 5.11 4.16 3.96 3.85 3.85 1.23   
3,4-α-Rhap 
(α-RhaI) 
101.0 70.2 78.9 73.6 68.6 16.9   
D 5.07 4.06 3.96 3.92 3.72 3.56   
t-β-Galf 108.6 81.8 77.0 82.8 70.3 62.7   
E 5.09 3.67 3.76 3.71 4.27 1.14   
t-α-Fucp 99.4 68.3 71.4 73.2 66.9 16.2   
F 4.47 3.29 3.48 3.36 3.36 3.82/3.62   
3-β-Glcp 102.5 73.5 82.4 69.9 75.6 60.8   
G 5.01 3.93 3.81 3.34 3.96 1.22   
t-α-Rhap 
(α-RhaII) 
100.8 70.4 69.7 71.9 67.4 17.0   
G′ 5.00 3.93 ND 3.58 3.88 1.22   
4-α-Rhap 
(α-Rha′II) 
100.8 70.4 ND 79.4 67.5 17.0   
H 4.72 3.45 3.75 3.80 3.71 3.93   
2,6-β-Galp 100.2 76.8 71.4 69.7 70.6 69.0   
I 4.86 3.90 3.94 3.58 3.89 1.22   
4-α-Rhap 
(α-RhaOC) 
99.7 70.3 70.3 79.4 67.5 17.0   
L 4.78 4.17 3.58 3.54 3.29 3.82/3.64   
3-β-Manp 100.3 66.6 76.6 65.0 76.1 60.8   
K - - 1.77/2.02 4.15 4.07 3.68 3.96 3.95/3.86 
5-α-Kdop 
 
  34.5 67.2 
1.64 
73.3 70.5 70.2 65.6 
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Supplementary Table 2.  317 
Interpretation of ESI-IT mass spectra of the saccharide domain of the LPS from B. vulgatus mpk. 318 
Oligosaccharide composition 
Mass of the 
observed 
ion 
Calculated 
mass of the 
ion 
monoisotopic mass of 
oligosaccharides (Da) 
(m/z) (m/z) observed 
 
calculated 
 
Kdo·HexN2·Hex2·DeoxyHex2·P 627.3 627.19 1256.6 1256.39 
Kdo·HexN·Hex3·DeoxyHex2·P 627.8 627.69 1257.6 1257.38 
Kdo·HexN2·Hex2·DeoxyHex2·P2 
444.6 (-3) 
667.3 (-2) 
444.45 (-3) 
667.18 (-2) 
1336.6 
1336.8 1336.36 
Kdo·HexN2·Hex2·DeoxyHex2·P2 678.3# - 1336.6 1336.36 
Kdo·HexN2·Hex3·DeoxyHex2·P2 748.3 748.20 1498.6 1498.41 
Kdo·HexN2·Hex3·DeoxyHex3·P1 781.4 781.25 1564.8 1564.50 
Kdo·HexN3·Hex3·DeoxyHex2·P1 788.8 788.76 1579.6 1579.52 
Kdo·HexN2·Hex3·DeoxyHex3·P2 821.3 821.23 1644.6 1644.47 
Kdo·HexN3·Hex3·DeoxyHex2·P2 828.8 828.74 1659.6 1659.48 
Kdo·HexN2·Hex4·DeoxyHex4·P2 
650.0 (-3) 
975.4 (-2) 
649.86 (-3) 
975.29 (-2) 
1953.0 
1952.8 1952.58 
Kdo·HexN2·Hex5·DeoxyHex5·P2 1129.4 1129.34 2260.8 2260.69 
# indicates [M-3H+Na]2- ion. 319 
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Supplementary Notes 330 
Supplementary Note 1   331 
B. vulgatus mpk LPS provides similar immunogenic properties on dendritic cells as live B. 332 
vulgatus mpk  333 
It is known that apathogenic commensal bacteria can have either symbiotic or pathobiotic properties 334 
concerning the activation of the immune system. As published and mentioned previously, we 335 
identified B. vulgatus mpk as such a symbiotic commensal. As a representative apathogenic 336 
pathobiotic commensal, we identified and characterized E. coli mpk2, 20, 21, which efficiently triggered 337 
the induction of colitis in Il2-/- mice2. We focused our attention on the immunological properties of the 338 
bacteria on dendritic cells in vitro and we tested whether such bacterial properties could be completely 339 
mimicked by their respective isolated LPS, thus explaining the observations made in in vivo 340 
experiments (Fig. 2). In view of this, we also isolated the LPS from E. coli mpk (LPSEC) which 341 
contains a bis-phosphorylated and hexaacylated lipid A. We generated and stimulated bone marrow 342 
derived dendritic cells (BMDCs) with either live B. vulgatus mpk, E. coli mpk (both at MOI 1) or 343 
isolated LPSBV or LPSEC, both at concentrations of 50 ng-1 per 106 BMDCs for a total of 16 h. As 344 
shown in Fig. 4, stimulation of BMDCs with LPS resulted in the same BMDC phenotype as 345 
stimulation with the respective bacteria from which the LPS was isolated. Both, B. vulgatus mpk and 346 
pure LPSBV stimulation led to a low expression of MHC-II, CD40, CD80 and CD86 (Supplementary 347 
Fig. 1a) as well as to very low secretion rates of pro-inflammatory cytokines, such as TNF, IL-12p40 348 
and IL-6 (Supplementary Fig. 1b). The secretion rates of these cytokines were low but higher when 349 
compared to PBS treated controls. In contrast, stimulation of BMDCs with either E. coli mpk or LPSEC 350 
led to a drastic increase of MHC-II and T cell co-stimulatory molecules (Supplementary Fig. 1a) as 351 
well as to strong secretion of pro-inflammatory cytokines (Supplementary Fig. 1b). Thus, it was 352 
confirmed that pure LPS was able to mimic the immunogenic properties of both commensal bacteria 353 
with LPSBV providing low and LPSEC providing strong immuno-stimulating properties. Therefore, it 354 
can be stated that LPSBV is not a MD-2/TLR4 receptor complex antagonist as it provided weakly 355 
agonistic activity as demonstrated by low, but still detectable amounts of secreted cytokines and by 356 
slight enhancement of T cell stimulatory surface proteins as MHC-II, CD40, CD80 and CD86. 357 
 358 
Supplementary Note 2  359 
Weakly agonistic LPSBV provides low replacement capacity at the MD-2/TLR4 receptor complex 360 
towards strong agonistic LPSEC  361 
Based on these latter results, we then tested the capability of each of these two distinct LPS to remove 362 
already bound LPS from the receptor complex. Thus, we incubated HEK-mTLR4 cells with different 363 
concentrations of either biotinylated LPSBV (bioLPSBV) or LPSEC for 1 h and subsequently added the 364 
opposite LPS for 1 h and in several concentrations. Subsequent additional incubation with Strep-PE 365 
allowed for flow cytometry based visualisation of HEK-mTLR4 cell bound bioLPSBV (Supplementary 366 
Fig. 2). Pre-incubation with LPSEC followed by subsequent incubation with bioLPSBV resulted in low 367 
detected PE fluorescence, more or less independent from the employed LPSEC and bioLPSBV 368 
concentrations (Supplementary Fig. 2a). This indicated that once the murine MD-2/TLR4 receptor 369 
complex is bound by LPSEC, bioLPSBV is not able to remove LPSEC from the receptor binding site. 370 
Pre-incubation with LPSEC even at low concentrations of 1.25 mg L-1, resulted in a decrease of the PE-371 
signal to about 20% of the PE-signal that arose when cells were not pre-incubated with LPSEC 372 
(Supplementary Fig. 2a). Conversely, pre-incubation of HEK-mTLR4 cells with bioLPSBV followed 373 
by subsequent incubation with LPSEC resulted in a strong reduction of the PE-signal, which is 374 
exclusively derived from bound bioLPSBV, of about 50%, even when low concentrations of LPSEC 375 
were added (Supplementary Fig. 2b). Since we assumed that the detected PE fluorescence was directly 376 
proportional to the amount of bound bioLPSBV, it can be stated that bioLPSBV was able to remove 377 
about 20% of already bound LPSEC (Supplementary Fig. 2a), while LPSEC was able to remove about 378 
50% of already bound bioLPSBV (Supplementary Fig. 2b). 379 
 380 
Supplementary Note 3  381 
DC semi-maturation cannot be induced in presence of agonistic LPS  382 
We have already demonstrated that LPSBV is able to induce tolerant semi-mature DCs in vitro (Fig. 4 383 
and 5). However, these experiments were performed in absence of other LPS structures for the first 16 384 
h of the semi-maturation process. Physiological conditions in the colonic lumen provide the presence 385 
of lots of different LPS structures at the same time. Therefore, we stimulated BMDCs with both LPS 386 
molecules, weakly agonistic LPSBV and strong agonistic LPSEC, at the same time and at different 387 
concentrations for 16 h (Supplementary Fig. 3a). We checked for secretion of pro-inflammatory 388 
cytokines and the surface expression of MHC-II and TLR4. We detected a concentration dependent 389 
effect of LPSBV stimulation on BMDCs in the absence of LPSEC (light blue lines in Supplementary 390 
Fig. 3b,c). LPSBV concentrations of up to 100 ng mL-1 (which equals to 50 ng per 106 BMDCs) led to a 391 
semi-mature BMDC phenotype, as previously demonstrated in Figs. 4 and 5. Using 1000 ng mL-1, or 392 
500 ng pure LPSBV per 106 cells led to strong activation of BMDCs as indicated by high IL-1β, TNF, 393 
IL-6 (Supplementary Fig. 3b) and MHC-II surface expression (Supplementary Fig. 3c). However, 500 394 
ng pure LPS exceeds physiological LPS-to-DC ratios in the mammalian intestine thus representing an 395 
artificial observation. Nevertheless, it underlined and confirmed the observation that LPSBV is not 396 
antagonistic but rather weakly agonistic and the overall concentration determines its final 397 
endotoxicity. Addition of agonistic LPSEC led to strong increases in secretion rates of pro-398 
inflammatory cytokines (Supplementary Fig. 3a) as well as in the expression of MHC-II 399 
(Supplementary Fig. 3c) for all used LPSEC concentrations. Simultaneous presence of LPSBV could not 400 
anticipate LPSEC-induced maturation effects on DCs as it was demonstrated in case of subsequent 401 
stimulation of DCs that were primed with LPSBV and challenged with LPSEC (Fig. 5). Surprisingly, 402 
TLR4 expression on the cell surface remained relatively constant among all differently stimulated 403 
BMDCs (Supplementary Fig. 3d), indicating that no significant TLR4 endocytosis is detectable upon 404 
binding of these two LPS structures to the TLR4 receptor complex in opposition to what was 405 
previously reported for other intestinal commensal-derived LPS 22. 406 
 407 
Supplementary Note 4  408 
Structural characterization of LPSBV 409 
In order to define the full structure of the LPS from B. vulgatus mpk, a multi-disciplinary approach 410 
was employed. In detail, a set of chemical analyses, on both intact and isolated LPS domains, was 411 
executed, furnishing the chemical composition of each LPS moiety. Data resulting from chemical 412 
analyses represented the guidelines to unveil the information provided by the other techniques, NMR 413 
spectroscopy and ESI mass spectrometry (MS) which enabled the complete structural characterization 414 
of the LPSBV. MALDI MS analysis also furnished fundamental information regarding the LPSBV lipid 415 
A, providing important clues such as the nature of the molecular lipid A species, their heterogeneity, 416 
the type, the location and the distribution of the fatty acid chains. 417 
 418 
Supplementary Note 5 419 
Extraction, purification and chemical analyses of LPSBV 420 
LPS material was extracted from lyophilized bacterial cells by the hot phenol/water procedure 3. The 421 
extracted LPS underwent an enzymatic digestion by DNase, RNase and protease in order to remove 422 
cell contaminants. A further step of purification by ultracentrifugation was also performed. The nature 423 
and purity of the LPS was determined by SDS-PAGE analysis after silver nitrate gel staining 4, 424 
disclosing the smooth-nature of the extracted LPS, as proven by the ladder-like pattern in the upper 425 
part of the gel indicating the occurrence of high molecular weight species.  426 
Chemical analyses 5, 6, 7  executed on pure LPS revealed the presence of terminal, 4-substituted and 427 
3,4-disubstituted rhamnopyranose (Rhap), terminal fucopyranose (Fucp), terminal galactofuranose 428 
(Galf), 3-substituted mannopyranose (Manp), 3-substituted glucopyranose (Glcp), 2,6-disubstituted 429 
galactopyranose (Galp), 6-substituted aminoglucopyranose (GlcpN) and 5-substituted Kdo. Fatty acid 430 
analysis 8 showed the occurrence of tetradecanoic acid (C14:0), pentadecanoic acid (C15:0), 431 
hydroxypentadecanoid acid (C15:(3-OH)), hydroxyhexadecanoid acid (C16:(3-OH)) and 432 
hydroxyheptadecanoic acid (C17:(3-OH)), in full agreement with previously reported data by 433 
Hashimoto et al. on the structure of lipid A from B. vulgatus IMCJ 1204 23.  434 
 435 
Supplementary Note 6 436 
NMR spectroscopy analysis 437 
An aliquot of the pure LPS isolated from B. vulgatus mpk underwent a full deacylation 9, 10 furnishing 438 
the complete LPS saccharide portion. The deacylated LPS fraction was then purified by gel 439 
permeation chromatography. Monosaccharide analysis of the isolated product confirmed the presence 440 
of the sugar residues detected in the intact LPS. The deacylated product was then analyzed by 1D and 441 
2D NMR spectroscopy. A combination of homo- and heteronuclear 2D NMR experiments (DQF-442 
COSY, TOCSY, NOESY, ROESY, 1H, 13C HSQC, 1H, 13C HMBC, 31P and 1H, 31P HSQC) was 443 
performed in order to elucidate the complete saccharide sequence of LPSBV. In detail, each spin system 444 
was assigned on the basis of the spin connectivity observed in both the double-quantum-filtered 445 
correlation spectroscopy (DQF-COSY) and the total correlation spectroscopy (TOCSY) spectra; each 446 
carbon atom was identified through the analysis of the heteronuclear single-quantum coherence 447 
(HSQC) spectrum. The anomeric configuration of all sugar units was defined by intra-residual NOE 448 
contacts, detectable in the nuclear Overhauser effect spectroscopy (NOESY) spectrum and the 3JH-1,H-2 449 
coupling constants from the DQF-COSY spectrum. The assignment of the relative configuration of 450 
each sugar residue was obtained through the observation of the vicinal 3JH,H coupling constant values. 451 
The combined study of rotating-frame NOE spectroscopy (ROESY), NOESY, and HMBC 452 
(heteronuclear multiple-bond correlation spectroscopy) spectra allowed the characterization of the 453 
entire primary structure of the LPS saccharide part. Finally, 31P and 31P,1H HSQC experiments were 454 
pivotal to establish the location of the phosphate groups decorating the LPSBV.  455 
In the 1H NMR spectrum (Supplementary Fig. 4) eleven anomeric signals from eleven spin systems 456 
were clearly identified (A–L; Supplementary Table 1); Furthermore, the signals at 1.77 and 2.02 ppm 457 
were attributed to the H-3 methylene protons of the Kdo unit (K; Supplementary Table 1). All the 458 
monosaccharide residues, except for D, were present as pyranose rings, according to both 13C chemical 459 
shift values and the presence of long-range correlations between C-1/H-1 and H-5/C-5 observable in 460 
the 1H,13C HMBC spectrum (for the Kdo residue between C-2 and H-6)24, 25. Conversely, residue D 461 
was present as furanose ring as shown by the occurrence of low-field shifted ring carbon signals 462 
resonating around 82.0 ppm, anomeric carbon over 108 ppm and further confirmed by the intra-463 
residual long-range H/C 1-4 correlations in the 1H,13C HMBC spectrum.  464 
Spin systems A (H-1 5.50 ppm) and B (H-1 4.90 ppm) were identified as the α-GlcpN and β-GlcpN 465 
of the lipid A moiety based on their H-2 proton signals, which correlated with two nitrogen-bearing 466 
carbon atoms at 54.3 and 55.6 ppm, respectively (Supplementary Fig. 5, Supplementary Table 1). This 467 
hypothesis was also corroborated by the presence of an inter-residue contact between H-1 of B and H-468 
6a,b of A observed in the NOESY spectrum. Furthermore, the occurrence of a correlation, in the 31P,1H 469 
HSQC spectrum (not shown), between the signal at 2.99 ppm and the anomeric proton signal of 470 
residue A (5.50 ppm, Supplementary Table 1), allowed the allocation of a phosphate group at such a 471 
position. Spin systems C, G, G′ and I were identified as α-rhamnopyranose residues as proven by the 472 
correlations, in the TOCSY spectrum, with the methyl group signals resonating at δH 1.23 and 1.24 473 
ppm (δC 16.9 and 17.0 ppm; Supplementary Table 1) respectively. As mentioned above, the α-474 
anomeric configuration was determined on the basis of the 3JH-1,H-2 coupling constant values and the 475 
intra-residual NOE contact of H-1 with H-2; whereas the manno configuration was established by 476 
evaluation of 3JH,H coupling constant values.  477 
Spin systems D, E and H were attributed to galacto-configured sugar units. In detail, residue D (H-1 478 
5.07 ppm, Supplementary Table 1), as stated above, revealed to be a β-galactofuranose (anomeric 479 
carbon signal at 108.6 ppm, Supplementary Table 1 and Supplementary Fig. 5) based on its chemical 480 
shifts and intra residual scalar and dipolar correlations. By contrast, spin system H (H-1 4.72 ppm, 481 
Supplementary Table 1) was assigned to a β-galactopyranose, as proven by the chemical shift values 482 
of ring protons and the 3JH,H ring coupling constants; furthermore, the large 3JH-1,H-2 values and the 483 
NOE correlations of H-1 with H-3 and H-5, were indicative of the β-anomeric configuration.  484 
The galacto-configured sugar residue E (H-1 5.09 ppm, Supplementary Table 1) was identified as an 485 
α-fucopyranose as shown by the correlations, in the TOCSY spectrum, with the methyl proton signal 486 
at 1.14 ppm (δC 16.2 ppm; Supplementary Table 1) and the 3JH-1,H-2 coupling constant values that 487 
confirmed the α-anomeric configuration.  488 
Spin system F (H-1 4.47 ppm, Supplementary Table 1) was assigned to a β-glucopyranose as 489 
indicated by the large 3JH,H ring coupling constants and the chemical shift values of ring protons, in 490 
agreement with gluco-configuration of pyranose rings (Supplementary Table 1 ). Moreover, the large 491 
3JH-1,H-2 values, together with the NOE contacts of H-1 with H-3 and H-5, were diagnostic of the β-492 
anomeric configuration. Finally, spin system L (H-1 4.78 ppm; Supplementary Table 1) was attributed 493 
to a β-mannopyranose residue, as proved by the small 3JH-1,H-2  and 3JH-2,H-3 values, diagnostic of a H-2 494 
equatorial orientation, whereas the intra-residual correlations between H-1 and H-5 in the NOESY and 495 
ROESY spectra allowed the β configuration assignment. The assignment of the Kdo unit (K) was 496 
achieved starting from the diastereotopic methylene signal, and its anomeric α-configuration was 497 
assigned on the basis of the chemical shift values of H-3 (1.77/2.02 ppm, Supplementary Table 1), and 498 
of the 3JH-7,H8a and 3JH-7,H-8b coupling constants 26, 27. Moreover, the Kdo residue was phosphorylated at 499 
position O-4, due to the occurrence of a correlation with a signal at 1.64 ppm in the 31P,1H HSQC 500 
spectrum (not shown).  501 
The down-field shifted carbon signals were indicative of glycosylation at position O-6 of A and B, 502 
O-5 of K, O-3 and O-4 of C, O-2 and O-6 of H, O-3 of F and L and O-4 of I and G′, whereas D, E 503 
and G were terminal sugar residues, in full accordance with the methylation data. The analysis of the 504 
inter-residual NOE contacts (observable in both the NOESY and ROESY spectra) and the long-range 505 
correlations in the HMBC spectrum allowed to define the complete sugar sequence of the LPS from B. 506 
vulgatus mpk. Starting from the lipid A disaccharide backbone, made up of residue A and B, this latter 507 
sugar unit was found to be substituted at position O-6 by Kdo residue (K); this was further confirmed 508 
by the weak downfield shift of signal of C-6 of residue B (61.3 ppm, Supplementary table 1), which is 509 
consistent with the α-(2→6) ketosidic linkage of Kdo with the β-GlcN of the lipid A. The Kdo unit 510 
was, in turn, substituted at position O-5 by the rhamnose residue C, as suggested by the long-range 511 
correlation between the anomeric proton signal of residue C and the carbon atom at 73.3 ppm (C-5, 512 
Supplementary Table 1) of residue K (Figure 3c and Supplementary Fig. 6). Rhamnose C revealed to 513 
be substituted at both positions O-3 and O-4 by the galacto-configured sugar units D and H 514 
respectively, as showed by the occurrence of the strong NOE contacts between H-1 of D and H-3 of C 515 
and between H-1 of H and H-4 of C. These glycosydic linkages were also confirmed by the 516 
observation of the respective long-range correlations in the HMBC spectrum (Figure 3c and 517 
Supplementary Fig. 6). Residue H, in turn, was substituted by the α-Fuc E at position O-2 and by the 518 
β-Glc F at position O-6, as proven by the long-range correlations between the H-1 of E and the C-2 519 
signal of H, and H-1 of F and C-6 of H (Figure 3c and Supplementary Fig. 6). This latter residue F 520 
turned out to be substituted at position O-3 by rhamnose G, as suggested by the long-range contact 521 
between the anomeric proton signal of G and the carbon atom signal at 82.4 ppm (C-3, Supplementary 522 
Table 1) of β-glucose F (Figure 3c and Supplementary Fig. 6). Interestingly, 2D NMR analysis 523 
allowed the identification of a second slight different glycoform of rhamnose G, referred to here as G′, 524 
differing for the presence of a glycosylated position, namely position O-4 (Supplementary Table 1). 525 
Sugar units I and L were attributed to the components of the disaccharide repeating unit of the O-526 
chain moiety as demonstrated by the long-range correlation of the anomeric proton signal of β-Man L 527 
with the carbon atom signal C-4 of α-Rha I (Figure 3c and Supplementary Fig. 6); further on, an 528 
HMBC correlation between anomeric proton signal of I and C-3 of β-Man L was also clearly visible. 529 
These data were in full agreement with the LPS O-chain repeating unit previously elucidated by 530 
Hashimoto et al. 18. Finally, we were able also to establish the biological repeating unit, in fact, residue 531 
G′, assigned to a 4-substituted α-Rha, was identified as the sugar likely connecting the O-chain moiety 532 
to the core region, as proven by the long-range correlation between H-1 of L and C-4 of G′ (Figure 3c 533 
and Supplementary Fig. 6). This hypothesis was also confirmed by MS and MS2 data (see below).  534 
All the above information taken together allowed to establish the complete structure of the fully 535 
deacylated LPSBV as follow: 536 
 537 
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Supplementary Note 7 541 
Mass spectrometry analysis 542 
The fully deacylated LPSBV was also analyzed by ESI MS. The corresponding spectrum is reported 543 
in Supplementary Fig. 7. The detailed investigation of the double and triple charged ions in the 544 
spectrum in the mass range m/z 400-1130 allowed the determination of the fine structure of the LPS 545 
saccharide domain. In detail, the spectrum showed three main signal clusters (M1–M3) of double 546 
charged ions (m/z 821.3, 975.4 and 1129.4, Supplementary Fig. 7 and Supplementary Table 2) 547 
originated from the monoisotopic molecules with a mass of 1644.47, 1952.58 and 2260.69 (calculated 548 
molecular masses 1644.6, 1952.8 and 2260.8 Da) respectively, differing by 308 u, which corresponded 549 
to the mass of an O-chain repeating unit (RU) built up of a hexose and a deoxyhexose, thus in full 550 
agreement with the NMR data. Briefly, M1 (the most abundant species) and M2 contained one and 551 
two O-chain RU respectively, whereas M3 possessed three O-chain RU. Interestingly, the main peak 552 
m/z 667.3 was attributed to the double charged ion originated from the monoisotopic mass of 1336.36 553 
(calculated molecular mass 1336.6 Da) which is consistent with an oligosaccharide composed of two 554 
hexosamines, one Kdo, two hexoses, two deoxyhexoses and two phosphates. The structural sequence 555 
of the core OS was also corroborated by the ESI-MS2 investigation executed on precursor ion 1336.36 556 
which is reported in Supplementary Fig. 8. The spectrum showed the occurrence of a daughter ion at 557 
m/z 419.2 (Y2) originated from the monoisotopic mass 420.11 (calculated molecular mass 420.2 Da) 558 
assignable to the mono-phosphorylated diglucosamine backbone of the lipid A. Moreover, the 559 
daughter ion at m/z 915.4 (B4) relative to a mass of 916.24 (calculated mass 916.4 Da) was attributed 560 
to the oligosaccharide fragment made up of one Kdo, one phosphate, two hexoses and two deoxy-561 
hexoses. Finally, the ESI-MS spectrum revealed also the occurrence of the two double charged ions at 562 
m/z 627.3 and 748.3 relative to the monoisotopic masses 1256.39 and 1498.41 (calculated molecular 563 
masses 1256.6 and 1498.6 Da) respectively, which matched with the above described core OS minus a 564 
phosphate group (1256.39) or carrying a further hexose unit (1498.41). Therefore, all above mentioned 565 
MS and MS2 data were in full accordance with the NMR structural elucidation of the saccharide 566 
moiety of the LPSBV.  567 
In order to define also the structure of the glycolipid portion of the LPSBV, an aliquot of pure LPS 568 
underwent a mild acid hydrolysis in order selectively cleave the acid-labile linkage between the Kdo 569 
and the β-GlcN unit and to isolate the lipid A fraction. After purification, this latter was then analyzed 570 
by MALDI MS. The MALDI MS spectrum (Figure 3a), acquired in negative polarity, matched 571 
perfectly with the MS analysis executed by Hashimoto et al. 23 In detail, a high heterogeneity of lipid 572 
A species was immediately apparent as demonstrated by the occurrence of four clusters of signals 573 
differing in the number of the fatty acid chains (Figure 3a). Moreover, each of these group of ions was 574 
characterized by the presence of mass differences that can be explained with the presence of lipid A 575 
species differing in the fatty acid chain length. In detail, the most intense cluster of ions in the mass 576 
range m/z 1617-1717 Da (Figure 3a) was consistent with mono-phosphorylated pentaacylated lipid A 577 
species whose fatty acid distribution and composition, as instance for ion peak at m/z 1688.28, was 578 
determined as two C17:(3-OH) as N-linked acyl chains, two C16:(3-OH) as primary O-linked fatty 579 
acids and C15:0 as a secondary O-acyl substitution. The less intense cluster of ions visible in the mass 580 
range m/z 1385-1479 Da (Figure 3a) was attributed to mono-phosphotylated tetraacylated lipid A 581 
species with the main ion peak at m/z 1436.02 assigned to a lipid A possessing the above mentioned 582 
fatty acid distribution and composition but lacking one primary O-linked C16:(3-OH). The minor 583 
cluster of ion at about m/z 1257 Da (Figure 3a) was identified as mono-phosphotylated lipid A species 584 
bearing three fatty acid chains. Interestingly, a further minor cluster in the mass range m/z 1768-1797 585 
(Figure 3a) Da was assignable to pentaacylated lipid A species carrying a further phosphate group 586 
whose location remains to be defined.  587 
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